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Alcoholic liver disease occurs after prolonged heavy drinking. Not everyone who 
drinks alcohol in excess develops serious forms of alcoholic liver disease. It is likely 
that genetic factors determine this individual susceptibility, and a family history of 
chronic liver disease may indicate a higher risk. Other factors include being overweight 
and iron overload. This book presents state-of-the-art information summarizing the 
current understanding of a range of alcoholic liver diseases. It is hoped that the target 
readers - hepatologists, clinicians, researchers and academicians  - will be afforded new 
ideas and exposed to subjects well beyond their own scientific disciplines. Additionally, 
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In most Western countries, alcoholic beverages contribute significantly to a person's 
overall caloric intake. Of greater significance is it's status as the most widely used drug 
worldwide and addictive properties in addition to the damage it causes to various 
organs within the human body - in particular the liver. Alcoholic liver disease occurs 
after prolonged heavy drinking, especially among persons who are physically 
dependent on alcohol. Not everyone who drinks alcohol to excess develops serious 
forms of alcoholic liver disease. It is likely that genetic factors determine this 
individual susceptibility, and a family history of chronic liver disease may indicate a 
higher risk. Other factors include being overweight (similar to hepatitis C and non-
alcoholic fatty liver disease), and iron overload. Women are more susceptible to 
alcoholic liver disease than men, partly because of differences in the rate of alcohol 
metabolism, but also for other biological reasons. Alcoholic liver disease encompasses 
a broad spectrum of diseases, ranging from steatosis (fatty liver), steatohepatitis, 
fibrosis, and cirrhosis, to hepatocellular carcinoma. 
There have been major advances in our understanding of the liver, and a growing 
number of mechanisms underlying alcoholic liver disease continue to pose new 
challenges. This book presents state-of-the-art information summarizing the current 
understanding of a range of alcoholic liver diseases. Additionally, key cellular, 
biochemical, immunological and microstructural mechanisms, and diagnostic and 
therapeutic advances are also reviewed. 
The book constitutes a collection of selected clinical and scientific topics. Some 
chapters treat the cellular, biochemical, immunological, and micro-structural 
mechanisms underlying alcoholic liver diseases. Some other chapters focus on clinical 
alcoholic liver disease pathophysiology, related diagnostics, and therapeutic insights. 
Each of the eleven chapters is followed by a detailed bibliography, enabling the reader 
to work in depth on specific topics. Collectively, this book represents a broad range of 
important updated topics. 
It is hoped that the target readers, such as hepatologists, clinicians, researchers and 
academicians, will be afforded new ideas and exposed to subjects which extend 
beyond their own scientific disciplines. In addition, students and all those who wish to 
X Preface 
 
increase their knowledge of advances in the field of alcoholic liver disease will find 
this book a valuable source of information. 
My thanks are extended to the authors, the publisher, and most importantly, my 
family. 
Ichiro Shimizu, MD, AGAF 
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Alcohol Drinking Patterns and Nutrition  
in Alcoholic Liver Disease 




In most Western countries alcoholic beverages contribute markedly to the overall caloric 
intake. Indeed, alcohol contributes to approximately 5% of the daily caloric intake in the 
American diet (Halsted, 2004). Alcohol, besides nicotine, is also the most widely used drug 
in our society, bearing a large potential for addiction but also organ damage and herein 
particularly liver damage. Chronic alcohol abuse is frequently accompanied with 
malnutrition with the degree of malnutrition varying not only between the type of alcohol 
abuse (e.g. binge drinker vs. chronic drinker) but also the degree of liver damage. For 
practitioners it is important to recognize the various factors contributing to the evolvement 
of malnutrition in alcoholic patients, as the correction of deficiencies or other strategies to 
improve nutritional status may have a beneficial effect in the prevention and treatment of 
alcoholic liver disease. The effects of alcohol ingestion on dietary pattern, nutrient intake 
and the intermediary metabolism have been investigated in numerous human but also 
animal studies. In this chapter the role of alcohol as energy source but also the effects of 
alcohol ingestion on energy metabolism, dietary pattern and micronutrient bioavailability as 
well as metabolism with special emphasize on the liver and the development of alcoholic 
liver disease are reviewed. Furthermore, current recommendations for treatment of 
malnutrition in patients with alcoholic liver disease are summarized. 
2. Alcohol drinking patterns 
When talking about “alcohol drinking”, two main patterns have to be distinguished: acute 
“binge drinking” and “chronic drinking”. As reviewed by Zakhari and Li (2007), the impact 
of the quantity and frequency of alcohol ingestion on alcoholic liver disease becomes more 
and more important. Indeed, the results of a Danish prospective study with a cohort of 6152 
alcohol misusing men and women indicate that periodic drinking leads to a significantly 
lower relative risk for developing cirrhosis than daily drinking (Kamper-Jorgensen et al.  
2004). The Italian Dionysos Study focused on drinking habits as cofactors of risk for alcohol-
induced liver damage. The results of this study show that drinking without food and 
drinking multiple different alcoholic beverages both increase the risk of developing 
alcoholic liver disease (Bellentani et al.  1997). Furthermore, it has been shown that the 
metabolic effects of binge drinking and chronic drinking on the liver also markedly differ 
(for overview see (Zakhari and Li, 2007)). For example, binge drinking may lead to glycogen 
1 
Alcohol Drinking Patterns and Nutrition  
in Alcoholic Liver Disease 




In most Western countries alcoholic beverages contribute markedly to the overall caloric 
intake. Indeed, alcohol contributes to approximately 5% of the daily caloric intake in the 
American diet (Halsted, 2004). Alcohol, besides nicotine, is also the most widely used drug 
in our society, bearing a large potential for addiction but also organ damage and herein 
particularly liver damage. Chronic alcohol abuse is frequently accompanied with 
malnutrition with the degree of malnutrition varying not only between the type of alcohol 
abuse (e.g. binge drinker vs. chronic drinker) but also the degree of liver damage. For 
practitioners it is important to recognize the various factors contributing to the evolvement 
of malnutrition in alcoholic patients, as the correction of deficiencies or other strategies to 
improve nutritional status may have a beneficial effect in the prevention and treatment of 
alcoholic liver disease. The effects of alcohol ingestion on dietary pattern, nutrient intake 
and the intermediary metabolism have been investigated in numerous human but also 
animal studies. In this chapter the role of alcohol as energy source but also the effects of 
alcohol ingestion on energy metabolism, dietary pattern and micronutrient bioavailability as 
well as metabolism with special emphasize on the liver and the development of alcoholic 
liver disease are reviewed. Furthermore, current recommendations for treatment of 
malnutrition in patients with alcoholic liver disease are summarized. 
2. Alcohol drinking patterns 
When talking about “alcohol drinking”, two main patterns have to be distinguished: acute 
“binge drinking” and “chronic drinking”. As reviewed by Zakhari and Li (2007), the impact 
of the quantity and frequency of alcohol ingestion on alcoholic liver disease becomes more 
and more important. Indeed, the results of a Danish prospective study with a cohort of 6152 
alcohol misusing men and women indicate that periodic drinking leads to a significantly 
lower relative risk for developing cirrhosis than daily drinking (Kamper-Jorgensen et al.  
2004). The Italian Dionysos Study focused on drinking habits as cofactors of risk for alcohol-
induced liver damage. The results of this study show that drinking without food and 
drinking multiple different alcoholic beverages both increase the risk of developing 
alcoholic liver disease (Bellentani et al.  1997). Furthermore, it has been shown that the 
metabolic effects of binge drinking and chronic drinking on the liver also markedly differ 
(for overview see (Zakhari and Li, 2007)). For example, binge drinking may lead to glycogen 
 
Trends in Alcoholic Liver Disease Research – Clinical and Scientific Aspects 
 
2 
depletion, acidosis and hypoglycemia; whereas chronic drinking results in the development 
of alcoholic liver damages. The differences between these two alcohol drinking patterns are 
detailed in the following.  
2.1 Binge drinking 
The World Health Organization (WHO) defines binge drinking as a pattern of heavy 
drinking that occurs in an extended period, which is usually defined as more than one day 
of drinking at a time (WHO, 1994). In the United States (US), the National Institute on 
Alcohol Abuse and Alcoholism defined a more common definition that a “binge” is a 
pattern of alcohol drinking that brings blood alcohol level to 0.08 gram-percent or above. 
For a typical adult, the amount of alcohol that has to be ingested to reach these blood alcohol 
levels is on average equivalent to consuming five or more drinks (men), or four or more 
drinks (women), in about two hours (National Institute on Alcohol Abuse and Alcoholism, 
2007). In contrast, in the United Kingdom binge drinking is defined as the consumption of 
more than eight drinks in men and more than six drinks in women in a single day (Institute 
of Alcohol Studies, 2010). In the United States, the prevalence of binge drinking among 
adults was 15.2% in 2009, with the prevalence being two times higher in men than in women  
(Kanny et al.  2011). This phenomenon can also be observed in most of the European 
countries, except for England and Ireland. In these two countries binge drinking is found to 
be particularly prevalent in women (Dantzer et al.  2006). In terms of age, the prevalence of 
binge drinking decreases, both in the United States and United Kingdom, with increasing 
age, indicating that the phenomenon “binge drinking” is as an important problem especially 
in young people (Institute of Alcohol Studies, 2010). In dependence on “drinking cultures” 
binge drinking occurs more or less in different countries. In Mediterranean culture, alcoholic 
beverages, especially wine, are consumed on a daily basis as part of meals and mostly in 
family settings. In contrast, in Northern cultures, drinking is less frequent in everyday life 
but heavier, typically around weekends (Institute of Alcohol Studies, 2010). 
2.2 Chronic drinking 
In a systemic review, the risks of moderate alcohol consumption have been weighed against 
its benefits. As a result of comparing the critical endpoints of alcohol intake related to 
morbidity and mortality, tolerable upper alcohol intake levels have been defined for the 
German adult population to be 20 to 24g alcohol per day for men and 10 to 12g alcohol per 
day for women (Burger et al.  2004). However, it is recommended that if this amount of 
alcohol is ingested, at least two days per week should be without any alcohol consumption. 
Exceeding this tolerable alcohol intake level alcohol consumption is classified as a risk factor 
for numerous organ damages (e.g. liver, pancreas, stomach, gut).   
In Germany, the per-capita consumption of pure ethanol was 9.7 l in 2009. Furthermore, in 
2006 3.8% of the German population met the criteria of alcohol abuse and 2.4% of alcohol 
dependence in 2006 (Deutsche Hauptstelle für Suchtfragen, DHS, 2006). According to the 
2001-2002 National Epidemiologic Survey on Alcohol and related Conditions, 5.8% of the 
US adult population meet the criteria for alcohol dependence or alcoholism and 7.1% meet 
the criteria for alcohol abuse (for overview see Zakhari and Li, 2007). Despite intense 
education on the risks associated with alcohol abuse, in industrialized countries in Europe 
as well as in the United States, the damage of liver and other organs as a consequence of 
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chronic alcohol consumption is still an important health problem. Especially, chronic alcohol 
abuse is one of the most important risk factors for liver damage (Lieber, 1994). The results of 
previous studies demonstrated the existence of a dose-response relation between alcohol 
intake and the risk of liver disease (Lelbach, 1975; Day, 1997). As a consequence of alcohol 
abuse different alcoholic liver disease patterns such as alcohol-caused fatty liver, alcoholic 
hepatitis, or alcohol-induced cirrhosis can be observed. 
3. Alcohol and energy metabolism 
3.1 Alcohol and its contribution to energy intake 
For many people regular alcohol consumption is still a part of their daily diet. Raw alcohol 
and even more so alcoholic beverages are rather energy dense nutrients. Alcoholic 
beverages primarily consist of water, ethanol, and, depending on the beverage, variable 
amounts of carbohydrates as well as to a lesser extend proteins, vitamins or minerals (see 





g             kcal 
Fat 
g           kcal 
Carbohydrate 
g               kcal 
Ethanol 
g               kcal 
Whiskey 250 0.0 0.0 0.0 0.0 0.1 0.4 36 252.0 
Vodka 232 0.0 0.0 0.0 0.0 0.0 0.0 33.4 233.8 
Dry red 
wine 60 0.7 2.9 0.0 0.0 4.6 18.9 5.5 38.5 
Dry white 
wine 42 0.5 2.1 0.0 0.0 3.1 12.7 4.0 28.0 
Stout 83 0.1 0.4 0.0 0.0 3.8 15.6 19.9 139.3 
Beer 67 0.1 0.4 0.0 0.0 0.2 0.8 9.5 66.5 
Sweet white 
wine 96 0.2 0.8 0.0 0.0 5.9 24.2 10.2 71.4 
Cocktail  141 0.2 0.8 0.9 8.4 9.1 37.3 13.7 95.9 
Table 1. Energy and caloric content of various alcoholic beverages per 100 mL. Values were 
calculated with the software program EBIS pro and are based on the German food index. 
Calories provided through the consumption of alcoholic beverages primarily stem from its 
content and metabolism of carbohydrates and ethanol. Indeed, hard spirits like whiskey, 
vodka and schnapps contain no sugar, whereas dry red and white wine contain 31 to 46 
grams of sugar per liter. Sugar content of beer various between 2 and 38 grams per liter 
depending whether stout or “normal” beer is consumed. Sugar content may even be as high 
as 120 grams per liter in sweet white wine (on average 59 g/L) and up to 91 grams per liter 
in mixed cocktails (average value of several cocktails). A similarly strong variability in 
content is also found when ethanol contents of different alcoholic beverages are compared. 
For example, a liter of beer with the exception of stout on average contains 200 grams of 
ethanol per liter whereas wine contains 40 to 100 grams of ethanol per liter. Hard spirits 
may even contain up to 300 to even 500 grams of ethanol per liter. An average serving of 
wine (125 mL), beer (330 mL) or hard spirits (40 mL) contains 12 to 14 grams of ethanol. 
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3.2 Alcohol metabolism and energy yield 
Using bomb calorimetry it was shown that ethanol yields 7.1 kcal (= 29.3 kJ) per gram when 
completely combusted (Lieber, 1991). However, as the digestibility of ethanol ranges from 
98 to 100 % and approximately 5% of ethanol is also lost through respiration, faeces and 
urine energy provide for metabolic purposes is only approximately 6.9 kcal per gram 
ethanol (= 28.8 kJ per gram ethanol) (Lieber, 1991). It was further shown that even when 
ethanol is ingested at constant rates and high levels (e.g. up to 171 grams of ethanol per day) 
the loss of alcohol derived energy through the respiratory tract und urine only accounts to 
approximately 50 kcal per day  (Reinus et al.  1989). Indeed, a marked loss of ethanol 
through urine or respiration was only observed when the amounts of ethanol ingested 
exceed the liver´s ethanol metabolizing capacity shown to be 105 mg/ kg body weight per h 
(Reinus et al.  1989).  
Taking the caloric content of alcoholic beverages into account and the fact that only little is 
lost through respiration, faeces, and urine, one would expect a positive association of 
alcohol intake and obesity. However, results of epidemiological studies are somewhat 
contradictory indicating no or only a weak association of alcohol consumption and body 
weight in men and even an inverse association in women (Müller et al. 1999). The results of 
these studies suggest that  
- ethanol either bears a negative effect on energy yield implying that ethanol is 
inefficiently metabolised or 
- the consumption of ethanol alters dietary intake, absorption and/ or metabolism of 
other nutrients subsequently leading to a negative or at least diminished energy yield. 
In the very early studies of Atwater and Benedict (1902), using direct calorimetry it was 
shown that in healthy non-alcoholic volunteers ethanol (72 grams ethanol per day) was 
utilized as efficiently as fat or carbohydrates as a source of energy. Furthermore, it was 
shown that the ingestion of 31.5 gram of ethanol per 65 kg of body weight did not increase 
oxygen consumption or thermogenesis in normal volunteers (Barnes et al.  1965).  However, 
contrary to these early finding, in the studies of Pirola and Lieber (1972), in which it was 
shown in normal volunteers that the progressive substitution of carbohydrates with ethanol 
in an otherwise balanced, normal diet results in a decrease in body weight. In line with these 
findings it was further shown that the addition of 90g of ethanol to the daily diet increased 
the daily energy expenditure by 7% (Suter et al.  1992) and that lipid oxidation may be 
inhibited by the ingestion of additional alcohol to 50% of calories (Sonko et al. 1994). 
Furthermore, in a study in which the energy intake of middle-class patients with alcoholic 
liver disease ranging from non-cirrhotic to cirrhotic was compared to that of controls with 
the same body mass index it was shown that non-alcoholic energy intake did not differ from 
that of controls (Bergheim et al.  2003). In this study it was further shown that the average 
energy intake form alcoholic beverages (e.g. from beer, wine and hard spirits) accounting to 
~1008 kcal/ day (= ~142 g Ethanol/ day) was added to the daily non-alcoholic energy intake 
without leading to the development of obesity. The results of this study are in line with 
other studies in which it was also shown that in middle-class alcohol consumers alcohol 
consumption is not associated with increased body weight compared with control subjects 
ingesting the same nonalcoholic energy intake, but lower total energy intake (Mezey, 1991; 
Rissanen et al.  1987). These data suggest that some of the energy ingested as alcohol is “lost” 
or “wasted”- that is, this energy is not available to the body for the production of energy 
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resources that can be used to produce or maintain body mass. However, when interpreting 
these data, it has to be kept in mind that when assessing nutritional intake and herein 
especially that of alcohol underreporting may be a problem. For example, when applying 
the formula published by the WHO to calculate for underreporting to a study performed by 
Colditz et al.  (1991) underreporting was found in ~25% of women and ~33% of men 
(Müller, 1999). 
Several mechanisms have been proposed to be responsible for the apparent loss of alcohol-
derived energy. In the following, some of the main mechanisms proposed are summarized.   
Three enzyme systems are known to be able to metabolize ethanol to acetaldehyde: 
- the alcohol dehydrogenase (ADH), a cytolic enzyme existing as several isoenzymes, is 
the major enzyme metabolizing ethanol  
- the microsomal ethanol oxidizing system (MEOS), a cytochrome P450-depending 
enzyme system, bound to the smooth endoplasmatic reticulum 
- the catalase, localized in the peroxisomes, under normal conditions plays a neglectable  
role and therefore shall not be discussed here (for overview also see Zakhari (2006)). 
The ADH is the major enzyme metabolizing ethanol. In order to facilitate the oxidation of 
ethanol ADH converts its cofactor nicotinamide adenine dinucleotide (NAD+) to NADH. 
The reaction mediated by the ADH are summarized as 
Ethanol + NAD+  Acetaldehyde + NADH 
NADH is an energy rich molecule that can donate electrons to the electron transport chain in 
the mitochondria subsequently leading to the synthesis of adenosine triphosphate (ATP). 
However, as the ADH-mediated ethanol oxidation is located in the cytoplasm and NADH 
cannot pass the mitochondrial membrane the cellular redox potential is markedly altered 
when ethanol is metabolised (e.g. the NADH/ NAD+ ratio) (van Haaren et al. 1999). As a 
consequence, ethanol derived NADH is mainly metabolized through the reduction of 
pyruvate to lactate and oxaloacetate to malate which in turn can then be used to utilize energy 
by the mitochondria (van Haaren et al. 1999). Acetaldehyde also produced in this reaction is 
rapidly metabolized, mainly by mitochondrial acetaldehyde dehydrogenase (ALDH) 2 to form 
acetate and NADH, which than is oxidized by the electron transport chain (for overview also 
see (Zakhari and Li, 2007)). The increase in mitochondrial NADH in hepatocytes resulting 
from the metabolism of acetaldehyde may result in a saturation of the NADH dehydrogenase 
and subsequently the impairment of the tricarboxylic acid (TCA) cycle as the acetyl coenzyme 
A (CoA) synthase 2, the mitochondrial enzyme involved in the oxidation of acetate is not 
found in the liver but is abundant in heart and skeletal muscles (Fujino et al.  2001). As a 
consequence, most of the acetate resulting from the breakdown of ethanol in the liver enters 
the circulation and is eventually metabolized to CO2 in the TCA in tissues that possess the 
enzymes to convert acetate to acetyl CoA (e.g. heart and skeletal muscle). 
Furthermore, ethanol is also metabolised through the MEOS. The MEOS differs from the 
ADH in several aspects as it has a higher Michaelis constant (Km) (MEOS: Km 10mM vs. 
ADH: Km 1mM) (Haseba and Ohno, 2010; Lieber and DeCarli, 1970) and its activity 
increases when ethanol is consumed chronically (Lieber, 1997). The reaction mediated by the 
MEOS, which requires Nicotinamide adenine dinucleotide phosphate (NADPH) rather than 
NAD+ and oxygen as a cofactor are summarized as 
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3.2 Alcohol metabolism and energy yield 
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Ethanol + NADPH + H+ + ½ O2  Acetaldehyde + NADP+ + 2H2O 
This metabolic route of ethanol was proposed as one possible explanation of the energy 
“waste” associated with the intake of alcohol (Lieber, 1994; Lieber, 2003). Lieber (1991) 
postulated that when alcohol is consumed chronically alcohol is metabolized preferentially 
through the MEOS implying that the production of NADP+ is increased whereas the 
formation of NADH through the ADH is decreased. This shift between the two enzyme 
systems would imply a loss in the net energy gain (e.g. through MEOS “only” ~67% of the 
energy gain that is achieved if ethanol is metabolised through ADH). Lands and Zakhari 
(1991) calculated that if ethanol is readily metabolized through mitochondrial oxidation 1 
Mol of ethanol can provide as much as 16 Mol of ATP. In contrast the first steps of 
microsomal-mediated ethanol oxidation require 1 Mol of NADPH equivalent to 3 Mol ATP. 
Subsequently the energy yield through this pathway is markedly lower.  
In addition, it was also postulated that the metabolism of acetate may also be associated 
with a loss of energy. Indeed, Müller et al. (1995 and 1998) showed that up to 80% of the 
acetate derived from ethanol metabolism in the human liver was found in the liver vein. It 
was further shown that in fasted subjects acetate blood levels raise with 90 min after ethanol 
ingestion up to 900-950 Mol/L after the ingestion of 47.5 g ethanol (Frayn et al.  1990). At the 
same time, acetate uptake by muscle tissue only accounted to ~3% of the ingested ethanol. 
The enhanced energy use needed for the lipogenesis of acetate actually was calculated to 
account to ~25% of the energy content of ethanol (Müller et al. 1999).  
3.3 Alcohol metabolism and its effect on general energy as well as fat, protein and 
carbohydrate metabolism 
The increased ratios of NADH to NAD+ in both mitochondria and cytosol in hepatocytes 
affect the “direction” of several reversible reactions resulting in alterations of hepatic lipid, 
carbohydrate, and protein but also lactate and uric acid metabolism. The latter are not 
discussed in this chapter. Most of these changes have been shown to happen as a 
consequence of acute excessive alcohol intake (e.g. binge drinking) and seem to be at least in 
part to be attenuated when alcohol is consumed chronically; however, some alterations, like 
the accumulation of fat in the liver are also found when alcohol is consumed chronically. 
Furthermore, it has been shown that acute but also chronic intake of alcohol may not only 
affect micronutrient uptake in the small intestine but may also disturb the absorption of 
macronutrients; however, most of the data summarized in the following stem from animal 
experiments.  
3.3.1 Effect of alcohol intake on fat metabolism 
Besides an altered dietary pattern (e.g. higher intake of pork and subsequently 
polyunsaturated fatty acids) found to be associated with an increased intake of alcohol 
(French, 1992) results of early animal studies suggested that the concomitant ingestion of 
alcohol and plant derived oils is associated with a markedly reduced absorption of these fats 
(Bode, 1980); however, this effect of alcohol was probably due to a slowed gastric empting 
resulting from the combination of the oil with a relatively high dose of alcohol. In later 
human and animal studies it was found that absorption of lipids decreased by the ingestion 
of alcohol doses of  1g/ kg body weight (Bode and Bode, 1992). It has further been 
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suggested, that fat malabsorption found in patients with alcoholic hepatitis may be due to 
reduced bile and pancreas enzyme secretion (Soberon et al.  1987). Regarding the effects of 
alcohol metabolism on hepatic lipid metabolism it has been shown that the altered ratio of 
NADH/ NAD+ results in an increase of the intermediate metabolite -glycerophosphate, 
which favours the accumulation of triglycerides in hepatocytes, but also inhibits -oxidation 
of fatty acids in mitochondria (for overview also see Zakhari and Li (2007); Lieber (1984)). 
3.3.2 Effect of alcohol intake on protein metabolism 
In Europe the average intake of proteins has been shown to be normal in patients with 
chronic alcohol abuse or alcoholic liver disease in the earlier stage (e.g. steatohepatitis) 
(Bergheim et al.  2003). However, results of animal but also human studies suggest that 
absorption of amino acids in the small intestine is markedly impaired when alcohol is 
consumed concomitantly. Indeed, it has been shown in animal studies that in the presence 
of 2-4.5% of alcohol the uptake of L-alanin, L-glycine, L-leucine, L-proline, L-methionine, L-
phenylalanin, and L-valin is in the small intestine impaired by more than 20% (Abidi et al. 
1992). Especially the decreased uptake of methionine but also the inhibition of the 
methionine synthase in combination with the deficiency of folic acid and pyridoxine has 
been shown to be a critical factor in the development and progression of alcoholic liver 
disease. Recent data from animal studies suggest that the shift in the NADH/ NAD+ ratio 
resulting from alcohol metabolism may also affect liver methionine metabolism (Watson et 
al.  2011). Indeed, it has been shown that the supplementation of methionine but also its 
metabolite S-adenosyl-L-methinone may improve alcoholic liver disease (for overview also 
see Beier and McClain (2010)).  
3.3.3 Effect of alcohol intake on hepatic glucose metabolism 
In animal experiments it was shown that alcohol at concentrations found in humans after 
moderate drinking (e.g. 1-5% w/v) depresses glucose uptake in the brush border membrane 
in a dose- and time-dependent manner (Dinda and Beck, 1981). Furthermore, the increase in 
NADH resulting from the ADH-mediated oxidation of alcohol has been shown to prevent 
the conversion of pyruvate to glucose, which in turn impairs the rate limiting step of the 
gluconeogenesis, the pyruvate carboxylase reaction (Krebs et al.  1969) subsequently leading 
to hypoglycaemia. Fasting, sustained physical exercise and malnutrition may even increase 
the likelihood of hypoglycaemia. 
4. Alcohol and dietary pattern 
Alcohol consumption and potential alterations of dietary habits have been extensively 
studied in various cohort studies in various regions of the world  (Thomson et al.  1988; 
Gruchow et al.  1985; Suter et al.  1997). 
4.1 Binge drinking and dietary pattern 
Kim et al. (2007) reported that both male and female binge drinkers have higher energy 
intake in comparison to non-binge drinkers. Among men, an inverse association between 
the frequency of binge drinking and the intake of polyunsaturated fatty acids (PUFA) 
including linoleic acid, α-linolenic acid and eicosapentaenoic acid was found; a similar 
 
Trends in Alcoholic Liver Disease Research – Clinical and Scientific Aspects 
 
6 
Ethanol + NADPH + H+ + ½ O2  Acetaldehyde + NADP+ + 2H2O 
This metabolic route of ethanol was proposed as one possible explanation of the energy 
“waste” associated with the intake of alcohol (Lieber, 1994; Lieber, 2003). Lieber (1991) 
postulated that when alcohol is consumed chronically alcohol is metabolized preferentially 
through the MEOS implying that the production of NADP+ is increased whereas the 
formation of NADH through the ADH is decreased. This shift between the two enzyme 
systems would imply a loss in the net energy gain (e.g. through MEOS “only” ~67% of the 
energy gain that is achieved if ethanol is metabolised through ADH). Lands and Zakhari 
(1991) calculated that if ethanol is readily metabolized through mitochondrial oxidation 1 
Mol of ethanol can provide as much as 16 Mol of ATP. In contrast the first steps of 
microsomal-mediated ethanol oxidation require 1 Mol of NADPH equivalent to 3 Mol ATP. 
Subsequently the energy yield through this pathway is markedly lower.  
In addition, it was also postulated that the metabolism of acetate may also be associated 
with a loss of energy. Indeed, Müller et al. (1995 and 1998) showed that up to 80% of the 
acetate derived from ethanol metabolism in the human liver was found in the liver vein. It 
was further shown that in fasted subjects acetate blood levels raise with 90 min after ethanol 
ingestion up to 900-950 Mol/L after the ingestion of 47.5 g ethanol (Frayn et al.  1990). At the 
same time, acetate uptake by muscle tissue only accounted to ~3% of the ingested ethanol. 
The enhanced energy use needed for the lipogenesis of acetate actually was calculated to 
account to ~25% of the energy content of ethanol (Müller et al. 1999).  
3.3 Alcohol metabolism and its effect on general energy as well as fat, protein and 
carbohydrate metabolism 
The increased ratios of NADH to NAD+ in both mitochondria and cytosol in hepatocytes 
affect the “direction” of several reversible reactions resulting in alterations of hepatic lipid, 
carbohydrate, and protein but also lactate and uric acid metabolism. The latter are not 
discussed in this chapter. Most of these changes have been shown to happen as a 
consequence of acute excessive alcohol intake (e.g. binge drinking) and seem to be at least in 
part to be attenuated when alcohol is consumed chronically; however, some alterations, like 
the accumulation of fat in the liver are also found when alcohol is consumed chronically. 
Furthermore, it has been shown that acute but also chronic intake of alcohol may not only 
affect micronutrient uptake in the small intestine but may also disturb the absorption of 
macronutrients; however, most of the data summarized in the following stem from animal 
experiments.  
3.3.1 Effect of alcohol intake on fat metabolism 
Besides an altered dietary pattern (e.g. higher intake of pork and subsequently 
polyunsaturated fatty acids) found to be associated with an increased intake of alcohol 
(French, 1992) results of early animal studies suggested that the concomitant ingestion of 
alcohol and plant derived oils is associated with a markedly reduced absorption of these fats 
(Bode, 1980); however, this effect of alcohol was probably due to a slowed gastric empting 
resulting from the combination of the oil with a relatively high dose of alcohol. In later 
human and animal studies it was found that absorption of lipids decreased by the ingestion 
of alcohol doses of  1g/ kg body weight (Bode and Bode, 1992). It has further been 
 
Alcohol Drinking Patterns and Nutrition in Alcoholic Liver Disease 
 
7 
suggested, that fat malabsorption found in patients with alcoholic hepatitis may be due to 
reduced bile and pancreas enzyme secretion (Soberon et al.  1987). Regarding the effects of 
alcohol metabolism on hepatic lipid metabolism it has been shown that the altered ratio of 
NADH/ NAD+ results in an increase of the intermediate metabolite -glycerophosphate, 
which favours the accumulation of triglycerides in hepatocytes, but also inhibits -oxidation 
of fatty acids in mitochondria (for overview also see Zakhari and Li (2007); Lieber (1984)). 
3.3.2 Effect of alcohol intake on protein metabolism 
In Europe the average intake of proteins has been shown to be normal in patients with 
chronic alcohol abuse or alcoholic liver disease in the earlier stage (e.g. steatohepatitis) 
(Bergheim et al.  2003). However, results of animal but also human studies suggest that 
absorption of amino acids in the small intestine is markedly impaired when alcohol is 
consumed concomitantly. Indeed, it has been shown in animal studies that in the presence 
of 2-4.5% of alcohol the uptake of L-alanin, L-glycine, L-leucine, L-proline, L-methionine, L-
phenylalanin, and L-valin is in the small intestine impaired by more than 20% (Abidi et al. 
1992). Especially the decreased uptake of methionine but also the inhibition of the 
methionine synthase in combination with the deficiency of folic acid and pyridoxine has 
been shown to be a critical factor in the development and progression of alcoholic liver 
disease. Recent data from animal studies suggest that the shift in the NADH/ NAD+ ratio 
resulting from alcohol metabolism may also affect liver methionine metabolism (Watson et 
al.  2011). Indeed, it has been shown that the supplementation of methionine but also its 
metabolite S-adenosyl-L-methinone may improve alcoholic liver disease (for overview also 
see Beier and McClain (2010)).  
3.3.3 Effect of alcohol intake on hepatic glucose metabolism 
In animal experiments it was shown that alcohol at concentrations found in humans after 
moderate drinking (e.g. 1-5% w/v) depresses glucose uptake in the brush border membrane 
in a dose- and time-dependent manner (Dinda and Beck, 1981). Furthermore, the increase in 
NADH resulting from the ADH-mediated oxidation of alcohol has been shown to prevent 
the conversion of pyruvate to glucose, which in turn impairs the rate limiting step of the 
gluconeogenesis, the pyruvate carboxylase reaction (Krebs et al.  1969) subsequently leading 
to hypoglycaemia. Fasting, sustained physical exercise and malnutrition may even increase 
the likelihood of hypoglycaemia. 
4. Alcohol and dietary pattern 
Alcohol consumption and potential alterations of dietary habits have been extensively 
studied in various cohort studies in various regions of the world  (Thomson et al.  1988; 
Gruchow et al.  1985; Suter et al.  1997). 
4.1 Binge drinking and dietary pattern 
Kim et al. (2007) reported that both male and female binge drinkers have higher energy 
intake in comparison to non-binge drinkers. Among men, an inverse association between 
the frequency of binge drinking and the intake of polyunsaturated fatty acids (PUFA) 
including linoleic acid, α-linolenic acid and eicosapentaenoic acid was found; a similar 
 
Trends in Alcoholic Liver Disease Research – Clinical and Scientific Aspects 
 
8 
association was not found in female binge drinkers (Kim et al.  2007). The lower intake of 
PUFA implies that binge drinking affects the choice of foods (e.g. intake of fish maybe 
lower) (Howe et al.  2006). Results of Toniolo et al. (1997) indicate that moderate drinkers (< 
5 g/d) have reduced intake of milk and fresh fruits in comparison to abstainers (Toniolo et 
al.  1991). However, results of Thomson et al. (1988) found higher intake of fiber, cereal fiber 
and PUFA in moderate drinking group (0.1-9 g/day). Results of Colditz et al. (1991) found a 
strong correlation between alcohol intake and carbohydrates, and herein particularly the 
intake of sucrose. To further investigate this relation the study examined consumption of 
candy and chocolates. Results of this study are summarized in Table 2. In women the intake 
of only candy was negatively related with alcohol intake (Spearmann r=-0.07, p<0.0001).  
 
                                                                                          Alcohol intake 






2.48g/d Only candy 






0.85g/d Only candy 
Candy + chocolate 1.98 g/d 1.70 g/d 0.85g/d 
Chocolate 3.69 g/d 3.69 g/d 2.27 g/d 
Table 2. Intake of alcohol vs. candy and chocolate in men and women (Adapted from 
Colditz et al. 1991). 
Earlier studies have repeatedly documented that consumption of alcohol is associated with 
losses in tissue PUFA (Salen and Olsson, 1997; Lands et al.  1998).   
4.1.1 Chronic alcoholics, dietary pattern and nutritional intake 
In Germany and in most industrialized countries chronic alcohol abuse is not only one of the 
most important causes of nutritional disorders but also of changes in dietary habits (Aaseth 
et al.  1986; Addolorato, 1998; Suter et al. 1997). For instance, studies have reported that 
increased alcohol consumption is positively associated with an increased consumption of 
coffee, cheese, eggs, fish, meat whereas negative association was found with the intake of 
fruits and milk consumption (Kesse et al.  2001). Similar results were also reported by 
Toniolo et al. (1991) in regards to intake of fruit and dairy products. As mentioned above the 
results of Colditz et al. (1991) have reported that consumption of alcohol up to 50g/d was 
associated with lower intake of sugar in men. Results of Nanji et al. (1985) reported that 
pork and alcohol consumption were significantly correlated to cirrhosis mortality (r=0.98, 
p<0.001). A study by Bergheim et al. (2003) performed on German male middle-class alcohol 
consumers found that in chronic alcohol consumption protein intake is within the 
recommended daily allowances. However, the intake of fat and carbohydrate was lower in 
alcohol consumers in comparison to controls. No significant differences were found in the 
intake of vitamin B1, B2, B6 and vitamin C as well as retinol in chronic alcohol consumers 
and controls. These results were in contrast with studies performed in the United States. 
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Linangpunsakul et al. (2010) used the Third National Health and Nutritional Examination 
Survey (NHANES III) to examine an association between the nutritional intake and alcohol 
consumption in the United States. These data reveal that in both male and female 
participants the energy derived from carbohydrates, proteins and fat decreased with 
increased alcohol consumption. The subjects consumed less fat and protein with increased 
consumption of alcohol. This large population study concluded that alcohol has replaced 
nutrients particularly in terms of energy. Furthermore, the increased consumption of alcohol 
has an inverse relation with macronutrient intakes. Studies have also shown that in alcohol 
consumers hepatic zinc and vitamin A are found to be depleted due to poor dietary intake 
(Leo and Lieber, 1999). Taken together, the results gathered in the United States from the 
above studies differ from Europe, where alcohol was added to the diet but has not 
substituted nutrients from food sources. 
5. Alcohol and vitamins 
5.1 Fat soluble vitamins 
Vitamin A: Vitamin A, which is vital for bone growth and normal eye function, is found to 
be deficient in patients with alcoholic cirrhosis (Lieber, 2003). Indeed, it has been found in 
human studies that patients with severe alcoholic liver disease have reduced levels of 
hepatic vitamin A (Ahmed et al.  1994). Interestingly, in these patients ß-carotene levels in 
the blood were found to be normal, indicating that liver disease may modify the ability of 
liver to convert ß-carotene to vitamin A (Ahmed et al.  1994). On the other hand, results of 
Manari et al. (2003) have indicated that chronic alcohol abusers without alcoholic liver 
disease have lower dietary intake of vitamin A than recommended by the reference nutrient 
intake. However, noteworthy results of Leo and Lieber (1982) showed that chronic alcohol 
administration in rats fed with vitamin A supplemented diet resulted in decrease of hepatic 
vitamin A levels. Thus, decreased levels of vitamin A in alcohol abuse may not be linked to 
reduced intake or malabsorption alone, suggesting that other mechanisms might be 
involved. Results of animal studies suggest that chronic ethanol ingestion has increased the 
peripheral vitamin A status and decreased hepatic vitamin A content (Leo et al.  1986; Leo 
and Lieber, 1988).  
Vitamin D: Results of several human studies have reported that chronic alcohol abuse 
resulted in reduction of plasma 1,25 dihydroxyvitamin D3 levels, which is an active form of 
vitamin D3 (Lund et al. 1977; Laitinen and Valimaki, 1991; Laitinen et al.  1990). Similar 
reduction of plasma 1,25 dihydroxyvitamin D3 levels were also found in animal studies after 
chronic ethanol exposure (Turner et al.  1988). Reduction of circulating vitamin D levels in 
alcohol abusers may lead to reduced bone mass and lower calcium levels (Sampson, 1997; 
Keiver and Weinberg, 2003). Vitamin D is crucial in maintaining insulin levels and deficiencies 
may lead to altered glucose metabolism (Clark et al.  1981; Gedik and Akalin, 1986).  
Vitamin E: Vitamin E is a well known anti-oxidant, whose metabolism is also altered in 
alcohol consumption (Drevon, 1991). Results of Bergheim et al. (2003) suggest that vitamin E 
consumption was markedly lower in patients with different stages of alcoholic liver disease. 
Furthermore, several animal and human studies suggest that consumption of alcohol 
reduces the hepatic stores of vitamin E (Bjorneboe et al.  1986, 1987, 1988a, 1988b). Indeed, 
rats fed with ethanol have increased hepatic α-tocopherol quinine levels, a product of α-
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association was not found in female binge drinkers (Kim et al.  2007). The lower intake of 
PUFA implies that binge drinking affects the choice of foods (e.g. intake of fish maybe 
lower) (Howe et al.  2006). Results of Toniolo et al. (1997) indicate that moderate drinkers (< 
5 g/d) have reduced intake of milk and fresh fruits in comparison to abstainers (Toniolo et 
al.  1991). However, results of Thomson et al. (1988) found higher intake of fiber, cereal fiber 
and PUFA in moderate drinking group (0.1-9 g/day). Results of Colditz et al. (1991) found a 
strong correlation between alcohol intake and carbohydrates, and herein particularly the 
intake of sucrose. To further investigate this relation the study examined consumption of 
candy and chocolates. Results of this study are summarized in Table 2. In women the intake 
of only candy was negatively related with alcohol intake (Spearmann r=-0.07, p<0.0001).  
 
                                                                                          Alcohol intake 






2.48g/d Only candy 






0.85g/d Only candy 
Candy + chocolate 1.98 g/d 1.70 g/d 0.85g/d 
Chocolate 3.69 g/d 3.69 g/d 2.27 g/d 
Table 2. Intake of alcohol vs. candy and chocolate in men and women (Adapted from 
Colditz et al. 1991). 
Earlier studies have repeatedly documented that consumption of alcohol is associated with 
losses in tissue PUFA (Salen and Olsson, 1997; Lands et al.  1998).   
4.1.1 Chronic alcoholics, dietary pattern and nutritional intake 
In Germany and in most industrialized countries chronic alcohol abuse is not only one of the 
most important causes of nutritional disorders but also of changes in dietary habits (Aaseth 
et al.  1986; Addolorato, 1998; Suter et al. 1997). For instance, studies have reported that 
increased alcohol consumption is positively associated with an increased consumption of 
coffee, cheese, eggs, fish, meat whereas negative association was found with the intake of 
fruits and milk consumption (Kesse et al.  2001). Similar results were also reported by 
Toniolo et al. (1991) in regards to intake of fruit and dairy products. As mentioned above the 
results of Colditz et al. (1991) have reported that consumption of alcohol up to 50g/d was 
associated with lower intake of sugar in men. Results of Nanji et al. (1985) reported that 
pork and alcohol consumption were significantly correlated to cirrhosis mortality (r=0.98, 
p<0.001). A study by Bergheim et al. (2003) performed on German male middle-class alcohol 
consumers found that in chronic alcohol consumption protein intake is within the 
recommended daily allowances. However, the intake of fat and carbohydrate was lower in 
alcohol consumers in comparison to controls. No significant differences were found in the 
intake of vitamin B1, B2, B6 and vitamin C as well as retinol in chronic alcohol consumers 
and controls. These results were in contrast with studies performed in the United States. 
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Linangpunsakul et al. (2010) used the Third National Health and Nutritional Examination 
Survey (NHANES III) to examine an association between the nutritional intake and alcohol 
consumption in the United States. These data reveal that in both male and female 
participants the energy derived from carbohydrates, proteins and fat decreased with 
increased alcohol consumption. The subjects consumed less fat and protein with increased 
consumption of alcohol. This large population study concluded that alcohol has replaced 
nutrients particularly in terms of energy. Furthermore, the increased consumption of alcohol 
has an inverse relation with macronutrient intakes. Studies have also shown that in alcohol 
consumers hepatic zinc and vitamin A are found to be depleted due to poor dietary intake 
(Leo and Lieber, 1999). Taken together, the results gathered in the United States from the 
above studies differ from Europe, where alcohol was added to the diet but has not 
substituted nutrients from food sources. 
5. Alcohol and vitamins 
5.1 Fat soluble vitamins 
Vitamin A: Vitamin A, which is vital for bone growth and normal eye function, is found to 
be deficient in patients with alcoholic cirrhosis (Lieber, 2003). Indeed, it has been found in 
human studies that patients with severe alcoholic liver disease have reduced levels of 
hepatic vitamin A (Ahmed et al.  1994). Interestingly, in these patients ß-carotene levels in 
the blood were found to be normal, indicating that liver disease may modify the ability of 
liver to convert ß-carotene to vitamin A (Ahmed et al.  1994). On the other hand, results of 
Manari et al. (2003) have indicated that chronic alcohol abusers without alcoholic liver 
disease have lower dietary intake of vitamin A than recommended by the reference nutrient 
intake. However, noteworthy results of Leo and Lieber (1982) showed that chronic alcohol 
administration in rats fed with vitamin A supplemented diet resulted in decrease of hepatic 
vitamin A levels. Thus, decreased levels of vitamin A in alcohol abuse may not be linked to 
reduced intake or malabsorption alone, suggesting that other mechanisms might be 
involved. Results of animal studies suggest that chronic ethanol ingestion has increased the 
peripheral vitamin A status and decreased hepatic vitamin A content (Leo et al.  1986; Leo 
and Lieber, 1988).  
Vitamin D: Results of several human studies have reported that chronic alcohol abuse 
resulted in reduction of plasma 1,25 dihydroxyvitamin D3 levels, which is an active form of 
vitamin D3 (Lund et al. 1977; Laitinen and Valimaki, 1991; Laitinen et al.  1990). Similar 
reduction of plasma 1,25 dihydroxyvitamin D3 levels were also found in animal studies after 
chronic ethanol exposure (Turner et al.  1988). Reduction of circulating vitamin D levels in 
alcohol abusers may lead to reduced bone mass and lower calcium levels (Sampson, 1997; 
Keiver and Weinberg, 2003). Vitamin D is crucial in maintaining insulin levels and deficiencies 
may lead to altered glucose metabolism (Clark et al.  1981; Gedik and Akalin, 1986).  
Vitamin E: Vitamin E is a well known anti-oxidant, whose metabolism is also altered in 
alcohol consumption (Drevon, 1991). Results of Bergheim et al. (2003) suggest that vitamin E 
consumption was markedly lower in patients with different stages of alcoholic liver disease. 
Furthermore, several animal and human studies suggest that consumption of alcohol 
reduces the hepatic stores of vitamin E (Bjorneboe et al.  1986, 1987, 1988a, 1988b). Indeed, 
rats fed with ethanol have increased hepatic α-tocopherol quinine levels, a product of α-
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tocopherol oxidation, suggesting that ethanol promotes vitamin E degradation (Kawase et al.  
1989). 
5.2 Water soluble vitamins 
Thiamine: Thiamine or vitamin B1 is essential for proper neurological and cardiovascular 
functioning (Wood and Breen, 1979). Thiamine is available as free thiamine (T), thiamine 
diphosphate ester (TDP 80%), thiamine triphosphate and thiamine monophosphate ester in 
the organism. Alcohol can inhibit the rate limiting mechanism of thiamine transport after its 
absorption from gastro-intestinal tract (Mancinelli and Ceccanti, 2009). In chronic alcohol 
abusers the concentrations of T and TDP were found to be reduced however, they were not 
related to liver injury (Mancinelli and Ceccanti, 2009). Furthermore, results of Manari et al. 
(2003) reported that 73% of the alcohol abusers have low thiamine intake in comparison to 
reference nutrient intake. Taken together, thiamine deficiency can be due to alcohol or 
malnutrition acting by itself or in combination. 
Riboflavin: Riboflavin or vitamin B2 is an essential component of the cofactors flavin 
adenine dinucleotide and flavin mononucleotide. Riboflavin deficiency seems to be 
prevalent in alcoholics due to poor dietary intake (Manari et al.  2003). However, ethanol 
seems not to have an effect on riboflavin absorption (Pekkanen and Rusi, 1979). 
Pyridoxine: Pyridoxine or vitamin B6 is an essential cofactor in amino acid metabolism. 
Studies have shown that 50% of alcohol abusers have lower circulating levels of pyridoxal-
phosphate (PLP), an indicator of vitamin B6 status; this deficiency might be attributed to 
poor dietary intake and demolition of the vitamin by phosphotases (Lumeng and Li, 1974; 
Lumeng, 1978; Fonda et al.  1989). Acetaldehyde, a product of ethanol oxidation in chronic 
alcohol abusers displaces protein bound PLP and exposes PLP to destruction of 
phosphotases (Lumeng and Li, 1974; Lumeng, 1978). Alteration in the amino acid 
metabolism due to PLP deficiency might be an aspect in the development of alcoholic liver 
disease. Indeed, animal studies have reported that chronic PLP deficient diet leads to the 
development of mild fatty liver (French and Castagna, 1967). 
Folic acid: Folic acid or vitamin B9 plays an important role in facilitating many body 
processes.  Folic acid deficiency is common in chronic alcohol abuse. For instance, a British 
study on alcoholics has reported that most of the patients had megaloblastic anaemia in 
association with lower liver folate levels and lower red blood cells (Wu et al.  1975). The 
causes of the deficiency are still unclear; however, numeral mechanisms have been 
proposed together with lower intake of folate, reduced intestinal absorption of polyglutamyl 
folates, alteration in hepatic and renal folate homeostasis and augmented folate catabolism 
(Halsted et al.  1973; Tamura and Halsted, 1983; Halsted et al.  1971; McMartin et al.  1989; 
Shaw et al.  1989). 
Cobalamin: Vitamin B12 deficiency in chronic alcohol abusers is rare due to large hepatic 
deposits (Klipstein and Lindenbaum, 1965). Results of Kanazawa and Herbert (1985) 
reported higher levels of plasma vitamin B12 in chronic alcohol abusers than in controls. 
However, analysis of the hepatic tissue confirmed that vitamin B12 concentration was 
significantly lower in chronic alcoholics than in controls. Therefore, it might be concluded 
that chronic alcohol ingestion affects hepatic cobalamin homeostasis but probably also that 
of other organs (Cravo and Camilo, 2000). 
 
Alcohol Drinking Patterns and Nutrition in Alcoholic Liver Disease 
 
11 
6. Alcohol and minerals and trace elements 
Nutritional disturbances are assumed to remain among the most relevant medical problems 
in alcohol consumers (Aaseth et al.  1986; Addolorato, 1998; Suter et al.  1997) but it is still not 
clear whether chronic alcohol consumption per se results in malnutrition (Lieber, 2003; Leo et 
al.  1993; Leo and Lieber, 1999; Morgan and Levine, 1988). As reviewed by Lieber (2003), 
malnutrition and malsupplementation of certain micronutrients can be observed in alcohol 
abusers in the United States, whereas in another study dietary intake of German middle-
class alcohol abusers with liver damage did not differ from that of control subjects 
consuming only very low amounts of ethanol (Bergheim et al. 2003). However, 
malsupplementation or an excessive intake of special micronutrients may contribute to the 
development of hepatic damage in alcoholic liver disease in single cases. 
6.1 Iron 
In contrast to other micronutrients iron is known to promote liver damage. Oxidative stress 
plays a key role in the pathogenesis of alcoholic liver diseases. By catalyzing the conversion 
of superoxide and hydrogen peroxide to hydroxyl radicals, iron can contribute to induce 
oxidative stress and, thus, induce liver cirrhosis in experimental settings in rats treated with 
ethanol (Tsukamoto et al. 1995). In other studies with rodents, iron also increased the 
hepatotoxicity caused by alcohol (Stal and Hultcrantz, 1993). Alcoholic liver diseases are 
often associated with an iron overload (Kohgo et al. 2008). Even mild to moderate alcohol 
consumption has recently been shown to increase the prevalence of iron overload (Ioannou 
et al.  2004). Iron has been shown to accumulate in Kupffer cells as well as in hepatocytes 
(Farinati et al.  1995; Ioannou et al.  2004). However, the mechanisms involved in the 
accumulation of iron in the liver when alcohol is ingested chronically are still poorly 
understood. Two possible mechanisms that are discussed to lead to an accumulation of iron 
in alcohol-inuced liver diseases are 1. an increased uptake of iron into hepatocytes, 2. an 
increased intestinal absorption of iron (Kohgo et al.  2008). In a study in Japanese patients 
with alcoholic liver disease it has been shown that the expression of transferrin receptor 1 
was increased in hepatocytes (Suzuki et al.  2002) indicating that ethanol may increase iron 
uptake in hepatocytes. Another important factor that may be involved in iron overload 
found in patients with alcoholic liver disease is the systemic iron hormone hepcidin. 
Hepcidin plays an important role in duodenal iron absorption. In recent years it has been 
shown that hepcidin expression is downregulated in alcoholic liver disease (for overview 
see (Kohgo et al.  2008)). 
6.2 Zinc 
Zinc is an essential trace element and the daily recommended intake for adults ranges from 
7 mg to 11mg. Zinc plays an essential role not only in catalytic reactions but also in the 
maintenance of the structural integrity of proteins by forming a “zinc finger-like” structure 
created by chelation centers, including cysteine and histidine residues (Klug and Schwabe, 
1995) and in the regulation of gene expression. For example, metallothionein expression is 
regulated by a mechanism that involves the binding of zinc to the metal regulatory 
transcription factor 1, which in turn activates gene transcription (Cousins, 1994; Dalton et al.  
1997). Zinc is necessary for the function of nearly 100 specific enzymes (e.g. alcohol 
dehydrogenase, retinol dehydrogenase) and is essential for macronutrient metabolism (e.g.  
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1989). 
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Riboflavin: Riboflavin or vitamin B2 is an essential component of the cofactors flavin 
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prevalent in alcoholics due to poor dietary intake (Manari et al.  2003). However, ethanol 
seems not to have an effect on riboflavin absorption (Pekkanen and Rusi, 1979). 
Pyridoxine: Pyridoxine or vitamin B6 is an essential cofactor in amino acid metabolism. 
Studies have shown that 50% of alcohol abusers have lower circulating levels of pyridoxal-
phosphate (PLP), an indicator of vitamin B6 status; this deficiency might be attributed to 
poor dietary intake and demolition of the vitamin by phosphotases (Lumeng and Li, 1974; 
Lumeng, 1978; Fonda et al.  1989). Acetaldehyde, a product of ethanol oxidation in chronic 
alcohol abusers displaces protein bound PLP and exposes PLP to destruction of 
phosphotases (Lumeng and Li, 1974; Lumeng, 1978). Alteration in the amino acid 
metabolism due to PLP deficiency might be an aspect in the development of alcoholic liver 
disease. Indeed, animal studies have reported that chronic PLP deficient diet leads to the 
development of mild fatty liver (French and Castagna, 1967). 
Folic acid: Folic acid or vitamin B9 plays an important role in facilitating many body 
processes.  Folic acid deficiency is common in chronic alcohol abuse. For instance, a British 
study on alcoholics has reported that most of the patients had megaloblastic anaemia in 
association with lower liver folate levels and lower red blood cells (Wu et al.  1975). The 
causes of the deficiency are still unclear; however, numeral mechanisms have been 
proposed together with lower intake of folate, reduced intestinal absorption of polyglutamyl 
folates, alteration in hepatic and renal folate homeostasis and augmented folate catabolism 
(Halsted et al.  1973; Tamura and Halsted, 1983; Halsted et al.  1971; McMartin et al.  1989; 
Shaw et al.  1989). 
Cobalamin: Vitamin B12 deficiency in chronic alcohol abusers is rare due to large hepatic 
deposits (Klipstein and Lindenbaum, 1965). Results of Kanazawa and Herbert (1985) 
reported higher levels of plasma vitamin B12 in chronic alcohol abusers than in controls. 
However, analysis of the hepatic tissue confirmed that vitamin B12 concentration was 
significantly lower in chronic alcoholics than in controls. Therefore, it might be concluded 
that chronic alcohol ingestion affects hepatic cobalamin homeostasis but probably also that 
of other organs (Cravo and Camilo, 2000). 
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malsupplementation or an excessive intake of special micronutrients may contribute to the 
development of hepatic damage in alcoholic liver disease in single cases. 
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In contrast to other micronutrients iron is known to promote liver damage. Oxidative stress 
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uptake in hepatocytes. Another important factor that may be involved in iron overload 
found in patients with alcoholic liver disease is the systemic iron hormone hepcidin. 
Hepcidin plays an important role in duodenal iron absorption. In recent years it has been 
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carbohydrate and protein metabolism), wound healing, the immune system, glucose control, 
growth, digestion, and fertility (King and Cousins, 2005; Prasad, 1995; Lipscomb and Strater, 
1996). In alcoholic abusers, evidence of zinc deficiency has been reported repeatedly (Aaseth 
et al.  1986; Bjorneboe et al.  1988). Results of a study in German middle-class alcohol 
consumers indicated that zinc concentrations in plasma were significantly decreased in 
alcohol consumers with different stages of alcoholic liver diseases (fatty liver, hepatitis, 
cirrhosis), whereas urinary zinc loss was increased in this patients (Bergheim et al.  2003). 
This is in line with the findings of previous studies, which reported decreased intestinal 
absorption of zinc (Valberg et al.  1985; Dinsmore et al.  1985) and increased zinc excretion in 
urine (Sullivan, 1962) being the most important reasons for zinc deficiency caused by 
alcohol consumption. Indeed, zinc deficiency is one of the most commonly observed 
nutritional manifestations of alcoholic liver disease (McClain et al.  1991). It has been 
discussed by Kang and Zhou (2005) that a supplementation of zinc may have a high 
potential to be developed as an effective agent in the prevention and treatment of alcoholic 
liver disease. 
6.3 Copper 
Copper plays an essential role as component of a number of metalloenzymes acting as 
oxidases (e.g cytochrome c oxidase). The daily recommended intake for adults ranges from 
0.9 mg to 1.5 mg. In humans, an isolated copper deficiency rarely occurs and is normally 
due to an insufficient intake. However, the consumption of alcohol has been shown to be 
associated with a significant reduction of the levels of copper in serum (Schuhmacher et al.  
1994). Results of a study in patients with alcoholic cirrhosis indicate that liver copper 
contents and urinary copper excretion were higher in cirrhotic patients and were related 
with the severity of chronic alcoholic liver disease (Rodriguez-Moreno et al., 1997). Besides 
zinc, copper is an essential cofactor of the copper/zinc superoxide dismutase, which is an 
enzyme that catalyzes the dismutation of superoxide into oxygen and hydrogen peroxide. In 
the liver, one of the most important antioxidants is the copper/zinc superoxide dismutase 
(Suter, 2005). In biopsies from patients with alcoholic liver disease it has been shown that 
the amount of copper/zinc superoxide dismutase reactivity was significantly lower than in 
control biopsies (Zhao et al., 1996). 
6.4 Magnesium 
As a cofactor for more than 300 enzyme systems (Wacker and Parisi, 1968) magnesium plays 
an essential role in anaerobic and aerobic energy generation and in glycolysis, being part of 
the Magnesium-ATP complex or acting as an enzyme activator (Garfinkel and Garfinkel, 
1985). The daily recommended intake for adults is 300-400mg. Magnesium deficiency leads 
to many specific and unspecific symptoms such as anxiety, insomnia, nervousness, high 
blood pressure, and muscle spasms. Alcohol abusers are at high risk for magnesium 
deficiency because alcohol dose-dependently increases urinary excretion of magnesium 
(Laitinen et al.  1992). Even in cases of moderate alcohol consumption an increased excretion 
of magnesium in urine can be observed (Rylander et al.  2001). In dependence on the severity 
of alcohol abuse, 30 to 60% of alcoholics and nearly 90% of patients experiencing alcohol 
withdrawal have low magnesium levels in serum/plasma (Flink, 1986). The increased loss 
of magnesium may be potentiated by an insufficient intake or by an intestinal loss (e.g. 
through diarrhoea and vomiting).  
 




Selenium plays an important role as cofactor in several enzyme systems, such as the 
glutathione peroxidase, which acts as a cellular protector against free radical oxidative 
damage (Foster and Sumar, 1997). Low levels of selenium in plasma, serum or blood have 
not only been reported in patients with alcohol-induced cirrhosis but also in other liver 
diseases (for overview see McClain et al.  (1991)). Results of a study in German middle-class 
alcohol consumers indicated that selenium concentrations in plasma and in erythrocytes 
were significantly decreased in alcohol consumers with different stages of alcoholic liver 
diseases compared to healthy controls, although the dietary intake of selenium was not 
decreased in these patients with alcoholic liver disease (Bergheim et al.  2003). In contrast, in 
other studies depressed serum selenium concentrations correlated closely with poor 
nutritional status (Tanner et al.  1986) and with the severity of alcohol-induced liver damage 
(Dworkin et al.  1985). In patients with alcohol-induced cirrhosis an additional decreased 
content of selenium in the liver was observed (Dworkin et al.  1988). 
7. Clinical manifestation, diagnosis and therapy of malnutrition 
As discussed in the previous sections of this chapter, alcohol consumption and herein 
particularly chronic intake of alcohol but also alcohol metabolism is associated with 
numerous alterations such as changes in dietary pattern (e.g. elevated intake of pork), 
impaired intestinal absorption of micro- but also macronutrients but also metabolism in the 
liver. As a consequence malnutrition is frequently found in patients with alcoholic liver 
disease. Indeed, as reviewed by Stickel et al.  (2003), malnutrition can be both, a primary 
event resulting from a poor diet and decreased caloric intake but also a secondary process 
resulting from malabsorption and maldigestion. The question if the progression of alcoholic 
liver disease can be improved by nutritional support to these patients has been addressed in 
several clinical trails using oral, enteral, or parenteral routs to deliver nutritional formulas 
(for overview also see Halsted (2004; DiCecco and Francisco-Ziller (2006)). However, many 
of the studies were inconclusive as in some studies control groups were inadequate or 
control formulas were unbalanced, duration of studies was too short or nutritional needs 
were not adequately assessed (Halsted, 2004). In the following, methods for the assessment 
of nutritional status and recommendations for nutritional support of patients with alcoholic 
liver disease are briefly summarized (for overview also see Halsted (2004; DiCecco and 
Francisco-Ziller (2006; Plauth et al.  (2006)). 
7.1 Assessment of nutritional status 
Assessing the nutritional status of a patient with alcoholic liver disease may be challenging 
as many of the traditional tools may be affected by the disease (e.g. body weight changes 
may stem from fluctuation in oedema or ascites). Indeed, diminished serum levels of hepatic 
protein such as albumin and transferrin may rather be indication of an altered protein 
biosynthesis in the liver than a protein caloric malnutrition (Fuhrman et al. 2004). In patients 
without fluid overload, midarm muscle area and creatinine excretion in urine have been 
shown to be the most reliable measures of nutritional status, whereas in those patients with 
ascites and oedema creatinine height index is more reliable (Nielsen et al.  1993). 
Furthermore, serum status of vitamins such as A, D, E, and folate as well as minerals like 
zinc and iron as well as skin turgor, poor oral health and temporal muscle wasting or night 
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an essential role in anaerobic and aerobic energy generation and in glycolysis, being part of 
the Magnesium-ATP complex or acting as an enzyme activator (Garfinkel and Garfinkel, 
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to many specific and unspecific symptoms such as anxiety, insomnia, nervousness, high 
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deficiency because alcohol dose-dependently increases urinary excretion of magnesium 
(Laitinen et al.  1992). Even in cases of moderate alcohol consumption an increased excretion 
of magnesium in urine can be observed (Rylander et al.  2001). In dependence on the severity 
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(Dworkin et al.  1985). In patients with alcohol-induced cirrhosis an additional decreased 
content of selenium in the liver was observed (Dworkin et al.  1988). 
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impaired intestinal absorption of micro- but also macronutrients but also metabolism in the 
liver. As a consequence malnutrition is frequently found in patients with alcoholic liver 
disease. Indeed, as reviewed by Stickel et al.  (2003), malnutrition can be both, a primary 
event resulting from a poor diet and decreased caloric intake but also a secondary process 
resulting from malabsorption and maldigestion. The question if the progression of alcoholic 
liver disease can be improved by nutritional support to these patients has been addressed in 
several clinical trails using oral, enteral, or parenteral routs to deliver nutritional formulas 
(for overview also see Halsted (2004; DiCecco and Francisco-Ziller (2006)). However, many 
of the studies were inconclusive as in some studies control groups were inadequate or 
control formulas were unbalanced, duration of studies was too short or nutritional needs 
were not adequately assessed (Halsted, 2004). In the following, methods for the assessment 
of nutritional status and recommendations for nutritional support of patients with alcoholic 
liver disease are briefly summarized (for overview also see Halsted (2004; DiCecco and 
Francisco-Ziller (2006; Plauth et al.  (2006)). 
7.1 Assessment of nutritional status 
Assessing the nutritional status of a patient with alcoholic liver disease may be challenging 
as many of the traditional tools may be affected by the disease (e.g. body weight changes 
may stem from fluctuation in oedema or ascites). Indeed, diminished serum levels of hepatic 
protein such as albumin and transferrin may rather be indication of an altered protein 
biosynthesis in the liver than a protein caloric malnutrition (Fuhrman et al. 2004). In patients 
without fluid overload, midarm muscle area and creatinine excretion in urine have been 
shown to be the most reliable measures of nutritional status, whereas in those patients with 
ascites and oedema creatinine height index is more reliable (Nielsen et al.  1993). 
Furthermore, serum status of vitamins such as A, D, E, and folate as well as minerals like 
zinc and iron as well as skin turgor, poor oral health and temporal muscle wasting or night 
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blindness should also be assessed and may also help to identify losses of muscle mass and 
micronutrient deficiencies (Figueiredo et al. 2000). The subjective global assessment method, 
which combines subjective and objective measures has been found to accurately reflect the 
nutritional status of patients with end-stage liver disease (Hirsch et al. 1991, Hasse et al.  
1993). Taken together, a detailed diet history, anthropometric measurements (e.g. triceps 
skinfold, arm circumference, body mass index), and measurements of handgrip strength but 
also measurements of vitamin and mineral status in serum are recommended when 
nutritionally assessing patients with alcoholic liver disease (DiCecco and Francisco-Ziller, 
2006). 
7.2 Oral nutritional supplementation 
One of the first-line therapies to prevent and treat malnutrition in patients with alcoholic 
liver disease is through oral feeding including supplements. Herein, avoiding a fasting state, 
minimizing dietary restrictions, and offering small, frequent feedings is critical to meet the 
caloric and protein requirements (DiCecco and Francisco-Ziller, 2006). The benefit of oral 
nutritional supplementation has been assessed in many studies; however, due to poor study 
design or to small patients numbers included a final conclusion regarding the efficacy of this 
approach cannot yet be drawn. As reviewed by Stickel et al.  (2003) and Halsted (2004) and 
stated in the guidelines from the European Society for Clinical Nutrition and Metabolism 
(ESPEN) on enteral nutrition for patients with liver disease (Plauth et al.  2006) oral 
nutritional supplements may improve nutritional status and complications of alcoholic liver 
disease and are recommend, although the true effect on survival is still unknown.  
7.3 Enteral nutritional supplementation 
Enteral tube feeding is second option to treat malnutrition in patients with alcoholic liver 
disease and is especially considered a save and efficient way to improve the nutritional 
status in those patients unable or willing to consume adequate oral nutrition. Indeed, 
despite the sometimes poor patient acceptance of the tube feeding it has been shown in 
several studies, that tube feeding may improve digestion but also has a short-term positive 
effect on liver function and may improve long-term survival (for overview also see Halsted, 
(2004; Plauth et al.  (2006)). 
7.4 Parenteral nutritional supplementation 
The advantage of parenteral nutrition is the delivery of a precisely defined amount of 
protein, total calories, micronutrients, fluid, and electrolytes; however, clinical trails 
performed to evaluate the effect of parenteral nutrition in patients with alcoholic liver 
disease are difficult to interpret as study design was mostly inadequate (e.g. intake of 
controls was not adjusted, length of study, follow-up). The ESPEN guidelines advise that 
parental formula should provide adequate calories and protein with careful monitoring of 
glucose and electrolytes (Plauth et al.  2006).  
8. Conclusion 
Results of several studies suggest that quantity and frequency of alcohol consumption are 
important in the pathogenesis of alcoholic liver disease. Malnutrition is frequently present 
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in patients with alcoholic liver disease and may result from an altered dietary pattern, 
disturbed intestinal absorption and nutrient utilization in the liver due to the concomitant 
alcohol metabolism and/ or alcohol-induced impairments of liver function. Nutritional 
support including provision of adequate calories and protein but also micronutrients 
avoiding extended fasting periods and restricted diets may help to improve health status of 
patients with alcoholic liver disease; however, more clinical trails are needed to clarify the 
long-term effects of nutritional treatment on liver status and survival in patients with 
alcoholic liver disease. 
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1. Introduction 
Alcoholic liver disease occurs after prolonged heavy drinking, particularly among persons 
who are physically dependent on alcohol. Alcoholic liver disease is pathologically classified 
into three forms: fatty liver (hepatic steatosis), alcoholic hepatitis, and cirrhosis. There is 
considerable overlap among these conditions. The incidence of alcoholic liver disease 
increases in a dose-dependent manner proportionally to the cumulative alcoholic intake. 
Alcoholism is increasing among females, owing to a decline in the social stigma attached to 
drinking and to the ready availability of alcohol in supermarkets. In general, however, 
males have a greater opportunity for drinking. In the United States, the National 
Comorbidity Survey estimated that, at some time in their lives, 6.4% of females and 12.5% of 
males will meet the criteria for alcoholic abuse (Kessler et al., 1994). The Italian longitudinal 
study on aging showed that 42% of elderly females and 12% of elderly males were lifelong 
abstainers (Buja et al., 2010). In Japan, based on data from the National Nutrition Survey, 
heavy drinkers with a daily consumption exceeded 40 g of ethanol per day for females and 
60 g of ethanol per day for males were more frequently observed in males (Figure 1). 
Despite the male predominance for alcoholism, chronic alcohol consumption induces more 
rapid and more severe liver injury in females than males.  
In contrast, the progression of hepatic fibrosis in chronic hepatitis B and C appears to be 
slower in females than in males (Poynard et al., 1997; Poynard et al., 2003; Rodriguez-Torres 
et al., 2006; Wright et al., 2003). Hepatic fibrosis is fibrous scarring of the liver in which 
excessive collagens build up along with the duration and extent of persistence of liver 
injury. In other words, overproduced collagens are deposited in injured areas instead of 
destroyed hepatocytes. Moreover, females, especially before menopause, produce antibodies 
against hepatitis B virus (HBV) surface antigen (HBsAg) and HBV e antigen (HBeAg) at 
higher frequency than males (Furusyo et al., 1999; Zacharakis et al., 2005). In chronic 
infection with hepatitis C virus (HCV), the clearance rate of blood HCV RNA appears to be 
higher in females (Bakr et al., 2006). Most asymptomatic carriers of HCV with persistent 
normal alanine aminotransferase (ALT) are females and have a good prognosis with a low 
risk of progression of hepatic fibrosis to the end-stage cirrhosis and its complications such as 
hepatocellular carcinoma (HCC) (Gholson et al., 1997; Puoti et al., 2002). The menopause is 
associated with accelerated progression of hepatic fibrosis, and the HCC risk is inversely 
related to the age at natural menopause (Shimizu, 2003; Shimizu et al., 2007a).  
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Fig. 1. Incidence of heavy drinkers with a daily consumption exceeded 40 g of ethanol per 
day for females and 60 g of ethanol per day for males based on data in 2002 from the 
National Nutrition Survey in Japan.  
The “female paradox” observed in patients with alcoholic liver disease in comparison with 
chronic viral hepatitis is based on susceptibility by females to liver damage from smaller 
quantities of ethanol.  
2. Alcoholic liver disease in females 
The amount of alcohol required producing hepatitis or cirrhosis varies among individuals, 
but as little as 40 g/day (Table 1) for 10 years is associated with an increased incidence of 
cirrhosis. There is considerable evidence to suggest that females require less total alcohol 
consumption (20 g ethanol/day) to produce clinically significant liver disease. Indeed, it is 
reported that the lowest point of weekly alcohol intake that helps to develop liver disease 
was higher in males (168-324 g) than in females (84-156 g), and that, in the case of heavy 
drinkers with a weekly consumption of 336-492 g, the relative risk for alcoholic liver disease 
was 3.7 in males and 7.3 in females, while it was 1.0 in the group with a weekly 
consumption of 12-72 g (Becker et al., 1996). Thus, safe drinking guidelines recommend that 
females do not drink more than 20 g ethanol per day, and males not more than 40 g ethanol. 
A common, reasonable recommendation is not to exceed 70 g of ethanol a week. 
Whisky 60 ml 20 g 
Wine 200 ml 20 g 
Beer 500 ml 20 g 
Table 1. Alcohol (ethanol) equivalents. 
The incidence of alcoholic liver disease correlates with the national per capita consumption of 
ethanol derived from sales of beer, wine and spirits (Figure 2). For instance, in France, the 
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United Kingdom and Germany, the annual per capita (average consumed by each person) 
ethanol consumption is over 9 litres per person per year, but in Asia such as China and Japan, 
it is 4 to 6.5 litres per person per year. Ethanol is metabolized by hepatic alcohol 
dehydrogenase (ADH) and the hepatic microsomal ethanol oxidizing system (MEOS) to 
acetaldehyde, which is subsequently converted by aldehyde dehydrogenase (ALDH) to 
acetate. The accumulation of acetaldehyde leads to the clinical syndrome of flushing, nausea 
and vomiting. Isoenzymes of ALDH with low activities are common among Asian populations 
and are associated with lower rates of alcoholism. These persons experience a similar flushing 
syndrome after consuming ethanol. This inhibits Asian populations from taking alcohol and is 
a negative risk for the development of alcoholic liver disease (Tanaka et al., 1996). 
 
Fig. 2. The annual per capita (average consumed by each person) consumption of ethanol 
derived from sales of beer, wine and spirits (whisky, brandy, vodka, rum, gin and all other 
spirits) in the world (National Tax Agency, 2008).  
In a study on the sex difference in Japanese patients hospitalized in Tokushima, western Japan, 
the incidence of alcoholic cirrhosis was 9-fold higher in males than females (Figure 3). 
However, females develop higher blood ethanol levels following a standard dose, at least in 
part, because of a smaller mean apparent volume of ethanol distribution. Moreover, sex 
differences in hepatic metabolism with increased production of acetaldehyde may contribute  
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Fig. 3. Male-to-female ratio in Japanese patients with alcoholic cirrhosis. Male-to-female 
ratio in alcoholic cirrhosis was examined from 1995 to 2000 and from 2001 to 2006 in 1,005 
Japanese patients (mean age 59.5 years, 10.4% females) hospitalized in Tokushima, western 
Japan. The subjects were seronegative for HBsAg and antibody against HCV. 
to vulnerability of females to alcohol consumption (Eriksson et al., 1996) (see below), 
suggesting that chronic alcohol consumption may induce more rapid and more severe liver 
injury in females than males. Females with alcoholic cirrhosis survive a shorter time than 
males (Sherlock & Dooley, 2002). 
3. Alcoholic liver injury and oxidative stress 
3.1 Ethanol hepatotoxicity 
Alcoholic liver injury is mainly due to ethanol hepatotoxicity linked to its metabolism by 
means of the ADH and cytochrome P450 2E1 (CYP2E1) pathways and the resulting 
production of toxic acetaldehyde (Figure 4). CYP2E1 is the key enzyme of the MEOS, and it 
is involved in the oxygenation of substrates such as ethanol and fatty acids. Although most 
ethanol is oxidized by ADH, CYP2E1 assumes a more important role in ethanol oxidation at 
elevated levels of ethanol or after chronic consumption of ethanol. CYP2E1 has a very high 
NADPH oxidase activity. NADPH/NADH oxidase is a primary source of reactive oxygen 
species (ROS) production in non-phagocytic cells such as hepatic stellate cells (HSCs) in the 
space of Disse (Figure 5). Therefore, excess of ethanol and fatty acids and their metabolism 
by means of CYP2E1 pathway produce extensively ROS, which cause oxidative stress with 
lipid peroxidation and membrane damage, leading to cell death. ROS and products of lipid 
peroxidation activate not only inflammatory cells including neutrophils, macrophages and 
Kupffer cells (hepatic resident macrophages), but HSCs as well. In the injured liver, HSCs 
are regarded as the primary target cells for inflammatory and oxidative stimuli, and 
undergo proliferation and transformation into myofibroblast-like cells. These HSCs are 
activated cells and are responsible for much of the collagen synthesis observed during 
hepatic fibrosis to cirrhosis. 
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Fig. 4. Ethanol oxidation by alcohol dehydrogenase (ADH) and the hepatic microsomal 
ethanol oxidizing system (MEOS), which involves cytochrome P450 2E1 (CYP2E1), produces 
acetaldehyde (Shimizu, 2009). CYP2E1 produces ROS (superoxide, O2-). Acetaldehyde is 
converted by aldehyde dehydrogenase (ALDH) to acetate. Both reactions of ethanol to 
acetaldehyde and then acetate reduce nicotinamide adenine dinucleotide (NAD) to its 
reduced form (NADH). Excess NADH causes inhibition of fatty acid oxidation, leading to 
fat accumulation (hepatic steatosis). 
 
Fig. 5. Schema of the sinusoidal wall of the liver. Schematic representation of hepatic stellate 
cells (HSCs) was based on the studies by Wake (Wake, 1999). Kupffer cells (hepatic resident 
macrophages) rest on fenestrated endothelial cells. HSCs are located in the space of Disse in 
close contact with endothelial cells and hepatocytes, functioning as the primary retinoid 
storage area. Collagen fibrils course through the space of Disse between endothelial cells 
and the cords of hepatocytes. 
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Fig. 5. Schema of the sinusoidal wall of the liver. Schematic representation of hepatic stellate 
cells (HSCs) was based on the studies by Wake (Wake, 1999). Kupffer cells (hepatic resident 
macrophages) rest on fenestrated endothelial cells. HSCs are located in the space of Disse in 
close contact with endothelial cells and hepatocytes, functioning as the primary retinoid 
storage area. Collagen fibrils course through the space of Disse between endothelial cells 
and the cords of hepatocytes. 
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3.2 Excess fatty acids lead to hepatic steatosis 
Increased lipid peroxidation and accumulation of end products of lipid peroxidation are 
commonly observed in alcoholic liver disease and non-alcoholic fatty liver disease (NAFLD) 
based on studies of human alcohol-related liver injury and animal models of diet-induced 
hepatic steatosis and drug-induced steatohepatitis (Berson et al., 1998; Letteron et al., 1993; 
Letteron et al., 1996). Fatty liver is the result of the deposition of triglycerides via the 
accumulation of fatty acids in hepatocytes. In the progression of fatty liver disease, lipid 
peroxidation products are generated because of impaired β-oxidation of the accumulated 
fatty acids. The major site for fatty acid β-oxidation (degradation of fatty acids) in the liver is 
hepatocyte mitochondria (Figure 6). Key mediators of impaired fatty acid β-oxidation 
include a reduced mitochondrial electron transport (respiratory chain dysfunction). In 
addition to impaired mitochondrial β-oxidation of fatty acids, an activity of CYP2E1 in the  
 
Fig. 6. Increased hepatic uptake of free fatty acids, increased triglyceride synthesis, and 
impaired transport of very low-density lipoprotein (triglyceride-rich lipoprotein) into the 
blood mainly contribute to the accumulation of hepatocellular triglycerides. Microsomal 
trigyceride transfer protein (MTP) is essential for the secretion of very low-density 
lipoprotein. Excess triglycerides are stored as lipid droplets in hepatocytes, which in turn 
results in a preferential shift to fatty acid degradation (β-oxidation), leading to the formation 
of ROS and lipid peroxidation products. 
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microsomes is increased. Elevated CYP2E1 and mitochondrial defects result in an increase 
in the ROS formation and lipid peroxidation products. ROS and lipid peroxidation in turn 
cause further mitochondrial dysfunction and oxidative stress, thus contributing to cell death 
via ROS-induced DNA injury and membrane lipid peroxidation and discharge of products 
of lipid peroxidation, malondialdehyde (MDA) and 4-hydroxynonecal (HNE), into the space 
of Disse. MDA and HNE besides ROS are able to activate inflammatory cells (neutrophils, 
macrophages and Kupffer cells) and HSCs. Activated inflammatory cells in turn produce 
chemokines as well as tumor necrosis factor-α (TNF-α) and ROS. Chemokines such as 
monocytes chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) attract neutrophils, 
lymphocytes, monocytes, macrophages, and Kupffer cells to inflammatory sites, leading to 
the persistent liver injury. 
3.3 CYP2E1 
Oxidation of ethanol through the ADH and CYP2E1 pathways produces acetaldehyde 
which is also toxic to the hepatocyte mitochondria. Acetaldehyde aggravates oxidative 
stress by binding to reduced glutathione, an antioxidant, and promoting its leakage, which 
triggers an inflammatory response of the host. This involves the activation of Kupffer cells 
and the attraction of inflammatory cells to injured sites. The inflammatory cells in the liver 
produce transforming growth factor–β (TGF-β) and proinflammatory mediators including 
TNF-α and ROS, leading to oxidative tress and hepatic fibrosis. Thus, TNF-α mediates not 
only the early stages of alcoholic liver disease but also the transition to more advanced 
stages of liver damage. 
Reactions of ethanol converted to acetaldehyde and subsequently acetate reduce 
nicotinamide adenine dinucleotide (NAD) to its reduced form (NADH). Excess NADH 
causes a number of metabolic disorders, including stimulation of the fatty acid synthesis 
and inhibition of the Krebs cycle and of its fatty acid oxidation (Lieber, 2004). The 
stimulation of the fatty acid synthesis and inhibition of fatty acid oxidation favor fat 
accumulation (hepatic steatosis) and hyperlipidemia.  
CYP2E1 activity is elevated in the livers of obese animals (Raucy et al., 1991) and non-
alcoholic steatohepatitis (NASH) patients (Weltman et al., 1998) as well as patients with 
alcoholic liver disease. The role of CYP2E1 in fatty acid metabolism supports the concept of 
a nutritional role for CYP2E1. Indeed, besides its ethanol-oxidizing activity, CYP2E1 
catalyzes fatty acid ω-hydroxylations (microsomal ω-oxidation of fatty acids) and 
metabolizes ketones. Fatty acids and ketones increase especially in obesity and diabetes, and 
their excess up-regulates CYP2E1. CYP2E1 leaks ROS as part of its operation, and when 
increased ROS production exceed the cellular antioxidant defense systems, excess ROS 
result in oxidative stress with its pathologic consequences. This is true when excess alcohol 
has to be metabolized, as in alcoholic steatohepatitis, or when CYP2E1 is confronted by an 
excess of fatty acids and ketones associated with obesity, diabetes, or both, resulting in 
NASH (Lieber, 2004).  
4. Endotoxin in alcoholic liver injury 
Alcohol ingestion disrupts gastrointestinal barrier function and subsequently induces the 
diffusion of luminal bacterial products including bacterial lipopolysaccharides (endotoxins) 
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into the portal vein. Experiments using animals show direct evidence of increased 
translocation of endotoxin from the gut lumen into the portal bloodstream caused by 
ethanol (Mathurin et al., 2000). Acute ethanol ingestion, especially at high concentrations, 
facilitates the absorption of endotoxin from rat small intestine via an increase in intestinal 
permeability, which may play an important role in endotoxemia observed in alcoholic liver 
injury (Tamai et al., 2000). Increased endotoxin levels in the portal blood are essential for 
initiation and progression of alcoholic liver disease (Bode & Bode, 2005). 
Bacterial translocation from the gastrointestinal tract, namely spillover endotoxemia, is 
important in the relationship between endotoxin and hepatotoxicity in the 
reticuloendothelial system such as monocytes-macrophages and Kupffer cells. Gut-derived 
endotoxin activates Kupffer cells, which produce proinflammatory mediators such as TNF-α 
and ROS. The ability of Kupffer cells to eliminate and detoxify various exogenous and 
endogenous substances including endotoxin is an important physiological regulatory 
function (Figure 7). 
 
Fig. 7. Activation of Kupffer cells by gut-derived endotoxin plays a pivotal role in alcoholic 
liver injury (Shimizu, 2009). Following chronic alcohol ingestion, endotoxin, also called 
lipopolysaccharide, released from intestinal gram-negative bacteria moves from 
gastrointestinal tract (gut) into the liver via the portal bloodstream. 
Like chronic ethanol feeding, TNF-α cytotoxicity is also with alteration of mitochondrial 
function. The mitochondria of TNF-α-exposed cells overproduce ROS derived from the 
respiratory chain. The mitochondria themselves then become the targets of ROS, thus setting 
up a cycle of injury (Nagata et al., 2007). In addition to ROS production, TNF-α prompts the 
opening of the mitochondrial permeability transition (MPT). The MPT is the regulatable 
opening of a large and non-specific pore across the outer and inner mitochondrial 
membrane. Ethanol may also increase the susceptibility of MPT induction by TNF-α at the 
 
Gender Difference in Alcoholic Liver Disease 31 
mitochondrial level, possibly through an increase in ROS production caused by respiratory 
chain dysfunction and/or CYP2E1 (Pastorino & Hoek, 2000). 
Ethanol-induced oxidative stress is the result of the combined impairment of antioxidant 
defense and the ROS production by the mitochondrial electron transport chain, the ethanol-
induced CYP2E1 and activated phagocyte such as macrophages and Kupffer cells (Albano, 
2006). Indirectly, chronic ethanol ingestion may augment oxidative stress by decreasing 
antioxidant defenses such as reducing glutathione peroxidase and glutathione homeostasis 
(Figure 8). 
 
Fig. 8. Oxidative stress and hepatocyte damage (Shimizu and Ito, 2007). A primary source of 
reactive oxygen species (ROS) production is mitochondrial NADPH/NADH oxidase. 
Hydrogen peroxide (H2O2) is converted to a highly reactive ROS, the hydroxyl radical, in 
the presence of transition metals such as iron (+Fe) and copper. The hydroxyl radical 
induces DNA cleavage and lipid peroxidation in the structure of membrane phospholipids, 
leading to cell death and discharge of products of lipid peroxidation, malondialdehyde 
(MDA) and 4-hydroxynonenal (HNE) into the space of Disse. Cells have comprehensive 
antioxidant protective systems, including SOD, glutathione peroxidase and glutathione 
(GSH). Upon oxidation, GSH forms glutathione disulfide (GSSG). 
5. Sex difference of ADH and CYP2E1 via growth hormone and estrogens 
5.1 Gastric ADH in females 
After an equivalent dose of alcohol, females have higher blood ethanol levels than males 
(Nolen-Hoeksema, 2004). There are multiple explanations for this. First, females are 
generally smaller than males so the same dose of alcohol leads to higher blood alcohol levels 
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(Nolen-Hoeksema, 2004). There are multiple explanations for this. First, females are 
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for females than males. Second, female body water content is smaller than male per 
kilogram of body weight. Thus, a dose of ethanol is distributed in a smaller volume of water 
in females than in males, leading to somewhat higher concentrations of ethanol in female 
blood (Frezza et al., 1990).  
Third, the first pass metabolism of alcohol in the stomach may lead to higher blood alcohol 
levels in females than males. In the stomach, alcohol is metabolized with the enzyme gastric 
ADH. The stomach thus acts as a barrier against the penetration of alcohol into the body, by 
retaining and breaking down part of the alcohol (Nolen-Hoeksema, 2004). Gastric ADH 
activity is lower in females than in males; one study found that for a given alcohol dose, 
male ADH levels were two times higher than female levels, and in turn, female blood 
alcohol levels were higher than those of males (Frezza et al., 1990).  
This sex difference in metabolism of alcohol appears to hold for younger adults but not 
older adults. ADH activity decreases with age, particularly for males, leading to similar 
blood alcohol concentrations in older males and females, or even higher concentrations in 
older males than older females (Nolen-Hoeksema, 2004). 
5.2 Growth hormone secretion in females 
The profile of growth hormone secretion pattern shows clear sex dimorphism (Ameen & 
Oscarsson, 2003). In female rats, the growth hormone is continuously secreted, and the 
hormone levels are always detectable in the circulation, while, in male rats, it is secreted by 
episodic bursts every 3.5 to 4 hours with low or undetectable levels between peaks (Shapiro 
et al., 1995). Integrated 24-hour growth hormone secretion (Clasey et al., 2001) and fasting 
blood growth hormone levels (Figure 9) are higher in women than in men. Growth hormone 
secretion is stimulated by estrogens (Ameen & Oscarsson, 2003). Oral and high-dose 
transdermal estrogen administration in menopausal women increases integrated 24-hour 
growth hormone secretion (Friend et al., 1996). 
 
Fig. 9. Fasting mean blood levels of growth hormone in 15 premenopausal women (mean 
age 41.3 years) and 15 age-matched men (mean age 41.1 years) of healthy non-obese (body 
mass index ≥ 18.5 to 24.9 kg/m2) individuals. The subjects had no history of alcohol abuse 
(defined as an alcohol intake >20 g/day). 
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Interestingly, growth hormone increases ADH activity in the liver. The steady exposure of 
hepatocytes in cultures to growth hormone resulting in increased ADH activity resembles 
the female pattern of growth hormone secretion (Potter et al., 1993). ADH activity is higher 
in female rats and mice than in their male counterparts (Mezey, 2000). Thus, increased rates 
of the resulting production of toxic acetaldehyde in females compared with males may be 
responsible for the known increased susceptibility to alcohol-induced liver injury by 
females. Females are more likely to progress from alcoholic hepatitis to cirrhosis even if they 
abstain. 
5.3 Endotoxin after ethanol in females 
Endotoxin-stimulated monocytes in males produce more TNF-α as compared to females 
(Bouman et al., 2004). Like Kupffer cells, monocytes stimulated by endotoxin induce 
proinflammatory cytokines and ROS. In studies using animals, however, the stimulation of 
Kupffer cells by estrogen increased sensitivity to endotoxin after ethanol (Ikejima et al., 
1998). It appears that monocytes-macrophages respond differently to endotoxins compared 
to Kupffer cells as far as the signaling pathways are concerned (Schultze et al., 1999). The 
estrogen addition to ethanol ingestion enhanced TNF-α production in Kupffer cells via 
elevation of the blood endotoxin level and hepatic endotoxin receptor (CD14) expression, 
resulting in increased inflammatory activity in the liver (Yin et al., 2000). The administration 
of ethanol in female rats induced the hepatic activity of CYP2E1, and the ethanol-induced 
CYP2E1 activity was reduced by the treatment with antiestrogen (Jarvelainen et al., 2001). 
Because activity of cytochrome P-450 (CYP) isoenzymes is regulated by circulating growth 
hormone, sex differences in growth hormone secretion profiles account for a different 
expression pattern of hepatic CYP isoenzymes between females and males (Agrawal & 
Shapiro, 2001).  
6. Favorable role of female factors in chronic viral hepatitis 
Clinical observations and death statistics support the view that chronic hepatitis C and B 
appears to progress more rapidly in males than in females (Poynard et al., 1997; Poynard et 
al., 2003; Rodriguez-Torres et al., 2006; Wright et al., 2003), and that cirrhosis is largely a 
disease of men and postmenopausal women with the exception of classically autoimmune 
liver diseases, such as primary biliary cirrhosis and chronic autoimmune hepatitis (Shimizu, 
2003). HCV infections are more common than HBV infections in Japan and Western 
countries, and are recognized as a major causative factor of chronic hepatitis, cirrhosis, and 
HCC. According to a report of the International Agency for Research on Cancer 
(Brannstrom et al., 1999), the male:female ratio of the age-standardized incidence per 
100,000 of liver cancer worldwide is 2.9：1, and in Asia (particularly in China, Japan, and 
Taiwan), the incidence of liver cancer is high and it accounts for half of all liver cancer cases 
in the world.  
The prevalence of HBsAg is reported to be higher in males than in females throughout the 
world (Blumberg et al., 1972). In a prospective follow-up study of up to 19 years on HBsAg 
carriers in Okinawa in Japan, clearance of HBsAg was found more frequently in females 
(7.8%) than in males (5.8%) (Furusyo et al., 1999). Seroconversion from HBeAg to its 
antibody (anti-HBe) occurs more frequently in females than in males (Zacharakis et al., 
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2005). In chronic HCV infection, the clearance rate of blood HCV RNA appears to be higher 
in females (Bakr et al., 2006). Demographic data from the United States (Gholson et al., 
1997), Europe (France and Italy) (Puoti et al., 2002; Renou et al., 2002), and Japan (Okanoue 
et al., 2005) show that most HCV carriers with persistently normal ALT (asymptomatic 
carriers) are females, and have a good prognosis with a low risk of progression to cirrhosis 
and HCC. The menopause is associated with accelerated progression of hepatic fibrosis, and 
the HCC risk is inversely related to the age at natural menopause (Shimizu, 2003; Shimizu et 
al., 2007a). Chronic HCV- and HBV-infected patients of female sex and under 50 years old, 
namely premenopausal women are least vulnerable to HCC (Shimizu, 2009). 
Premenopausal women have lower hepatic iron stores and a decreased production of 
proinflammatory cytokines such as TNF-α (Clerici et al., 1991; Pfeilschifter et al., 2002; 
Shimizu et al., 2007b). Iron is essential for life, but is toxic in excess, because it produces ROS 
that react readily with lipids and DNA, leading to cell death and DNA mutagenesis. An 
experimental animal study showed that hepatic steatosis spontaneously becomes evident in 
an aromatase-deficient mouse, which lacks the intrinsic ability to produce estrogen and is 
impaired with respect to hepatocellular fatty acid β-oxidation. Estrogen replacement 
reduces hepatic steatosis and restores the impairment in mitochondrial and peroxisomal 
fatty acid β-oxidation to a wild-type level (Nemoto et al., 2000). In addition, tamoxifen is a 
well known antiestrogen used in the hormone treatment of estrogen receptor-positive breast 
cancer, and it has been shown to be associated with an increased risk of developing fatty 
liver and NASH in such patients (Oien et al., 1999; Van et al., 1996). Estrogens are potent 
endogenous antioxidant (Lacort et al., 1995; Yoshino et al., 1987), suppresses hepatic fibrosis 
in animal models, and attenuates induction of redox sensitive transcription factors, 
hepatocyte apoptosis and HSC activation by inhibiting the generation of ROS and TGF-β in 
primary cultures (Itagaki et al., 2005; Lu et al., 2004; Shimizu et al., 1999; Yasuda et al., 1999; 
Zhou et al., 2001). Variant estrogen receptors are expressed in HCC patients and, to a greater 
extent, in male patients with chronic liver disease than in female patients, even at an early 
stage of chronic liver disease (Villa et al., 1995; Villa et al., 1998). The occurrence of variant 
estrogen receptors leads to the loss of estrogen responsiveness. These lines of evidence 
suggest that the greater progression of hepatic fibrosis and HCC in men and 
postmenopausal women may be due, at least in part, to both a lower production of estrogen 
and a lower response to the action of estrogen.  
7. Heavy alcohol intake and HCC 
Chronic alcohol intake (mostly heavy alcohol use of more than 50 g/day) and alcoholic 
cirrhosis have long been recognized as a cause of HCC. In alcoholic cirrhosis, the risk of 
HCC is about 1% per a year. Most HCC cases are in males. There are no clinical or 
pathological differences compared with HCC complicating chronic HBV and HCV infection. 
However, it is not certain whether alcohol is a true carcinogen. Several epidemiologic 
studies among alcoholics show a high prevalence of HBV markers (16%-70%) and HCV 
markers (10%-20%) as compared with a background prevalence of close to 5% and less than 
1%, respectively (Bosch et al., 2004). These prevalences are even higher in HCC cases who 
are also alcoholics (27% to 81% of HBV markers and 50% to 77% of HCV markers), 
suggesting a complex interaction between alcohol and viral infections in the etiology of 
HCC (Di Bisceglie et al., 1998).  
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Case-control studies have shown that, as a result of the synergy between alcohol intake and 
HCV infection, the risk of liver cancer is increased approximately 2- to 4-fold among cases 
drinking more 60-80 g/day of alcohol (Fattovich et al., 2004). The presumed basis for this is 
that both alcohol and HCV infection independently promote the development of cirrhosis. 
In a longitudinal cohort study of cirrhotic patients with HCV infection, heavy alcohol intake 
(>65 g/day) was an independent factor for the development of HCC, increasing the risk 
approximately 3-fold (Aizawa et al., 2000).  
A case-control study also shows a synergism between alcohol drinking and HBV infection on 
the risk of HCC, increasing the risk approximately 2-fold for HBsAg-positive subject of both 
sexes who drink more than 60 g/day of ethanol compared with HBsAg-positive non-drinkers 
(Donato et al., 2006). In a longitudinal cohort study of patients with HBV-related cirrhosis, 
heavy alcohol intake was associated with a 3-fold increased risk for HCC (Ikeda et al., 1998).  
Studies in northern Italy and Greece estimated that the attributable fraction of high levels of 
alcohol consumption, once adjusted for HBV and HCV status, were 45% in Italy (Donato et 
al., 1997) and 15% in Greece (Kuper et al., 2000). In low-risk populations, heavy alcohol 
intake may account for the majority of the HCC cases who are seronegative for HBV and 
HCV markers. 
8. Conclusion 
A large body of evidence has been accumulated suggesting that increased oxidative stress is 
an essential step in the development of hepatic fibrogenesis and carcinogenesis. 
Environmental and lifestyle risk factors such as HCV and HBV infection and heavy alcohol 
intake lead to increased oxidative stress, which in general occurs more frequently in males. 
Moreover, biological female sex factors such as estrogens, hepatic iron storage status, and 
growth hormone play antioxidative and cytoprotective roles in the functional and 
morphological modulation of the liver physiopathology. However, it should be noted that 
females consistently drink less than males and appear to suffer serious negative 
consequences of alcohol consumption earlier and to a greater degree than males. 
Specifically, chronic alcohol consumption induces more rapid and more severe liver injury 
in females than males. The “female paradox” observed in patients with alcoholic liver 
disease in comparison with chronic viral hepatitis is based on susceptibility by females to 
liver damage from smaller quantities of ethanol. Being female or male is an important basic 
human variable that affects health and liver disease throughout the life span. Sex is defined 
as female or male according to their biological functions, while gender is shaped by 
environment and experience. Better knowledge of the basic mechanisms underlying the sex-
associated differences during hepatic fibrogenesis and carciogenesis may open up new 
avenues for the prevention and treatment of chronic liver disease. 
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1. Introduction  
Excessive ingestion of alcohol is one of the major causes of chronic liver disease worldwide. 
Alcoholic liver disease (ALD) encompasses a broad spectrum of diseases ranging from 
steatosis (fatty liver), steatohepatitis, fibrosis, cirrhosis to hepatocarcinoma. Almost all heavy 
drinkers develop fatty liver; however, only up to 30% of heavy drinkers may develop more 
several forms of chronic liver injury such as alcoholic hepatitis, fibrosis, cirrhosis, and 
hepatocellular carcinoma (O'Shea et al., 2010). Despite extensive research, cellular and 
molecular mechanisms contributing to the pathogenesis of ALD remain to be fully 
elucidated. Classically, direct hepatotoxicity and production of reactive oxygen species 
(ROS) induced by alcohol and its metabolites (e.g. acetaldehyde, acetate) are considered the 
major causative factors. Nevertheless, growing evidence suggests innate immunity also 
plays an important role in the pathogenesis of ALD (Byun & Jeong, 2010; Gao et al., 2011; 
Miller et al., 2011).  
In this chapter we discuss the association between innate immunity and ALD. Specifically, 
we discuss the following topics: i) role of liver in innate immunity; ii) mechanisms of 
alcohol-induced dysregulation of innate immunity; iii) role of dysregulation of innate 
immunity in the pathogenesis of ALD; iv) modulation of innate immunity in the treatment 
of ALD. Additionally, we also discuss the role of innate immunity impairment in ALD-
associated infection risk.  In this topic, we detail the data of our recent study on Toll-like 
receptor (TLR)2- and 4-mediated immune response in patients with alcoholic cirrhosis. 
2. Role of liver in innate immunity 
Innate immunity is an important first line of defense against infection, quickly responding to 
potential attacks by pathogens. It consists of anatomic barriers (e.g., skin, epidermis, dermis, 
and mucous membranes), physiologic barriers (e.g., temperature, low pH, oxygen), humoral 
factors (e.g., pepsin, lysozyme, anti-microbial substances, interferons, complement), 
phagocytic cells (e.g., neutrophils and macrophages), and lymphocyte cells (e.g., natural 
killer [NK] and NKT cells). Many of these barriers and factors can prevent or destroy the 
invading pathogens nonspecifically. However, recent evidence suggests that innate 
immunity can also specifically detect infection through pattern-recognition receptors (PRRs) 
that recognize specific structures, called pathogen-associated molecular patterns (PAMPs), 
that are expressed by invading pathogens. Many PAMPs have been identified, including 
bacterial carbohydrates (e.g., lipopolysaccharide or LPS, mannose), bacterial peptides  
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that are expressed by invading pathogens. Many PAMPs have been identified, including 
bacterial carbohydrates (e.g., lipopolysaccharide or LPS, mannose), bacterial peptides  
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(flagellin), peptidoglycans and lipoteichoic acids (from Gram-positive bacteria), N-
formylmethionine, lipoproteins and fungal glucans, and nucleic acids (e.g., bacterial or viral 
DNA or RNA). The PRRs can be divided into 3 categories: secreted PRRs, membrane-bound 
PRRs, and phagocytic PRRs. Secreted PRRs are a group of proteins that kill pathogens through 
complement activation and opsonization of microbial cells for phagocytosis. Secreted PRRs 
include complements, pentraxins, and peptidoglycan-recognition proteins, which are mainly 
produced by hepatocytes and secreted into the blood stream. Membrane-bound or 
intracellular PRRs include TLRs, nucleotide-binding oligomerization domain (NOD)-like 
receptors, and retinoic acid-induced gene I-like helicases. Phagocytic (or endocytic) PRRs 
which are expressed on the surface of macrophages, neutrophils, and dendritic cells can bind 
directly to pathogens, and this is followed by phagocytosis into lysosomal compartments and 
elimination. These phagocytic PRRs include scavenger receptors, macrophage mannose 
receptors, and β-glucan receptors (Janeway & Medzhitov, 2002).  
Blood circulating from the intestines to the liver is rich in bacterial products, environmental 
toxins, and food antigens. To effectively and quickly defend against potentially toxic agents 
without launching harmful immune responses, the liver relies on its strong immune system. 
Interestingly, increasing evidence has suggested that the immune system in the liver 
consists of predominantly innate immunity (Gao et al., 2008). First, the liver is responsible 
for the biosynthesis of 80–90% innate proteins including complements, secreted PRRs and 
acute phase proteins. Second, the liver contains a large number of Kupffer cells (KCs), which 
account for 80-90% of the total population of fixed tissue macrophages in the body. KCs, in 
combination with liver sinusoidal cells, are responsible for clearance of soluble 
macromolecules and insoluble waste in the body. Third, liver lymphocytes are enriched in 
innate immune cells including NK and NKT cells. Human intrahepatic lymphocyte 
population contain about 30% to 50% NK cells and up to 10% NKT cells. Fourth, liver non-
parenchymal cells also express high levels of membrane-bound PRRs, such as TLRs. Finally 
and interestingly, the adaptive immunity in the liver seems less active because the liver is a 
major site to induce T cell apoptosis. 
3. Dysregulation of innate immunity in ALD 
Growing evidence suggests alcohol induces dysregulation of innate immunity through three 
main mechanisms: i) activation of LPS/TLR4 signalling pathway; ii) activation of 
complement system; iii) inhibition of innate immunity cells, namely NK cells. 
3.1 Activation of LPS/TLR4 signalling pathway 
LPS is a component of Gram-negative bacteria cell wall. It consists of hydrophilic 
polysaccharides of the core and O-antigen and a hydrophobic lipid A component. This 
hydrophobic component corresponds to the conserved molecular pattern of LPS and is the 
main inducer of biological responses to LPS. TLR4, a member of human TLR family, is the 
receptor of LPS. Stimulation of TLR4 by LPS involves the participation of several molecules 
[LPS binding protein (LBP), cluster of differentiation-14 (CD14) and myeloid differentiation-
2 (MD-2)] (figure 1). LBP (a soluble protein) extracts LPS from the bacterial membrane and 
shuttles it to CD14 (a glycosylphosphatidylinositol-anchored protein, which also exists in a 
soluble form). CD14 then transfers the LPS to MD-2 (a soluble protein that non-covalently 
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associates with the extracellular domain of TLR4). Binding of LPS to MD-2 induces a 
conformational change in MD-2 which then allows the complex MD-2-TLR4 to bind to a 
second TLR4 receptor thus achieving TLR4 homo-dimerisation and signalling.  
 
Fig. 1. Overview of LPS/TLR4 signalling pathway. Stimulation of TLR4 by LPS involves the 
participation of several molecules (LBP, CD14 and MD-2). Activation of TLR4 induces two 
downstream signalling pathways. First, the MyD88-dependent pathway is initiated by 
recruitment of TIRAP and MyD88 to the TLR4 complex which leads to early-phase 
activation of NF-κB and subsequent induction of the expression of NF-κB-controlled genes 
including pro-inflammatory cytokines (TNF-α). The MyD88-dependent pathway can also 
activate JNK, leading to transcription of several genes including TNF-α, via activation of 
AP-1. Second, the MyD88-independent pathway is initiated by recruitment of TRAM and 
TRIF to the TLR4 complex, followed by late activation of NF-κB complex and activation of 
IRF3 which leads to the transcription of IFN-β as well as other interferon-induced genes. See 
text for abbreviations. 
Activation of TLR4 induces two downstream signalling pathways (figure 1). First, the 
MyD88-dependent pathway is initiated by recruitment of TIR domain-containing adaptor 
protein (TIRAP) and myeloid differentiation factor 88 (MyD88) to the TLR4 complex which 
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hydrophobic component corresponds to the conserved molecular pattern of LPS and is the 
main inducer of biological responses to LPS. TLR4, a member of human TLR family, is the 
receptor of LPS. Stimulation of TLR4 by LPS involves the participation of several molecules 
[LPS binding protein (LBP), cluster of differentiation-14 (CD14) and myeloid differentiation-
2 (MD-2)] (figure 1). LBP (a soluble protein) extracts LPS from the bacterial membrane and 
shuttles it to CD14 (a glycosylphosphatidylinositol-anchored protein, which also exists in a 
soluble form). CD14 then transfers the LPS to MD-2 (a soluble protein that non-covalently 
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associates with the extracellular domain of TLR4). Binding of LPS to MD-2 induces a 
conformational change in MD-2 which then allows the complex MD-2-TLR4 to bind to a 
second TLR4 receptor thus achieving TLR4 homo-dimerisation and signalling.  
 
Fig. 1. Overview of LPS/TLR4 signalling pathway. Stimulation of TLR4 by LPS involves the 
participation of several molecules (LBP, CD14 and MD-2). Activation of TLR4 induces two 
downstream signalling pathways. First, the MyD88-dependent pathway is initiated by 
recruitment of TIRAP and MyD88 to the TLR4 complex which leads to early-phase 
activation of NF-κB and subsequent induction of the expression of NF-κB-controlled genes 
including pro-inflammatory cytokines (TNF-α). The MyD88-dependent pathway can also 
activate JNK, leading to transcription of several genes including TNF-α, via activation of 
AP-1. Second, the MyD88-independent pathway is initiated by recruitment of TRAM and 
TRIF to the TLR4 complex, followed by late activation of NF-κB complex and activation of 
IRF3 which leads to the transcription of IFN-β as well as other interferon-induced genes. See 
text for abbreviations. 
Activation of TLR4 induces two downstream signalling pathways (figure 1). First, the 
MyD88-dependent pathway is initiated by recruitment of TIR domain-containing adaptor 
protein (TIRAP) and myeloid differentiation factor 88 (MyD88) to the TLR4 complex which 
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leads to  early-phase activation of nuclear factor-κB (NF-κB) and subsequent induction of the 
expression of NF-κB-controlled genes including pro-inflammatory cytokines  [tumor 
necrosis factor-α (TNF-α), interleukin-6 (IL-6)] and chemokines [monocyte chemotactic 
protein-1 (MCP-1)] genes. The MyD88-dependent pathway can also activate c-Jun N-
terminal kinase (JNK), leading to activator protein-1 (AP-1) activation that initiates the 
transcription of genes involved in regulation of cell proliferation, morphogenesis, apoptosis, 
and differentiation. Second, the MyD88-independent pathway is initiated by recruitment of 
TIR-domain containing adaptor inducing interferon-β (TRIF) and TRIF-related adaptor 
molecule (TRAM) to the TLR4 complex, followed by late activation of NF-κB complex and 
activation of interferon regulatory factor 3 (IRF3) which leads to the transcription of 
interferon-β (IFN-β) as well as other interferon-induced genes (Lu et al., 2008). 
Most parenchymal and non-parenchymal liver cells express TLR4. Nonetheless, with the 
exception of KCs, the amount of TLR4 expression and the level of responsiveness to LPS in 
most liver cells appear to be low in non-inflamed liver (Su et al., 2000; Zarember & 
Godowski, 2002). 
Several studies suggest that chronic alcohol ingestion can enhance hepatic LPS/TLR4 
signalling through increase of portal and systemic levels of LPS and upregulation and 
sensitization of hepatic TLR4 (Soares et al., 2010). Chronic ingestion of alcohol leads to a 
strong elevation of portal and systemic levels of LPS in animal models and humans 
(Mathurin et al., 2000; Parlesak et al., 2000). The elevation of LPS levels appears to be 
predominantly caused by two mechanisms. First, alcohol exposure can promote the growth 
of Gram-negative bacteria in the intestine, which leads to enhanced production of LPS 
(Hauge et al., 1997). Second, alcohol metabolism by Gram-negative bacteria and intestinal 
epithelial cells can result in accumulation of acetaldehyde, which in turn can increase 
intestinal permeability by opening intestinal tight junctions. Increased intestinal 
permeability can lead to increased transfer of LPS from the intestine to portal and systemic 
circulation (Purohit et al., 2008). Furthermore, chronic alcohol consumption upregulates 
hepatic TLR4 and sensitizes it to LPS to enhance TNF-α production, a process known as 
priming (Gustot et al., 2006). 
Besides LPS, TLR4 also senses endogenous ligands initiating danger signals, such as high 
mobility group box 1 (HMGB1), hyaluronan, heat shock protein 60 and free fatty acids 
(C12:0, C14:0, C16:0, and C18:0) (Erridge, 2010). In particular, HMGB1 has been shown to be 
released from damaged hepatocytes and contribute to liver injury (Tsung et al., 2005). Due 
to the association of many endogenous ligands with tissue injury, they are termed damage-
associated molecular patterns (DAMPs). Interestingly, recent studies show that many of the 
proposed endogenous TLR4 ligands may also have the capacity to bind and transport LPS 
and/or enhance the sensitivity of cells to LPS, suggesting that many of these molecules may 
be more accurately described as PAMP-binding molecules or PAMP-sensitizing molecules, 
rather than genuine ligands of TLR4 (Erridge, 2010). Therefore, these endogenous ligands, 
namely HMGB1, may enhance TLR4 signalling in ALD. 
3.2 Activation of complement system 
The complement system is a component of innate immunity that consists of multiple plasma 
proteins which act to fight infection by opsonizing pathogens, inducing inflammatory 
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responses, enhancing antibody responses, and attacking some pathogens directly. 
Activation of the complement cascade relies on cleavage of a zymogen to yield an active 
enzyme that in turns cleaves and activates the next zymogen in the cascade. Through this 
series of cleavage and enzyme activation, the immune system is able to produce a wide-
reaching response to few stimulation events (Gasque, 2004). The complement system is 
activated by three different pathways: classical, lectin and alternative pathways (figure 2). 
The classical pathway is activated by IgM- or IgG-containing immune complexes. The lectin 
pathway is activated when mannose-binding lectin binds its receptor, mannose, which is 
expressed by microbial pathogens. The alternative pathway is activated by C3b-coated 
pathogens. The three pathways converge at the generation of a C3 convertase that cleaves 
C3 to C3a and C3b. C3b is an opsonizing protein that coats pathogen surfaces to facilitate 
their uptake and destruction by phagocytes. C3b can also activate alternative pathway or 
associate to C3 convertase forming C5 convertase that cleaves C5 to C5a and C5b.  C3a and 
C5a lead to increased migration of phagocytes to the site of infection and induce mast cells 
to release histamine and TNF-α, which contribute to the enhancement of inflammatory 
response. C5b forms with C6, C7, C7, C8 and C9 the membrane-attack complex that destroys 
certain pathogens by disrupting their membrane integrity (Gasque, 2004).  
The liver (primarily hepatocytes) is a major site that biosynthesizes complement 
components found in plasma. Hepatocytes are also primarily responsible for the 
biosynthesis of several complement regulator proteins found in plasma, such as factor I, 
factor H, and the C1 inhibitor. Additionally, cells in the liver also express complement factor 
receptors, as well as intrinsic regulatory proteins (Qin & Gao, 2006). 
A growing body of evidence in mouse models suggests that alcohol exposure results in 
activation of the complement system and inhibition of regulatory proteins. Chronic alcohol 
feeding to mice for 4-6 weeks increases activation of C3, as evidenced by increased C3a in 
the circulation (Pritchard et al., 2007), as well as increased accumulation of C3 or its 
proteolytic end product C3b/iC3b/C3c in liver (Jarvelainen et al., 2002; Roychowdhury et 
al., 2009). In rats, chronic alcohol exposure increases C3 activity and decreases expression of 
Crry, the rat homologue of the complement inhibitory protein CD55/DAF (decay-
accelerating factor), and CD59 in the liver (Jarvelainen et al., 2002). 
Complement is activated early in the progression of alcohol-induced liver injury, prior to 
detectable increases in ALT/AST or accumulation of hepatic triglycerides (Roychowdhury 
et al., 2009). Early activation of complement contributes to increased inflammatory cytokine 
expression, mediated via the activation of the anaphylatoxin receptors, C3aR (C3a receptor) 
and C5aR (C5a receptor), on KCs (Roychowdhury et al., 2009). The contribution of each 
pathway of complement activation in response to alcohol exposure is still unclear. It has 
been suggested that alcohol-induced increase in LPS levels may contribute to activation of 
complement via the alternative pathway (Jarvelainen et al., 2002). Recent evidence shows 
that alcohol feeding activates the classical complement pathway via C1q binding to 
apoptotic cells in the liver, suggesting that the classical complement pathway also 
contributes to complement activation in the pathogenesis of ALD (Cohen et al., 2010). It is 
also likely that activation of complement by any mechanism will initiate the alternative 
pathway-mediated feedback loop (Gasque, 2004). Further studies are still needed to 
elucidate the specific role of each pathway of complement activation in response to alcohol 
exposure. 
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Fig. 2. Overview of complement system. The complement system is activated by three 
different pathways: the classical, lectin and alternative pathways. The classical pathway is 
activated by IgM- or IgG-containing immune complexes. The lectin pathway is activated 
when mannose-binding lectin bind its receptor, mannose, which is expressed by microbial 
pathogens. The alternative pathway is activated by C3b-coated pathogens. The three 
pathways converge at the generation of a C3 convertase that cleaves C3 to C3a and C3b. C3b 
is an opsonizing protein that coats pathogen surfaces to facilitate their uptake and 
destruction by phagocytes. C3b can also activate alternative pathway or associate to C3 
convertase forming C5 convertase that cleaves C5 to C5a and C5b.  C3a and C5a lead to 
increased migration of phagocytes to the site of infection and induce mast cells to release 
histamine and TNF-α, which contribute to the enhancement of inflammatory response. C5b 
forms with C6, C7, C7, C8 and C9 the membrane-attack complex that destroys certain 
pathogens by disrupting their membrane integrity. 
3.3 Inhibition of NK cells  
Over last several decades, many studies have shown that liver lymphocytes are rich in NK 
cells and that these cells play an important role in innate immune response against tumors 
and microbial pathogens including viruses, bacteria and parasites (Gao et al., 2009). NK cells 
can kill virus-infected cells and tumor cells via releasing granules containing granzyme and 
perforin, death ligand as TNF-related apoptosis-inducing ligand (TRAIL) and a variety of 
proinflammatory cytokines such as IFN-γ and TNF-α (Gao et al., 2009). Increasing evidence 
suggests that NK cells may also be involved in the pathogenesis of liver injury, fibrosis, and 
regeneration. For example, it has been shown that activation of NK cells inhibits liver 
fibrosis in vivo (Melhem et al., 2006).  
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Chronic alcohol consumption inhibits NK cells and such inhibition likely contributes to the 
pathogenesis of ALD. The inhibitory effect of chronic alcohol consumption on NK cells 
function has been observed for many years in alcoholic patients and rodents fed alcohol 
diets (Cook et al., 1997). This inhibitory effect is mediated by multiple mechanisms. First, 
chronic alcohol consumption directly attenuates NK cell cytotoxicity against activated 
hepatic stellate cells (HSCs) via down regulation of NK cell-associated molecules such as 
TRAIL, Natural killer group 2, member D (NKG2D) and interferon-γ (IFN-γ) (Jeong et al., 
2008). Second, chronic alcohol consumption indirectly attenuates NK cell killing activity by 
stimulating HSCs to produce transforming growth factor-β (TGF-β), an inhibitor of NK cells 
(Jeong et al., 2008), by elevating serum levels of corticosterone, which inhibits NK cells 
functions (Arjona et al., 2004), and by reducing central and peripheral levels of opioid 
peptide β-endorphin that can induce NK cells activation (Boyadjieva et al., 2004). Third, 
chronic alcohol exposure renders activated HSCs resistant to NK cell killing, because it 
induces higher expression of suppressor of cytokine signaling 1 (SOCS1) and ROS that 
inhibit IFN-γ activation of signal transducer and activator of transcription 1 (STAT1) (Jeong 
et al., 2008). Lastly, alcohol consumption blocks NK cells release from the bone marrow and 
enhances splenic NK cell apoptosis (Zhang & Meadows, 2009). 
4. Role of dysregulation of innate immunity in ALD 
Recent studies have revealed how alcohol-induced dysregulation of innate immunity may 
contribute to the pathogenesis of ALD (figure 3). 
4.1 Alcoholic liver steatosis 
Alcoholic liver steatosis corresponds to fat accumulation in hepatocytes, which is the result 
of unbalanced fat metabolism characterized by decreased mitochondrial lipid oxidation and 
enhanced synthesis of triglycerides. This unbalancing may be related with increased 
nicotinamide adenine dinucleotide (NADH)/NAD+ ratio (Fromenty et al., 1997), increased 
sterol regulatory element-binding protein-1 (SREBP-1) activity (You et al., 2004), decreased 
peroxisome proliferator-activated receptor-α (PPAR-α) activity (Ip et al., 2003) and 
decreased AMP-activated protein kinase (AMPK) activity (You et al., 2004).  
In addition to these mechanisms, growing evidence suggests alcohol-induced dysregulation 
of innate immunity may also contribute to alcohol-induced liver steatosis, mainly through 
increased TNF-α production by KCs in response to LPS. Increased expression of TNF-α has 
been observed in alcoholic liver steatosis of mice (Pritchard et al., 2007) and absence of its 
receptor (TNF-α R1) activity inhibits the development of alcoholic liver steatosis (Yin et al., 
1999). In addition, it has been reported that TNF-α has a potential to increase mRNA 
expression of SREBP-1, a potent transcription factor of fat synthesis, in the liver of mice and 
to stimulate the maturation of SREBP-1 in human hepatocytes, respectively (Endo et al., 
2007). In contrast, IL-6 produced by KCs in response to LPS has been shown to protect 
against alcoholic liver steatosis via activation of signal transducer and activator of 
transcription 3 (STAT3), consequently inhibiting of SREBP-1 gene expression in hepatocytes 
(El-Assal et al., 2004). Interestingly, chronic alcohol exposure inhibits IL-6 activation of 
STAT3 in hepatocytes and thus can counterbalance the protective effective of IL-6 (Weng et 
al., 2008). 
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Fig. 3. Overview of the role of alcohol-induced innate immunity dysregulation in the 
pathogenesis of ALD. Chronic alcohol consumption activates complement system (C3a, 
C5a) and LPS/TLR4 signalling pathway on KCs, which produce large amounts of pro-
inflammatory cytokines, including TNF-α, leading to liver steatosis and inflammation. 
LPS/TLR4 signalling pathway activation on hepatocytes may lead to hepatocarcinoma 
through expression of Nanog gene. LPS/TLR4 signalling pathway activation on HSCs 
contributes to liver fibrosis via two independent mechanisms: it induces the secretion of 
chemokines from HSCs leading to chemotaxis of KCs which secrete the profibrogenic 
cytokine TGF-β; additionally, it augments TGF-β signalling on HSCs via down-regulation of 
the TGF-β pseudoreceptor Bambi. Inhibition of NK cells during chronic alcohol 
consumption also contributes to alcoholic liver fibrosis, since NK cells have anti-fibrotic 
effects through suppression of HSCs. See text for abbreviations. 
In addition to alcohol-induced activation of LPS/TLR4 signalling pathway, alcohol-
induced inhibition of NK cell cytotoxicity against HSCs can also contribute liver steatosis 
as HSCs have been shown to stimulate accumulation of fat in hepatocyte (Jeong et al., 
2008). It has been shown that chronic alcohol drinking activates HSCs to produce 2-
arachidonoylglycerol (2-AG), one of endocannabinoids, which, activating its receptor, 
cannabinoid receptor 1 (CB1R) on hepatocytes increases the expression of SREPB-1 and 
fatty acid synthase (FAS) but decreased AMPK activation, consequently leading to 
accumulation of fat in hepatocytes. These data, however, are provided by a single study 
and require further studies. 
4.2 Alcoholic liver steatohepatitis 
Alcoholic steatohepatitis (ASH) refers to infiltration of liver by inflammatory cells, mainly 
granulocytes, in addition to fat accumulation. The recruitment of inflammatory cells 
seems to be related with the production of cytokines, chemokines and ROS. Although this 
production was historically linked to direct hepatotoxicity of alcohol and its metabolites, 
recent evidence suggest that alcohol-induced LPS/TLR4 signalling can also contribute to  
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this production and be a key player in the pathogenesis of ASH. Exposure to LPS during 
chronic alcohol consumption results in increased production of inflammatory mediators 
(TNF-α, IL-1, IL-6 and IL-8) as well as in induction of ROS, which subsequently aggravate 
steatohepatitis (Arteel, 2003). The role of LPS/TLR4 signalling pathway in the 
pathogenesis of ASH is further supported by studies showing that inhibition of 
LPS/TLR4 signalling, by altering intestinal microbiota and LPS production (through the 
use of antibiotics or probiotics) or suppressing TLR4, LBP or CD14 genes expression, 
protects against ASH. Indeed treatment with antibiotics or probiotics suppresses alcohol-
induced liver injury by reducing LPS circulating levels (Adachi et al., 1995; Nanji et al., 
1994). Studies in knockout mouse models have shown that chronic alcohol feeding in mice 
deficient of TLR4, LBP or CD14 results in attenuation of alcohol-induced liver injury 
despite elevated LPS circulating levels (Uesugi et al., 2001; Uesugi et al., 2002; Yin et al., 
2001).  
Recent studies have clarified the cellular and molecular pathways by which LPS/TLR4 
signalling promotes ASH. KCs have been established as a crucial cellular target of LPS in 
ASH as demonstrated by a strong reduction of alcoholic liver injury following depletion of 
KCs with gadolium chloride (Adachi et al., 1994). Moreover, it was shown that disruption of 
the TLR4 downstream signaling molecule MyD88 in mice failed to prevent ASH (Hritz et al., 
2008), while disruption of the MyD88-indepdenent signaling molecule TRIF in mice 
abolished ASH (Zhao et al., 2008), suggesting that the MyD88-independent pathway 
contributes to TLR4-mediated alcoholic liver injury. Further studies suggest that TRIF/IRF-3 
plays a critical role in alcohol-induced transactivation of the TNF-α gene in 
KCs/macrophages in vitro and in vivo, thereby initiating alcoholic liver injury (Zhao et al., 
2008). Furthermore, it was also shown that TLR4 deficiency prevented hepatic alcohol-
induced production of inflammatory mediators (TNF-α and IL-6), TLR4 coreceptors (CD14 
and MD2) and ROS by cytochrome P450 and the nicotinamide adenine dinucleotide 
phosphate (NADPH) complexes (Hritz et al., 2008). These data suggest that TLR4-mediated 
alcoholic liver injury is carried out by increased inflammatory mediators (TNF-α and IL-6) 
and ROS production and that there is a crosstalk between oxidative stress and TLR4 
pathways in ALD. This is further supported by studies showing that mice deficient in 
p47phox, the main cytosolic component of NADPH complex, show an absence of free-
radical production, NF-kB activation, TNF-α mRNA induction and liver pathology after 
alcohol treatment (Kono et al., 2000) and that inhibition of NADPH complex prevents 
upregulation of TLR4 and sensitization to LPS-induced liver injury (Gustot et al., 2006). 
Taken together these data suggest that activation of TLR4 in KCs by LPS is a key 
pathogenetic mediator of ASH, through production of inflammatory cytokines and ROS.  
In addition to alcohol-induced activation of LPS/TLR4 signalling pathway, alcohol-induced 
activation of complement can also contribute to ASH. This is mainly supported by studies 
showing that mice deficient in C3 and C5 are protected against alcohol-induced increases in 
hepatic triglycerides and circulating ALT, respectively (Pritchard et al., 2007) and that 
chronic alcohol-induced liver injury is exacerbated in mice lacking CD55/DAF, a 
complement regulatory protein, compared to wild-type controls (Pritchard et al., 2007). At 
present, the molecular mechanisms by which C3 and C5 contribute to ASH are not fully 
understood and require further studies. 
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this production and be a key player in the pathogenesis of ASH. Exposure to LPS during 
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induced liver injury by reducing LPS circulating levels (Adachi et al., 1995; Nanji et al., 
1994). Studies in knockout mouse models have shown that chronic alcohol feeding in mice 
deficient of TLR4, LBP or CD14 results in attenuation of alcohol-induced liver injury 
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4.3 Alcoholic liver fibrosis 
Alcoholic liver fibrosis is characterized by excessive deposition of extracelular matrix 
components due to increased matrix production and decreased matrix degradation 
(Henderson & Iredale, 2007). Several studies have highlighted the central role of HSCs in the 
production of extracellular matrix and the promotion of liver fibrosis.  
Alcohol contributes to activation of HSCs by several mechanisms, including upregulation of 
collagen transcription in HSCs by acetaldehyde or ROS from alcohol-exposed hepatocytes. 
Recently, alcohol-induced innate immunity dysregulation has also been shown to contribute 
to liver fibrosis, mainly through activation of LPS/TLR4 signalling in HSCs and inhibition 
of NK cells, as discussed below (figure 4).  
 
Fig. 4. Overview of the role of alcohol-induced innate immunity dysregulation in liver 
fibrosis. LPS/TLR4 signalling pathway activation on HSCs induces the secretion of 
chemokines that lead to chemotaxis of KCs which secrete the profibrogenic cytokine TGF-β 
(in a TLR4-independent manner); additionally, it augments TGF-β signalling on HSCs via 
down-regulation of the TGF-β pseudoreceptor Bambi. Chronic alcohol consumption directly 
attenuates NK cell cytotoxicity against activated HSCs via down regulation of NK cell-
associated molecules such as NKG2D, TRAIL and IFN-γ. Alcohol also renders HSCs 
resistant to NK cell killing, because it induces higher expression of ROS and SOCS1 that 
inhibit IFN-γ activation of STAT1 and apoptosis. Finally, alcohol stimulates HSCs to 
produce TGF-β, an inhibitor of NK cells. ↓, decrease; ↑, increase. See text for abbreviations. 
The crucial role of LPS/TLR4 signalling in liver fibrosis is supported by studies showing 
that inhibition of LPS/TLR4 signalling by altering intestinal microbiota and LPS production 
(through use of antibiotics or probiotics) or suppressing TLR4, LBP or CD14 genes 
expression protects against liver fibrosis. It has been shown that antibiotics prevent fibrosis 
induced by CCl4 treatment or a choline-deficient diet (MCDD), and that LPS enhances 
hepatic fibrosis induced by a MCDD (Luckey et al., 1954; Rutenburg et al., 1957). Treatment 
of mice with nonabsorbable broad-spectrum antibiotics also resulted in a clear reduction in 
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the fibrotic response of mice, upon bile duct ligation (Seki et al., 2007). Recently, 
Velayudham et al showed that VSL#3 (a probiotic) protects against MCDD–induced liver 
fibrosis, through modulation of collagen expression and inhibition of TGF-β expression and 
signalling (Velayudham et al., 2009). TLR4-, LBP- and CD14-deficient mice also have 
demonstrated the crucial role for the LPS–TLR4 pathway in hepatic fibrogenesis (Isayama et 
al., 2006; Seki et al., 2007). TLR4-mutant mice display a profound reduction in hepatic 
fibrogenesis in three different experimental models of biliary and toxic fibrosis (Seki et al., 
2007). LBP- and CD14-deficient mice also have a marked reduction of hepatic fibrosis upon 
bile duct ligation (Isayama et al., 2006). 
In a recent study, Seki et al analyzed the cell-specific molecular mechanism underlying the 
role of LPS/TLR4 on liver fibrosis (Seki et al., 2007). They showed that chimeric mice that 
contain TLR4-mutant KCs and TLR4-intact HSCs developed significant fibrosis and the 
mice that contain TLR4-intact KCs and TLR4-mutant HSCs developed minimal fibrosis 
after bile duct ligation, indicating that TLR4 on HSCs, but not on KCs, is crucial for hepatic 
fibrosis.  Notably, KCs are essential for fibrosis by producing TGF-β independent of TLR4. 
TLR4-activated HSCs produce CC-chemokines [chemokine ligand (CCL)2, CCL3, and 
CCL4] and express adhesion molecules [inter-cellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1)] that recruit KCs to the site of injury. 
Simultaneously, TLR4 signalling downregulates the TGF-β decoy receptor (Bambi) to boost 
TGF-β signalling and allow for unrestricted activation of HSCs by KCs, leading to hepatic 
fibrosis. Finally, by using adenoviral vectors expressing an inhibitor of NF-κB kinase (IκB)-
superrepressor and knockout mice for MyD88 and the adapter molecule TRIF, the authors 
demonstrated that TLR4-dependent down-regulation of Bambi is mediated via a pathway 
involving MyD88 and NF-κB, but not TRIF. In summary, they demonstrated that 
LPS/TLR4 signalling acts in a profibrogenic manner via two independent mechanisms: it 
induces the secretion of chemokines from HSCs and chemotaxis of KCs which secrete the 
profibrogenic cytokine TGF-β (in a TLR4-independent manner); additionally, TLR4-
dependent signals augment TGF-β signalling on HSCs via down-regulation of the TGF-β 
pseudoreceptor Bambi. 
The strong association of the LPS/TLR4 signalling pathway and liver fibrosis has been 
recently confirmed in patients with chronic hepatitis C virus (HCV) infection by studying 
TLR4 single nucleotide polymorphisms (SNPs). Huang et al conducted a gene centric 
functional genome scan in patients with chronic HCV infection, which yielded a Cirrhosis 
Risk Score signature consisting of seven SNPs that may predict the risk of developing 
cirrhosis (Huang et al., 2007). Among these, a major CC allele of TLR4 encoding a threonine 
at amino acid 399 (p.T399I) was the second most predictive SNP among the seven, 
indicating a protective role in fibrosis progression of its c.1196C>T (rs4986791) variant at this 
location (p.T399I), along with another highly cosegregated c.896A>G (rs4986790) SNP 
located at coding position 299 (p.D299G). In a subsequent study the same group examined 
the functional linkage of these SNPs to HSCs responses (Guo et al., 2009).  They showed that 
both HSCs from TLR4-deficient mice and a human HSC line (LX-2) reconstituted with either 
TLR4 D299G and/or T399I complementary DNAs were hyporesponsive to LPS stimulation 
compared to those expressing wild-type TLR4, as assessed by the expression and secretion 
of LPS-induced inflammatory and chemotactic cytokines (i.e., MCP-1, IL-6), downregulation 
of Bambi expression and activation of NF-κB–responsive luciferase reporter. In addition, 
spontaneous apoptosis, as well as apoptosis induced by pathway inhibitors of NF-κB,  
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the fibrotic response of mice, upon bile duct ligation (Seki et al., 2007). Recently, 
Velayudham et al showed that VSL#3 (a probiotic) protects against MCDD–induced liver 
fibrosis, through modulation of collagen expression and inhibition of TGF-β expression and 
signalling (Velayudham et al., 2009). TLR4-, LBP- and CD14-deficient mice also have 
demonstrated the crucial role for the LPS–TLR4 pathway in hepatic fibrogenesis (Isayama et 
al., 2006; Seki et al., 2007). TLR4-mutant mice display a profound reduction in hepatic 
fibrogenesis in three different experimental models of biliary and toxic fibrosis (Seki et al., 
2007). LBP- and CD14-deficient mice also have a marked reduction of hepatic fibrosis upon 
bile duct ligation (Isayama et al., 2006). 
In a recent study, Seki et al analyzed the cell-specific molecular mechanism underlying the 
role of LPS/TLR4 on liver fibrosis (Seki et al., 2007). They showed that chimeric mice that 
contain TLR4-mutant KCs and TLR4-intact HSCs developed significant fibrosis and the 
mice that contain TLR4-intact KCs and TLR4-mutant HSCs developed minimal fibrosis 
after bile duct ligation, indicating that TLR4 on HSCs, but not on KCs, is crucial for hepatic 
fibrosis.  Notably, KCs are essential for fibrosis by producing TGF-β independent of TLR4. 
TLR4-activated HSCs produce CC-chemokines [chemokine ligand (CCL)2, CCL3, and 
CCL4] and express adhesion molecules [inter-cellular adhesion molecule-1 (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1)] that recruit KCs to the site of injury. 
Simultaneously, TLR4 signalling downregulates the TGF-β decoy receptor (Bambi) to boost 
TGF-β signalling and allow for unrestricted activation of HSCs by KCs, leading to hepatic 
fibrosis. Finally, by using adenoviral vectors expressing an inhibitor of NF-κB kinase (IκB)-
superrepressor and knockout mice for MyD88 and the adapter molecule TRIF, the authors 
demonstrated that TLR4-dependent down-regulation of Bambi is mediated via a pathway 
involving MyD88 and NF-κB, but not TRIF. In summary, they demonstrated that 
LPS/TLR4 signalling acts in a profibrogenic manner via two independent mechanisms: it 
induces the secretion of chemokines from HSCs and chemotaxis of KCs which secrete the 
profibrogenic cytokine TGF-β (in a TLR4-independent manner); additionally, TLR4-
dependent signals augment TGF-β signalling on HSCs via down-regulation of the TGF-β 
pseudoreceptor Bambi. 
The strong association of the LPS/TLR4 signalling pathway and liver fibrosis has been 
recently confirmed in patients with chronic hepatitis C virus (HCV) infection by studying 
TLR4 single nucleotide polymorphisms (SNPs). Huang et al conducted a gene centric 
functional genome scan in patients with chronic HCV infection, which yielded a Cirrhosis 
Risk Score signature consisting of seven SNPs that may predict the risk of developing 
cirrhosis (Huang et al., 2007). Among these, a major CC allele of TLR4 encoding a threonine 
at amino acid 399 (p.T399I) was the second most predictive SNP among the seven, 
indicating a protective role in fibrosis progression of its c.1196C>T (rs4986791) variant at this 
location (p.T399I), along with another highly cosegregated c.896A>G (rs4986790) SNP 
located at coding position 299 (p.D299G). In a subsequent study the same group examined 
the functional linkage of these SNPs to HSCs responses (Guo et al., 2009).  They showed that 
both HSCs from TLR4-deficient mice and a human HSC line (LX-2) reconstituted with either 
TLR4 D299G and/or T399I complementary DNAs were hyporesponsive to LPS stimulation 
compared to those expressing wild-type TLR4, as assessed by the expression and secretion 
of LPS-induced inflammatory and chemotactic cytokines (i.e., MCP-1, IL-6), downregulation 
of Bambi expression and activation of NF-κB–responsive luciferase reporter. In addition, 
spontaneous apoptosis, as well as apoptosis induced by pathway inhibitors of NF-κB,  
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extracellular signal-regulated kinase (ERK), and phosphatidylinositol 3-kinase were greatly 
increased in HSCs from either TLR4-deficient or Myd88-deficient mice, as well as in murine 
HSCs expressing D299G and/or T399I SNPs (Guo et al., 2009). Thus, the protective effect of 
the TLR4 SNP (c.1196C>T [rs4986791, p.T399I]) is explained at least in part by its ability to 
increase apoptosis and decrease fibrogenic signalling in HSCs. Recently, Li et al expanded 
the list of TLR4 SNPs that are independently associated with the risk of liver fibrosis 
progression and the development of cirrhosis (Li et al., 2009). Taken together these data 
suggest LPS/TLR4 signalling in HSCs is essential for liver fibrosis development, by 
stimulating production chemokines that recruit KCs and at the same time allowing for 
unrestricted activation of HSCs by KCs-derived TGF-β.    
 
Fig. 5. Mechanisms of killing of activated stellate cells by NK cells. NK cells kill early 
activated HSCs but not quiescent HSCs. This is because early activated HSCs express 
increased RAE-1 via retinol metabolism, a NK cell-activating ligand of NKG2D, but express 
MHC-I, a NK cell-inhibitory ligand of iKIR, thus activating NK cells. After activation, NK 
cells initiate killing of activated HSCs through releasing of TRAIL, which targets TRAILR 
that is upregulated on activated HSCs, and IFN-γ, which targets IFN-γR on HSCs to induce 
cell cycle arrest and apoptosis in a STAT1-dependent manner. ↓, decrease; ↑, increase. See 
text for abbreviations.  
In addition to alcohol-induced activation of LPS/TLR4 signalling pathway, alcohol-induced 
NK cells inhibition, can also lead liver fibrosis as these cells have been shown to have anti-
fibrotic effects via multiple mechanisms (figure 5). Interestingly, NK cells directly kill early 
activated HSCs but not quiescent HSCs (Melhem et al., 2006; Radaeva et al., 2006; Radaeva 
et al., 2007). This is because early activated HSCs express increased retinoic acid early 
inducible gene 1 (RAE-1) via retinol metabolism, a NK cell-activating ligand of NKG2D but 
express decreased class I major histocompatibilty complex (MHC-I), a NK cell-inhibitory 
ligand of inhibitory killer immunoglobulin-related receptor (iKIR), thus activating NK cells 
(Radaeva et al., 2007; Taimr et al., 2003). After activation, NK cells initiate killing of activated 
HSCs through releasing of TRAIL, which targets TRAIL receptor (TRAILR) that is 
upregulated on activated HSCs, and IFN-γ, which targets IFN-γ receptor (IFN-γR) on HSCs 
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to induce cell cycle arrest and apoptosis in a STAT1-dependetent manner (Baroni et al., 1996; 
Jeong et al., 2006). The crucial role of alcohol-induced NK cells inhibition on alcoholic liver 
fibrosis has been suggested by the finding that attenuated NK cell cytotoxicity against HSCs 
in alcohol-fed mice contributed to acceleration of liver fibrosis associated with CCl(4) 
treatment (Jeong et al., 2008).  
Few studies have evaluated the role of complement in alcoholic liver fibrosis. By using 
intercross studies in animal models of liver fibrosis, Hillebrandt et al (Hillebrandt et al., 
2005) demonstrated that C5 plays an important role in promoting liver fibrogenesis via 
targeting C5aR on activated HSCs and KC in mice, because C5 deficiency resulted in 
lowered liver fibrosis, whereas overexpression of the C5 gene resulted in increased liver 
fibrosis. Thus, C5 activation during alcohol consumption, as discussed above, likely also 
contributes to the development of alcoholic liver fibrosis. In addition, Hillebrandt et al 
(Hillebrandt et al., 2005) also reported that two C5 htSNPs (rs 2300929 and rs17611) are 
associated with the high risk for developing advanced fibrosis in patients with chronic HCV 
infection. At present, the molecular mechanisms by which the C5 contributes to liver fibrosis 
are not fully understood and require further studies. 
4.4 Hepatocarcinoma 
Hepatocarcinoma is a complication of ALD, which always develops in a cirrhotic liver. 
Thus, alcoholic liver cirrhosis is a premalignant condition with approximately fourfold 
increase in the risk of hepatocarcinoma. The five-year cumulative incidence of 
hepatocarcinoma reaches 8%. In addition, clinical and epidemiological evidence implicates 
long-term alcohol consumption in accelerating HCV-mediated tumorigenesis (Hassan et al., 
2002). A recent study provided evidence that TLR4 mediates the synergism between alcohol 
and HCV in hepatic oncogenesis (Machida et al., 2009).  Machida et al studied the molecular 
mechanism of synergism between alcohol and HCV, using mice with hepatocyte-specific 
transgenic expression of the HCV nonstructural protein NS5A, which is known to have a 
cryptic trans-acting activity for cellular gene promoters. They demonstrated that NS5A and 
alcohol synergistically induce hepatocellular damage and transformation via accentuated 
and/or sustained activation of TLR4 signalling, which results from HCV NS5A-induced 
hepatic TLR4 expression and alcohol-induced endotoxaemia. Additionally, Nanog, a stem 
cell marker, was identified as a novel downstream gene transcriptionally induced by 
activated TLR4 signalling, that is largely responsible for TLR4-mediated liver tumor 
development.  
Taken together these data suggest TLR4 signalling in hepatocytes may constitute the link 
between alcoholic liver cirrhosis and hepatocarcinoma.  
5. Role of innate immunity impairment in ALD infection risk  
Patients with ALD are particularly susceptible to infections, with increased morbidity and 
mortality from sepsis, mainly in the presence of cirrhosis (Linderoth et al., 2006; Navasa et 
al., 1999). We and others have shown that in advanced stages of alcoholic liver disease the 
alcohol-induced pro-inflammatory state is replaced by a state of immune paralysis that can 
greatly decrease the innate immune response of immunological cells (Lin et al., 2007; 
Pimentel-Nunes et al., 2010; Wasmuth et al., 2005). These data support the hypothesis that 
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to induce cell cycle arrest and apoptosis in a STAT1-dependetent manner (Baroni et al., 1996; 
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Pimentel-Nunes et al., 2010; Wasmuth et al., 2005). These data support the hypothesis that 
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patients with alcoholic cirrhosis are likely to have underlying immune dysfunction, 
particularly innate immunity dysfunction that makes them susceptible to increased risk of 
infections.  
Homman et al have shown that acquired C3 deficiency and decreased haemolytic 
complement function predisposes to infection and increased mortality in patients with 
alcoholic cirrhosis (Homann et al., 1997). 
Recently we evaluated ex vivo TLR2- and TLR4-mediated innate immune response in 
patients with stable well-compensated alcoholic cirrhosis (Pimentel-Nunes et al., 2010). 
Namely, we evaluated TNF-α production by peripheral blood monocytes (PM) primary 
cultures after stimulation with the TLR2/TLR6 ligand zymosan and the TLR2/TLR1 ligand 
lipopeptide, as well as with the TLR4 ligand LPS. We found an attenuated TLR2 response 
to zymosan and lipopetide whereas the TLR4-mediated response to LPS was not 
significantly different to controls. We also studied a subset of patients with decompensated 
liver disease, where in addition to the blunted TLR2 response, the TLR4 response to LPS 
was also defective. Interestingly, we could not find any changes in protein or mRNA 
expression of TLRs between PM of patients and controls, which suggest that this blunted 
TLR2- and TLR4-response probably implies dysfunction in intracellular signalling 
pathways. To further clarify the molecular mechanisms underlying the selective 
attenuation of TLR2-mediated innate immune response in patients with stable 
compensated alcoholic cirrhosis, the differential effect of zymosan and LPS in PM 
stimulation on TLR2 and TLR4 gene expression was analyzed. In fact, zymosan and LPS 
stimulation has distinct effects on TLR2 and TLR4 expression levels. Whereas zymosan-
mediated TLR2 stimulation induced a downregulation of both TLR2 and TLR4, LPS-
mediated TLR4 stimulation was accompanied by a selective upregulation of TLR2 and a 
downregulation of TLR4. These differences could be related to distinct intracellular 
pathway activation. In fact, although TLR2 and TLR4 share most of its intracellular 
pathways, TLR4 also activates MyD88-independent pathways.  
Other authors also found a decrease TLR2- and TLR4- response in immune cells, 
particularly in advanced stages of disease,  that was associated with decreased, normal or 
increased levels of TLRs, depending on the study (Riordan et al., 2003; Stadlbauer et al., 
2008; Stadlbauer et al., 2009; Tazi et al., 2006; Testro et al., 2009; Wasmuth et al., 2005). The 
data of these studies are compared in table 1. Analyzing all these studies, we conclude that 
decreased TLRs levels are insufficient to alter TLR function. Instead blunted TLRs response 
probably implies dysfunction in intracellular signalling pathways. Actually, in our study, 
we found blunted TLR2 activation that was independent of TLR2 levels (Pimentel-Nunes et 
al., 2010). Furthermore, we have shown in vitro that TLR2 and/or TLR4 agonists change the 
expression levels of these receptors (Pimentel-Nunes et al., 2010). Hence, we believe that the 
frequent episodes of bacteraemia that occur in cirrhosis, by changing TLR expression on 
immune cells, can help explain these discrepancies concerning TLR expression. This also 
might be the reason why Stadlbauer et al (Stadlbauer et al., 2008), using probiotics, 
promoted the decrease, and Testro et al (Testro et al., 2009), using antibiotics, the increase in 
TLR4 levels, both trending towards normal levels of expression. Possibly, these two 
different therapeutic agents decrease episodes of bacteraemia, consequently with less 
fluctuation of TLR levels. Why they restored TLR4 function remains unclear because 
expression levels cannot explain the results from these two studies.  
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Taking in consideration data from all these studies several conclusions can be made. Firstly, 
the data point to important role of bacterial translocation, endotoxaemia and alteration of 
TLR2 and TLR4 signalling providing potential biomarkers to identify patients at risk of 
infection and potential targets for intervention. Secondly, our study (Pimentel-Nunes et al., 
2010) and others (Riordan et al., 2003) clearly suggest a blunted TLR2 function even in the 
early stages of cirrhosis, which may help explain the growing risk of Gram-positive bacteria 
infection in these patients. Thirdly, at least in advanced cirrhosis, TLR4 impairment is also 
present (Pimentel-Nunes et al., 2011). Fourthly, taking together the discrepancies in the 
expression levels of TLRs, it appears that other factors, probably intracellular, are 
fundamental to this immunodeficiency. Finally, this process may be reversible with 
antibiotics and/or probiotics (Stadlbauer et al., 2008; Testro et al., 2009). However, further 
studies are needed before generalization since Riordan et al. (Riordan et al., 2003) showed 
that the use of a symbiotic (mixture of probiotic and probiotic) further compromised TLR2 
function, in contrast to the positive immunological effects obtained by Stadlbauer et al. 
(Stadlbauer et al., 2008) and Testro et al. (Testro et al., 2009). 
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to zymosan and lipopetide whereas the TLR4-mediated response to LPS was not 
significantly different to controls. We also studied a subset of patients with decompensated 
liver disease, where in addition to the blunted TLR2 response, the TLR4 response to LPS 
was also defective. Interestingly, we could not find any changes in protein or mRNA 
expression of TLRs between PM of patients and controls, which suggest that this blunted 
TLR2- and TLR4-response probably implies dysfunction in intracellular signalling 
pathways. To further clarify the molecular mechanisms underlying the selective 
attenuation of TLR2-mediated innate immune response in patients with stable 
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stimulation on TLR2 and TLR4 gene expression was analyzed. In fact, zymosan and LPS 
stimulation has distinct effects on TLR2 and TLR4 expression levels. Whereas zymosan-
mediated TLR2 stimulation induced a downregulation of both TLR2 and TLR4, LPS-
mediated TLR4 stimulation was accompanied by a selective upregulation of TLR2 and a 
downregulation of TLR4. These differences could be related to distinct intracellular 
pathway activation. In fact, although TLR2 and TLR4 share most of its intracellular 
pathways, TLR4 also activates MyD88-independent pathways.  
Other authors also found a decrease TLR2- and TLR4- response in immune cells, 
particularly in advanced stages of disease,  that was associated with decreased, normal or 
increased levels of TLRs, depending on the study (Riordan et al., 2003; Stadlbauer et al., 
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data of these studies are compared in table 1. Analyzing all these studies, we conclude that 
decreased TLRs levels are insufficient to alter TLR function. Instead blunted TLRs response 
probably implies dysfunction in intracellular signalling pathways. Actually, in our study, 
we found blunted TLR2 activation that was independent of TLR2 levels (Pimentel-Nunes et 
al., 2010). Furthermore, we have shown in vitro that TLR2 and/or TLR4 agonists change the 
expression levels of these receptors (Pimentel-Nunes et al., 2010). Hence, we believe that the 
frequent episodes of bacteraemia that occur in cirrhosis, by changing TLR expression on 
immune cells, can help explain these discrepancies concerning TLR expression. This also 
might be the reason why Stadlbauer et al (Stadlbauer et al., 2008), using probiotics, 
promoted the decrease, and Testro et al (Testro et al., 2009), using antibiotics, the increase in 
TLR4 levels, both trending towards normal levels of expression. Possibly, these two 
different therapeutic agents decrease episodes of bacteraemia, consequently with less 
fluctuation of TLR levels. Why they restored TLR4 function remains unclear because 
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Taking in consideration data from all these studies several conclusions can be made. Firstly, 
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fundamental to this immunodeficiency. Finally, this process may be reversible with 
antibiotics and/or probiotics (Stadlbauer et al., 2008; Testro et al., 2009). However, further 
studies are needed before generalization since Riordan et al. (Riordan et al., 2003) showed 
that the use of a symbiotic (mixture of probiotic and probiotic) further compromised TLR2 
function, in contrast to the positive immunological effects obtained by Stadlbauer et al. 
(Stadlbauer et al., 2008) and Testro et al. (Testro et al., 2009). 











PBMC ↑ = TLR4 = 
TLR2 ↓ 
Symbiotic ↑ TLR2 






PM NE NE TLR4 ↓ NE 




PM NE ↓ TLR4 ↑ NE 











PN ↑ ↑ TLR4 =§ Probiotic decreased 
TLR4 levels to 
normal§ 
Pimentel-
Nunes et al., 
2010*,† 
Stable (n=26) and 
advanced (n=5) 
alcohol 

















TLR4 levels to 
normal with 
increase of function 
*TLRs quantified by RNA.  
†TLRs quantified by flow cytometry.  
‡TLR4 quantified by Western blotting.  
§Despite presenting decrease phagocytic capacity, stimulated TNF-α in culture was not different to 
controls and probiotic restored phagocytic capacity.  
ATB, antibiotics; PBMC, peripheral blood mononuclear cell; PM, peripheral monocytes; PN, peripheral 
neutrophils; NE, not evaluated; = , equal to controls; ↓, decrease when compared with controls;  
↑, increase when compared with controls. Adapted with permission from Liver Int 2011;31:140-1. 
Table 1. Review of the studies about the role of TLR2 and TLR4 in cirrhotic patients 
according to TLR expression and function (considered as TNF-α production in culture). 
 
Trends in Alcoholic Liver Disease Research – Clinical and Scientific Aspects 
 
56
6. Modulation of innate immunity in the treatment of ALD  
Recently, a number of different approaches that modulate innate immunity, mainly 
LPS/TLR4 signalling pathway, have been developed and studied in the treatment of ALD 
(Petrasek et al., 2010). Among these approaches, two of them, modulation of LPS release by 
probiotics or antibiotics and interference with cytokines induced by TLR4 signalling, have 
progressed into clinical trials in patients with ALD.  
Modulation of intestinal microbiota using probiotics has been shown to reduce bacterial 
translocation, circulating LPS levels in animal models, and bacterial infection, a marker for 
bacterial translocation, in patients with liver cirrhosis (Petrasek et al., 2010). In liver cirrhosis, 
probiotics have shown positive effects on several parameters including the improvement of 
liver function, prevention of infection, improvement of the hyperdynamic circulation and 
prevention of hepatic encephalopathy (Liu et al., 2004). Beneficial effects of probiotics have 
been reported in an animal model of alcohol-induced liver injury (Nanji et al., 1994) and of 
LPS-induced liver injury (Ewaschuk et al., 2007; Osman et al., 2007). Patients with alcoholic 
liver cirrhosis treated with Lactobacillus casei Shirota three times daily for 4 weeks showed 
restoration of deranged neutrophil phagocytic capacity, compared to controls (Stadlbauer et 
al., 2008). A recent open-label pilot trial showed that a 5-day administration of Bifidobacterium 
bifidum and Lactobacillus plantarum in alcohol-addicted psychiatric patients with mild alcoholic 
hepatitis ameliorated serum markers of liver injury to a significantly higher extent compared 
to control group treated with abstinence only (Kirpich et al., 2008). However, not all studies 
associate probiotics with improvement, since in the study from Riordan et al, the use of 
symbiotic (mixture of probiotic and prebiotic) further compromised TLR2 function (Riordan et 
al., 2003). Other problem with probiotics is that the number of studies is relatively small and 
many of these are uncontrolled studies. The large number of probiotic strains and 
combinations of strains represents other important problem, and it will require additional 
studies to confirm and ideally compare the efficacy of these probiotic strains. 
A second approach to reduce TLR4 ligand is the treatment with antibiotics to achieve 
selective intestinal decontamination of Gram-negative bacteria, the predominant source of 
LPS. Selective intestinal decontamination has been shown to reduce bacterial translocation 
in many studies performed in rats (Runyon et al., 1995). Importantly, norfloxacin 
administration reduced the 1 year probability of developing spontaneous bacterial 
peritonitis (SBP), hepatorenal syndrome, and improved the 3 month and 1 year probability 
of survival compared with placebo (Fernandez et al., 2007). While the reduction of SBP in 
norfloxacin treated patients is a direct consequence of reducing bacterial strains in the 
microbiota responsible for spontaneous peritonitis, some of the positive effect on mortality 
are likely SBP-independent and related to reducing bacterial translocation and circulating 
levels of LPS (Fernandez et al., 2007). One problem with antibiotics is the severe 
consequences of long-term antibiotics treatment. Rifaximin may help to solve this problem 
(Butterworth, 2011). Rifaximin is a minimally absorbed oral antimicrobial agent that is 
concentrated in the gastrointestinal tract, has broad-spectrum in vitro activity against gram-
positive and gram-negative aerobic and anaerobic enteric bacteria, and has a low risk of 
inducing bacterial resistance. In randomized studies, rifaximin was more effective than 
nonabsorbable disaccharides and had efficacy that was equivalent to or greater than that of 
other antibiotics used in the treatment of acute hepatic encephalopathy. Furthermore, with 
minimal systemic bioavailability, rifaximin may be more conducive to long-term use than 
other, more bioavailable antibiotics with detrimental side effects. 
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These data suggest that modulation of the bowel flora may play a role in the pathogenesis 
and treatment of ALD and indicate a need for larger and rigorously designed clinical trials 
to support the use of probiotics or antibiotics in treatment of ALD. 
While the role of TNF-α in the development of ALD has been well characterized, clinical 
investigations of the therapeutic efficacy of antibodies to TNF-α (e.g., infliximab) to treat 
patients with acute alcoholic hepatitis have generated variable results (Naveau et al., 2004; 
Tilg et al., 2003). There is particular concern about off-target effects of completely inhibiting 
TNF-α function. For example, since TNF-α is a critical component of immunity, infectious 
disease is a primary concern during TNF-α therapy (Naveau et al., 2004). Moreover, TNF-α 
is required for normal liver regeneration as hepatocyte proliferation in response to injury is 
impaired in mice lacking TNF-α receptors (Yamada et al., 1997). Etanercept, a TNF-α 
neutralizing antibody, appeared to increase short-term survival of patients with alcoholic 
hepatitis in a small pilot study (Menon et al., 2004), although a subsequent randomized, 
placebo-controlled trial conducted by the same investigators showed a worse 6-month 
survival rate in the group treated with etanercept than in the placebo group (Boetticher et 
al., 2008). Thus, it seems very unlikely that inhibition of TNF-α may become a therapeutic 
target in ALD, especially at the long-term. 
7. Conclusion 
In summary, the liver is an organ with predominant innate immunity function. 
Dysregulation of many components of innate immunity in the liver due to chronic alcohol 
consumption likely contributes additively or synergistically to alcohol-induced liver disease. 
Chronic alcohol consumption activates LPS/TLR4 signalling pathway on KCs, which 
produce large amounts of pro-inflammatory cytokines, including TNF-α, leading to liver 
steatosis and inflammation.  Alcohol-induced LPS/TLR4 signalling pathway activation also 
contributes to alcoholic liver fibrosis via two independent mechanisms: it induces the 
secretion of chemokines from HSCs and chemotaxis of KCs which secrete the profibrogenic 
cytokine TGF-β; additionally, TLR4-dependent signals augment TGF-β signalling on HSCs 
via down-regulation of the TGF-β pseudoreceptor Bambi. Inhibition of NK cells during 
chronic alcohol consumption also seem to contribute to alcoholic liver fibrosis, since NK 
cells have anti-fibrotic effects through suppression of HSCs. Activation of LPS/TLR4 
signalling pathway on hepatocytes may also contribute to hepatocarcinoma development, 
through activation of Nanog gene. In contrast to activation LPS/TLR4 signalling pathway 
and inhibition of NK cells, the role of complement activation in the pathogenesis of ALD 
remains largely obscure. Few studies suggest that alcohol-induced complement activation 
may contribute to liver steatosis, inflammation and fibrosis, but more studies are needed to 
clarify the underlying mechanisms. 
Alcohol-induced dysregulation of innate immunity also seem to contribute to the increased 
risk of infections of patients with alcoholic cirrhosis, as we and others have demonstrated a 
blunted response of immune cells to TLR2/4 ligands, probably associated with 
compromised intracellular signalling, in these patients.  
Modulation of innate immunity, mainly of LPS/TLR4 signalling through the use of 
probiotics or antibiotics, may play a role in the treatment of ALD, but we need for larger and 
rigorously designed clinical trials to support the use of probiotics or antibiotics in treatment 
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These data suggest that modulation of the bowel flora may play a role in the pathogenesis 
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to support the use of probiotics or antibiotics in treatment of ALD. 
While the role of TNF-α in the development of ALD has been well characterized, clinical 
investigations of the therapeutic efficacy of antibodies to TNF-α (e.g., infliximab) to treat 
patients with acute alcoholic hepatitis have generated variable results (Naveau et al., 2004; 
Tilg et al., 2003). There is particular concern about off-target effects of completely inhibiting 
TNF-α function. For example, since TNF-α is a critical component of immunity, infectious 
disease is a primary concern during TNF-α therapy (Naveau et al., 2004). Moreover, TNF-α 
is required for normal liver regeneration as hepatocyte proliferation in response to injury is 
impaired in mice lacking TNF-α receptors (Yamada et al., 1997). Etanercept, a TNF-α 
neutralizing antibody, appeared to increase short-term survival of patients with alcoholic 
hepatitis in a small pilot study (Menon et al., 2004), although a subsequent randomized, 
placebo-controlled trial conducted by the same investigators showed a worse 6-month 
survival rate in the group treated with etanercept than in the placebo group (Boetticher et 
al., 2008). Thus, it seems very unlikely that inhibition of TNF-α may become a therapeutic 
target in ALD, especially at the long-term. 
7. Conclusion 
In summary, the liver is an organ with predominant innate immunity function. 
Dysregulation of many components of innate immunity in the liver due to chronic alcohol 
consumption likely contributes additively or synergistically to alcohol-induced liver disease. 
Chronic alcohol consumption activates LPS/TLR4 signalling pathway on KCs, which 
produce large amounts of pro-inflammatory cytokines, including TNF-α, leading to liver 
steatosis and inflammation.  Alcohol-induced LPS/TLR4 signalling pathway activation also 
contributes to alcoholic liver fibrosis via two independent mechanisms: it induces the 
secretion of chemokines from HSCs and chemotaxis of KCs which secrete the profibrogenic 
cytokine TGF-β; additionally, TLR4-dependent signals augment TGF-β signalling on HSCs 
via down-regulation of the TGF-β pseudoreceptor Bambi. Inhibition of NK cells during 
chronic alcohol consumption also seem to contribute to alcoholic liver fibrosis, since NK 
cells have anti-fibrotic effects through suppression of HSCs. Activation of LPS/TLR4 
signalling pathway on hepatocytes may also contribute to hepatocarcinoma development, 
through activation of Nanog gene. In contrast to activation LPS/TLR4 signalling pathway 
and inhibition of NK cells, the role of complement activation in the pathogenesis of ALD 
remains largely obscure. Few studies suggest that alcohol-induced complement activation 
may contribute to liver steatosis, inflammation and fibrosis, but more studies are needed to 
clarify the underlying mechanisms. 
Alcohol-induced dysregulation of innate immunity also seem to contribute to the increased 
risk of infections of patients with alcoholic cirrhosis, as we and others have demonstrated a 
blunted response of immune cells to TLR2/4 ligands, probably associated with 
compromised intracellular signalling, in these patients.  
Modulation of innate immunity, mainly of LPS/TLR4 signalling through the use of 
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of ALD. Inhibition of TNF-α has produced variable results in the treatment of ALD and may 
be associated with serious off-target effects. 
Although, in the last decade, we have gain significant insight over the role of alcohol-
induced innate immunity dysregulation in ALD, further research is still needed to further 
clarify and identify the interrelationships between innate immunity components involved in 
ALD. Examples of questions for future studies are: 
1. Which is the role of other TLRs than TLR2 and TLR4 in the development of ALD? 
2. Which is the role of DAMPs (HMGB1, heat shock proteins) and Myd88-independent 
pathway in ALD progression? 
3. Which are the molecular mechanisms by which complement system contribute to 
alcohol-induced liver steatosis, inflammation and fibrosis? 
4. Which are the molecular mechanisms underlying blunted response of immune cells to 
TLR2/4 ligands in patients with alcoholic cirrhosis? 
5. Is there any correlation between TLR4 SNPs and the progression of ALD? 
6. Which is the effect in ALD of neutralization of LPS or LPS-signalling through the use of 
TLR4 anatgonists (e.g., CyP, CRX-526, Eritoran), or LPS signalling interfering molecules 
(e.g., TAK-242, besifloxacin, compound K)? 
The answers to these questions may help us identify novel therapeutic targets to treat ALD. 
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of ALD. Inhibition of TNF-α has produced variable results in the treatment of ALD and may 
be associated with serious off-target effects. 
Although, in the last decade, we have gain significant insight over the role of alcohol-
induced innate immunity dysregulation in ALD, further research is still needed to further 
clarify and identify the interrelationships between innate immunity components involved in 
ALD. Examples of questions for future studies are: 
1. Which is the role of other TLRs than TLR2 and TLR4 in the development of ALD? 
2. Which is the role of DAMPs (HMGB1, heat shock proteins) and Myd88-independent 
pathway in ALD progression? 
3. Which are the molecular mechanisms by which complement system contribute to 
alcohol-induced liver steatosis, inflammation and fibrosis? 
4. Which are the molecular mechanisms underlying blunted response of immune cells to 
TLR2/4 ligands in patients with alcoholic cirrhosis? 
5. Is there any correlation between TLR4 SNPs and the progression of ALD? 
6. Which is the effect in ALD of neutralization of LPS or LPS-signalling through the use of 
TLR4 anatgonists (e.g., CyP, CRX-526, Eritoran), or LPS signalling interfering molecules 
(e.g., TAK-242, besifloxacin, compound K)? 
The answers to these questions may help us identify novel therapeutic targets to treat ALD. 
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several studies suggest that CD31 plays a major role in angiogenesis (DeLisser et al., 1997; 
Matsumura et al., 1997; Zhou et al., 1999).  
CD34 is a 110-kDa transmembrane glycoprotein present on leukemic cells, endothelial cells 
and stem cells) (Pusztaszeri et al., 2006). CD34 is preferentially expressed on the surface of 
regenerating or migrating endothelial cells and is a marker of proliferating endothelial cells 
in the growing sprouts during angiogenesis (Poon et al., 2002). Usually, the liver sinusoids 
do not express CD34. But, pathological conditions can alter their phenotype and express this 
marker. Capillarization of hepatic sinusoids is a well-recognized phenomenon that occurs in 
long-standing liver disease and hepatic cirrhosis as well as in hepatocellular carcinoma 
(HCC) (Pusztaszeri et al., 2006). 
The investigation of the expression of the endothelial cell markers CD31 and CD34 allow 
determining the degree of vascular distribution hepatic inflammation. 
2. Histochemical and immunohistochemical diagnosis methods used for 
study of alcoholic hepatitis 
2.1 Morphological diagnosis methods   
The biological material harvesting by percutaneous liver biopsy or after a necropsy follows the 
same histological processing, involving fixing in formaldehyde 10%, inclusion in paraffin and 
making multiple serial sections. For routine diagnosis, deparaffinized sections from paraffin-
embedded liver tissue were stained with hematoxylin-eosin technique (HE). For diagnostic 
purposes and to assess histopathological lesions, especially liver fibrosis, trichrome staining 
methods are applied in order to complement the data obtained on sections stained with HE.  
Gömori method highlights collagen in green, on red background of hepatocytes cytoplasm. By 
Masson method, the results are similar; the color obtained for fibrosis is green-blue on a red 
background of the cytoplasm. The lumen of the centrilobular vein – collapsed or difficult to 
distinguish on HE staining – can be easily observed on reticulin silver staining, following the 
shape and wall thickness, the presence of inflammation or fibrosis. Silver impregnation by 
Gordon-Sweet method to highlight reticulin fibers (type III collagen) applied in all cases with 
histological activity and fibrosis, has proved useful in diagnosis of piecemeal necrosis 
indicating the outline of portal spaces altered by piecemeal necrosis, in evaluation of focal 
necrosis area and to highlight reticulin fibers in nodular regeneration conditions. The silver 
staining for reticulin highlight the components of extracellular liver matrix from Disse space 
and centrilobular venules (Cornianu et al., 2007).  
2.2 Additional immunohistochemical diagnosis methods 
Using immunohistochemical methods (IHC) as special techniques is a next step in diagnosis 
after histological staining, allowing highlighting of new structures and functions. In order to 
perform immunohistochemical reactions, the staining techniques based on monoclonal 
antibodies which react with specific tissue antigens are applied. The immunohistochemical 
detection is performed on 5-μm thick, routinely formalin-fixed, paraffin-embedded 
specimens. Briefly, the sections are deparaffinied in xylene and rehydrated in serial 
solutions of ethanol and water. To block endogenous peroxidase activity the sections are 
incubated in 3% hydrogen peroxide in PBS (phosphate buffered saline). Immunostaining are 
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performed with a monoclonal antibody diluted 1:50 in 1% bovine serum albumin in 
phosphate buffered saline. Antibody detection is usually performed using a horseradish 
peroxidase (HRP)–labeled goat anti-mouse secondary antibody followed by staining with a 
3, 3′-diaminobenzidine chromogen (DAB) solution. Finally, slides are counterstained with 
hematoxylin. Positive staining is considered the cells with brown stain with a dotty, linear, 
semicircular or circular pattern. 
3. Histopathological features in alcoholic chronic hepatitis 
Alcohol hepatotoxicity is well known and generally related to the amount and duration of 
excessive consumption of alcohol. Alcoholic liver disease is characterized by a spectrum of 
clinical manifestations of liver, morphological modifications (Table 1)(Delladetsima et al., 
1987; Kondili et al., 2005; Lefkowich, 2005; Lackner et al., 2008), as well associated injuries. 
 
A. Alcoholic steatosis (fatty liver) 
1. Macrovesicular steatosis 
2. Microvesicular steatosis 
3. Mixed variant of steatosis 
4. Lipogranulomas 
5. Foamy fatty degeneration 
B. Alcoholic steatohepatitis 
1. Ballooned hepatocytes (cell swelling) 
2. Steatosis 
3. Inflammation 
4. Perivenular fibrosis 
5. Vein occlusion 
C. Cirrhosis 
1. Micronodular cirrhosis that progress to macronodular cirrhosis 
D. Hepatocellular carcinoma 
Table 1. Morphological features in alcoholic liver chronic disease. 
To establish the chronic character of liver disease three types of lesions proved to be definitive: 
portal inflammation, hepatocyte necrosis and fibrosis. For stabilization and determining the 
degree of chronic hepatitis can be taken in consideration other histopathological aspects: 
steatosis; lesions of biliary canaliculi which translates by swelling of biliary epithelial cells; 
intralobular degeneration lesions evidenced by presence of apoptotic bodies.  
3.1 Steatosis 
Alcoholic steatosis is the most common histopatological feature of chronic alcoholic liver 
disease, is the first manifestation of excessive alcohol consumption. In terms of histology is 
translated by the accumulation of lipid droplets in the form of vacuoles of various sizes in 
the cytoplasm. Hepatic steatosis is present under three forms: microvesicular, 
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macrovesicular a  and mixed.  In microvacuolar form the lipid inclusions have small 
dimensions and they are evenly distributed in cytoplasm without changing the nucleus 
position while the macrovacuolar form is characterized by the presence of a single large 
vacuole, occupying the entire cytoplasm of the hepatocyte pushing the nucleus to the 
periphery. Although histologically can be traced all three forms, in most cases is present the 
macrovacuolar steatosis (Figure 1). Some authors use the term steatosis and steatohepatitis 
to designate the same lesion while alcohol can induce a pure steatosis without inflammatory 
components. At other patients alcohol induces an acute hepatitis superposed steatosis. 
Zonal distribution of steatosis in alcoholic liver disease involves initially zone three and then 
the acinar part of zone two following that in severe steatosis the distribution to be diffuse 
involving the entire acinus (Cornianu et al., 2007). 
 
Fig. 1. Alcoholic chronic hepatitis, HE, x200 – panlobular macrovesicular steatosis with 
degenerative change. 
3.2 Necroinflammatory process 
The most important lesion in chronic hepatitis is “interface hepatitis” (piecemeal necrosis). 
Hepatocyte necrosis is with variable disposition and extension. It highlights coagulation 
necrosis of some isolated cells or Councilman acidophil bodies in periportal areas.  
  
Fig. 2. Alcoholic chronic hepatitis. Focal necrosis, inflammatory infiltrate and acidophilic 
hepatocytes, HE, x200 (left). Bridging necrosis – large hepatocyte destruction (right).    
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Destruction of nearby group of hepatocytes located at the edge of liver parenchyma and 
portal connective structures, through cell-mediated immune mechanism, causes 
piecemeal necrosis. Unicellular necrosis located intralobular is betrayed by the presence of 
acidophil hepatocytes in an inflammatory outbreak. The infiltrative inflammatory process 
is made up of lymphocytes, plasmocytes but also of fibroblasts and fibrocytes (Figure 2). 
A more severe injury is confluent hepatic necrosis which forms porto-portal and porto-
centrolobular bridges - bridging necrosis (Figure 2). Damaged hepatocytes place is taken 
by the collagen fibers and lymphocytes forming cords which linking the neighboring 
portal spaces and/or portal spaces and centrilobular veins. Association of periportal 
necrosis in bridges indicates a rapid progression to cirrhosis, in which the formed bridges 
become dense collagen septum which disorganizes the lobular architecture, forming 
hepatocyte nodules (Ishak, 2000).  
3.3 Fibrosis 
Fibrosis is an important element in chronic alcoholic hepatitis, being useful for the correct 
diagnosis, prognosis and the evolution of the disease. Toxic liver injury characterized by 
sinusoidal fibrosis, necrosis of pericentral hepatocytes, and narrowing and eventual fibrosis 
of central veins. The primary site of the toxic injury is represented by sinusoidal endothelial 
cells, followed by a circulatory compromise of centrilobular hepatocytes and fibrosis (De 
Leve et al., 2002). Liver cell necrosis is associated with varying degrees of perivenular, 
centrilobular, and pericellular fibrosis (Yip & Burt, 2006). Liver fibrosis is translated by a 
wide range of histopathological lesions:    
- collagenization of the port areas (Figure 3) 
- presence of bridging fibrosis porto-portal and porto-central fibrosis (as a consequence 
of disease progression) (Figure 3) 
- perivenular fibrosis (Figure 4) (designated as a histological feature of alcoholic liver 
disease) – evidenced as a fibrous sleeve surrounding the terminal hepatic venula on at 
least two thirds of its circumference, being considered as a marker of progress to liver 
cirrhosis 
  
Fig. 3. Alcoholic chronic hepatitis. Portal fibrosis, Gömöri staining, x200 (left). Bridging 
fibrosis (porto-portal), silver staining, x200 (right). 
 
Trends in Alcoholic Liver Disease Research – Clinical and Scientific Aspects 
 
68
macrovesicular a  and mixed.  In microvacuolar form the lipid inclusions have small 
dimensions and they are evenly distributed in cytoplasm without changing the nucleus 
position while the macrovacuolar form is characterized by the presence of a single large 
vacuole, occupying the entire cytoplasm of the hepatocyte pushing the nucleus to the 
periphery. Although histologically can be traced all three forms, in most cases is present the 
macrovacuolar steatosis (Figure 1). Some authors use the term steatosis and steatohepatitis 
to designate the same lesion while alcohol can induce a pure steatosis without inflammatory 
components. At other patients alcohol induces an acute hepatitis superposed steatosis. 
Zonal distribution of steatosis in alcoholic liver disease involves initially zone three and then 
the acinar part of zone two following that in severe steatosis the distribution to be diffuse 
involving the entire acinus (Cornianu et al., 2007). 
 
Fig. 1. Alcoholic chronic hepatitis, HE, x200 – panlobular macrovesicular steatosis with 
degenerative change. 
3.2 Necroinflammatory process 
The most important lesion in chronic hepatitis is “interface hepatitis” (piecemeal necrosis). 
Hepatocyte necrosis is with variable disposition and extension. It highlights coagulation 
necrosis of some isolated cells or Councilman acidophil bodies in periportal areas.  
  
Fig. 2. Alcoholic chronic hepatitis. Focal necrosis, inflammatory infiltrate and acidophilic 
hepatocytes, HE, x200 (left). Bridging necrosis – large hepatocyte destruction (right).    
 
Endothelial Markers and Fibrosis in Alcoholic Hepatitis 
 
69 
Destruction of nearby group of hepatocytes located at the edge of liver parenchyma and 
portal connective structures, through cell-mediated immune mechanism, causes 
piecemeal necrosis. Unicellular necrosis located intralobular is betrayed by the presence of 
acidophil hepatocytes in an inflammatory outbreak. The infiltrative inflammatory process 
is made up of lymphocytes, plasmocytes but also of fibroblasts and fibrocytes (Figure 2). 
A more severe injury is confluent hepatic necrosis which forms porto-portal and porto-
centrolobular bridges - bridging necrosis (Figure 2). Damaged hepatocytes place is taken 
by the collagen fibers and lymphocytes forming cords which linking the neighboring 
portal spaces and/or portal spaces and centrilobular veins. Association of periportal 
necrosis in bridges indicates a rapid progression to cirrhosis, in which the formed bridges 
become dense collagen septum which disorganizes the lobular architecture, forming 
hepatocyte nodules (Ishak, 2000).  
3.3 Fibrosis 
Fibrosis is an important element in chronic alcoholic hepatitis, being useful for the correct 
diagnosis, prognosis and the evolution of the disease. Toxic liver injury characterized by 
sinusoidal fibrosis, necrosis of pericentral hepatocytes, and narrowing and eventual fibrosis 
of central veins. The primary site of the toxic injury is represented by sinusoidal endothelial 
cells, followed by a circulatory compromise of centrilobular hepatocytes and fibrosis (De 
Leve et al., 2002). Liver cell necrosis is associated with varying degrees of perivenular, 
centrilobular, and pericellular fibrosis (Yip & Burt, 2006). Liver fibrosis is translated by a 
wide range of histopathological lesions:    
- collagenization of the port areas (Figure 3) 
- presence of bridging fibrosis porto-portal and porto-central fibrosis (as a consequence 
of disease progression) (Figure 3) 
- perivenular fibrosis (Figure 4) (designated as a histological feature of alcoholic liver 
disease) – evidenced as a fibrous sleeve surrounding the terminal hepatic venula on at 
least two thirds of its circumference, being considered as a marker of progress to liver 
cirrhosis 
  
Fig. 3. Alcoholic chronic hepatitis. Portal fibrosis, Gömöri staining, x200 (left). Bridging 
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Fig. 4. Alcoholic chronic hepatitis – perivenular fibrosis. Gömöri staining, x400 (left) and 
Immunohistochemistry, collagen IV staining,  x100 (right). 
- collagenosis of the Disse space - capillarization of the hepatic sinusoids –   accompanies 
progressive necroinflammation (Figure 5) 
- regenerative nodules surrounded by fibrous connective septa (Figure 5) 
  
Fig. 5. Alcoholic hepatitis. Collagenization of the Diss space, silver staining, x400 (left) 
Fibrous connective septa, Gömöri staining, x400 (right). 
 
 
Fig. 6. Immunohistochemistry, collagen III positive staining at the portal area, x100. 
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In the fibrotic liver, the amounts of type III collagen (specific stroma) are increased not only 
in regions of portal fibrosis but also in the sinusoidal wall (Figure 6) (Sato et al., 2000). The 
first sign that the specific stroma participates in this liver injury is mirrored in the structure 
of the argyrophylic fibres. In the areas displaying of the hepatocytes necrosis, the process 
affects the argyrophylic fibres network of the specific stroma (Márcia Bersane et al., 2008). In 
an immunohistochemical study made on rat liver, Wei-Dong and collab., showed that in the 
normal liver, collagen I, III and IV is to be found at the level of the hepatic capsule, in the 
walls of blood vessels and in portal areas (Du et al., 1999). The hepatic sinusoids present 
positive reaction for collagen III and IV, but negative for collagen I (Marcia Bersane, 2008). 
Under pathological circumstances that engage the proliferation of the conjunctive tissue at 
hepatic level, numerous procollagen peptides-type IV and especially type III are formed in 
an excessive manner (Zhou et al., 2008). Collagen IV, being a constituent of the base 
membrane, accumulates in a precocious way both in viral hepatitis and in alcoholic 
hepatitis. Under conditions of viral or toxic aggression, collagen III and IV accumulates at 
the level of necrosis areas and along fibrous septa. In alcoholic hepatic fibrosis, increase the 
extracellular matrix protein expression of such as type III and IV collagen (Buck & Chojkier, 
2003; Márcia Bersane, 2008; Bo et al., 2001; Fu et al., 2004). In the case of the alcoholic liver, in 
the fibroses areas, are detected an intensely positive reaction for collagen IV at the level of 
the portal tract and the central vein, but also at the level of Disse space, between the 
sinusoid cells and hepatocytes (Gorrellet al., 2003). After repeated injury, the extracellular 
matrix of basement membrane including type I, III, and IV collagen is over-deposited in 
perisinusoid (Li et al., 2005, Iwahashi et al., 2001).   
4. Endothelial markers CD31 and CD34 expression and liver fibrosis 
Under normal condition, the hepatic sinusoidal cells and the Kupffer cells express cell 
adhesion molecule like PECAM-1 (CD31) and ICAM-2 (intercellular cell adhesion molecule). 
Several studies were done to evaluate CD31 immunoreactions in liver disease, including 
alcoholic hepatitis. Ramadori et al. concluded that the expression pattern of CD31 is down 
regulated during inflammatory liver injury (Ramadori et al., 2008; Saile & Ramadori, 2007). 
In a study made on 103 patients with chronic viral and alcoholic hepatitis, Asanaza 
remarked that the pattern of the CD31 expression is negative in lymphocytes, in the bile 
epithelium cells, in the hepatocytes in the periportal area and in the central lobular area, but 
positive in sinusoidal endothelial cells, as well as at the level of the lobular and portal 
vessels, both in mild affections of the liver and in severe hepatic inflammation (Asanza et al., 
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Fig. 4. Alcoholic chronic hepatitis – perivenular fibrosis. Gömöri staining, x400 (left) and 
Immunohistochemistry, collagen IV staining,  x100 (right). 
- collagenosis of the Disse space - capillarization of the hepatic sinusoids –   accompanies 
progressive necroinflammation (Figure 5) 
- regenerative nodules surrounded by fibrous connective septa (Figure 5) 
  
Fig. 5. Alcoholic hepatitis. Collagenization of the Diss space, silver staining, x400 (left) 
Fibrous connective septa, Gömöri staining, x400 (right). 
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angiogenesis (Schlingemann et al., 1990). Microvessels stained by anti-CD34 are capillary-
like, rather than having the appearance of sinusoids in normal liver (Poon  et al., 2002). In  
nontumor liver  tissues CD34 expression was mainly confined to small vessels in the portal 
area and also seen in sinusoids in the liver parenchyma near potral areas, with dotty, linear, 
semicircular and circular staining patterns. In tumor tissues, the characteristics of positive 
staining were similar to those in nontumor tissues. A study made on 324 patients with 
chronic alcoholic hepatitis, proved that the pattern of expression CD34 was moderately 
expressed in the periportal endothelium cells (Chedidi et. al., 2004). Some researchers have 
proved that CD34 is expresses in chronic hepatitis at the level the progenitor oval cells 
(Paku, 2001; Forbes et al., 2002; Weiss et. al., 2008). 
In our recent study, we investigated the expression of the endothelial cell markers CD31 and 
CD34 to determine the degree of vascular distribution in alcoholic chronic hepatitis and 
compare it with liver fibrosis. The immunohistochemical technique was made in order to 
complete the histological study and in order to highlight certain particular aspects of the 
liver when under aggression of toxic agents.   
We noticed an unspecific lesion pattern, with variable histological aspects both at the level 
of the parenchyma and at the level of the extracellular matrix. At the lobular level we 
noticed areas with apparently unaltered architectonics but also some altered areas caused by 
the enlargement of the port spaces as a result of the inflammatory processes and/or fibrosis. 
At the port level, we signaled inflammation of varied intensity. The infiltrative 
inflammatory process is made up of lymphocytes, plasmocytes but also of fibroblasts and 
fibrocytes. The perilobular inflammatory process turns into an interlobular one on some 
preparations, the inflammatory infiltrate having the same structure as the one present at the 
level of the port area. The capacity of the immune system cells to infiltrate the liver 
represent a consequence of the hepatic toxic injury and has been characterized in alcoholic 
hepatitis. Leukocyte infiltration into the liver parenchyma of immune cells includes 
monocytes, lymphocytes and neutrophils (Thiele et. al., 2004). At the cell level, especially at 
the cells in the peripheral lobule area, thus in the proximity of the portal areas, we identified 
hepatocytes which displayed alterations of degenerative type: micro- and macro-vesicular 
steatosis and balloon cell degeneration (Le Bousse-Kerdilès et al., 2008). 
By means of the trichromic colorations applied in all the study cases, we were able to identify 
the collagenization of the port areas, the collagenosis of the Disse spaces, perivenular fibrosis, 
and the extension of the fibrosis under the form of real fibrosis bridges. Through this the 
hepatic lesions were grouped in: minimum, mild, moderate and severe; while for fibrosis was 
obtained a valor scale from 1 to 4. Conform to fibrosis scoring methods the pathologic grading 
of fibrosis may be grouped in four categories (Table 2) (Brunt, 2000). 
Score                                         Description 
0                         No fibrosis 
1                         Stellate enlargement of portal tract but without septa formation 
2                         Enlargement of portal tract with rare septa formation 
3                         Numerous septa without cirrhosis 
4                         Cirrhosis 
Table 2. Fibrosis Scoring. 
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Histological examination revealed no fibrosis (F0) in 8 patients (19,51%), stage 1 fibrosis (F1) 
in 6 patients (14,6%), stage 2 (F2) in 12 patients (29,2%), stage 3 (F3) in 12 patients (29,2%) 
and stage 4 (F4) in 3 patients (7,3%)(Figure 7). 
 
Fig. 7. The stage of fibrosis in patient with alcoholic liver disease. 
In our study, all the cases with normal liver histology were CD31 and CD34 negative. By 
analyzing the immunohistochemical reaction for CD31 we have noticed that this one is 
negative for the central lobular area, but CD31-positive cells were observed in vessels of the 
portal area and in the sinusoids of the hepatic parenchyma near the portal area (Figure 8).  
  
Fig. 8. Immunohistochemistry, anti CD31 staining, x100. Negative immunoexpression in 
central area (left) and positive expression in periportal space (right). 
CD34 displays positive immunoreactions at the level of endothelium cells in the hepatic 
sinusoid in the periportal area, at the level of the central lobular vein as well as at the level 
of the venules and arterioles in the portal area (Figure 9) (Popescu et al., 2009). 
CD34 pozitive reaction was found in 27,7% patients with F1 and F2 fibrosis and  73,3% 
patients with F3 and F4 fibrosis (Table 3). Additionally, the CD31 expression in all cases was 
mainly restricted to portal vessels and sinusoidal cells, in close relation with the periportal 
histological features or with inflammatory injury degree. CD31 pattern was positively 
expressed in 22,2% of cases with F1-F2 fibrosis and in 77,7% with F3-F4 of cases (Table 4). 
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Fig. 9. Immunohistochemistry, anti CD34 staining, x100. CD34 expression in portal area 
(left) and central area (right). 
CD 34 Stage F1 and F2 Stage F3 and F4 
CD 34 positives cells 27.7% 73.3% 
Table 3. Expression of CD34 in alcoholic liver. 
CD 31 Stage F1 and F2 Stage F3 and F4 
CD 31 positives cells 22.2% 77.7% 
Table 4. Expression of CD31 in alcoholic liver. 
Regarding correlation between stage of fibrosis and endolthelial cells markers, similar 
studies was done in liver disease. Akyol et al. investigate the relationships between the 
histopathological features of nonalcoholic fatty liver disease (NAFLD) and CD31 expression 
to identify hepatic stellate cell activation and capillarization. Their results showed a 
correlation between the fibrotic stage and CD31 expression, the highest staining scores of 
CD31 in zone 3, while the portal/septal area was the dominant zone for control groups 
(Akyol et al., 2005). On the other hand, angiogenesis plays an important role in chronic 
inflammation, accumulation of inflammatory infiltrate and fibrosis.  In liver, angiogenesis is 
characterized by capillarization of the sinusoid. Also, Amarapurkar and colleague evaluate 
the expression of CD34, vascular endothelial growth factor (VEGF) and fibrosis in chronic 
liver disease (Amarapurkar et al., 2007). They report that none of patient with normal liver 
histology expressed the CD34 or VEGF positives cells. The capillarization and the 
histological change at the sinusoidal level occur with inflammation and fibrosis (Park et al., 
1998). The degree of positivity increases with the stage of fibrosis. Also, they found 
significantly high expression of CD34 in hepatocellular carcinoma as compared to chronic 
disease. Increased vascular proliferation and pathological angiogenesis in hepatocellular 
carcinoma was reported in a comparison with chronic hepatitis and cirrhosis. The 
extracellular matrix affects the phenotype of the endothelial cells. The sinusoidal 
capillarization has the consequence the loss of endothelial fenestration and formation of 
variable amounts of basal membrane (Ichida et al., 1990; Semela & Dufour, 2004). 
Endothelial cells become positive for CD31 and CD34 and are used as indirect markers to 
detect microvascular density in liver carcinogenesis (Frachon et al., 2001).       
 




To sum up, a direct correlation existed between endothelial cell markers CD31 and 
CD34 epression and the progression of fibrosis in alcoholic liver disease. The 
immunohistochemical methods of this molecule can be an important clue in future 
prognostic strategies.  
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1. Introduction 
Alcohol consumption is one of the major source for chronic liver diseases. It is striking that 
women are more susceptible to the toxic effects of alcohol although alcoholic liver disease 
(ALD) is common in men (1). In recent times, global burden on ALD has prompted 
researchers to investigate this disease based on age, gender, social status and race. However, 
in all these conditions and known variable severities of ALD, the basic pathophysiological 
condition is oxidative stress, which leads to liver damage (1, 2). In an overview, ALD leads 
to hepatocyte death, liver cirrhosis and organ dysfunction through production of reactive 
oxygen species (ROS), inflammatory cytokines and mitochondrial impairment. ROS are 
important mediators of apoptosis in liver diseases and are produced in response to 
paracrine factors such as ethanol (EtOH) (2). This chapter focuses on the role of EtOH 
induced ROS mediated cell death.  
Over two decades, several pathways have been proposed in ALD. Recent studies have 
educated our understanding on these pathways, most of which work as cohort induced by 
direct/indirect effects of alcohol metabolism and clearance. Majority of cell death pathways 
(apoptosis, necrosis and the recently described necroptosis) converge at cellular damage 
associated with excessive production of ROS (superoxide (O2•–) and hydrogen peroxide 
(H2O2)) that results in oxidative stress (3, 4). Under pathophysiological conditions, 
NAD(P)H oxidase, xanthine oxidase (XO) and the mitochondrial respiratory chain are the 
major sources of ROS. Normally, 5% of the metabolized cellular oxygen is converted into 
ROS which are effectively detoxified by endogenous antioxidants such as superoxide 
dismutase (SOD), glutathione peroxidase (GPx) and catalase (Cat). ROS overproduction 
resulting from acute and chronic exposure to alcohol can exceed the capacity of endogenous 
antioxidants (5, 6).  Excessive ROS triggers various cellular signaling pathways leading to 
cell death in both vascular and epithelial cells. Although ROS is known to elicit liver 
damage, the signaling pathways operative in alcohol induced ROS overproduction in liver 
cells remain elusive. 
Mitochondrial respiratory chain is the second major source of cellular ROS. However, 
mitochondria itself is an important target for cellular ROS resulting in mitochondrial 
dysfunction and permeabilization of outer mitochondrial membrane (OMM) (7, 8). In 
addition, studies have demonstrated that inhibition of mitochondrial electron transport 
 
Trends in Alcoholic Liver Disease Research – Clinical and Scientific Aspects 
 
78
Schlingemann, R.O.; Rietveld, F.J.; de-Waal, R.M.; Bradley, N.J.; Skene, A.I.; Davies, A.J.; 
Greaves, M.F.; Denekamp, J. & Ruiter, D.J. (1990). Leukocyte antigen CD34 is 
expressed by a subset of cultured endothelial cells and on endothelial abluminal 
microprocesses in the tumor stroma. Lab. Invest., Vol.62, No. 6, pp. 690-696, ISSN 
0023-6837 
Thiele, G.M.; Duryeei, M.J.; Willisi, M.S.; Sorrelli, M.F.; Freemani, T.L.; Tumai, D.J. & 
Klasseni, L.W. (2004). Malondialdehyde-acetaldehyde (MAA) modified proteins 
induce pro-inflammatory and pro-fibrotic responses by liver endothelial cells. 
Comparative Hepatology, Vol.3, No.1, pp. 25, ISSN 1476-5926 
Poon, T.N.R.; Oi-Lin Ng, I.; Lau, C.; Yu, W.C.; Yang, Z-F.; Fan, S.T. & Wong, J. (2002). Tumor 
Microvessel Density as a Predictor of Recurrence After Resection of Hepatocellular 
Carcinoma: A Prospective Study, Journal of Clinical Oncology, Vol.20, No.7, pp. 1775-
1785, ISSN 0732-183X 
Yip, W.W. & Burt, A.D. (2006). Alcoholic liver disease. Semin Diagn Pathol. Vol.23, No.3-4, 
pp. 149-60, ISSN 0740-2570 
Zhou, Z.; Christofidou-Solomidou, M.; Garlanda, C. & DeLisser, H.M. (1999). Antibody 
against murine PECAM-1 inhibits tumor angiogenesis in mice. Angiogenesis, Vol.3, 
No.2, pp.181-188, ISSN 0969-6970 
Zhou, Y.J.; Yao, H.Q.; Wang, J.; Wang, H. & Chen, Y.C. (2008). Influence of spleen-firming 
therapeutics on collagen fibers of hepatic fibrosis rat. Journal of Chinese Clinical 
Medicine, Vol.3, No.2, pp. 82-86, ISSN 1562-9023 
Wang, L.T.; Zhang, B. & Chen, J.J. (2000). Effect of anti-fibrosis compound on collagen 
expression of hepatic cells in experimental liver fibrosis of rats. World Journal 
Gastroenterology, Vol.6, No.6, pp. 877-880, ISSN 1007-9327 
Weiss, T.S.; Lichtenauer, M.; Kirchner, S.; Stock, P.; Aurich, H.; Christ, B.; Brockhoff, G.; 
Kunz-Schughart, L.A.; Jauch, K.W.; Schlitt, H.J. & Thasler, W.E. (2008). Hepatic 
progenitor cells from adult human livers for cell transplantation. Gut, Vol.57, pp. 
1129-1138, ISSN 0017-5749 
5 
Ethanol-Induced Mitochondrial Induction  
of Cell Death-Pathways Explored 
Harish Chinna Konda Chandramoorthy,  
Karthik Mallilankaraman and Muniswamy Madesh 
Department of Biochemistry, Temple University School of Medicine, Philadelphia, PA, 
USA 
1. Introduction 
Alcohol consumption is one of the major source for chronic liver diseases. It is striking that 
women are more susceptible to the toxic effects of alcohol although alcoholic liver disease 
(ALD) is common in men (1). In recent times, global burden on ALD has prompted 
researchers to investigate this disease based on age, gender, social status and race. However, 
in all these conditions and known variable severities of ALD, the basic pathophysiological 
condition is oxidative stress, which leads to liver damage (1, 2). In an overview, ALD leads 
to hepatocyte death, liver cirrhosis and organ dysfunction through production of reactive 
oxygen species (ROS), inflammatory cytokines and mitochondrial impairment. ROS are 
important mediators of apoptosis in liver diseases and are produced in response to 
paracrine factors such as ethanol (EtOH) (2). This chapter focuses on the role of EtOH 
induced ROS mediated cell death.  
Over two decades, several pathways have been proposed in ALD. Recent studies have 
educated our understanding on these pathways, most of which work as cohort induced by 
direct/indirect effects of alcohol metabolism and clearance. Majority of cell death pathways 
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associated with excessive production of ROS (superoxide (O2•–) and hydrogen peroxide 
(H2O2)) that results in oxidative stress (3, 4). Under pathophysiological conditions, 
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major sources of ROS. Normally, 5% of the metabolized cellular oxygen is converted into 
ROS which are effectively detoxified by endogenous antioxidants such as superoxide 
dismutase (SOD), glutathione peroxidase (GPx) and catalase (Cat). ROS overproduction 
resulting from acute and chronic exposure to alcohol can exceed the capacity of endogenous 
antioxidants (5, 6).  Excessive ROS triggers various cellular signaling pathways leading to 
cell death in both vascular and epithelial cells. Although ROS is known to elicit liver 
damage, the signaling pathways operative in alcohol induced ROS overproduction in liver 
cells remain elusive. 
Mitochondrial respiratory chain is the second major source of cellular ROS. However, 
mitochondria itself is an important target for cellular ROS resulting in mitochondrial 
dysfunction and permeabilization of outer mitochondrial membrane (OMM) (7, 8). In 
addition, studies have demonstrated that inhibition of mitochondrial electron transport 
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results in ROS production leading to alteration in mitochondrial morphology and 
bioenergetics (9). Furthermore, OMM permeabilization leads to cytochrome c release and 
mitochondrial dysfunction (10). 
Multidomain proapoptotic Bcl-2 family proteins are suggested to play a role in O2•– induced 
mitochondrial dysfunction (11, 12). Studies have shown that chronic EtOH consumption 
increases the expression of anti-apoptotic Bcl-2 and Bcl-xL proteins by an interleukin-6-
dependent mechanism (13, 14). Though, up regulation of proapoptotic Bax protein is 
observed in patients with ALD, the roles of Bax and Bak in initiating mitochondrial 
apoptotic events are poorly understood. Our previous studies have shown that O2•–-
mediated mitochondrial phase of apoptosis is mainly dependent on Bid but not Bax (15, 16).  
Enhanced circulation of TNF-and other cytokines have been reported in both ALD 
patients and animal models (17). In ALD, alcohol-induced O2•– elicits production of 
proinflammatory cytokine such as TNF-which subsequently sensitizes hepatocyte cell 
death through gangliosides (18-23). Interestingly, in hepatocytes, TNF-binds to either 
TNFR1 (type1 tumor necrosis factor receptor) or TNFR2 (type 2 tumor necrosis factor 
receptor) to initiate cell death. TNF-mediated activation of apoptosis requires two adaptor 
molecules such as TNF receptor associated death domain protein (TRADD) and Fas –
activated death domain protein (FADD). These in turn activate caspase 8 which further 
proteolytically cleaves downstream caspases and pro apoptotic bcl-2 family protein Bid. The 
active form of Bid (t-Bid) facilitates OMM permeabilization (15). On the other hand, ligation 
of TNF-TNFRrecruits receptor-interacting protein 1 kinase (RIP1), TNFR death domain 
serine-theronine kinase 2 (TRAF2) which generates ceramide via activation of 
sphingomyelinases. Ceramide induces mitochondrial permeability transition pore (MPTP) 
opening, mitochondrial matrix swelling and membrane permeabilization, in concert with 
pro-apoptotic Bcl-2 family protein Bad (24). Recently our study has shown that TNF-α-
induced necroptosis, the alternate form of cell death, requires TNFR adaptor protein FADD 
and NFB downstream signaling molecule NEMO. FADD mediates the formation of 
necrosome consisting of RIP1-RIP3 kinases. The necrosome induced mitochondrial 
dysfunction in necroptosis requires Bax and Bak (25). TNFR1 mediated cell death is an 
extensively studied model and has been associated in many disease conditions including 
ALD.  
Ca2+ has been known as an important intracellular second messenger that plays a dual role 
in cell survival and death. In liver, Ca2+ signaling is known to regulate a variety of cellular 
functions ranging from proliferation to apoptosis. Under pathological conditions, elevation 
in intracellular calcium ([Ca2+]i) facilitates cell death (26, 27) via inositol 1,4,5-triphosphate 
(InsP3) (28, 29) and oxidation of STIM1(30). Inositol 1,4,5-triphosphate receptor (InsP3R)  
mediated [Ca2+]i changes leads to rapid Ca2+ release from ER and the subsequent Ca2+ entry 
through slow-activating plasma membrane store operated channels (SOC) (31-33). In 
hepatocytes, the Type II InsP3 R is known to trigger Ca2+ waves that can transmit through 
intercellular junctions throughout the liver (34). ER-mitochondria link and the 
mitochondrial Ca2+ ([Ca2+]m) uptake through uniporter is known to promote [Ca2+]m 
overload which subsequently leads to mitochondrial depolarization and increased mROS 
production (10, 28, 35, 36). The aberrant Ca2+ homeostasis has been linked with ALD (37, 38). 
Despite the vast knowledge, the actual intricacies on the mechanism of Ca2+ induced 
mitochondrial dysfunction remain largely unexplored. In addition to the functional damage, 
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the structural damage to the mitochondrion is known to play a very important role in 
accelerating EtOH induced apoptosis in hepatocytes. In support, a recent study has 
evidenced the mitochondrial structural changes (fig.1) in an animal model for ALD (39). 
 
Fig. 1. Mitochondria appearance under electron microscope (EM × 6000); A: Mitochondria in 
normal group; B: Mitochondria in model group. M: mitochondria, G: glycogen, N nucleus, 
ER: endoplasmic reticulum, LD: lipid droplet. The long arrow shows abnormally distributed 
chromatin in nuclei, the short one is megamitochondrion and the arrow head is U-type 
mitochondria (Electron micrograph reproduced with permission from  2007 Yan, M  et al. 
Originally published in World J Gastroenterology 2007April 28;13(16): 2352-2356). 
2. Role of ethanol in ROS production 
Oxidative stress has been implicated to play a major role in ALD. The formation of reactive 
oxygen species (ROS) and reactive nitrogen species (RNS) represent an important cause of 
oxidative injury associated with free radical formation. ROS is known to damage and 
degrade lipids, proteins and DNA by which it affects the structure and function of the cell. 
Using animal models and samples from subjects with ALD, studies have shown the role of 
ROS in EtOH induced tissue damage (40, 41). Modification of mitochondrial proteins by 
ROS to disulphide, sulphenic, sulphinic and sulphonic residues and RNS  to nitration 
products of tyrosine residues and nitrosation products of thiols have been well documented 
to occur in membrane and matrix proteins within mitochondria (42, 43). This section 
describes in detail the role of ROS in ALD.  Oxygen is foremost common chemical 
frequently involved in the formation of free radical. Molecular oxygen is oxidized to 
generate two molecules of water by accepting four electrons and protons at one time. 
During this process several intermediary state of reactants exist like superoxide (O2•–); 
peroxide (O22-), which normally exists in cells as hydrogen peroxide (H2O2); and the 
hydroxyl radical (OH•). Superoxide, peroxide, and the hydroxyl radical are considered the 
primary free radicals. It has been estimated that only about 3 to 5 percent of the 
O2 consumed by the mitochondrial respiratory chain is converted to ROS. Nevertheless, the 
toxic effects of oxygen in biological systems—such as oxidation of lipids, inactivation of 
enzymes, nucleic acid mutations and destruction of cell membranes are attributed to the 
reduction of O2 to free radicals. The first and foremost effect of alcohol metabolism in the 
cellular milieu is the loss of NAD+/NADH ratio that affects mitochondrial respiratory chain 
and subsequent generation of superoxide anion (44). In respect to EtOH induced ROS  
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results in ROS production leading to alteration in mitochondrial morphology and 
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production, our laboratory has demonstrated that EtOH induced mROS production lead to 
mitochondrial morphology changes and functional alterations (Fig. 2). Briefly, (1) Acute 
delivery of EtOH (50mM) resulted in mitochondrial fragmentation (filamentous to globular 
morphology - fig.2A). (2) EtOH-fragmented mitochondria exhibit exaggerated O2•–
production (fig.2B &C). (3) EtOH treatment induced elevated mROS, altered mitochondrial 
Ca2+ handling and mitochondrial dysfunction (fig.2D&E). (4) O2•– induced mitochondrial 
membrane potentialm) loss and cytochrome c release was abrogated by the 
antiapoptotic Bcl-2 protein Bcl-xL and (5) Bax/Bak double knockout cells are resistant to 
O2•– -mediated m loss and cytochrome c release, however, Bak but not Bax is essential for 
O2•–-induced m loss and cytochrome c release (fig 3A-D).  
 
Fig. 2. EtOH augments alterations of mitochondrial morphology, O2•– production, and 
mitochondrial Ca2+ uptake in live cells. (A) Mito-eGFP (enhanced GFP)-expressing vascular 
endothelial cells (left panel) were exposed to 50 mM EtOH for 30 h (right panel). EtOH 
treatment resulted in short, globular mitochondrial tubules. (B) Mito-eGFP-expressing cells 
either left untreated (top) or exposed for 30 h to 50 mM EtOH (bottom) were loaded with the 
mitochondrion-derived O2.– indicator MitoSOX Red and imaged by confocal microscopy. 
EtOH-treated cells, but not control cells, displayed enhanced mitochondrial O2•– production. 
(C) Quantitation of mitochondrial ROS production in live cells. Following treatment, cells 
were loaded with the mitochondrial Ca2+ indicator rhod-2 for 45 min and stimulated with 
bradykinin (BK; 10 nM). Representative traces of mitochondrial Ca2+ uptake in response to 
bradykinin in (D) control and (E) EtOH-treated cells. EtOH-treated cells, but not control 
cells, displayed sustained mitochondrial Ca2+ elevation. f.a.u., fluorescence arbitrary units. 
(Reproduced with permission from © 2009 Madesh et al. Originally published in Mol Cell 
Biol. 2009 Jun;29(11):3099-112). 
 




Fig. 3. (A) Wild type, bax–/– bak–/–  double knockout, bax–/–  and bak–/– MEFs were  probed for 
cytochrome c  in O2•– -generating system. m was measured after O2•– treatment in 
permeabilized, TMRE-loaded bax–/– bak–/– MEFs expressing (B) GFP alone or together with 
(C) Bak or (D) Bax. Cells were exposed to the O2•– -generating system or FCCP as indicated. 
(Reproduced with permission from © 2009 Madesh et al. Originally published in Mol Cell 
Biol. 2009 Jun;29(11):3099-112). 
Taken together it is evident that O2•–evokes mitochondrial phase of apoptosis during 
chronic EtOH exposure. In addition, O2•– mediated tBid generation induces selective 
activation of mitochondrial Bak, triggering cytochrome c release and m loss that lead to 
apoptosis (15). Though mitochondria is known to play a crucial role in EtOH induced cell 
death, the upstream signaling molecules other than O2•– that target mitochondria is a open 
area of research in ALD.  
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3. Calcium and its role in ROS mediated apoptosis  
[Ca2+]m signals are known to control variety of responses in liver including apoptosis. 
Chronic EtOH exposure in rats leads to sustained Ca2+ elevation that triggers MPTP 
opening. MPTP opening leads to Ca2+ overload in the mitochondria and results in 
mitochondrial swelling a phenomenon observed in EtOH fed rats but not in control rats (45). 
Cells at basal metabolic rate tightly regulate free Ca2+ in the range of 100 to 200 nM in both 
cytosol and mitochondria through NCX (Na+/Ca2+ exchanger), PMCA (Plasma membrane 
Ca2+-ATPase) and SERCA (Sarcoendoplasmic reticulum Ca2+-ATPase) pumps. Mitochondria 
play an important role in rapid uptake of Ca2+ through a uniporter and is then released 
slowly back into the cytosol (46-48). EtOH is known to induce elevated [Ca2+]i by altering 
the [Ca2+]m buffering capacity.  Endothelial cells lining the capillaries and veins are first to 
encounter ethanol. Ethanol exposure activates the endothelial cells which are known to 
signal the immune cells. Our studies have previously shown ROS generation by activated 
macrophages evoked an [Ca2+]i transient in endothelial cells (28). However sustained 
increase in [Ca2+]i coupled with altered mitochondrial Ca2+ handling capacity leads to 
irreversible cell injury (16, 28, 49). Though, the exact source of increased cellular Ca2+ in 
ALD is poorly understood, several pathways have been proposed for the increased calcium 
flux. Receptor mediated pathways (G Protein-Coupled Receptor and tyrosine kinase 
receptor) that generate second messengers like InsP3 which binds to InsP3R on endoplasmic 
reticulum trigger Ca2+ release (50). Further the [Ca2+]m uptake was directly proportional to 
the magnitude of  [Ca2+]c. Under pathophysiological conditions, the GPCR (G Protein-
Coupled Receptor) Ca2+ linked mROS is essential for leukocyte/endothelial cell adhesion 
(50). EtOH exposure in HepG2 cells induces [Ca2+]m overload that triggers mROS (fig 2D & 
E). In the cellular milieu, Ca2+ is compartmentalized as gradients in different organelles in 
the range of M to nM  (Ca2+=ER>mitochondria>lysosomes>cytosol=nucleus). During ALD 
the alterations in Ca2+ homeostasis leads to [Ca2+]m overload. Under pathological or 
physiological conditions [Ca2+]m  levels dictate the cells to program either towards cell death 
or survival signals in the liver. Accumulation of Ca2+ in mitochondria beyond the transition 
threshold opens the MPTP, resulting in m loss, mitochondrial swelling, mROS 
overproduction and finally leading to cell death (51).  
4. Mitochondrial permeability transition 
Ca2+-linked cell death program in ALD may be either apoptotic or necrotic phenomenon 
determined by OMM permeabilization and MPTP opening respectively. Ca2+ overload leads 
to oxidative stress that permanently leads to MPTP opening exposing the mitochondrial 
inner membrane permeable to all solutes of molecular weight up to 1.5Kd (39). Furthermore, 
the persistent MPTP opening leads to irreversible mitochondrial depolarization. 
Mitochondrial depolarization, in conjunction with mROS overproduction and subsequent 
inner mitochondrial membrane (IMM) damage sets the stage for apoptosis (52). A major 
pathway that leads to mitochondrial damage in a broad spectrum of inflammatory or 
ischemia-related conditions results from the amplification of mitochondrial and cytosolic 
O2•– production (53). ROS mediated cell death, in particular O2•–-mediated apoptosis, begins 
with rupture of the outer mitochondrial membrane (OMM) and cytochrome c release that 
subsequently trigger MPTP opening resulting in mitochondrial swelling. MPTP opening is 
also known to be involved in initiation of the apoptotic machinery without damage to the 
OMM. ROS and [Ca2+]m overload acts synergistically to trigger MPTP opening, and evokes 
cytochrome c release and subsequent activation of caspases (10).  
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O2•– or H2O2 exposure amplifies the Ca2+-induced MPTP opening in a permeabilized cell 
system which in turn could be attenuated with either O2•– scavengers SOD or SOD mimetic, 
MnTBAP, or H2O2 scavenger catalase (fig 4A & B). However, O2•– -induced cytochrome c 
release was insensitive to inhibitors of MPTP (16). Thus, MPTP opening is not essential for 
O2•–-induced cytochrome c release. In addition, exogenous delivery of cytochrome c 
eliminated the O2•– -induced m loss. These data suggest that integrity of the IMM and 
matrix space was preserved during O2•– -induced cytochrome c release (15, 16). 
 
Fig. 4. Effect of ROS on Ca2+-induced PTP opening and Cytochrome c release in 
permeabilized HepG2 cells. (A) O2•– -generating system (xanthine [0.1mM] plus xanthine 
oxidase [20 mU/ml]) and (B) H2O2 (90 mM) augmented Ca2+-induced depolarization (three 
pulses, 30 M CaCl2 each) and decreased mitochondrial Ca2+ uptake. These effects were 
inhibited by an O2•–-scavenger, MnTBAP (20 M; 68 ±4.5% decrease in depolarization and 
78 ±13% decrease in [Ca2+]c rise at 900 s; n=  3), and catalase (Cat; 2500U/ml), respectively. 
At the end of the measurements, cells were exposed to FCCP (Unc; 1M), a protonophore 
that caused rapid and complete dissipation of m. (Reproduced with permission from © 
2001 Madesh and Hajnóczky. Originally published in J. Cell Biol. 155:1003-1015). 
5. Role of Bcl-2 family proteins in ROS-induced m loss 
Although ROS-induced Ca2+ dependent MPTP opening is associated with cytochrome c 
release, in particular, superoxide selectively triggers OMM permeabilization and 
cytochrome c release independent of Ca2+ dependant MPTP opening. O2•– produced by the 
mitochondrial respiratory chain has been reported to cause cardiolipid destruction in the 
IMM and dissipation of the ΔΨm (54, 55). However, O2•– produced under various 
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pathophysiological conditions including ALD, causes OMM permeabilization in a Bax/Bak 
dependant manner. Antiapoptotic Bcl-2 family protein Bcl-xL prevents O2•–-induced m 
loss and cytochrome c release, implying a role for proapoptotic Bcl-2 proteins Bax and Bak. 
Despite their high homology, Bax and Bak have distinct subcellular localization and 
functional regulation. Bax is largely a cytosolic protein that undergoes conformational 
change that is prerequisite for mitochondrial phase of apoptosis. In contrast, Bak is a 
mitochondrial integral membrane protein which undergoes oligomerization upon activation 
by proapoptotic BH3-only proteins (tBid). O2•– -induced mitochondrial functional changes 
require either Bax or Bak. BH3 which constitute a subset of pro-apoptotic members of the 
Bcl-2 protein family are necessary to induce apoptosis (10, 56). O2•– -mediated m loss and 
cytochrome c release is absent in Bax/Bak (bax–/– bak–/–) doubly deficient cells. Interestingly, 
Bak is necessary and sufficient for O2•–-induced m loss and cytochrome c release. 
Mitochondria isolated from heart of bak–/– mice are resistant to O2•–-induced mitochondrial 
depolarization. Further, bid–/– deficient MEFs are also insensitive to O2•– -induced 
mitochondrial phase of apoptosis. Conversely, mitochondria from Bax-deficient mice 
display O2•– -induced mitochondrial depolarization. Upon TNF, Fas ligand or O2•– challenge, 
the cytosolic BH3-only protein Bid undergoes proteolytic processing (caspase 8 and caspase 
2) to generate active form of Bid-tBid. tBid elicited O2•–-induced mitochondrial 
depolarization and cytochrome c release requires Bak. Taken together, these findings  
 
Fig. 5. Mitochondria are prime target for EtOH-induced cell death-Scheme.  
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implicate the requirement of Bak and Bid for O2•–-induced m loss and cytochrome c 
release (15, 16, 24, 10, 57).  
6. Conclusion 
The aberrant rate of cell death is a hallmark of ALD. It is evident that ethanol induced ROS 
mediated oxidative stress is responsible for induction of apoptosis. The sequential events 
such as changes in redox status, increase in cytosolic ROS, sustained [Ca2+]m elevation and 
translocation of pro-apoptotic proteins from cytosol to mitochondria are intimately linked 
with ethanol metabolism (fig 5). Major cell death pathways such as apoptosis, necrosis and 
the recently described necroptosis are associated with oxidative stress. Though, ROS 
production is proposed as a major factor in ethanol induced cell death little is known about 
the downstream mechanisms of the multimode cell death. In conclusion, mitochondria are 
prime target where multiple stress signaling pathways converge to induce cell death in the 
context of ALD. 
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endogenous substances. Chronic alcohol consumption has long been associated with 
progressive liver disease towards the development of hepatic cirrhosis and subsequent 
increased risk for developing hepatocellular carcinomas. Many of the deleterious effects of 
alcohol can be attributed to its metabolism primarily occurring in hepatocytes (Lu & 
Cederbaum, 2008). 
Acute and chronic alcohol exposure increases the production of reactive oxygen species 
(ROS), lowers cellular antioxidant levels, and enhances oxidative stress in the liver 
(Cederbaum et al., 2009). Ethanol-induced oxidative stress plays a major role in the 
mechanisms by which ethanol sensitizes to liver injury (Cederbaum et al., 2009). In isolated 
hepatocytes, this damaging effect of chronic ethanol is evident in that a greater sensitivity to 
proapoptotic challenges is observed, more specifically, to the cytotoxic actions of tumor 
necrosis factor α (TNFα) (Hoek & Pastorino, 2004). The presence of alcohol results in an 
oxidative environment and TNFα mediated hepatocyte death (Pastorino & Hoek, 2000). 
Ethanol administration also facilitates apoptosis by increasing the amount of Fas protein 
expression on hepatocytes (McVicker et al., 2006). Besides ROS, reactive nitrogen species 
(RNS) generated in response to inducible nitric oxide synthase (iNOS) activation in 
hepatocytes during chronic alcohol exposure also contributes to liver injury (McKim et al., 
2003). iNOS knock-out mice were protected from ALD (McKim et al., 2003). Ethanol 
promotes oxidative stress, not only by increased formation of ROS but also depletion of anti-
oxidative defenses in hepatocytes. For instance, depletion of glutathione from mitochondria 
leads to increased accumulation of ROS (Fernandez-Checa et al., 1997).  
The induction of mitochondrial dysfunction is also linked to the metabolism of alcohol by 
cytochrome P4502E1 (CYP2E1) and increased oxidative stress (Cederbaum et al., 2009). 
Primary hepatocytes and rat hepatoma cells when treated with ethanol led to an increase in 
ROS/RNS and loss of mitochondrial function due to damaged mitochondrial DNA and 
ribosomes and subsequent inhibition of mitochondrial protein synthesis (Mantena et al., 
2007). These studies suggest that alcohol induced oxidative stress pathways in hepatocytes 
set the stage for proinflammatory cytokine induced cell death and alcoholic liver injury. 
2.2 Kupffer cells or liver resident macrophages 
Kupffer cells, non-parenchymal cells of the liver, are specialized macrophages located in the 
liver and their activation plays a central role in early ethanol-induced liver injury. In the 
universally accepted “two-hit” model of alcoholic liver injury, recognition of gut-derived 
endotoxin by the Kupffer cells is the first step leading to induction of pro-inflammatory 
responses (Thurman et al., 1999). Engagement of endotoxin with the Toll-like receptor 4 
(TLR4) and CD14 receptor on Kupffer cells activates the down-stream kinases, interleukin-1 
receptor associated kinase (IRAK) and I-kappa-B kinase (IKK) and transcription factor 
nuclear factor-κB (NFκB) and induction of pro-inflammatory cytokines such as TNFα 
(Takeda & Akira, 2005). Kupffer cells produce reactive oxygen species (ROS) in response to 
chronic alcohol exposure as well as endotoxin (Kono et al., 2000). Alcohol-induced 
sensitization to lipopolysaccharide (LPS) has been attributed to ROS production (Thakur et 
al., 2006a). Previous studies from Nagy and colleagues (Nagy, 2003) show that chronic 
ethanol feeding increases the sensitivity of Kupffer cells to LPS, leading to increased TNF 
expression. This sensitization can be reversed by treatment of primary cultures of alcohol-
exposed Kupffer cells with adiponectin, an anti-inflammatory adipokine (Thakur et al., 
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2006b). Globular adiponectin prevents LPS-stimulated TNFα expression in Kupffer cells 
through the activation of the interleukin (IL)-10/STAT3/HO-1 (heme oxygenase-1) pathway 
(Mandal et al., 2010). In vivo pretreatment with diphenyliodonium (DPI), an inhibitor of 
NADPH oxidase, in alcohol-fed rats, normalized ROS production, decreased LPS-induced 
extracellular signal-regulated kinase (ERK1/2) phosphorylation and inhibited TNF 
production in Kupffer cells (Kono et al., 2000; Thakur et al., 2006b). The importance of toll-
like receptors (TLR) particularly TLR4 expressed on Kupffer cells plays a major part in ALD. 
Based on studies so far, it is perceivable that increased sensitization of Kupffer cells to 
endotoxin/LPS resulting in enhanced inflammatory responses contributes to alcoholic liver 
disease.  
2.3 Dendritic cells 
Dendritic cells (DCs) are central mediators of immune regulation, yet little is known about 
liver DCs. Myeloid DCs (mDCs), one of the most potent antigen-presenting cells (APC) in 
vivo, represent a terminally differentiated stage of monocytes (Palucka et al., 1998). Myeloid 
dendritic cells (mDCs) capture antigens in the periphery and then migrate to the lymphoid 
organs to initiate immunity (Steinman & Inaba, 1999). Alcohol-treated mDCs show reduced 
IL-12, increased IL-10 production, and a decrease in expression of the costimulatory 
molecules CD80 and CD86 (Mandrekar et al., 2004). Cytokine profiles of mDCs isolated 
from ethanol-fed mice indicate enhanced interleukin (IL)-1β and IL-10 and decreased TNFα, 
IL-12, interferon gamma (IFN), and IL-6 secretion (Aloman et al., 2007; Eken et al., 2011). 
Altered DC function is one of the major changes induced by long-term alcohol consumption, 
which subsequently impairs the cellular immune response. Chronic alcoholism in the 
absence of liver disease in patients is associated with an increased secretion of inflammatory 
cytokines by peripheral blood dendritic cells (Laso et al., 2007). Hepatic DCs from chronic 
alcohol-fed mice are less affected than splenic DCs, which exhibit impaired functional 
maturation following CpG stimulation (Lau et al., 2006). Thus, alcohol exerts a negative 
influence on innate and adaptive immunity leading to severe immunosupression (Lau et al., 
2009). Inflammatory responses mediated by increased TNFα in liver fibrosis were associated 
with altered dendritic cell function (Connolly et al., 2009). Future studies are needed to 
identify signaling mechanisms contributing to DC dysfunction during chronic alcohol 
exposure. 
2.4 Neutrophils 
Neutrophils, the most abundant phagocyte constitutes 50% to 60% of the total circulating 
white blood cells and can secrete products that stimulate monocytes and macrophages. 
Neutrophil secretions increase phagocytosis and the formation of reactive oxygen 
compounds involved in intracellular killing (Soehnlein et al., 2008). In the alcoholic liver, 
damage by neutrophils can contribute to injury in response to the release of endotoxins 
produced by bacteria (Ricevuti, 1997). Neutrophil dysfunction in alcoholic hepatitis is 
associated with endotoxemia, increased expression of TLR2, 4, and 9 as well as energy 
depletion leading to increased incidence of infection (Stadlbauer et al., 2009). Augmentation 
of TLR 2, 4, and 9 did not improve phagocytic function of neutrophils, indicating that TLR 
overexpression may be the result and not the cause of neutrophil activation (Stadlbauer et 
al., 2009). Neutrophil contact with hepatocytes mediates oxidative killing of hepatocytes by 
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initiation of oxidative-stress mediated respiratory burst and neutrophil degranulation 
leading to hepatocellular necrosis (Ramaiah & Jaeschke, 2007). Induction of osteopontin 
(OPN), an important mediator of inflammation regulated by oxidative stress pathways 
(Maziere et al., 2010) is the likely contributing factor for higher neutrophil recruitment to the 
liver in female rats during alcoholic steatohepatitis (Banerjee et al., 2006). Hepatic neutrophil 
infiltration can be largely inhibited in vivo by a neutralizing OPN antibody (Banerjee et al., 
2006).  
2.5 T cells 
In alcoholic liver disease, the number of lymphocytes in the liver increases and the type and 
distribution of these infiltrating cells determines the nature of inflammation. Steatohepatitis 
is associated with a T helper (Th)1 cytokine response characterized by IFNγ and TNFα 
elevation, that reflects involvement of T lymphocytes, in particular CD4+ T cells (Tiegs, 
2007). In the liver, IL-17 secreting cells contribute to inflammatory infiltrates in alcoholic 
cirrhosis, and alcoholic hepatitis foci show many Th17 cells, including T lymphocytes and 
neutrophils (Lemmers et al., 2009). Chronic alcohol consumption significantly induces 
peripheral T cell lymphopenia in female C57BL/6 mice, up-regulates expression of CD43 on 
CD8+ T cells, increases the percentage of interferon--producing T cells; decreases the 
percentage of CD8+CD28+ T cells; and down-regulates the expression of CD28 on CD4+ T 
cells (Gurung et al., 2009; Laso et al., 2000). In vivo bromodeoxyuridine incorporation in the 
same experiments demonstrated that chronic alcohol consumption increases proliferation of 
memory T cells, and accelerates peripheral T cell turnover (Zhang & Meadows, 2005). 
Patients with advanced ALD show a high prevalence of circulating IgG and T-lymphocytes 
towards epitopes derived from protein modification by hydroxyethyl free radicals (HER) 
and end-products of lipid peroxidation. In both chronic alcohol-fed rats and heavy drinkers 
the elevation of IgG against lipid peroxidation-derived antigens is associated with an 
increased production of pro-inflammatory cytokines/chemokines and severity of 
histological signs of liver inflammation (Albano & Vidali, 2009).  
2.6 Natural killer (NK) and natural killer T (NKT) cells 
Although a variety of cell populations infiltrate the liver during inflammation, it is generally 
assumed that CD8+ T lymphocytes promote while natural killer (NK) cells inhibit liver 
fibrosis (Park et al., 2009). NK cells inhibited liver fibrosis by directly killing activated 
hepatic stellate cells and production of gamma-interferon (IFN) (Jeong & Gao, 2008). In a 
chronic alcohol exposure model, poly I:C activation of NK cell cytotoxicity against hepatic 
stellate cells was attenuated in ethanol-fed mice compared with pair-fed mice, which was 
due to reduced natural killer group 2 member D (NKG2D), tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL), and IFN expression on NK cells from ethanol-fed mice 
(Jeong et al., 2008). 
On the other hand, natural killer T cells (NKT) are an important subset of T lymphocytes 
and are unique in their ability to produce both Th1 and Th2 associated cytokines, thus being 
capable of steering the immune system into either inflammation or tolerance. Disruption of 
NKT cell numbers or function results in severe deficits in immune surveillance against 
pathogens and tumor cells. Experimental evidence suggests that hepatosteatosis may 
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increase resident hepatic as well as peripheral NKT cells. The change in NKT cell numbers 
in animal models of alcohol-related hepatosteatosis are associated with a disruption of 
cytokine homeostasis, resulting in a more pronounced release of proinflammatory cytokines 
which renders the steatotic liver highly susceptible to secondary insults (Minagawa et al., 
2004). In alcohol-fed animals, liver NKT cells increase, and further activation by alpha-
galactosylceramide causes lethal liver injury (Minagawa et al., 2004). This can be explained 
by alcohol-induced hepatocyte sensitization to cell-mediated lysis, which develops 
concomitant to increased cytolytic activity of natural killer T cells. Alcohol-fed natural killer 
T cell-deficient mice exhibit a delay in alcohol-induced liver injury (Minagawa et al., 2004). 
In general, based on the tissue microenvironment, NK and NKT cells can accelerate early 
liver injury by producing proinflammatory cytokines and killing hepatocytes in an oxidative 
milieu.  
2.7 Bone-marrow derived stem cells (BMSCs) 
While maturation, activation, and proliferation of lymphoid cells occurs in secondary 
lymphoid organs (spleen, thymus, and lymph nodes), generation of these cells occurs from 
progenitor cells termed as bone marrow derived stem cells. Bone marrow derived stem cells 
were originally thought to contribute to liver repair based on the environmental insult but 
recent evidence suggests these cells may contribute to liver injury and fibrosis (Dalakas et 
al., 2010). Alcoholic hepatitis patients show increased CD34+ cell counts in liver tissue and 
in blood as compared with matched controls. Alcohol induced liver injury mobilizes CD34+ 
stem cells into circulation and recruits them into the liver. These bone marrow derived stem 
cells contribute to the hepatic myofibroblast population but not to parenchymal lineages 
and do not promote hepatocyte repair (Dalakas et al., 2010). Bone marrow stem cells 
generally reside in a hypoxic environment and increased reactive oxygen species (ROS) 
modulates their cell cycle allowing them to escape the bone marrow and affecting their self-
renewal (Iwasaki & Suda, 2009). Recent studies show that acute alcohol exposure affects the 
hematopoeitic stem cell response to bacterial infections by inhibiting differentiation and 
impairing host defense in alcohol abusers (Raasch et al., 2010). Further Inokuchi et. al. 
(Inokuchi et al., 2011) indicate the importance of bone marrow derived cells in alcohol 
induced liver injury. Whether the effect of alcohol on stem cells links to alteration in 
immune and hepatocyte injury during ALD is unclear. 
3. Signaling pathways and inflammation 
3.1 Toll like receptors in ALD 
Toll-like receptors (TLRs) are membrane-associated or endosomal and recognize distinct 
microbial components activating different signaling pathways by selective utilization of 
adaptor molecules (Takeda & Akira, 2005). TLRs mediate responses to a number of danger 
signals including extracellular pathogens and intracellular mediators such as ROS, high 
mobility group protein (HMGB)1, fibrinogen and heat shock proteins (hsps) (Lotze et al., 
2007). The role of toll-like receptors (TLRs) and particularly TLR4 has been investigated in 
alcoholic tissue injury (Hritz et al., 2008; Uesugi et al., 2001; Inokuchi et al., 2011). Increasing 
evidence suggests that various TLRs, signaling components activated by TLRs play an 
important role in the pathogenesis of ALD. Figure 1 shows signaling adapters and kinases 
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(Maziere et al., 2010) is the likely contributing factor for higher neutrophil recruitment to the 
liver in female rats during alcoholic steatohepatitis (Banerjee et al., 2006). Hepatic neutrophil 
infiltration can be largely inhibited in vivo by a neutralizing OPN antibody (Banerjee et al., 
2006).  
2.5 T cells 
In alcoholic liver disease, the number of lymphocytes in the liver increases and the type and 
distribution of these infiltrating cells determines the nature of inflammation. Steatohepatitis 
is associated with a T helper (Th)1 cytokine response characterized by IFNγ and TNFα 
elevation, that reflects involvement of T lymphocytes, in particular CD4+ T cells (Tiegs, 
2007). In the liver, IL-17 secreting cells contribute to inflammatory infiltrates in alcoholic 
cirrhosis, and alcoholic hepatitis foci show many Th17 cells, including T lymphocytes and 
neutrophils (Lemmers et al., 2009). Chronic alcohol consumption significantly induces 
peripheral T cell lymphopenia in female C57BL/6 mice, up-regulates expression of CD43 on 
CD8+ T cells, increases the percentage of interferon--producing T cells; decreases the 
percentage of CD8+CD28+ T cells; and down-regulates the expression of CD28 on CD4+ T 
cells (Gurung et al., 2009; Laso et al., 2000). In vivo bromodeoxyuridine incorporation in the 
same experiments demonstrated that chronic alcohol consumption increases proliferation of 
memory T cells, and accelerates peripheral T cell turnover (Zhang & Meadows, 2005). 
Patients with advanced ALD show a high prevalence of circulating IgG and T-lymphocytes 
towards epitopes derived from protein modification by hydroxyethyl free radicals (HER) 
and end-products of lipid peroxidation. In both chronic alcohol-fed rats and heavy drinkers 
the elevation of IgG against lipid peroxidation-derived antigens is associated with an 
increased production of pro-inflammatory cytokines/chemokines and severity of 
histological signs of liver inflammation (Albano & Vidali, 2009).  
2.6 Natural killer (NK) and natural killer T (NKT) cells 
Although a variety of cell populations infiltrate the liver during inflammation, it is generally 
assumed that CD8+ T lymphocytes promote while natural killer (NK) cells inhibit liver 
fibrosis (Park et al., 2009). NK cells inhibited liver fibrosis by directly killing activated 
hepatic stellate cells and production of gamma-interferon (IFN) (Jeong & Gao, 2008). In a 
chronic alcohol exposure model, poly I:C activation of NK cell cytotoxicity against hepatic 
stellate cells was attenuated in ethanol-fed mice compared with pair-fed mice, which was 
due to reduced natural killer group 2 member D (NKG2D), tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL), and IFN expression on NK cells from ethanol-fed mice 
(Jeong et al., 2008). 
On the other hand, natural killer T cells (NKT) are an important subset of T lymphocytes 
and are unique in their ability to produce both Th1 and Th2 associated cytokines, thus being 
capable of steering the immune system into either inflammation or tolerance. Disruption of 
NKT cell numbers or function results in severe deficits in immune surveillance against 
pathogens and tumor cells. Experimental evidence suggests that hepatosteatosis may 
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increase resident hepatic as well as peripheral NKT cells. The change in NKT cell numbers 
in animal models of alcohol-related hepatosteatosis are associated with a disruption of 
cytokine homeostasis, resulting in a more pronounced release of proinflammatory cytokines 
which renders the steatotic liver highly susceptible to secondary insults (Minagawa et al., 
2004). In alcohol-fed animals, liver NKT cells increase, and further activation by alpha-
galactosylceramide causes lethal liver injury (Minagawa et al., 2004). This can be explained 
by alcohol-induced hepatocyte sensitization to cell-mediated lysis, which develops 
concomitant to increased cytolytic activity of natural killer T cells. Alcohol-fed natural killer 
T cell-deficient mice exhibit a delay in alcohol-induced liver injury (Minagawa et al., 2004). 
In general, based on the tissue microenvironment, NK and NKT cells can accelerate early 
liver injury by producing proinflammatory cytokines and killing hepatocytes in an oxidative 
milieu.  
2.7 Bone-marrow derived stem cells (BMSCs) 
While maturation, activation, and proliferation of lymphoid cells occurs in secondary 
lymphoid organs (spleen, thymus, and lymph nodes), generation of these cells occurs from 
progenitor cells termed as bone marrow derived stem cells. Bone marrow derived stem cells 
were originally thought to contribute to liver repair based on the environmental insult but 
recent evidence suggests these cells may contribute to liver injury and fibrosis (Dalakas et 
al., 2010). Alcoholic hepatitis patients show increased CD34+ cell counts in liver tissue and 
in blood as compared with matched controls. Alcohol induced liver injury mobilizes CD34+ 
stem cells into circulation and recruits them into the liver. These bone marrow derived stem 
cells contribute to the hepatic myofibroblast population but not to parenchymal lineages 
and do not promote hepatocyte repair (Dalakas et al., 2010). Bone marrow stem cells 
generally reside in a hypoxic environment and increased reactive oxygen species (ROS) 
modulates their cell cycle allowing them to escape the bone marrow and affecting their self-
renewal (Iwasaki & Suda, 2009). Recent studies show that acute alcohol exposure affects the 
hematopoeitic stem cell response to bacterial infections by inhibiting differentiation and 
impairing host defense in alcohol abusers (Raasch et al., 2010). Further Inokuchi et. al. 
(Inokuchi et al., 2011) indicate the importance of bone marrow derived cells in alcohol 
induced liver injury. Whether the effect of alcohol on stem cells links to alteration in 
immune and hepatocyte injury during ALD is unclear. 
3. Signaling pathways and inflammation 
3.1 Toll like receptors in ALD 
Toll-like receptors (TLRs) are membrane-associated or endosomal and recognize distinct 
microbial components activating different signaling pathways by selective utilization of 
adaptor molecules (Takeda & Akira, 2005). TLRs mediate responses to a number of danger 
signals including extracellular pathogens and intracellular mediators such as ROS, high 
mobility group protein (HMGB)1, fibrinogen and heat shock proteins (hsps) (Lotze et al., 
2007). The role of toll-like receptors (TLRs) and particularly TLR4 has been investigated in 
alcoholic tissue injury (Hritz et al., 2008; Uesugi et al., 2001; Inokuchi et al., 2011). Increasing 
evidence suggests that various TLRs, signaling components activated by TLRs play an 
important role in the pathogenesis of ALD. Figure 1 shows signaling adapters and kinases 
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down-stream of TLRs, some of which have been directly or indirectly altered by alcohol 
exposure and implicated in liver injury. The cross-talk of stress regulated intracellular 
molecules with TLRs, intracellular kinases and transcription factors resulting in alterations 
in cytokines/chemokines in ALD are of great importance and need further investigation.  
 
Fig. 1. Innate immune signaling in ALD. Toll like receptors particularly TLR4, in ALD, 
activate down-stream signaling adaptors, kinases and transcription factors to induce pro-
inflammatory cytokines and chemokines. All signaling molecules that have been studied in 
ALD are identified by black color font whereas molecules not studied in ALD yet are seen in 
white color font.  
Pattern recognition receptors (PRRs) are expressed on liver non-parenchymal and 
parenchymal cells and function as sensors of microbial danger signals enabling the 
vertebrate host to initiate an immune response. The complexity of cellular expression of 
PRRs in the liver provides unique aspects to pathogen recognition and tissue damage in the 
liver (Szabo et al., 2006). It is now well accepted that the innate immune system recognizes 
both damage (or danger)- and pathogen-associated molecular patterns (DAMPs and PAMPs, 
respectively) through pattern recognition receptors, such as Toll-like receptors (TLRs) 
and/or Nod-like receptors (NLRs). TLRs such as TLR4 and TLR2 that detect PAMPs for 
instance LPS and lipoproteins are located on the cell surface whereas TLRs such as TLR3, 
TLR7 and TLR9 that detect viral RNA and DNA are located in the endosome (Takeda & 
Akira, 2005). Engagement of LPS and activation of the CD14/TLR4 complex activates down-
stream signaling molecules such as IRAK1/4, TRAF6 leading to activation of MAP kinases  
 
Cellular Signaling Pathways in Alcoholic Liver Disease 
 
97 
and NFκB in the liver (Mandrekar & Szabo, 2009). Recent studies by (Hritz et al., 2008; 
Inokuchi et al., 2011) indicate the requirement for TLR4 in alcohol induced steatosis.  
Oxidative stress also contributes to TLR4 signaling in macrophages and various other cell 
types in the liver via NADPH oxidase (Park et al., 2004). A pivotal role for NADPH oxidase 
in TLR4 mediated alcoholic liver injury has been recently shown (Hritz et al., 2008; Thakur 
et al., 2006a). Gustot et. al. (Gustot et al., 2006) also showed that oxidative stress regulates 
TLR 2, 4, 6 and 9 mRNA induction in alcoholic liver injury. In vivo alcohol exposure 
activates oxidative stress pathways and increases sensitization to TLR ligands, particularly 
TLR4, in alcoholic liver disease (Hritz et al., 2008; Gustot et al., 2006). TLR2 deficiency did 
not seem to have a significant effect on alcoholic liver injury (Hritz et. al., 2008).  
The role of DAMPs in chronic liver diseases has been reported previously. Amongst the well 
characterized DAMPs, HMGB1, S100 proteins, hyaluronan and heat shock protein 60 
(hsp60) are known to be recognized by TLR2 and TLR4 (Lotze et al., 2007) . In addition, 
necrotic or apoptotic cells are also recognized as DAMPs by TLRs (Sloane et al., 2010). In 
alcoholic liver injury, apoptotic bodies generated due to alcohol-induced oxidative stress 
could be recognized by DAMPs (McVicker et al., 2007) and thus play an important role in 
inflammatory responses in the liver. 
3.2 IKK and MAPK signaling 
Activation of TLR4 recruits IRAK-1 to the TLR4 complex via interaction with MyD88 and 
IRAK-4 (Takeda & Akira, 2005). The role of MyD88, the common TLR4 adaptor molecule 
was recently evaluated in a mouse model of alcoholic liver injury (Hritz et al., 2008). These 
studies showed that MyD88 knock-out mice were highly susceptible to alcohol-induced 
fatty liver (Hritz et al., 2008). While alcohol feeding in TLR4 deficient mice prevented liver 
injury, alcohol-fed MyD88 deficient mice showed increased oxidative stress and liver injury 
(Hritz et al., 2008). TLR4-induced MyD88-dependent and independent pathways lead to 
IKK kinase activation resulting in pro-inflammatory cytokine production (Takeda & Akira, 
2005). Chronic alcohol exposure induces LPS-mediated IRAK-1 kinase activation in murine 
macrophages (Mandrekar et al., 2009).  
Members of the mitogen-activated protein kinase (MAPK) family including extracellular 
receptor activated kinases 1/2 (ERK1/2), p38 and c-jun-N-terminal kinase (JNK) are 
activated down-stream of TLRs resulting in pro-inflammatory cytokine TNFα production 
(Weinstein et al., 1992). Chronic alcohol increases LPS-induced ERK1/2 activation and 
subsequent transcription of Egr-1, an immediate early gene transcription factor, contributing 
to expression of TNF in murine hepatic macrophages (Kishore et al., 2002; Shi et al., 2002). 
LPS stimulation of Kupffer cells in vitro exposed to chronic alcohol in vivo exhibited 
increased p38 activity and decreased JNK activity (Kishore et al., 2001). Inhibition of p38 
activation completely abrogated alcohol-mediated stabilization of TNF mRNA likely via 
interaction with tristetraprolin (TTP) (Mahtani et al., 2001). Conversely, ERK1/2 inhibition 
did not alter TNFα mRNA stability but affected mRNA transcription in chronic alcohol 
exposed macrophages (Kishore et al., 2002).  
3.3 Transcription factors and alcohol 
TLR4-induced MyD88-independent signaling leads to activation of NFκB and/or interferon 
regulatory factor 3 (IRF3) resulting in induction of pro-inflammatory cytokines or Type I 
 
Trends in Alcoholic Liver Disease Research – Clinical and Scientific Aspects 
 
96
down-stream of TLRs, some of which have been directly or indirectly altered by alcohol 
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both damage (or danger)- and pathogen-associated molecular patterns (DAMPs and PAMPs, 
respectively) through pattern recognition receptors, such as Toll-like receptors (TLRs) 
and/or Nod-like receptors (NLRs). TLRs such as TLR4 and TLR2 that detect PAMPs for 
instance LPS and lipoproteins are located on the cell surface whereas TLRs such as TLR3, 
TLR7 and TLR9 that detect viral RNA and DNA are located in the endosome (Takeda & 
Akira, 2005). Engagement of LPS and activation of the CD14/TLR4 complex activates down-
stream signaling molecules such as IRAK1/4, TRAF6 leading to activation of MAP kinases  
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and NFκB in the liver (Mandrekar & Szabo, 2009). Recent studies by (Hritz et al., 2008; 
Inokuchi et al., 2011) indicate the requirement for TLR4 in alcohol induced steatosis.  
Oxidative stress also contributes to TLR4 signaling in macrophages and various other cell 
types in the liver via NADPH oxidase (Park et al., 2004). A pivotal role for NADPH oxidase 
in TLR4 mediated alcoholic liver injury has been recently shown (Hritz et al., 2008; Thakur 
et al., 2006a). Gustot et. al. (Gustot et al., 2006) also showed that oxidative stress regulates 
TLR 2, 4, 6 and 9 mRNA induction in alcoholic liver injury. In vivo alcohol exposure 
activates oxidative stress pathways and increases sensitization to TLR ligands, particularly 
TLR4, in alcoholic liver disease (Hritz et al., 2008; Gustot et al., 2006). TLR2 deficiency did 
not seem to have a significant effect on alcoholic liver injury (Hritz et. al., 2008).  
The role of DAMPs in chronic liver diseases has been reported previously. Amongst the well 
characterized DAMPs, HMGB1, S100 proteins, hyaluronan and heat shock protein 60 
(hsp60) are known to be recognized by TLR2 and TLR4 (Lotze et al., 2007) . In addition, 
necrotic or apoptotic cells are also recognized as DAMPs by TLRs (Sloane et al., 2010). In 
alcoholic liver injury, apoptotic bodies generated due to alcohol-induced oxidative stress 
could be recognized by DAMPs (McVicker et al., 2007) and thus play an important role in 
inflammatory responses in the liver. 
3.2 IKK and MAPK signaling 
Activation of TLR4 recruits IRAK-1 to the TLR4 complex via interaction with MyD88 and 
IRAK-4 (Takeda & Akira, 2005). The role of MyD88, the common TLR4 adaptor molecule 
was recently evaluated in a mouse model of alcoholic liver injury (Hritz et al., 2008). These 
studies showed that MyD88 knock-out mice were highly susceptible to alcohol-induced 
fatty liver (Hritz et al., 2008). While alcohol feeding in TLR4 deficient mice prevented liver 
injury, alcohol-fed MyD88 deficient mice showed increased oxidative stress and liver injury 
(Hritz et al., 2008). TLR4-induced MyD88-dependent and independent pathways lead to 
IKK kinase activation resulting in pro-inflammatory cytokine production (Takeda & Akira, 
2005). Chronic alcohol exposure induces LPS-mediated IRAK-1 kinase activation in murine 
macrophages (Mandrekar et al., 2009).  
Members of the mitogen-activated protein kinase (MAPK) family including extracellular 
receptor activated kinases 1/2 (ERK1/2), p38 and c-jun-N-terminal kinase (JNK) are 
activated down-stream of TLRs resulting in pro-inflammatory cytokine TNFα production 
(Weinstein et al., 1992). Chronic alcohol increases LPS-induced ERK1/2 activation and 
subsequent transcription of Egr-1, an immediate early gene transcription factor, contributing 
to expression of TNF in murine hepatic macrophages (Kishore et al., 2002; Shi et al., 2002). 
LPS stimulation of Kupffer cells in vitro exposed to chronic alcohol in vivo exhibited 
increased p38 activity and decreased JNK activity (Kishore et al., 2001). Inhibition of p38 
activation completely abrogated alcohol-mediated stabilization of TNF mRNA likely via 
interaction with tristetraprolin (TTP) (Mahtani et al., 2001). Conversely, ERK1/2 inhibition 
did not alter TNFα mRNA stability but affected mRNA transcription in chronic alcohol 
exposed macrophages (Kishore et al., 2002).  
3.3 Transcription factors and alcohol 
TLR4-induced MyD88-independent signaling leads to activation of NFκB and/or interferon 
regulatory factor 3 (IRF3) resulting in induction of pro-inflammatory cytokines or Type I 
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IFN (Fig 1) (Kawai et al., 2001; Fitzgerald et al., 2003). Studies so far have shown that chronic 
alcohol exposure induces LPS/TLR4 mediated NFκB activation in human monocytes and 
macrophages contributing to production of pro-inflammatory cytokine, TNFα (Mandrekar 
et al., 2009). Other investigators found that activated IRF3 binds to the TNFα promoter in 
macrophages after chronic alcohol administration (Zhao et al., 2008) and induces TNFα 
production. While IRF3 in myeloid cells contributes to alcoholic liver injury, IRF3 and Type I 
interferons in parenchymal cells appears to be protective (Petrasek et. al., 2010). Whether 
NFκB and IRF3 in myeloid cells act in concert with each other to increase pro-inflammatory 
cytokines and liver injury is not yet clear. LPS stimulation of JNK leads to phosphorylation 
of c-jun and subsequent binding of c-jun to CRE/activator protein (AP)-1 site in the TNF 
promoter (Diaz & Lopez-Berestein, 2000). Although chronic alcohol feeding decreased JNK 
activity without any effect on TNF mRNA, short-term alcohol exposure increased JNK 
phosphorylation as well as AP-1 binding in the presence of combined TLR4 plus TLR2 
stimulation (Oak et al., 2006) in human monocytes. Recent studies indicate a role for AP-1 in 
RANTES expression during alcohol mediated inflammation (Yeligar et al., 2009). 
Alcoholic steatosis is associated with increased expression of genes regulating fatty acid 
synthesis and suppression of genes involved in fatty acid oxidation (Crabb & 
Liangpunsakul, 2006). Transcription factors like sterol regulatory element binding protein 
(SREBP) and peroxisome proliferator activated receptor (PPAR) play a pivotal role in early 
alcoholic liver injury and rodent models as well as in vitro treatment with alcohol show 
downregulation of PPAR mRNA (Wan et al., 1995). Further, DNA binding activity of 
PPAR is significantly reduced resulting in decreased target gene expression after alcohol 
exposure (Galli et al., 2001). Decreased PPAR activity was accompanied by increased 
oxidative stress in the liver resulting in increased sensitization of TNFα induced liver injury 
(Crabb & Liangpunsakul, 2006). Further studies are needed to establish a direct relationship 
between oxidative stress, cytokines and hepatic fatty acid metabolism in alcoholic liver 
disease.  
The role of STAT3, another transcription factor in alcoholic liver injury has been 
investigated (Gao, 2005). Compared with wild-type mice, Kupffer cells from alcohol-fed 
hepatocyte-specific STAT3KO mice produced similar amounts of ROS and hepatic 
proinflammatory cytokines compared to control mice. On the other hand, Kupffer cells from 
M/N-STAT3KO mice produced higher ROS and TNFα compared with wild-type controls. 
These results suggest that STAT3 in hepatocytes promotes ROS production and 
inflammation whereas myeloid cell STAT3 reduces ROS and hepatic inflammation during 
alcoholic liver injury (Horiguchi et al., 2008). Endothelial STAT3 seems to play an important 
dual role of attenuating hepatic inflammation and sinusoidal endothelial cell death during 
alcoholic liver injury (Miller et al., 2010). Thus, STAT3 may regulate liver injury during 
alcohol exposure in a cell-type dependent manner. 
3.4 Anti-inflammatory pathways in ALD 
Diminution of inflammatory gene expression to curb the inflammatory response during 
ALD is pivotal to development of injury. Various anti-inflammatory mediators such as IL-
10, prostaglandins, transforming growth factor (TGF)-β (Schmidt-Weber & Blaser, 2004; 
Asadullah et al., 2003) have been identified to control the inflammatory response. In 
addition, intracellular signaling molecules such as IRAK-M, ST2, phosphoinositide (PI)3-
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kinase (K), suppressor of cytokine signaling (SOCS) 1, A20 and single immunoglobulin IL-
1R-related molecule (SIGIRR) (Han & Ulevitch, 2005) also contribute to the anti-
inflammatory pathway. While chronic alcohol did not significantly affect IL-10 during 
alcohol exposure in wild-type mice (Hill et al., 2002), IL-10 deficient mice showed greater 
susceptibility to alcoholic liver injury due to increase in pro-inflammatory cytokines (Hill et 
al., 2002). These results suggest that anti-inflammatory cytokine IL-10 is unable to counter-
regulate the sustained pro-inflammatory activation in the chronic alcoholic liver. Recent 
studies show that IL-10 was decreased in alcohol exposed Type-I IFN receptor deficient 
mice, indicating a role for Type I IFNs in induction of anti-inflammatory responses during 
ALD (Petrasek et al., 2011). Other immunoinhibitory molecules such as SOCS1 and SOCS3 
and adiponectin appear to induce anti-inflammatory responses during ALD. Adiponectin is 
decreased after chronic alcohol feeding and treatment of mice with adiponectin (Thakur et 
al., 2006b) prevents alcohol-induced liver injury. This protective effect of adiponectin has 
been attributed to decreased LPS-induced ERK1/2 signaling resulting in normalization of 
TNFα production by Kupffer cells after chronic alcohol exposure (Thakur et al., 2006b). 
Additional studies to understand anti-inflammatory mechanisms will provide a better 
understanding of the contribution of these molecules in alcohol-induced liver injury.  
4. Signaling pathways and hepatocyte injury 
Alcohol-induced liver disease is linked to a state of “oxidative stress” and induction of cell 
death. Alcohol exposure, whether acute or chronic increases production of ROS, lowers the 
anti-oxidant systems, and results in enhancement of oxidative stress. The consequences of 
ROS generation in the alcoholic liver are widespread. Some ROS related effects of alcohol 
include oxidative stress induced by metabolizing enzymes such as CYP2E1, formation of 
adducts, stress at the level of the endoplasmic reticulum, stress-induced heat shock proteins, 
regulation of nuclear receptors, all leading to sensitization of hepatocytes to cellular injury 
and death. 
4.1 Alcohol metabolism and oxidative stress  
The classical pathway of alcohol metabolism involves enzymatic breakdown of alcohol by 
the enzyme, alcohol dehydrogenase and its subsequent conversion to acetaldehyde and 
formation of free radicals. In addition, the microsomal electron transport system also 
oxidizes ethanol via catalysis by the cytochrome P450 enzymes. The 2E1 isoform of the 
cytochrome P450 system is induced during chronic alcohol consumption and results in 
formation of ROS and increased generation of hydroxyl radicals (Cederbaum, 2001). The 
role of CYP2E1 in hepatocyte injury has been elucidated using HEPG2 cells expressing 
CYP2E1 (Wu & Cederbaum, 1996). Increased oxidative stress from induction of CYP2E1 in 
vivo sensitizes hepatocytes to LPS and TNF toxicity (Wu & Cederbaum, 1996). Oxidants, 
such as peroxynitrite, activation of p38 and JNK MAP kinases and mitochondrial 
dysfunction are downstream mediators of the CYP2E1-LPS/TNF potentiated hepatotoxicity 
(Lu & Cederbaum, 2009). Further, studies indicate that oral alcohol feeding of CYP2E1 
knock-out mice prevents alcoholic liver injury and this may be due to inhibition of oxidative 
stress and up-regulation of PPAR (Lu et al., 2008). Oxidation of ethanol by alcohol 
dehydrogenase and subsequent metabolism of acetaldehyde results in increased 
NADH/NAD+ ratio in the cytoplasm and mitochondria. The increase in NADH results in 
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IFN (Fig 1) (Kawai et al., 2001; Fitzgerald et al., 2003). Studies so far have shown that chronic 
alcohol exposure induces LPS/TLR4 mediated NFκB activation in human monocytes and 
macrophages contributing to production of pro-inflammatory cytokine, TNFα (Mandrekar 
et al., 2009). Other investigators found that activated IRF3 binds to the TNFα promoter in 
macrophages after chronic alcohol administration (Zhao et al., 2008) and induces TNFα 
production. While IRF3 in myeloid cells contributes to alcoholic liver injury, IRF3 and Type I 
interferons in parenchymal cells appears to be protective (Petrasek et. al., 2010). Whether 
NFκB and IRF3 in myeloid cells act in concert with each other to increase pro-inflammatory 
cytokines and liver injury is not yet clear. LPS stimulation of JNK leads to phosphorylation 
of c-jun and subsequent binding of c-jun to CRE/activator protein (AP)-1 site in the TNF 
promoter (Diaz & Lopez-Berestein, 2000). Although chronic alcohol feeding decreased JNK 
activity without any effect on TNF mRNA, short-term alcohol exposure increased JNK 
phosphorylation as well as AP-1 binding in the presence of combined TLR4 plus TLR2 
stimulation (Oak et al., 2006) in human monocytes. Recent studies indicate a role for AP-1 in 
RANTES expression during alcohol mediated inflammation (Yeligar et al., 2009). 
Alcoholic steatosis is associated with increased expression of genes regulating fatty acid 
synthesis and suppression of genes involved in fatty acid oxidation (Crabb & 
Liangpunsakul, 2006). Transcription factors like sterol regulatory element binding protein 
(SREBP) and peroxisome proliferator activated receptor (PPAR) play a pivotal role in early 
alcoholic liver injury and rodent models as well as in vitro treatment with alcohol show 
downregulation of PPAR mRNA (Wan et al., 1995). Further, DNA binding activity of 
PPAR is significantly reduced resulting in decreased target gene expression after alcohol 
exposure (Galli et al., 2001). Decreased PPAR activity was accompanied by increased 
oxidative stress in the liver resulting in increased sensitization of TNFα induced liver injury 
(Crabb & Liangpunsakul, 2006). Further studies are needed to establish a direct relationship 
between oxidative stress, cytokines and hepatic fatty acid metabolism in alcoholic liver 
disease.  
The role of STAT3, another transcription factor in alcoholic liver injury has been 
investigated (Gao, 2005). Compared with wild-type mice, Kupffer cells from alcohol-fed 
hepatocyte-specific STAT3KO mice produced similar amounts of ROS and hepatic 
proinflammatory cytokines compared to control mice. On the other hand, Kupffer cells from 
M/N-STAT3KO mice produced higher ROS and TNFα compared with wild-type controls. 
These results suggest that STAT3 in hepatocytes promotes ROS production and 
inflammation whereas myeloid cell STAT3 reduces ROS and hepatic inflammation during 
alcoholic liver injury (Horiguchi et al., 2008). Endothelial STAT3 seems to play an important 
dual role of attenuating hepatic inflammation and sinusoidal endothelial cell death during 
alcoholic liver injury (Miller et al., 2010). Thus, STAT3 may regulate liver injury during 
alcohol exposure in a cell-type dependent manner. 
3.4 Anti-inflammatory pathways in ALD 
Diminution of inflammatory gene expression to curb the inflammatory response during 
ALD is pivotal to development of injury. Various anti-inflammatory mediators such as IL-
10, prostaglandins, transforming growth factor (TGF)-β (Schmidt-Weber & Blaser, 2004; 
Asadullah et al., 2003) have been identified to control the inflammatory response. In 
addition, intracellular signaling molecules such as IRAK-M, ST2, phosphoinositide (PI)3-
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kinase (K), suppressor of cytokine signaling (SOCS) 1, A20 and single immunoglobulin IL-
1R-related molecule (SIGIRR) (Han & Ulevitch, 2005) also contribute to the anti-
inflammatory pathway. While chronic alcohol did not significantly affect IL-10 during 
alcohol exposure in wild-type mice (Hill et al., 2002), IL-10 deficient mice showed greater 
susceptibility to alcoholic liver injury due to increase in pro-inflammatory cytokines (Hill et 
al., 2002). These results suggest that anti-inflammatory cytokine IL-10 is unable to counter-
regulate the sustained pro-inflammatory activation in the chronic alcoholic liver. Recent 
studies show that IL-10 was decreased in alcohol exposed Type-I IFN receptor deficient 
mice, indicating a role for Type I IFNs in induction of anti-inflammatory responses during 
ALD (Petrasek et al., 2011). Other immunoinhibitory molecules such as SOCS1 and SOCS3 
and adiponectin appear to induce anti-inflammatory responses during ALD. Adiponectin is 
decreased after chronic alcohol feeding and treatment of mice with adiponectin (Thakur et 
al., 2006b) prevents alcohol-induced liver injury. This protective effect of adiponectin has 
been attributed to decreased LPS-induced ERK1/2 signaling resulting in normalization of 
TNFα production by Kupffer cells after chronic alcohol exposure (Thakur et al., 2006b). 
Additional studies to understand anti-inflammatory mechanisms will provide a better 
understanding of the contribution of these molecules in alcohol-induced liver injury.  
4. Signaling pathways and hepatocyte injury 
Alcohol-induced liver disease is linked to a state of “oxidative stress” and induction of cell 
death. Alcohol exposure, whether acute or chronic increases production of ROS, lowers the 
anti-oxidant systems, and results in enhancement of oxidative stress. The consequences of 
ROS generation in the alcoholic liver are widespread. Some ROS related effects of alcohol 
include oxidative stress induced by metabolizing enzymes such as CYP2E1, formation of 
adducts, stress at the level of the endoplasmic reticulum, stress-induced heat shock proteins, 
regulation of nuclear receptors, all leading to sensitization of hepatocytes to cellular injury 
and death. 
4.1 Alcohol metabolism and oxidative stress  
The classical pathway of alcohol metabolism involves enzymatic breakdown of alcohol by 
the enzyme, alcohol dehydrogenase and its subsequent conversion to acetaldehyde and 
formation of free radicals. In addition, the microsomal electron transport system also 
oxidizes ethanol via catalysis by the cytochrome P450 enzymes. The 2E1 isoform of the 
cytochrome P450 system is induced during chronic alcohol consumption and results in 
formation of ROS and increased generation of hydroxyl radicals (Cederbaum, 2001). The 
role of CYP2E1 in hepatocyte injury has been elucidated using HEPG2 cells expressing 
CYP2E1 (Wu & Cederbaum, 1996). Increased oxidative stress from induction of CYP2E1 in 
vivo sensitizes hepatocytes to LPS and TNF toxicity (Wu & Cederbaum, 1996). Oxidants, 
such as peroxynitrite, activation of p38 and JNK MAP kinases and mitochondrial 
dysfunction are downstream mediators of the CYP2E1-LPS/TNF potentiated hepatotoxicity 
(Lu & Cederbaum, 2009). Further, studies indicate that oral alcohol feeding of CYP2E1 
knock-out mice prevents alcoholic liver injury and this may be due to inhibition of oxidative 
stress and up-regulation of PPAR (Lu et al., 2008). Oxidation of ethanol by alcohol 
dehydrogenase and subsequent metabolism of acetaldehyde results in increased 
NADH/NAD+ ratio in the cytoplasm and mitochondria. The increase in NADH results in 
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inhibition of mitochondrial -oxidation and accumulation of intracellular lipids leading to 
steatosis (Polavarapu et al., 1998; Wu & Cederbaum, 2003). Future studies on pathways 
activated by alcohol metabolism in various cell types of the liver would provide additional 
information to identify strategies to alleviate alcoholic liver injury. 
4.2 Alcohol and protein adducts 
Alcohol metabolism and oxidative stress results in the formation of reactive aldehydes such 
as acetaldehyde, malondialdehyde (MDA) and 4-hydroxy-2-nonenal (HNE) that can bind to 
proteins to form adducts. In vivo models of chronic alcohol consumption have shown that 
acetaldehyde, MDA and HNE adduct formation is increased in various organs including the 
liver. Acetaldehyde and MDA react with proteins synergistically to form hybrid protein 
adducts called malondialdehyde- acetaldehyde (MAA) adducts (Niemela et al., 1994). 
Recognition of MAA-adducts by Kupffer cells, endothelial and stellate cells via the 
scavenger receptor leads to upregulation of cytokine and chemokine production, and 
increased expression of adhesion molecules (Thiele et al., 2004; Duryee et al., 2005). 
Circulating antibodies to MAA-adducts were detected in patients with alcoholic hepatitis 
and cirrhosis and correlated with the severity of liver injury (Rolla, 2000). Although 
evidence suggests the existence of protein adducts during chronic alcohol consumption, 
their identification in animal models has been challenging and limits their role in 
pathogenesis of ALD.   
4.3 ER stress and ALD 
The unfolded protein response (UPR) that is a protective response of the cell is referred to as 
the ER stress response during pathological conditions. In alcoholic liver disease increased 
expression of GRP78, GRP94, CHOP and caspase-12 indicated a UPR/ER stress response 
(Kaplowitz & Ji, 2006). Up-regulation of ER-localized transcription factors and activation 
such as SREBP-1c and SREBP-2 was associated with increased lipid accumulation and 
induction of fatty liver during chronic alcohol (Ji et al., 2006). Another important inducer of 
ER stress, homocysteine, was increased in alcoholic human subjects leading to 
hyperhomocystenemia, also observed in alcohol feeding models (Ji & Kaplowitz, 2003). The 
role of ER stress in triglyceride accumulation and fatty liver comes from studies showing 
that betaine increases an enzyme, betaine homocysteine methyltransferase (BHMT) and 
reduces homocysteine levels to inhibit lipid accumulation (Ji & Kaplowitz, 2003). Although 
several studies suggests a pivotal role for ER stress in alcoholic liver disease, the alcohol-
mediated mechanisms that trigger ER stress are not fully understood.  
4.4 Alcohol and heat shock proteins 
Stress or heat shock proteins (hsps) are ubiquitious, highly conserved proteins and 
originally identified for their cytoprotective function and assistance in the correct folding of 
nascent and stress-accumulated misfolded proteins. Oxidative stress induces heat shock 
proteins via activation of the heat shock transcription factor (HSF) (Finkel & Holbrook, 
2000). Earlier studies on the effects of ethanol on the heat shock proteins in neuronal cells 
(Miles et al., 1991) showed that chronic alcohol increases Hsc 70 mRNA transcription and 
this may be important in neuronal adaptation and development of tolerance and 
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dependence in alcoholics. Male Wistar rats fed with acute as well as chronic ethanol feeding 
(for 12 weeks) showed induction of hsp70 in the various regions of the brain and the liver 
(Calabrese et al., 1996; Calabrese et al., 1998). Hsp90 levels were also increased in cultured 
rat hepatocytes exposed to acute alcohol (Ikeyama et al., 2001). Studies have also shown that 
acute and chronic alcohol induces HSF activation and differentially induces hsp70 and 
hsp90 to affect inflammatory cytokine production in macrophages (Mandrekar et al., 2008). 
Comprehensive studies on the role of heat shock proteins and their chaperone function in 
the liver will provide further information to develop therapeutic strategies in ALD.  
4.5 Alcohol and nuclear receptors 
Nuclear receptors are a class of unique intracellular transcription factors that are activated 
by their ligands and can directly bind to DNA to regulate transcription of target genes that 
play key roles in development and cellular homeostasis (Wang & Wan, 2008). Three groups 
of nuclear receptors exist: the first is the classic steroid or thyroid hormone receptors such as 
glucocorticoid reeptor (GR) and thyroid receptor (TR), the second is the nuclear orphan 
receptors such as the nuclear receptor related-1 (Nurr-1) and neuron derived orphan 
receptor-1 (NOR1), the third class receptors that include the retinoid X receptor (RXR), 
peroxisome proliferators activated receptors (PPARs) and liver X receptor (LXR). It is the 
third class of nuclear receptors, particularly PPARs that are implicated in hepatic lipid 
metabolism and inflammatory processes and have been the main area of interest in alcohol-
induced steatosis. Among various PPARs, the importance of PPAR in lipid metabolism 
and PPAR in inflammatory processes is being investigated in alcoholic liver disease (Crabb 
& Liangpunsakul, 2006). PPAR dimerizes with another nuclear receptor, RXR to control 
transcription of target genes involved in free fatty acid transport and oxidation (Issemann & 
Green, 1990; Bocos et al., 1995). Whereas PPAR is an essential regulator for adipocyte 
differentiation and lipid storage in mature adipocytes (Rosen & Spiegelman, 2001; Tsai & 
Maeda, 2005), both PPAR and PPAR exert anti-inflammatory effects (Wang & Wan, 2008). 
Ethanol feeding of mice induced fatty liver injury and was accompanied by inhibition of 
transcriptional and DNA binding activity of PPAR, resulting in decreased expression of 
target genes such as carnitine palmitoyl transferase-1 (CPT-1) (Galli et al., 2001; Nakajima et 
al., 2004). Ethanol seemed to down-regulate RXR expression and PPAR levels to influence 
PPRE binding (Wan et al., 1995; Beigneux et al., 2000). Like hepatocyte-specific RXR 
deficient mice, PPAR-null mice are more susceptible to alcohol-induced liver injury 
(Nakajima et al., 2004; Gyamfi et al., 2008). Treatment with PPAR agonists WY14643 
resulted in increased expression of genes related to fatty acid oxidation and hence 
amelioration of alcoholic liver disease (Fischer et al., 2003). Thus, it appears that impaired 
activation of PPAR during ethanol consumption contributes to alcoholic fatty liver 
induction. Recent studies show that PPARα and γ agonists can reduce severity of chronic 
alcohol induced liver injury even in the context of continued alcohol consumption (de la 
Monte et al., 2011). Thus, nuclear localization of PPARs and their DNA binding partners, 
RXRs seem to play an important role in alcohol induced fatty liver injury.  
4.6 Death receptor pathways: intrinsic and extrinsic 
Chronic alcohol-induced hepatocyte apoptosis is a multifactorial process and involves 
interactions of oxidative stress and cytokines that activate death receptors and 
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mitochondrial death pathways (Fig 2). Studies show that chronic alcohol-induced 
hepatocyte apoptosis occurs via the receptor-mediated pathway: TNF and Fas receptors, 
and the intrinsic pathway: mitochondrial apoptotic pathway (Hoek & Pastorino, 2002). 
Activation of the death receptor pathways, Fas/FasL and TNF/TNFR1 is strongly 
implicated in alcoholic liver disease (Hoek & Pastorino, 2002). Increased TNF and TNF-R1 
levels in animal models and humans with alcohol steatohepatitis have suggested an 
involvement of the TNF/TNF-R1 pathway in hepatocyte killing (Pastorino et al., 2003; 
Pianko et al., 2000). Increased oxidative stress in chronic alcohol exposed rats promotes 
hepatocyte apoptosis and necrosis and is implicated in the alcohol-induced sensitization to 
the pro-apoptotic action of TNF (Pastorino et al., 2003; Pastorino & Hoek, 2000). 
Additionally, TNFR1 knock-out mice, but not TNFR2 knock-out mice, were resistant to 
alcoholic liver injury (Yin et al., 2008) further strengthening a role for the TNF/TNFR1  
 
Fig. 2. Apoptotic signaling pathways in ALD. Two major apoptotic pathways are illustrated: 
one activated via death receptor activation ('extrinsic') and the other by stress-inducing 
stimuli ('intrinsic'). Triggering of cell surface death receptors of the tumour necrosis factor 
(TNF) receptor superfamily, including CD95 (Fas) and TNF-related apoptosis-inducing 
ligand (TRAIL)-R results in rapid activation of the initiator caspase 8 through the adaptor 
molecule Fas-associated death domain protein (FADD). In the intrinsic pathway, stress-
induced apoptosis results in perturbation of mitochondria, release of cytochrome c and cell 
death. All signaling molecules that have been studied in ALD are identified by black color 
font whereas molecules not studied in ALD yet are seen in white color font.  
 
Cellular Signaling Pathways in Alcoholic Liver Disease 
 
103 
pathway in alcoholic liver disease. Besides TNF, FasL and Fas receptor expression were 
increased in livers of alcohol-fed mice (Deaciuc et al., 1999) leading to Fas-mediated cell 
killing, suggesting a significant role for the Fas/FasL pathway. Expression of Fas receptor 
also increased in human hepatocytes during alcoholic liver disease (Taieb et al., 1998). 
Studies have shown that alcohol induced ROS generation leads to alteration in 
mitochondrial membrane permeability and membrane potential that in turn initiates the 
release of proapoptotic factors such as cytochrome c (Hoek & Pastorino, 2002; Hoek, 2002). 
Transition of mitochondrial permeability then results in increased caspase-3 activation in 
hepatocytes and this depends on p38 MAPK activation but is independent of caspase-8 
(Pastorino et al., 2003; Pastorino & Hoek, 2000). Studies also implicate a role for MAP kinase, 
JNK2, independent of caspase-8, in TNF-induced mitochondrial death pathways 
(Schattenberg et al., 2006). The exposure of hepatocytes to ethanol induces ROS-mediated 
JNK activation, c-jun phosphorylation, Bid fragmentation, cytochrome c release and pro-
caspase 3 cleavage (Cabrales-Romero Mdel et al., 2006). Whether alcohol affects JNK2 
activation is not clear. But recent studies indicate a role for JNK1, but not JNK2, in CYP2E1 
and TNFα mediated hepatoxicity (Wang et al., 2011). Chronic ethanol feeding also decreases 
ATP concentration associated with decreased viability in hepatocytes isolated from rats fed 
either high- or low-fat, ethanol-containing diets (Bailey & Cunningham, 1999). Various 
studies now show that decreased ATP synthesis accompanied by reduced mitochondrial 
protein synthesis, inhibition of the oxidative phosphorylation system (OxPhos) and damage 
to mitochondrial DNA leads to dysfunctional mitochondria in alcoholic liver disease (Bailey 
& Cunningham, 2002). Detailed studies of death receptors and mitochondrial sensitization 
mechanisms leading to hepatocyte death by alcohol will improve our understanding of 
ALD. 
5. Therapeutic targets in ALD 
While mechanistic studies have pointed to various therapeutic targets, abstinence from 
alcohol appears to be most effective in resolution of ALD. However, motivating patients to 
maintain sobriety, follow their compliance and prevent relapse are major obstacles in 
treatment of ALD. Pharmacotherapy using naltrexone and disulfuram assist in reducing or 
eliminating alcohol intake (Bouza et al., 2004; Williams, 2005). Nutritional therapy with 
supplementation of minerals like Zn (Kang & Zhou, 2005) and vitamins have been used to 
improve and attenuate alcoholic hepatitis. While multiple clinical trials have supported the 
use of glucocorticosteroids in patients with alcoholic hepatitis (McCullogh & O’Connor, 
1998), their benefit still remains in question (Christensen, 2002). Considering the 
dysregulated inflammatory response in alcoholic hepatitis, various studies used specific 
anti-TNFα antibody therapy (Tilg et al., 2003) with little or no success. Complete 
neutralization of TNFα led to increased complications such as tuberculosis infections 
limiting its clinical utility. Future therapeutic interventions will thus have to be focused on 
partial attenuation of TNFα with lower infectious complications. Recent studies show that 
treatment with IL-22 ameliorates alcoholic liver injury in a mouse model of ALD (Ki et al., 
2010). Based on induction of oxidative stress by alcohol, a combined regimen of anti-oxidant 
therapies including N-acetylsysteine and vitamins has been tested without significant 
differences in improvement rates of ALD (Stewart et al., 2007). Other alternative therapies 
using silymarin, S-adenosylmethionine and betaine have been suggested for future clinical 
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pathway in alcoholic liver disease. Besides TNF, FasL and Fas receptor expression were 
increased in livers of alcohol-fed mice (Deaciuc et al., 1999) leading to Fas-mediated cell 
killing, suggesting a significant role for the Fas/FasL pathway. Expression of Fas receptor 
also increased in human hepatocytes during alcoholic liver disease (Taieb et al., 1998). 
Studies have shown that alcohol induced ROS generation leads to alteration in 
mitochondrial membrane permeability and membrane potential that in turn initiates the 
release of proapoptotic factors such as cytochrome c (Hoek & Pastorino, 2002; Hoek, 2002). 
Transition of mitochondrial permeability then results in increased caspase-3 activation in 
hepatocytes and this depends on p38 MAPK activation but is independent of caspase-8 
(Pastorino et al., 2003; Pastorino & Hoek, 2000). Studies also implicate a role for MAP kinase, 
JNK2, independent of caspase-8, in TNF-induced mitochondrial death pathways 
(Schattenberg et al., 2006). The exposure of hepatocytes to ethanol induces ROS-mediated 
JNK activation, c-jun phosphorylation, Bid fragmentation, cytochrome c release and pro-
caspase 3 cleavage (Cabrales-Romero Mdel et al., 2006). Whether alcohol affects JNK2 
activation is not clear. But recent studies indicate a role for JNK1, but not JNK2, in CYP2E1 
and TNFα mediated hepatoxicity (Wang et al., 2011). Chronic ethanol feeding also decreases 
ATP concentration associated with decreased viability in hepatocytes isolated from rats fed 
either high- or low-fat, ethanol-containing diets (Bailey & Cunningham, 1999). Various 
studies now show that decreased ATP synthesis accompanied by reduced mitochondrial 
protein synthesis, inhibition of the oxidative phosphorylation system (OxPhos) and damage 
to mitochondrial DNA leads to dysfunctional mitochondria in alcoholic liver disease (Bailey 
& Cunningham, 2002). Detailed studies of death receptors and mitochondrial sensitization 
mechanisms leading to hepatocyte death by alcohol will improve our understanding of 
ALD. 
5. Therapeutic targets in ALD 
While mechanistic studies have pointed to various therapeutic targets, abstinence from 
alcohol appears to be most effective in resolution of ALD. However, motivating patients to 
maintain sobriety, follow their compliance and prevent relapse are major obstacles in 
treatment of ALD. Pharmacotherapy using naltrexone and disulfuram assist in reducing or 
eliminating alcohol intake (Bouza et al., 2004; Williams, 2005). Nutritional therapy with 
supplementation of minerals like Zn (Kang & Zhou, 2005) and vitamins have been used to 
improve and attenuate alcoholic hepatitis. While multiple clinical trials have supported the 
use of glucocorticosteroids in patients with alcoholic hepatitis (McCullogh & O’Connor, 
1998), their benefit still remains in question (Christensen, 2002). Considering the 
dysregulated inflammatory response in alcoholic hepatitis, various studies used specific 
anti-TNFα antibody therapy (Tilg et al., 2003) with little or no success. Complete 
neutralization of TNFα led to increased complications such as tuberculosis infections 
limiting its clinical utility. Future therapeutic interventions will thus have to be focused on 
partial attenuation of TNFα with lower infectious complications. Recent studies show that 
treatment with IL-22 ameliorates alcoholic liver injury in a mouse model of ALD (Ki et al., 
2010). Based on induction of oxidative stress by alcohol, a combined regimen of anti-oxidant 
therapies including N-acetylsysteine and vitamins has been tested without significant 
differences in improvement rates of ALD (Stewart et al., 2007). Other alternative therapies 
using silymarin, S-adenosylmethionine and betaine have been suggested for future clinical 
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trials (Frazier et al., 2011). While liver transplantation offers the most effective treatment, 
limited organ availability and post-transplant drinking dampen long-term outcomes. Future 
research combining biologics and anti-oxidant therapies may offer lasting therapeutic 
efficacies in ALD patients.   
6. Conclusions and future directions 
Alcoholic liver disease is a very complex and multifactorial disorder. Alcohol exerts its 
effects at many levels; individual signaling molecules, cells and finally the entire organ. 
Integrative approaches providing a comprehensive picture of how alcohol affects 
intracellular signaling pathways in tissues at different levels (Guo & Zhakari, 2008) is 
needed. A multidimensional analysis of inflammation and death signaling pathways in 
immune and non-immune cells of the liver to identify molecular targets in the host leading 
to systemic and organ inflammation will enhance our understanding of the pathogenesis of 
alcoholic liver disease. Until now various key signaling cascades triggered in the innate 
immune response such as toll-like receptor, interferon, NFκB and stress pathways such as 
ROS mediated activation of transcription factors, heat shock proteins or chaperones, 
mitochondrial damage and ER stress, have been viewed as separate entities rather than an 
integrated network of molecular interactions in alcoholic liver injury. A pathway diagram 
map which attempts to integrate these pathways will present a powerful aid for interpreting 
pathway interactions and highlight the valuable contributions of molecular interactions 
contributing to initiation and perpetuation of ALD. Future approaches to enable 
comprehensive analysis of these interactions could offer a powerful tool to understand 
diagnosis, prognosis, and treatment of ALD.  
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in vivo by alcohol and lipopolysaccharide. Alcoholism, Clinical and Experimental 
Research, 23(2), 349-356.  
Diaz, B., & Lopez-Berestein, G. (2000). A distinct element involved in lipopolysaccharide 
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trials (Frazier et al., 2011). While liver transplantation offers the most effective treatment, 
limited organ availability and post-transplant drinking dampen long-term outcomes. Future 
research combining biologics and anti-oxidant therapies may offer lasting therapeutic 
efficacies in ALD patients.   
6. Conclusions and future directions 
Alcoholic liver disease is a very complex and multifactorial disorder. Alcohol exerts its 
effects at many levels; individual signaling molecules, cells and finally the entire organ. 
Integrative approaches providing a comprehensive picture of how alcohol affects 
intracellular signaling pathways in tissues at different levels (Guo & Zhakari, 2008) is 
needed. A multidimensional analysis of inflammation and death signaling pathways in 
immune and non-immune cells of the liver to identify molecular targets in the host leading 
to systemic and organ inflammation will enhance our understanding of the pathogenesis of 
alcoholic liver disease. Until now various key signaling cascades triggered in the innate 
immune response such as toll-like receptor, interferon, NFκB and stress pathways such as 
ROS mediated activation of transcription factors, heat shock proteins or chaperones, 
mitochondrial damage and ER stress, have been viewed as separate entities rather than an 
integrated network of molecular interactions in alcoholic liver injury. A pathway diagram 
map which attempts to integrate these pathways will present a powerful aid for interpreting 
pathway interactions and highlight the valuable contributions of molecular interactions 
contributing to initiation and perpetuation of ALD. Future approaches to enable 
comprehensive analysis of these interactions could offer a powerful tool to understand 
diagnosis, prognosis, and treatment of ALD.  
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1. Introduction  
Hepatocyte growth factor (HGF), also known as a scatter factor plays a major role in liver 
repair and regeneration during injury. HGF displays a complex network of signaling 
pathways that activate key functions for liver repair, survival and cellular redox control 
(Gomez-Quiroz, et al. 2008; Nakamura and Mizuno 2010) all these functions are initiated by 
the binding of HGF to its receptor c-Met which, after autophosphorylation, recruits a wide 
variety of signal transduction proteins. 
After injury, liver initiates repair process which could be leaded by proliferation of the 
mature, and normally quiescent, hepatocytes or, when damage is extensive and mature 
hepatocytes are enable to proliferate, by the activation of progenitor cells population or oval 
cells (Riehle, et al. 2011) 
It is well recognized that the repair process begins with the activation of Kupffer cells, the 
liver-resident macrophagues, which respond to damage secreting tumor necrosis factor 
alpha (TNF-) and interleukin (IL-) 6, these cytokines induce the activation of signaling 
pathways in hepatocytes such as nuclear factor κB (NF-κB) and signal transducer and 
activator of transcription 3 (Stat3), respectively. In addition, hepatic stellate cells (HSC) and 
inflammatory cells initiate the production of HGF which together with TNF- and IL-6 lead 
to a cooperative signal to overcome cell-cycle checkpoint controls and shift cells from G0 
through G1, to S phase, leading to hepatocytes proliferation and repair.(Riehle et al. 2011) 
2. HGF/c-Met and its function in liver repair  
HGF gene is encoded on chromosome 7 band 7q21.1 and its product is a precursor 
glycopolypeptide of 697 amino acids which is proteolytic processed in the extracellular 
environment by the serine endoprotease urokinase-type plasminogen activator (uPA) 
(Naldini, et al. 1992) generating the mature HGF consisting in a heterodimeric disulphide-
linked two polypeptide chains ( and β). The -chain consists of 463 amino acids residues 
and four kringle domains. The β-chain consists of 234 amino acid residues. It is thought that 
in vivo HGF acts in a paracrine fashion, being produced by mesenchymal or stromal cells 
(Stoker, et al. 1987), and targeting epithelial cells nearby (Sonnenberg, et al. 1993). 
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Among the multiple biological function triggered by HGF is important underline: cell 
proliferation, apoptosis protection, morphogenesis, scattering, cell motility, invasion and 
metastasis (Hanna, et al. 2009). The signal transduction that drives all these effects starts by 
the ligand-induced dimerization and activation of the HGF receptor, the proto-oncogen c-
Met (cellular-mesenchymal epithelial transition factor) (Ma, et al. 2003). 
Human c-Met gene is located on chromosome 7 band 7q21-q31; the product is a 150-kDa 
polypeptide that, after glycosylation and proteolytic processing, generates the mature α-β 
heterodimer receptor composed of one extracellular 50-kDa -chain linked by disulfide 
bonds to a transmembrane 140-kDa β-chain. The β-subunit encloses multiple sites of 
regulatory phosphorylation. Ligand binding to the receptor leads to autophosphorylation of 
the tyrosines 1230, 1234 and 1235 located within the activation loop of the tyrosine kinase 
domain and activates the intrinsic kinase activity of the receptor. (Ma et al. 2003). 
HGF also induces tyrosine 1313 phosphorylation which is preferred by phosphoinositide 3-
kinase (PI3K) binding, while in the multi-substrate signal transducer docking site, located in 
the  C-terminus domain, phosphorylation of tyrosines 1349, and 1356 lead to the activation 
of adapter and effectors proteins such as Shc, Src, Gab1, Grb2, PI3K, SHP2, phospholipase C-
γ (PLC-γ) among others (Bertotti and Comoglio 2003), these pathways have been widely 
characterized both in vivo and in vitro, and it has been well defined the difference between 
HGF and other growth factors with tissue repair activities such as epidermal growth factor 
(EGF), TNF-, or IL-6. Under this context it has been reported that HGF promotes 
tubulogenesis by the activation of GAB1, SHP-2, and Stat3; survival and antiapoptosis by 
NF-κB, Stat3 and Erk1/2; and proliferation and growth by Grb2 and PI3K (Boccaccio, et al. 
1998; Fan, et al. 2005; Maroun, et al. 1999; Maroun, et al. 2000; Trusolino, et al. 2010)  
In addition of these phosphorylations, there are other regulatory sites within the β-subunit; 
in the juxtamembrane domain the phosphorylation of serine 956 and tyrosine 1093 have 
negative regulatory functions (Ma et al. 2003) which are involved in the receptor 
internalization after activation (Kermorgant and Parker 2005) and posterior degradation by 
ubiquitin-proteosome pathway (Jeffers, et al. 1997).  
Functions elicited by HGF are particularly important for liver repair and regeneration after 
liver injury by alcohol, drugs, viral infections or partial hepatectomy. In fact, HGF was 
originally discovered as a potent mitogen of adult rat hepatocytes (Nakamura, 1984). HGF is 
produced in the liver by non-parenchymal cells, such as HSC, sinusoidal endothelial, 
Kupffer cells and immune cells; but also it can be produced by other distant organs in the 
body, including lungs, and kidneys where it displays repair process as well. (Grenier, et al. 
2002; Nakamura and Mizuno 2010; Taieb, et al. 2002b).  
In healthy humans circulating levels of HGF are always present, and can be affected by age, 
gender and pregnancy. It can be established a normal range from 0.26 to 0.39 ng/ml, 
however it is well known the increase in serum HGF after both, acute and chronic liver 
damage (Funakoshi and Nakamura 2003), and this increment depends on the kind of 
damage or disease. For example, in alcoholic liver cirrhosis the HGF levels reported is 0.78 
ng/ml (Antoljak, et al. 2001), in patients with hepatocarcinoma the average level is 1.06 ± 
1.45 ng/ml and in patients with fulminant hepatitis it could reach values of 16.40 ± 14.67 
ng/ml (Funakoshi and Nakamura 2003). The increment shows a positive correlation with 
markers of liver failure such as serum bilirubin or gamma-glutamyl transpeptidase, and  
 




Fig. 1. Signaling pathways and effects elicited by HGF/c-Met. HGF, hepatocyte growth 
factor; Grb2, growth factor receptor-bound protein 2; Grb1 binding-associated binder1; 
PI3K, phosphoinositide-3-kinase; STAT3, signal transducer and activator of transcription 3; 
PLCγ, Phospholipase C gamma; SOS, son of sevenless, guanine nucleotide exchange factor; 
RAS, rat sarcoma, GTPase; Akt, Protein Kinase B; NF-κB, nuclear factor kappa B. 
negative correlation with albumin content, suggesting that HGF levels can reflect the grade 
of illness and can be considered as a prognosis indicator.  
The main evidence of the relevance of HGF on liver regeneration and repair came with the 
creation of the hepatocyte-specific c-Met signaling deletion mouse (MetKO) (Huh, et al. 
2004). Loss of c-Met signaling appeared not to be detrimental to hepatocyte function under 
physiological conditions, but sublethal doses of Fas agonist (Jo2 antibody) induced a 
hypersensitization to damage generating massive liver apoptosis and necrosis, with no 
important effects in wild type mouse. Hepatocytes derived from MetKO mice exhibited 
sensitization to Jo2-induced apoptosis and impairment in motility and phagocytosis, 
activities which are required for a proper repair process (Gomez-Quiroz et al. 2008; Huh et 
al. 2004) 
3. HGF and c-Met in alcoholic liver disease 
Functions of HGF in ALD remains partially characterized. However it is clear that HGF and 
c-Met are involved in every stage of ALD, from inflammatory response to alcoholic 
steatohepatitis, fibrosis, cirrhosis and hepatocarcinoma (Cornella, et al. 2011; Tahara, et al. 
1999; Taieb et al. 2002b). 
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1999; Taieb et al. 2002b). 
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3.1 Ethanol impairs HGF release from neutrophils 
Ethanol-initiated damage lead to an inflammatory response characterized by neutrophilia 
and hepatic polymorphonuclear neutrophil (PMN) infiltration (Taieb et al. 2002b). We 
reported previously that acetaldehyde, the main metabolite of ethanol biotransformation, 
induces the production of IL-8, chemotactic factor for PMN, in HepG2 cells (Gomez-Quiroz, 
et al. 2003) and Taieb and coworkers (Taieb et al. 2002b) have shown that PMN are an 
important source of HGF specifically in patients with severe alcoholic hepatitis, finding that 
these patients presented higher levels of HGF (6.07 ± 0.738 ng/ml) in comparison with 
alcoholic hepatitis-free patients with cirrhosis (3.24 ± 0.438 ng/ml) and healthy controls 
(0.407 ± 0.027 ng/ml). Hepatic HGF levels correlated with the degree of hepatic PMN 
infiltration (P=0.0015, ρ=0.76). This study provides evidences that PMN cells are an 
important source of HGF, particularly in patients with large PMN infiltration, pointing out 
the PMN cells as coadjutants in liver repair, at least in acute processes.  
Although PMN cells provide HGF to the injured liver, ethanol inhibits this effect. PMN cells 
treated with degranulation promoter agents (cytochalasin B and N-formyl-methionyl-leucyl-
phenylalanine) induced the release of HGF, however the presence of different 
concentrations of ethanol significantly inhibited HGF degranulation in a concentration-
dependent manner (Taieb, et al. 2002a), indicating that ethanol impairs HGF release from 
PMN cells obstructing liver repair process. 
3.2 Free radicals, oxidative stress and ethanol metabolism  
In terms of ethanol metabolism-induced oxidative stress, we can define two main levels of 
HGF-mediated protection. The first level is generating system regulation, particularly the 
microsomal ethanol oxidizing system (MEOS), and the second one is the control or 
neutralization of the free radicals formed as a consequence of ethanol metabolism. 
A free radical is a molecule or atom that contains one or more unpaired electron, this 
characteristic makes them highly instable and reactive. In the cellular context, oxygen and 
nitrogen free radicals have a wide variety of actions ranging from modulation of gene 
expression to the induction of cell death.  
Physiologically 1-2% of molecular oxygen is converted, by enzymatic and non-enzymatic 
mechanisms, to reactive oxygen species (ROS) which include hydrogen peroxide (H2O2), 
superoxide anion (O2•), singlet molecular oxygen (1O2), hydroxyl (HO•), alkoxyl (RO•), and 
Peroxyl (ROO•) radicals (Cadenas 1989). In order to avoid the harmful effects of these 
molecules, cells enclose a battery of antioxidant defenses which include enzymatic and non-
enzymatic components. Among the antioxidant enzymes superoxide dismutase (SOD), 
catalase,  glutathione (GSH) peroxidase (GSHPx) and GSH reductase (GSHRd) sustain the 
major detoxifying activities. SOD1, 2 and 3 which are located in cytosol, mitochondria and 
plasma membrane respectively drive the transformation of O2• in H2O2, although hydrogen 
peroxide is not a free radical, it is the precursor of the highest reactive and toxic specie 
among the ROS, the hydroxyl radical via either, Fenton reaction, which requires the 
presence of Fe3+ or Cu2+ for the process, or Haber-Weiss reaction. (Valko, et al. 2007)  
To counteract this phenomenon H2O2 is transformed to H2O by the action of catalase or 
GSHPx. GSHPx uses two molecules of GSH to reduce H2O2, generating the oxidized form of 
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glutathione (GSSG) which can be regenerated to GSH by the action of GSHRd using 
NADPH as electron donor.  
GSH is the naturally occurring major thiol. It is produced in the cytosol by the action of two 
enzymes, the γ-glutamyl cysteine ligase (also known as γ-glutamyl cysteine synthetase, γ-
GCS) that catalyses the formation of the dipetide L-γ-glutamyl-L-cysteine, and by glutathione 
synthase which converts this dipeptide in GSH (L-γ-glutamyl-L-cysteinyl-Glycine). 
The ability of GSH to deal with ROS is not restricted as a cofactor of GSHPx, because GSH 
has, by itself, the capacity to scavenge free radicals, as it happens with others non-enzymatic 
antioxidants such as vitamin C and E, and β-carotene . 
Ethanol metabolism  is mainly driven by both, alcohol dehydrogenase and MEOS which 
main member is cytochrome P450 (Cyp) 2E1, both enzymes generate acetaldehyde as 
primary metabolite, but only MEOS produces, in addition, ROS such as O2•, H2O2, and the 
highly toxic HO•, responsible of DNA, protein and lipid oxidation (Cadenas 1989). It has 
been reported that Cyp2E1 is induced by ethanol consumption principally in zone 3 
hepatocytes. Biopsies from recently drinking subjects revealed an increment from 4- to 10-
fold over normal values (Tsutsumi, et al. 1989). 
 
Fig. 2. Major alcohol metabolism processes. EtOH, ethanol; ADH, alcohol dehydrogenase; 
AldDH, aldeyde dehydrogenase; ROS, reactive oxygen species; MEOS, microsomal ethanol 
oxidizing system; NADH, reduced nicotine adenine dinucleotide.  
Other Cyp isoforms have been implicated in ethanol metabolism, such as Cyp1A2 and 
Cyp3A4, thus the term MEOS characterizes the total microsomal ethanol oxidation, not only 
Cyp2E1 (Salmela, et al. 1998). 
3.3 HGF regulates the ROS generating systems 
Donato and coworkers reported in 1998 that HGF regulates the expression and activities of 
Cyp1A1/2, Cyp2A6, Cyp2E1 and, Cyp2B6 in human hepatocytes in primary culture 
(Donato, et al. 1998). Activities of Cyp1A2, Cyp3A4 and Cyp1A1/2 were significantly 
diminished at 72 h of HGF treatment (10 ng/ml). Particularly in five hepatocytes cultures 
from five different healthy donors, HGF treatment resulted in the reduction of Cyp2E1 
activity ranging from 55 to 69% regarding not treated cultures. These effects were correlated 
with the decrease in the corresponding mRNA, suggesting that HGF transcriptionally and 
post-translationally downregulates some of the MEOS components. This regulation 
represents the first frontline of HGF-induced defense against the toxicity of ethanol.  
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3.1 Ethanol impairs HGF release from neutrophils 
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glutathione (GSSG) which can be regenerated to GSH by the action of GSHRd using 
NADPH as electron donor.  
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The ability of GSH to deal with ROS is not restricted as a cofactor of GSHPx, because GSH 
has, by itself, the capacity to scavenge free radicals, as it happens with others non-enzymatic 
antioxidants such as vitamin C and E, and β-carotene . 
Ethanol metabolism  is mainly driven by both, alcohol dehydrogenase and MEOS which 
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highly toxic HO•, responsible of DNA, protein and lipid oxidation (Cadenas 1989). It has 
been reported that Cyp2E1 is induced by ethanol consumption principally in zone 3 
hepatocytes. Biopsies from recently drinking subjects revealed an increment from 4- to 10-
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diminished at 72 h of HGF treatment (10 ng/ml). Particularly in five hepatocytes cultures 
from five different healthy donors, HGF treatment resulted in the reduction of Cyp2E1 
activity ranging from 55 to 69% regarding not treated cultures. These effects were correlated 
with the decrease in the corresponding mRNA, suggesting that HGF transcriptionally and 
post-translationally downregulates some of the MEOS components. This regulation 
represents the first frontline of HGF-induced defense against the toxicity of ethanol.  
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In addition to the abrogation of MEOS components by HGF, it is reported that it can also 
downregulate another ROS generating systems such as NADPH oxidase (Gomez-Quiroz et 
al. 2008), which is involved  in many liver diseases such as fibrosis(De Minicis, et al. 2010), 
hepatitis C virus infection (de Mochel, et al. 2010) and alcoholic liver disease where it is 
mainly activated in Kupffer cells  leading to TNF- production (Kono, et al. 2000). 
3.4 HGF regulates the ROS produced by ethanol metabolism 
The second HGF frontline against the oxidative effect of ethanol metabolism is leaded by the 
generation of antioxidants. It is well known that HGF/c-Met can regulate the activation of 
survival transcription factors such as NF-κB or Nrf2 (Gomez-Quiroz et al. 2008; Kaposi-
Novak, et al. 2006; Valdes-Arzate, et al. 2009) which are responsible of the expression of a 
wide range of antioxidant, detoxifying and antiapoptotic proteins and it has been well 
documented elsewhere (Fan et al. 2005; Klaassen and Reisman 2010).  
In vitro studies have revealed the prominent role of HGF in cellular survival against ethanol 
toxicity. One of the main problems to address the molecular mechanism of alcohol induced 
damage, at the cellular level, is that hepatocytes in primary culture loss the capacity to 
metabolize ethanol due to a downregulation in the MEOS and alcohol dehydrogenase. Cell 
lines expressing stable and constitutively Cyp2E1 and/or alcohol dehydrogenase have been 
established to sort the inconvenience in the absent of alcohol metabolism in normal 
hepatocytes in culture (Chen and Cederbaum 1998; Donohue, et al. 2006), particularly 
relevant is the cell line VL17A, which is a suitable in vitro model of ALD due to the 
expression of both Cyp2E1 and alcohol dehydrogenase (Donohue et al. 2006), which mimics 
much better conditions in normal hepatocytes than single gene transfected cells (Chen and 
Cederbaum 1998).  
VL17A have been used to address the mechanism of HGF-induced protection in ALD 
(Valdez-Arzate 2009). HGF was capable to decrease ROS production, protein oxidation and 
lipid peroxidation damage due to ethanol metabolism, correlating with an increase in cell 
viability. Analysis of the mechanism involved in the HGF-induced protection against 
ethanol metabolism toxicity revealed that HGF induces the activation of NF-κB, with a 
concomitant expression of antioxidant enzymes such as catalase, SOD1, and γ-GCS, as well 
as an elevation in GSH synthesis as a consequence of the expression of γ-GCS. Inhibition of 
NF-κB, or the main upstream activators of this transcription factor (PI3K and Akt), 
significantly abrogated the protective role of HGF (Gomez-Quiroz et al. 2008; Valdes-Arzate 
et al. 2009) 
HGF has demonstrated to increase the expression of catalse and GSHRd (Arends, et al. 
2008). Catalase transforms H2O2 in H2O, and GSHRd restores GSH from GSSG (Figure 2). 
It has been widely characterized the relevance of GSH in ALD by Fernandez-Checa and 
coworkers (Fernandez-Checa, et al. 2002; Fernandez-Checa, et al. 1993; Fernandez-Checa, et 
al. 1996; Hirano, et al. 1992), and it is proposed as one of the key mechanism in the alcohol-
induced hepatocellular damage, mainly by GSH depletion in mitochondria.  
HGF has shown regulate strongly GSH homeostasis by inducing the expression of γ-GCS 
(Tsuboi 1999; Valdes-Arzate et al. 2009), and we are claiming that this is the main 
mechanism of protection against oxidative stress. In fact, c-Met KO mice are under oxidative 
 
Alcoholic Liver Disease and the Survival Response of the Hepatocyte Growth Factor 
 
119 
stress due to the increment in the NADPH oxidase activity, and depletion in GSH. MetKO 
mice subjected to the carcinogenic agent N-nitrosodiethylamine were more susceptible to 
the development of tumors in the liver, presenting an increment in multiplicity, size and 
incidence. This effect was abrogated by the oral administration of N-acetyl cysteine (NAC) 
which is precursor of GSH synthesis (Takami, et al. 2007). These findings were correlated in 
in vitro studies, MetKO hepatocytes are more susceptible to Jo2-induced damage, effect that 
was abrogated by NAC treatment, which induced GSH reservoirs restoration (Gomez-
Quiroz et al. 2008).  
The main consequence in ROS generation is the induction of hepatocytes apoptosis. ROS can 
induce the activation of jun kinease signaling pathway leading to the activation of AP-1 
transcription factor that promotes the expression of proapoptotic proteins such as FasL, 
TNF- and Bak. ROS also targets mitochondria inducing membrane permeabilization and 
the release of proapoptotic proteins (cytochorme c, Smac/diablo, EndoG, among 
others(Serviddio, et al. 2010), which participate in the cell death process.  
 
Fig. 3. Alcohol-mediated reactive oxygen species production and antioxidant response 
driven by HGF. Molecules downregulated (red) and upregulated (green) by HGF. EtOH, 
ethanol; MEOS, microsomal ethanol oxidizing system, Ald, Acetaldehyde; H2O2, hydrogen 
peroxide; O2•,  superoxide anion; HO•,hydroxyl; SOD, Superoxide Dismutase; Cat, catalase; 
GSH Glutathione; GSHPX, Glutathione peroxidasa; Gluatathione –reductase; GSSG, 
Oxidized glutathione; γ-GCS, γ-glutamyl cysteine synthetase; GS, Glutathione Synthase.  
It is well known the antiapoptotic effect of HGF, not only in hepatocytes, but in many cell 
types (Arends et al. 2008; Fan et al. 2005; Kitta, et al. 2001; Santangelo, et al. 2007). In 
addition to the control of ROS, HGF can induce the expression of antiapoptotic proteins by 
the activation of survival canonical pathways for example, Akt/NF-κB, Erk1/2 or Stat3, 
which induce Bcl2, Bcl-XL, and Mcl-1 expression (Gomez-Quiroz et al. 2008; Valdes-Arzate 
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et al. 2009), but also HGF-induction of GSH supports its antiapoptotic function, based in the 
fact that NAC treatment significantly reduced the Jo2-induced apoptosis in hepatocytes, and 
pretreatment with BSO, an inhibitor of γ-GCS, abrogated the protective effect of both NAC 
and HGF(Gomez-Quiroz et al. 2008). 
The evidence gathered here clearly shows the central role of HGF in the control of ethanol-
induced oxidative stress and GSH homeostasis as key issues in the hepatoprotective 
mechanism in ALD (Figure 2). 
3.5 Regulation of lipid homeostasis and recovery from alcohol-induced fatty liver 
The mechanism of alcohol-induced fatty liver disease is complex and remains not fully 
characterized. The main mechanism proposed is that alcohol impacts at three levels.  
The first level is the induction of oxidative stress, starting by MEOS, and continuing with 
mitochondria dysfunction due to a decrease in mitochondrial GSH reservoirs. The second 
level is the increase in TNF-, which augments mitochondria failure, and ROS production 
and deregulates adiponectin, which promotes fatty acids oxidation. The third level is the 
activation of transcription factors involved in lipid biosynthesis and export.  
Liver packages triglycerides into a very low density lipoproteins (VLDL), forming a 
complex with the apolipoprotein B 100 in a process facilitated by the microsomal 
triglyceride transfer protein (MTTP), which is downregulated in rats fed with an ethanol-
containing liquid diet (Sugimoto, et al. 2002). The first and second levels converge in the 
generation of endoplasmic reticulum (ER) stress and in the increment in the activation of 
sterol regulatory element binding protein 1c (SREBP1c), which is in the third level. 
SREBP1c is a transcription factor that remains inactivated in ER, and after stimulus, 
migrates to the Golgi for further process and finally arrives to the nucleus where it 
promotes the expression of genes involved in fatty acids synthesis (Ferre and Foufelle 
2010). Furthermore, the AMP-activated protein kinase (AMPK), a serine-threonine kinase, 
which stimulates both, fatty acid oxidation by the activation of the peroxisome 
proliferator-activated receptors alpha (PPARα) and glycolisis, and inhibits fatty acid 
synthesis due to the inactivation of acetyl-CoA carboxylase (ACC), leads to the decrease 
of malonyl-CoA, a precursor in fatty acid synthesis and inhibitor of the carnitine 
palmitoyl transferase 1, the rate-limiting enzyme in fatty acid oxidation (Dobrzyn, et al. 
2004; Hardie and Pan 2002). AMPK also inhibits the activation of SREBP1c, presenting 
AMPK as a multimodal regulator of lipid metabolism in the liver. Animals fed with an 
alcohol-containing diet exhibit a decrease in the activity of AMPK resulting in the 
development of hepatic steatosis (Garcia-Villafranca, et al. 2008). 
In addition, it has been proposed that the increase in NADH/NAD+ ratio due to alcohol 
metabolism drives the inhibition of the tricarboxylic acids cycle and fatty acid oxidation, but 
also it can induce ER stress (figure 3) (Lieber 2004) 
HGF involvement in lipid homeostasis has been experimentally demonstrated, Kaibori and 
collaborators reported that HGF is capable to induce lipid synthesis under liver regeneration 
(Kaibori, et al. 1998), and the genetic elimination of c-Met signaling in hepatocytes induced 
changes in the expression of many proteins related to lipid metabolism such as Acox1, ASS1, 
Crot, Cyp4a10, Cyp 4a14, Fasn, Lipc, among others (Kaposi-Novak et al. 2006). 
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One of the firsts studies focused to address  the regulation of alcohol-induced fatty liver by 
HGF was reported in 1999 by Tahara and collaborators (Tahara et al. 1999), they observed 
that rats fed with an ethanol containing diet for 30 days developed hepatic steatosis. The 
administration of HGF for 7 days (37 days on the diet) reduced lipid deposition in liver 
tissue. The major mechanism observed was the increment on lipid secretion via VLDL by 
the induction of ApoB100 expression. 
The second HGF effect related to steatosis control is the restoration of the mRNA levels and 
activity of MTTP. Injection of HGF on animals subjected to an alcoholic diet restored MTTP 
levels,  this observation was corroborated in HepG2 cells which were exposed to HGF 
resulting an enhanced expression of both MTTP and ApoB100 (Sugimoto et al. 2002).   
The induction of VLDL and MTTP by HGF seems not to be exclusive for alcohol-induced 
steatosis, due to Kosone and collaborators (Kosone, et al. 2007) found the same results in a 
model of fatty liver generated by a high-fat diet and confirmed in HepG2 cells the decrease 
in lipid content. 
Another evidence of HGF-induced alcoholic steatosis protection comes from the effect of 
pioglitazone, this drug is used in the treatment of diabetes and non-alcoholic 
steatoshepatitis, but it has been postulated that it can be also used in the treatment of 
alcoholic steatohepatitis (Tomita, et al. 2004). Ethanol reduced the mRNA and protein levels 
of c-Met, and pioglitazone restored the c-Met expression decreasing the lipid content in liver 
tissue. Both HGF and pioglitazone showed downregulate the expression of key genes 
involved in lipid homeostasis such as SREBP 1c and stearoyl-CoA desaturase, improving the 
deleterious effects in the alcoholic fatty liver. 
Finally, recently has been published that HGF can promote the activation of AMPK 
signaling pathway (Chanda, et al. 2009) inducing the suppression on lipid synthesis and 
gluconeogenesis. 
3.6 Fibrosis 
The main consequence in the chronic alcohol ingestion is liver fibrosis/cirrhosis which is 
characterized by the hyper-accumulation of connective tissue components, mainly collagen, 
and a disorganization of the normal hepatic structure of regenerative nodules. Many reports 
have clarified the preventive and therapeutic effects of HGF on liver fibrosis or cirrhosis 
(Inagaki, et al. 2008; Jones, et al. 2010; Matsuda, et al. 1995; Matsuda, et al. 1997; Ueki, et al. 
1999; Xia, et al. 2006). 
HGF treatment in animals challenged with different inducers of liver fibrosis suppressed the 
connective tissue components expression and hydroxyproline levels, preventing the onset of 
scar formation (Matsuda et al. 1997). The mechanism of HGF-induced anti-fibrotic 
protection is focused to antagonize the transforming growth factor beta (TGF-β) signaling 
pathway. TGF-β is the main profibrogenic factor, inducing the expression of collagen, 
fibronectin and hepatocytes apoptosis. The effect of HGF on TGF-β has been observed at 
different levels. In the model of fibrosis induced by the bile duct ligation, HGF showed 
suppress the expression of TGF-β and the conversion bile duct epithelial to mesenchymal 
transition (Xia et al. 2006). TGF-β suppression by HGF was also observed in the model of 
DEN-induced fibrosis (Ueki et al. 1999).  
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pathway. TGF-β is the main profibrogenic factor, inducing the expression of collagen, 
fibronectin and hepatocytes apoptosis. The effect of HGF on TGF-β has been observed at 
different levels. In the model of fibrosis induced by the bile duct ligation, HGF showed 
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transition (Xia et al. 2006). TGF-β suppression by HGF was also observed in the model of 
DEN-induced fibrosis (Ueki et al. 1999).  
 




Fig. 4. Molecular mechanism of ethanol-mediated lipid deposition in the liver. Molecules or 
processes downregulated (red) and upregulated (green) by HGF. EtOH, ethanol; TNF-α, 
Tumor necrosis factor-alpha; ROS, reactive oxygen species; ER, Endoplasmic reticulum; 
NADH, Nicotine Adenine dinucleotide reduced; SREBP1c,  sterol regulatory element 
binding protein 1c; AMPK, AMP-activated protein kinase; MTTP, microsomal triglyceride 
transfer protein; VLDL, very low density lipoproteins; PPAR-α; peroxisome proliferator-
activated receptors alpha; FA, Fatty acid. 
Another study showed that HGF decreased the expression of collagen 1A2 gene in a model 
of fibrosis induced by carbon tetrachloride by a mechanism dependent of the nuclear export 
of smad3 mediated by galectin-7 (Inagaki et al. 2008). 
Recently an innovator system to study the anti-fibrotic and protective effect of HGF was 
developed (Jones et al. 2010). HGF was mixed with collagen and robotically printed onto 
standard glass slides to create arrays of 500 µm diameter spots, and then rat hepatocytes 
were seeded and challenged with 100 mM ethanol. Results showed that hepatocytes in the 
HGF-containing collagen spots presented less apoptosis comparing with those seeded in 
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HGF-free spots. To investigate impact on the fibrosis, a mix of hepatocytes and HSC were 
seeded and again challenged with alcohol. HSC were less activated (less fibrotic) in spots 
containing HGF compared to control. This in vitro study confirms the anti-fibrotic response 
of HGF 
3.7 HGF, alcohol and cancer 
Heavy long-term alcohol drinking ( ≥69.0 g alcohol/day in men, and ≥ 23.0 g alcohol/day in 
women) is a significant risk factor for the development of hepatocellular carcinoma (HCC) 
(Shimazu et al. 2011) . There is no efficient animal model to study the direct mechanism of 
alcohol-induced HCC, recently it has been reported that rats selectively bred for high 
alcohol preference with free access to water supplemented with 10% ethanol for 18 months 
developed hepatic neoplasia, ERK pathway activation, increased Cyp2E1 activity and 
oxidative stress (Yip-Schneider et al. 2011). As mentioned here, ethanol metabolism is the 
main harmful mechanism, due to ROS production; in addition ethanol increases the 
infiltration of inflammatory cells enhancing the oxidative damage, accelerating telomere 
shortening and favoring oncogenic mutation (Cornellá et al. 2011) in the carcinogenesis 
process.  
The HGF functions, previously described inhere; strongly suggest the prominent role of this 
growth factor in the prevention of HCC. In fact, MetKO mice exhibited an accelerated DEN-
induced hepatocarcinogenesis, demonstrating the protective and preventive roles of HGF in 
liver carcinogenesis (Takami et al. 2007), in this study, the accelerated tumor development 
was associated with increased rate of cell proliferation and prolonged activation of 
epidermal growth factor receptor (EGFR) signaling, MetKO mice also exhibited an elevated 
lipid peroxidation, decreased levels of GSH, and SOD expression increment, suggesting that 
oxidative stress could be a determinant factor for the acceleration of hepatocarcinogenesis. 
MetKO mice were more susceptible than WT mice to DEN-induced liver cancer increasing 
multiplicity, incidence and size of tumors. The negative effects of c-Met deletion were 
reversed by the chronic administration of NAC, blocking EGFR activation and reducing 
initiated hepatocarcinogenesis, confirming that c-Met deletion-induced oxidative stress is 
the main hallmark in the accelerated carcinogenesis and that c-Met integrity is required as a 
protective mechanism against chemical-induced carcinogenesis by the induction of 
cytoprotective enzymes such as antioxidant enzymes. 
In contrast, a wide variety of human tumors exhibit sustained activation, overexpression or 
mutation of c-Met, including liver tumors. It is not hard to imagine that beneficial and 
protective roles of HGF in all stages of alcoholic liver disease are not longing in liver cancer. 
HGF-induced protection ends in the early stages of hepatocarcinogenesis. Once initiated the 
carcinogenic process, HGF and c-Met trigger signaling cascades resulting in proliferation, 
growth, survival, motogenesis and angiogenesis (Eder et al. 2009). Mouse and human cell 
lines that overexpress c-Met or/and HGF become tumorigenic and metastatic in athymic 
mice (Rong et al. 1994) and, in contrast, downregulation of c-Met or HGF expression 
decreases tumorigenic potential (Abounader et al., 2002), in fact, overexpression of c-Met or 
HFG are associated with poor prognosis and aggressive phenotype (Kaposi-Novak et al. 
2006). In summary HGF/c-Met protects from carcinogenesis, but in established tumors 
induces the aggravation of the disease. Mutations in c-Met and HGF predispose to human 
cancer.   
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In conclusion HGF and c-Met are introduced as promissory therapeutic targets for the 
treatment of ALD, they can reverse or abrogate almost every stage of the disease, controlling 
the metabolism, the harmful molecules, the lipid homeostasis disturbing and the chronic 
effects of alcohol consumption. Although more research is needed to figure out the proper 
point of intervention in the signaling activated by HGF and c-Met, the experimental 
evidences gathered here support the promising success of HGF/c-Met.  
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1. Introduction 
On a worldwide perspective chronic liver diseases (CLDs) are very common pathologic 
conditions which are characterized by reiteration of hepatocyte injury that is mainly 
induced by chronic infection by hepatitis B and C viruses (HBV and HCV), autoimmune 
injury and metabolic and/or toxic/drug – induced causes, with chronic alcohol 
consumption being predominant particularly in western countries. Chronic liver injury is 
reported to result in the chronic activation of both inflammatory and wound healing 
response that, in association with other major pathogenic mechanisms (oxidative stress, 
derangement of epithelial-mesenchymal interactions and possibly epithelial to 
mesenchymal transition, see later in section 3), can sustain persistent liver fibrogenesis (i.e., 
the process) and represent the prominent driving force for liver fibrosis (i.e., the result) 
(Parola and Robino, 2001; Friedman 2003; Bataller and Brenner, 2005; Friedman 2008b; Novo 
and Parola, 2008; Parola et al., 2008).  
Literature data from the last two decades indicate that hepatic fibrogenesis in a CLD has to 
be envisaged as a dynamic and highly integrated molecular, tissue and cellular process that, 
irrespective of the aetiology, leads to the progressive accumulation of extracellular matrix 
(ECM) components in an attempt to limit hepatic injury. Persistent liver fibrogenesis is 
currently considered as the critical process responsible for the progression of any CLD to the 
end-points of liver cirrhosis and hepatic failure. According to current definition, cirrhosis 
should be regarded as an advanced stage of fibrosis, being characterized by the following 
major features: a) the formation of regenerative nodules of hepatic parenchyma surrounded 
and separated by fibrotic septa; b) the development of significant changes in organ vascular 
architecture, portal hypertension and related clinical complications (i.e., variceal bleeding, 
hepatic encephalopathy, ascites and hepatorenal syndrome) (Friedman, 2003, 2004; Pinzani 
and Rombouts, 2004; Bataller and Brenner, 2005; Friedman 2008b). 
In any CLDs fibrotic progression can proceed through at least four distinct patterns of 
fibrosis that have close relationships with the underlying aetiology and are also related to 
the “topographic site” of tissue injury, the involvement of different populations of 
myofibroblasts (MFs) and the predominant pro-fibrogenic mechanism (Cassiman and 
Roskams, 2002; Pinzani and Rombouts, 2004; Parola et al., 2008; Parola and Pinzani, 2009).  
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1.1 Bridging fibrosis 
This pattern of ECM deposition and fibrotic septa formation is typically described in the 
liver of patients carrying HBV- or HCV-related chronic hepatitis. As a result of portal-
central bridging necrosis the pattern is characterized by the formation of a) portal-central 
fibrotic septa, that connect portal areas with the area of central vein, b) portal-portal fibrotic 
septa, that connect distinct portal areas, as well as of c) blind fibrotic septa in the 
parenchyma. As any pathologist may easily recall, to this pattern belong classic 
histopathological images of fibrotic septa leading to the obliteration of central veins and of 
early changes in vascular architecture and connections with the portal system, events that 
with the time favor the development of portal hypertension. The pattern of bridging fibrosis 
recognizes the chronic activation of wound healing as the major pathogenic mechanism 
driving fibrosis progression and, as detailed later in this chapter, fibrogenesis is 
predominantly sustained in these settings by hepatic populations of pro-fibrogenic MFs that 
originate mainly from hepatic stellate cells (HSCs) or, to a less extent, from either portal 
fibroblasts or from bone marrow - derived stem cells. Extensive literature data also suggest 
that oxidative stress and reactive oxygen species (ROS) offer an additional major 
contribution in sustaining liver fibrogenesis in this pattern of bridging fibrosis. 
1.2 Perisinusoidal / Pericellular fibrosis 
This specific pattern of fibrosis has been described in CLDs which follow either excess 
alcohol consumption (ASH or alcoholic steatohepatitis) or metabolic derangement and then 
progression from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis 
(NASH). In these clinical settings, which are increasingly common particularly in western 
countries, excess deposition of ECM components is first detected in the space of Disse 
leading to the peculiar “chicken-wire” pattern. MFs originating from the activation of 
hepatic stellate cells (HSC/MFs) are believed to represent the most relevant pro-fibrogenic 
cellular effectors in these conditions, with ROS and oxidative stress playing a predominant 
pro-fibrogenic and pathogenic role. 
1.3 Biliary fibrosis 
This is a pattern which in humans is typically detected in a number of conditions affecting 
the biliary tree (primary biliary cirrhosis, primary sclerosizing cholangitis, secondary 
biliary cirrhosis) that are characterized by a peculiar scenario involving concomitant 
proliferation of bile ductules and periductular MFs. In these clinical settings MFs mainly 
derive from periportal fibroblasts or, as recently suggested, by epithelial to mesenchymal 
transition (EMT) of cholangiocytes, an issue that at present is controversial and highly 
debated (see section 3.4). In any case, the biliary fibrosis scenario is dominated by the 
formation of portal-portal fibrotic septa that in human patients for long time do not 
significantly affect vascular connections with the portal system. Major pathogenic 
mechanisms sustaining this pattern of fibrosis have been identified either in alterations in 
the interactions between cholangiocytes and mesenchymal cells (with cholangiocyte 
transition into MF-like phenotype being still debated) or in alterations of redox 
equilibrium (i.e., oxidative stress).  
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1.4 Centrilobular fibrosis 
Although this pattern is commonly included in the classification, centrilobular fibrosis is 
indeed unrelated to CLDs but, rather, is typically observed in those patients being affected 
by chronic heart failure: in these patients a significant alteration of venous outflow is 
realized that, with the time, leads to the formation of fibrotic septa developing among 
central vein areas (central-central septa) which, in turn, result in the unique scenario which 
is often described as of “reversed lobulation”. 
2. Hepatic myofibroblasts 
Hepatic myofibroblasts (MFs) represent a heterogenous population of pro-fibrogenic cells, 
mostly positive for α–smooth muscle actin (α-SMA), that are mainly found in chronically 
injured livers (i.e., fibrotic and or cirrhotic) (Cassiman et al., 2002; Friedman, 2008a, 2008b; 
Parola et al., 2008; Parola and Pinzani, 2009) and, irrespective the specific aetiology of a CLD 
and of the prevalent pattern of fibrosis, sustain liver fibrogenesis in addition to injured 
hepatocytes, activated Kupffer cells and sinusoidal endothelial cells. Hepatic populations of 
MFs share a number of common properties which include high proliferative attitude, the 
ability to contract in response of vasoactive mediators, and the ability to actively participate 
to CLD progression by means of their multiple phenotypic responses. This includes excess 
deposition of ECM components and ECM altered remodelling as well as the synthesis and 
the release (paracrine/autocrine) of critical polypeptide mediators which sustain and 
perpetuate fibrogenesis, chronic inflammatory response and angiogenesis. Along these 
lines, hepatic MFs can be envisaged as a unique and crucial cellular crossroad where 
incoming paracrine and autocrine signals, including growth factors, inflammatory and 
angiogenic signals, chemokines, adipokines, as well as ROS, are integrated in order to 
“operate” phenotypic responses designed to sustain fibrogenesis and the progression of 
CLDs to the end-points of cirrhosis and hepatic failure.  
As recently reviewed (Parola et al., 2008; Parola & Pinzani, 2009) progressive fibrogenesis is 
believed to be sustained by four main pro-fibrogenic mechanisms: a) chronic activation of 
the wound healing response, a mechanism that applies virtually to any CLDs and 
predominates in HBV or HCV chronic injury or autoimmune liver diseases; b) oxidative 
stress, with the generation of ROS and other oxidative stress – related reactive mediators, a 
mechanism that again applies to all CLDs but is predominant in either alcoholic liver 
disease (ALD) and NASH; c) derangement of epithelial-mesenchymal interactions, as 
detected in chronic cholangiopaties and, more generally, all the conditions of biliary fibrosis; 
d) EMT.  
Some years ago it has been proposed a classification of the different hepatic populations of 
MFs which is based on the specific antigen profile and the tissue localization of these pro-
fibrogenic cells in the context of a chronically injured liver (Cassiman et al., 2002). This 
classification recognizes at least three different kind of MFs.  
2.1 Portal/septal MFs (PS/MFs) 
These MFs are believed to originate mainly from portal fibroblasts (i.e., fibroblasts residing 
in the connective tissue of portal areas in normal conditions) through a process of 
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1.4 Centrilobular fibrosis 
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These MFs are believed to originate mainly from portal fibroblasts (i.e., fibroblasts residing 
in the connective tissue of portal areas in normal conditions) through a process of 
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activation/transdifferentiation. PS/MFs are typically detected in the expanded connective 
tissue around portal tracts (portal MFs) or in the inner part of fibrotic septa (septal MFs). 
Irrespective of their localization, they share a common and overlapping antigen repertoire 
that allows their recognition “in vivo”. The antigen profile of human PS/MFs includes, in 
addition to α-SMA, expression of glial fibrillary acidic protein (GFAP), brain-derived nerve 
growth factor (BDNGF) and α-B-crystallin (ABCRYS). 
2.2 Interface MFs (IF/MFs)  
Interface MFs are α-SMA – positive cells detected at the edge between fibrotic septa and the 
surrounding parenchyma (i.e., where active fibrogenesis occurs). These cells can originate 
from activation/transdifferentiation of hepatic stellate cells, portal fibroblasts as well as 
from bone marrow – derived mesenchymal stem cells (Russo et al., 2006; Valfrè di Bonzo et 
al., 2008; Forbes & Parola, 2011) following their engraftment into chronically injured livers. 
Human IF/MFs express all the typical markers already mentioned (α-SMA, GFAP, BDNF, 
ABCRYS) as well as nerve growth factor (NGF), neural cell adhesion molecule (N-CAM) 
and neurotrophin-4 (NT-4).  
2.3 Activated, MF-like, hepatic stellate cells (HSC/MFs)  
HSC/MFs are α-SMA-positive cells found primarily in or around capillarised sinusoids of 
fibrotic/cirrhotic livers that by definition originate only through a process of 
activation/differentiation from hepatic stellate cells (HSC), a kind of cells which have their 
physiological location in the space of Disse and in normal conditions are believed to store 
vitamin A and retinoids, to contribute to the synthesis of the local ECM components as well 
as to act as liver specific pericytes. HSC/MFs are positively stained “in vivo” for -SMA and 
can be recognized from other MFs for their positivity to a list of additional markers which 
includes neurotrophin-3 (NT-3), tyrosine kinase B or C (Trk-B, Trk-C), synaptophysin and 
p75, the low-affinity nerve growth factor receptor.  
3. The multiple origin of hepatic myofibroblasts 
A fascinating and still incompletely resolved issue is represented by the “in vivo” origin of 
hepatic MFs. According to current literature hepatic MFs mainly originate from hepatic 
stellate cells or from fibroblasts of portal areas through a process of activation and trans-
differentiation. In addition, hepatic MFs have been reported to originate also from bone 
marrow – derived stem cells, including mesenchymal stem cells or circulating fibrocytes, 
able to engraft chronically injured liver (Forbes & Parola, 2011). It has also been proposed 
that myofibroblasts or pro-fibrogenic cells may originate from either hepatocytes or 
cholangiocytes through a process of EMT, an issue that is at present highly controversial 
and debated (see section 3.4). Although hepatic MFs may then originate from different 
sources the interested reader should note that these cells are likely to display the same pro-
fibrogenic properties and phenotypic responses. Moreover, it has been proposed that 
HSC/MFs may play a critical role in the modulation of immune responses in CLDs and to 
strictly interact with either hepatic progenitor (stem) cells and/or with malignant cells of 
primary hepatocellular carcinomas or of metastatic cancers. In the following sections we will 
briefly summarize major information on the different intra- and extra-hepatic origin of MFs.  
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3.1 Hepatic stellate cells as a major intrahepatic source of MFs  
Under physiological conditions HSC are perisinusoidal cells of still uncertain embryological 
origin which are responsible for at least four main functions: a) HSC are responsible for the 
synthesis of basal membrane like – ECM components of the subendothelial space of Disse 
where they are located; b) HSC are responsible for the storage and the metabolism of 
vitamin A and retinoids (HSC represent the main site of storage for these compounds in 
mammalians); c) HSC act as “liver specific pericytes” taking intimate contacts with liver 
sinusoidal endothelial cells (LSEC); d) HSC contribute significantly to hepatic development 
and regeneration following either acute liver injury of liver resection (Friedman 2008a).  
HSC have been the first cell source of pro-fibrogenic MF-like cells to be identified and most 
of published studies performed on the pathogenic mechanisms of liver fibrosis deal with 
HSC/MFs. For these cells Scott Friedman’s laboratory has proposed the two-step process of 
activation and trans-differentiation, i.e. the process that leads HSC to acquire the MF-like 
phenotype (Friedman, 2003, 2008a). HSC-MFs are currently believed to be involved in most 
of clinical conditions of CLDs, with a predominant involvement in the pattern of fibrosis 
progression defined as “perisinusoidal/pericellular fibrosis”, recognising a metabolic or 
alcoholic aetiology. HSC contribute significantly also to the origin of IF/MFs and to the 
pattern of “bridging fibrosis” found in patients affected by chronic viral hepatitis (Friedman, 
2008a,b; Parola et al., 2008).  
Experimental and clinical studies dealing with HSC and HSC/MFs have been fundamental 
for our present knowledge concerning liver fibrogenesis and related molecular mechanisms 
by revealing that, under conditions of chronic liver injury, quiescent HSC located in the 
perisinusoidal space of Disse can undergo a peculiar process of activation. Human as well as 
rodent HSC undergo “in vitro”changes in morphology and operate phenotypical responses 
in their trans-differentiation from the original “storing or quiescent phenotype” to the one of 
activated MFs. The activated MF-like phenotype includes the following relevant pro-
fibrogenic features (Friedman 2008a; 2008b; Pinzani and Marra, 2001; Pinzani and 
Rombouts, 2004; Bataller and Brenner, 2005; Parola et al., 2008): a) a high proliferative 
attitude in response to growth factors and other mediators; b) an increased ability to 
synthesize ECM components, mainly fibrillar collagens (i.e., collagen type I and type III), as 
well as of factors involved in ECM remodelling; c) the ability to migrate in response to 
chemoattractants; d) the property to produce and release growth factors (autocrine loops) 
and pro-inflammatory cytokines; e) the ability to contract in response to vasoactive 
compounds. All these changes and phenotypic responses are considered to be similar to 
those occurring “in vivo” and to represent a functional paradigm common to all pro-
fibrogenic MFs, whatever the origin (Friedman 2008b; Parola et al., 2008; Parola and Pinzani 
2009; Forbes & Parola, 2011).  
3.2 Portal fibroblasts as an emerging additional intrahepatic source of MFs  
Portal fibroblasts (PFs) in the normal liver are α-SMA positive cells characterized by a 
morphological phenotype and by an antigen repertoire which are close to those expressed 
by other fibroblasts. Moreover, PFs express the highly specific fibroblast marker TE7, that is 
not expressed by other potential cellular sources of MFs like HSC (Dranoff & Wells, 2010), as 
well as other rather specific markers including IL-6, fibulin 2, elastin and the ecto-ATPase 
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nucleoside triphosphate diphosphohydrolase-2 (NTPD2). The origin of PFs is still uncertain 
and these cells may alternatively originate either from α-SMA positive cells of the ductal 
plate during human embryogenesis or, as recently proposed by a murine study, from a 
putative precursor in the early embryo development able to give also raise to HSCs 
(Asahina et al., 2009).  
According to current literature PFs undergo myofibroblastic differentiation in the 
chronically injured liver and when cultured on plastic or glass. Portal myofibroblasts 
(P/MFs), like typical myofibroblasts, express large numbers of α-SMA–containing 
microfilament bundles arrayed in parallel to the long axis of the cell. At present no definitive 
evidence has been presented to establish whether P/MFs can proliferate and can be 
passaged in culture or whether they can revert to a non MF state either “in vitro” or “in 
vivo”, as shown in the past for HSC and HSC/MFs.  
Accumulating evidence suggest that PFs as well as P/MFs have a relevant role in liver 
fibrogenesis. In particular, evidence for the pro-fibrogenic role is unequivocal in 
experimental conditions of biliary fibrosis such as those from experimental models of 
cholestatic injury, namely the model of bile duct ligation (BDL) in rodents as recently 
reviewed (Dranoff and Wells, 2010). The first studies reported that PFs start to deposit 
matrix in portal areas following BDL before undergoing myofibroblastic differentiation; 
moreover, PFs proliferate very rapidly around bile ductular cells following BDL and 
desmin-negative MFs (not originating from HSC) appear early (i.e., within 48 hrs) after BDL 
adjacent to the proliferating ductules. More recent studies provide evidence suggesting that 
the pro-fibrogenic role of PFs and P/MFs in biliary fibrosis mostly relies on the fact that the 
injury to bile duct epithelial cells (BDEC) is a prerequisite for the differentiation of PFs into 
P/MFs. The elegant and now validated hypothesis is that, once damaged, BDEC start to 
express transforming growth factor β2 (TGFβ2) and release a number of growth factors and 
pro-inflammatory mediators, including platelet-derived growth factor -BB (PDGF-BB), 
interleukin-6 (IL-6) and monocyte chemotactic protein-1 (MCP-1 or CCL2), that can be 
responsible for differentiation of PFs (that express related receptors) towards the P/MF 
phenotype. This process closely resemble the process of HSC activation and even more 
relevant, emerging evidence indicate that the acquisition of the P/MF phenotype is 
apparently followed by a process of perpetuation in which P/MFs start to behave like 
HSC/MFs.  
An emerging issue is that P/MFs may significantly contribute to CLD progression not only 
in biliary fibrosis but also in other clinical conditions characterised by bridging fibrosis 
irrespective of the aetiology. Indeed, as recently reviewed (Dranoff and Wells, 2010), the 
critical point is likely to be represented by the cross-talk between damaged and/or activated 
BDEC and PFs rather than the specific aetiology. Accordingly, several investigators have 
shown the existence of a direct correlation between the intensity of the so-called ductular 
reaction (a peculiar form of hyperplastic response of BDEC) and the severity of fibrosis in 
human liver disease of a variety of etiologies, including chronic HCV and NASH, as well as 
in animal models (Beaussier et al., 2007; Clouston et al., 2005; Fabris et al., 2007; Richardson 
et al., 2007). In particular, IL-6 and MCP-1 are emerging as important mediators of cell–cell 
communication between BDEC and PFs, with IL-6 being expressed specifically by BDEC 
and PFs expressing the IL-6 coreceptor glycoprotein 130 (gp130). It has been proposed the 
existence of a paracrine loop in which IL-6, by down-regulating NTPD2 on PFs (without 
 
Hepatic Myofibroblasts in Liver Fibrogenesis 
 
135 
altering PF myofibroblastic differentiation), can favor proliferation of BDEC that, in turn, 
provide stimuli like TGFβ2, PDGF and MCP-1 that sustain proliferation and MF-like 
differentiation of PFs.  
As a final comment for the present section on the putative role of PFs and P/MFs in liver 
fibrogenesis, one should note that as proposed by Dranoff and Wells (2010) PFs and P/MFs 
may be as multifunctional as activated HSCs or HSC/MFs, then having a role in the liver 
progenitor cell niche and in hepatic progenitor cell expansion and differentiation (see 
paragraph 4 dedicated to the roles attributed to hepatic MFs for more details).  
3.3 Bone marrow-derived cells as an extra-hepatic source of MFs  
Clinical and experimental evidence indicates that under conditions of chronic liver injury, 
pro-fibrogenic MFs (mainly IF/MFs and, possibly, some P/MFs) may also originate from 
progressive recruitment of bone marrow-derived cells (Forbes et al., 2004; Kisseleva et al., 
2006; Kallis et al., 2007; Henderson and Forbes, 2008; Friedman, 2008b; Parola et al. 2008; 
Forbes & Parola, 2011; Kisseleva & Brenner, 2011). This extrahepatic source of MFs is at 
present believed to offer a significant although modest contribution to liver fibrogenesis. 
Moreover, such a contribution, from a quantitative point of view, is likely to vary depending 
on both the aetiology and the progression rate of the specific form of CLD.  
From an historical point of view, the first evidence for a bone marrow-derived origin of 
hepatic MFs was provided in 2004 (Forbes et al., 2004) in a study in which were analysed 
fibrotic liver obtained from two different kind of patients: a) from male patients (affected by 
CLDs of different aetiology) that had received liver transplants from female donors and 
subsequently developed CLD; b) from a female patient that received bone marrow 
transplant from a male donor and afterward developed HCV-related cirrhosis. By 
employing fluorescence in situ hybridization (FISH) for the Y chromosome together 
immune-histochemistry for MFs specific antigens, Authors showed unequivocally that a 
significant numbers of Y chromosome in fibrotic areas of were found in the nuclei of α-SMA 
positive cells having a MF phenotype. In the liver transplant cases, a percentage of α-SMA 
positive MFs ranging from 6.8% to 22.2% contained the Y chromosome whereas in the 
female recipient of a bone marrow transplant from a male donor, 12.4% of the MFs were 
positive for the Y chromosome. This first study was followed by other carefully designed 
experimental studies that confirmed the concept (i.e., MFs may originate from circulating 
cells derived from bone marrow recruited into chronically injured liver) and were 
instrumental to identify at least two distinct populations of bone marrow-derived MFs 
precursors, including circulating fibrocytes (Kisseleva et al., 2006) and mesenchymal stem 
cells (MSC; Russo et al., 2006; Valfrè di Bonzo et al., 2008).  
In their study Kisseleva and coworkers performed experiments in which chimeric mice, 
transplanted with donor bone marrow from collagen alpha1(I)-green fluorescent protein 
(GFP)+ reporter mice, were subjected to the BDL model for biliary fibrosis. In response to 
injury, bone marrow-derived collagen-expressing GFP+ cells were detected in the liver 
tissues of chimeric mice and these bone marrow-derived cells, that were negative for α-SMA 
and desmin (then not originating from HSC/MFs), were found to co-express collagen-GFP+ 
and CD45+. This led Authors to suggest that these cells were representing a unique 
population of circulating fibrocytes that, in addition, increased numerically in bone marrow 
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precursors, including circulating fibrocytes (Kisseleva et al., 2006) and mesenchymal stem 
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and spleen of chimeric mice in response to injury. These fibrocytes when cultured in the 
presence of TGF-β1 differentiated into α-SMA and desmin positive collagen-producing MFs, 
confirming then to be potentially able to contribute to liver fibrosis. 
In the same year Russo and coworkers (Russo et al., 2006) employed female mice that were 
submitted to an experimental protocol consisting in: a) lethal irradiation, followed by b) 
transplant of either whole bone marrow or cell population enriched in MSC from mice male 
donors to be finally submitted to c) different protocols of fibrosis induction. BM-derived 
cells were tracked through FISH analysis for the Y chromosome FISH and results obtained 
indicated unequivocally that the bone marrow contributed significantly to hepatic stellate 
cell and MFs populations. Moreover, these bone marrow - derived MFs were able to actively 
synthesize collagen type 1 and originated largely from mesenchymal stem cells.  
In a subsequent study (Valfrè di Bonzo et al., 2008), non-obese diabetic - severe combined 
immuno-deficient (NOD-SCID) mice were sub-lethally irradiated, transplanted with highly 
purified populations of ex-vivo expanded human MSC and then submitted to a protocol of 
chronic injury in order to induce fibrosis. When chimeric livers were then analyzed for 
expression of human transcripts and antigens it was found that a significant number of cells 
of human origin (identified by expression of HLA class I antigens) exhibited a 
myofibroblast-like morphology. Moreover, human MSC in their MF-like phenotype were 
found to respond by proliferation and or migration to PDGF-BB and MCP-1 which are 
known to be effective on HSC/MFs. This strongly suggests that the pattern of polypeptide 
mediators known to be generated in CLDs may have a role in the hepatic 
recruitment/engraftment of MSC.  
Along these lines it seems correct to mention also a single study (Higashiyama et al., 2009), 
perhaps quite controversial (see Kallis and Forbes, 2009), that has questioned the real 
relevance of the phenomenon, suggesting that the contribution to liver fibrogenesis of MFs 
from bone marrow-derived cells recruited may be negligible.  
3.4 Hepatocytes or cholangiocytes are an unlikely sources of MFs through EMT 
process 
Epithelial to mesenchymal transition (EMT) must be envisaged as a fundamental biological 
process, paradigmatic of the concept of cell plasticity, that leads epithelial cells to lose their 
polarization and specialized junctional structures, to undergo cytoskeleton reorganization, 
and to acquire morphological and functional features of mesenchymal-like cells, including 
the ability to migrate and to produce and secrete components of the extracellular matrix 
(Cannito et al., 2010). Although EMT and the related opposite process of MET 
(mesenchymal to epithelial transition) have been originally described in embryonic 
development (i.e., where cell migration and tissue remodeling have a primary role in 
regulating morphogenesis in multicellular organisms), extensive literature data have 
recently provided evidence suggesting that the EMT process is a more general process that 
may have a significant role in several pathophysiological conditions, including cancer 
progression and organ fibrosis (Thiery and Sleeman, 2006; Acloque et al., 2009; Kalluri and 
Weinberg, 2009; Zeisberg and Neilson, 2009; Cannito et al., 2010).  
Pertinent to this chapter, EMT has been proposed to have a pathogenic role in organ fibrosis 
and particularly in those conditions in which fibrosis may result from chronic and 
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uncontrolled activation of wound-healing response, then in conditions where progressive 
fibrogenesis result in the progressive accumulation of ECM components, derangement of 
tissue and vascular architecture and eventually organ failure. The involvement of EMT in 
organ fibrosis was first claimed in experimental studies dedicated to the pathogenesis of 
kidney fibrosis (Iwano et al., 2002; Yang et al., 2002; Zeisberg and Kalluri, 2004) in which it 
was shown that a significant number of pro-fibrogenic kidney fibroblasts were positive for 
FSP1 (fibroblast specific protein 1), an antigen believed to be specific for fibroblast-like cells 
derived from local EMT. More recently, several studies (reviewed in Choi and Diehl, 2009; 
Cannito et al., 2010) have proposed that pro-fibrogenic cells may originate in CLDs through 
EMT involving either cholangiocytes (BDEC) or hepatocytes.  
EMT of hepatocytes was suggested quite recently in an experimental study (Zeisberg et al., 
2007) describing a progressive appearance in the injured livers of FSP-1 positive cells, 
although less than 10% of FSP-1+ cells were shown to co-express the typical and widely 
accepted MFs marker α-SMA. In such a study Authors also performed lineage-tracing 
experiments using AlbCre.R26RstoplacZ double transgenic mice in order to investigate 
whether hepatocytes undergoing EMT may contribute significantly to fibrosis induced by 
chronic treatment with the hepatotoxin CCl4. They reported that approx. 15% of hepatic cells 
were FSP-1 positive at the time of severe fibrosis and that approx. 5% of the hepatic cells 
were co-expressing either FSP-1 and albumin or FSP-1 and β-gal, then suggestive of EMT. 
Moreover, these authors also performed experiments showing that bone morphogenetic 
protein-7 (BMP-7), which is known to antagonize TGFβ1 signalling, significantly inhibited 
progression of liver fibrosis and almost abolished putative EMT-derived fibroblasts. Similar 
results, were described by another group that employed a transgenic mouse model of 
Smad7 over-expression in hepatocytes to counteract CCl4 – induced fibrosis (Dooley et al; 
2008). The latter study also reported preliminary morphological evidence for “in vivo” EMT 
in biopsies from chronic HBV patients in terms of positive hepatocyte nuclear staining for 
SNAI1 (a specific and EMT-related transcription factor).  
Involvement of EMT of cholangiocytes or BDEC has been reported in either experimental 
and clinical conditions associated with a form of biliary fibrosis. The first report was 
published in 2006 (Xia et al., 2006) and provided evidence suggesting that BDEC undergoing 
the process of bile ductular reaction in the rat model of secondary biliary fibrosis due to bile 
duct ligation were co-expressing α-SMA and cytokeratin 19 (CK-19, a BDEC marker that 
also stain hepatic progenitor cells or HPCs). The same scenario was confirmed in the same 
model of BDL (rat and murine) by a series of elegant studies from the group of Anna Mae 
Diehl (reviewed in Choi and Diehl, 2009), the most relevant (Omenetti et al., 2008a, 2008b, 
and reference therein) being able to describe an apparently clear cause-effect relationships 
among EMT of BDEC, appearance of portal MFs and biliary fibrosis as well as the closely 
related major involvement of Hedgehog signalling pathway. Other studies from the same 
and other research groups described morphological evidence for EMT of BDEC also in liver 
biopsies from human patients affected by primary sclerosing cholangitis (PSC, Kirby et al., 
2008), primary biliary cirrhosis (PBC, Jung et al., 2007; Robertson et al., 2007; Omenetti et al., 
2008b) or biliary atresia (Diaz et al., 2008). Similar evidence has been reported EMT of BDEC 
in post-transplantation recurrence of PBC (Robertson et al., 2007) and the relevance of 
Hedgehog and TGFβ1-Smad2/3 signalling was reported also in human patients (Jung et al., 
2007, 2008; Omenetti et al., 2008b; Robertson et al., 2007; Rygiel et al., 2008).  
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Following initial enthusiasm, however, a number of issues have very recently questioned 
whether EMT may be really involved in CLDs. A first cautionary issue is represented by 
actual re-evaluation of the specificity of FSP1 as a marker of EMT which comes from 
carefully performed experiments in kidney. Indeed, some studies have revealed that FSP1 is 
not at all a marker for fibroblasts but rather for leukocytes and other non-fibroblastic cell 
types (Le Hir et al., 2005; Lin et al., 2008). In addition, a recent elegant fate tracing study 
(using Cre/Lox techniques) has clearly shown that although genetically labelled primary 
proximal epithelial cells exposed in culture to TGFβ underwent apparent EMT becoming 
MF-like cells, no “in vivo” evidence was detected that epithelial cells may migrate outside of 
the tubular basement membrane and differentiate into interstitial MFs in a model of kidney 
fibrosis (Humphreys et al., 2010).  
Whether liver fibrogenesis is concerned, the group of Brenner has very recently published 
three elegant experimental studies that are challenging the involvement of EMT of either 
hepatocytes or cholangiocytes (or BDEC) as a pathogenic mechanism in liver fibrogenesis. In 
a first study Authors employed triple transgenic mice expressing ROSA26 stop beta-
galactosidase (beta-gal), albumin Cre, and collagen alpha1(I) green fluorescent protein 
(GFP), in order to have hepatocyte-derived cells permanently labeled by beta-gal and type I 
collagen-expressing cells labeled by GFP (Taura et al., 2010). These engineered hepatocytes 
underwent changes towards a fibroblast morphology if cultured in the presence of TGFβ1 
but when authors isolated hepatic cells from the liver of triple transgenic mice after 
induction of fibrosis (carbon tetrachloride chronic model) they could not find cells 
expressing double-positivity for GFP and beta-gal. All beta-gal-positive cells exhibited the 
typical morphology of hepatocytes and did not expressed mesenchymal markers like α-
SMA, FSP-1, desmin, or vimentin. On the other hand, GFP-positive areas in fibrotic livers 
were coincident with fibrotic septa but never overlapped with X-gal-positive areas and then 
Authors concluded that type I collagen-producing cells were not originating from 
hepatocytes.  
A very similar conclusion was reached in a second study (Scholten et al., 2010) in which 
EMT was again investigated with Cre/LoxP system in order to map cell fate CK-19 positive 
BDEC in CK-19(YFP) or FSP-1(YFP) mice that were generated by crossing tamoxifen-
inducible CK-19(CreERT) mice or FSP-1(Cre) mice with Rosa26(f/f-YFP) mice. MET of 
GFAP(+) HSCs was studied in GFAP(GFP) mice. Transgenic mice were then subjected to 
bile duct ligation or chronic carbon tetrachloride treatment. When the livers of fibrotic 
transgenic mice were analyzed specific immunostaining of CK-19(YFP) cholangiocytes 
showed no expression of EMT markers such as α-SMA, desmin, or FSP-1. Moreover, cells 
genetically labeled by FSP-1(YFP) expression did not coexpress neither the cholangiocyte 
marker CK-19 nor E-cadherin. These results led again Authors to conclude that EMT of 
BDEC were not contributing to liver fibrogenesis in murine models.  
The third study by the group of Brenner was even more relevant because provided 
compelling evidence that FSP-1 (the putative marker of EMT-derived fibroblasts) in either 
human and experimental CLDs was not expressed by HSC or type I collagen-producing 
fibroblasts (Osterreicher et al. 2011). Moreover, FSP1-positive cells did not express classical 
myofibroblast markers, including α-SMA and desmin, and were not myofibroblast 
precursors in injured livers as evaluated by genetic lineage tracing experiments. According 
to what already described by studies on kidney fibrosis FSP1-positive cells expressed F4/80 
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and other markers of the myeloid-monocytic lineage and the overall characterization 
pointed out that FSP1 was expressed by a specific subset of inflammatory macrophages in 
liver injury, fibrosis, and cancer that differed from Kupffer cells for reduced expression of 
MMP-3 and TIMP-3. 
Few months ago a study from the laboratory of Rebecca Wells provided what looks like as 
an unequivocal proof against EMT in the liver as a source of MFs (Chu et al. 2011). This 
study uses lineage tracing generated by crossing the alpha-fetoprotein (AFP) Cre mouse 
with the ROSA26YFP stop mouse in order to trace the fate of any cell ever expressing AFP. 
As expected, all the cholangiocytes and all the hepatocytes were genetically labeled, because 
they are derived from AFP-expressing precursor cells. Furthermore, AFP+ progenitor cells 
were also irreversibly genetically marked. The critical result was that after inducing liver 
fibrosis using different models, none of the resulting myofibroblasts was found to originate 
from the genetically marked epithelial (AFP+) cells.  
As a final comment for this section, at present the real involvement of EMT as a pathogenic 
mechanism contributing to liver fibrogenesis in CLDs is then more than controversial, with 
accumulating evidence deposing against EMT from either hepatocytes or cholangiocytes. 
This has generated an intense debate that the interested reader may find recapitulated in 
three recently published editorials (Wells, 2010; Popov and Schuppan, 2010; Kisseleva & 
Brenner, 2011).  
4. The role of hepatic myofibroblasts in liver fibrogenesis and chronic liver 
disease progression 
In the previous section we outlined that hepatic MFs may originate from intra- and, to a less 
extent, extra-hepatic cellular sources; whether the origin of MFs from HSC or PFs is 
concerned (Friedman, 2008a; 2008b; Dranoff & Wells, 2010), this is likely to occur through a 
process of activation/transdifferentiation that is believed to involve common mediators, 
mechanisms and signalling pathways. Although this scenario may apply also to circulating 
bone marrow-derived cells recruited in the chronically injured liver, at present most of our 
knowledge derives from “in vivo” and “in vitro” studies performed on activated human or 
rodent HSC and then in the following sections we will mainly refer to the paradigm of HSC 
activation and transdifferentiation to HSC/MFs as well as to all those phenotypic responses 
which have been attributed to HSC/MFs.  
As nicely outlined by Scott Friedman and coworkers, under condition of persisting chronic 
liver injury HSC activation is believed to progress in sequential stages of initiation and 
perpetuation (Friedman, 2008a; 2008b; Lee & Friedman, 2011). HSC initiation should be 
envisaged as an early response which is stimulated by several paracrine signals that lead 
quiescent HSC to acquire a transient and potentially reversible contractile and profibrogenic 
phenotype. This “transient” phenotype is typically characterized by the rapid induction of 
platelet-derived growth factor (PDGF)β receptor expression being then primed to respond 
to several additional growth factors and mediators that, in turn, will be crucial in eliciting 
major phenotypic responses operated by fully activated MF-like phenotype (i.e., 
perpetuation). These responses include proliferation, migration/chemotaxis, contractility, 
excess deposition and altered remodelling of ECM as well as the emerging role in 
modulating angiogenesis and the immune respose.  
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4.1 Proliferation and migration/chemotaxis of HSC/MFs 
Cultured HSC/MFs proliferate in response to a number of mitogenic stimuli, including 
primarily PDGF, basic fibroblast growth factors (bFGF), angiotensin II (AT-II), vascular 
endothelial growth factor A (VEGF-A) and thrombin (Pinzani and Marra, 2001; Friedman, 
2008b; Parola et al., 2008). The most powerful mitogenic stimulus is by far represented by 
PDGF, particularly by PDGF-BB homodimeric isoform which can be released in the scenario 
of a CLD by either activated Kupffer cells, sinusoidal endothelial cells, platelets or by 
activated MFs in a well established autocrine/paracrine loop. PDGF-BB mitogenic signalling 
pathways requires first interaction with PDGF β-receptor subunit (PDGFβR), which is a 
tyrosine kinase receptor, leading then to the activation of the classic downstream signalling 
involving Ras/ERK pathway, phosphatidyl-inositol 3-kinase (PI-3K), ERK5 and others 
(Pinzani and Marra, 2001; Friedman, 2008b). This pathway is also responsible for migratory 
response since PDGF-BB also represents the best characterized and most potent 
chemoattractant for HSC/MFs (Pinzani and Marra, 2001) as well as for MF-like cells from 
human MSC (Valfrè di Bonzo et al., 2008). Indeed, migration/chemotaxis of HSC/MFs and, 
more generally, of hepatic MFs represents a relevant pro-fibrogenic response that allow MFs 
to reach the site of injury and to align with both nascent and established fibrotic septa. 
Migration/chemotaxis of hepatic MFs is also elicited by MCP-1, AT-II, VEGF-A, 
Angiopoietin-1, C-X-C chemokine receptor type 3 (CXCR3) ligands and, interestingly, ROS 
(Novo et al., 2007; Friedman, 2008; Novo and Parola, 2008; Parola et al., 2008). Along these 
lines, a recently published study from our laboratory has established that all 
chemoattractant polypeptides activate, in both HSC/MFs or MFs derived from MSC, a 
common signalling involving phosphorylation of ERK1/2 and c-Jun-NH2 kinase 1/2 
(JNK1/2) through a redox-dependent mechanism that requires a NADPH-oxidase - 
mediated increase in intracellular generation of ROS. Moreover, the same pro-migratory 
pathways can also be elicited by intracellular ROS in a polypeptide-independent manner 
(Novo et al., 2011).  
4.2 ECM synthesis/remodelling by HSC/MFs and the concept of fibrosis reversion 
Hepatic MFs are of course the main responsible for excess deposition of ECM components, 
particularly of fibrillar matrix (mainly collagen type I and III), which represent an 
undisputed hallmark of fibrotic and cirrhotic livers. Indeed, progressive fibrogenesis is 
typically characterized by the replacement of the low-density basement membrane of the 
subendothelial space of Disse with fibril-forming matrix, a scenario that negatively affect 
differentiated cell functions (mainly of hepatocytes). This scenario is believed to result 
primarily from a disequilibrium between excess deposition of fibrillar collagens as well as of 
other ECM components and a reduced/altered degradation and remodelling of fibrotic 
ECM. According to current literature HSC/MFs and likely all hepatic MFs have a 
predominant role in modulating both ECM deposition and remodelling.  
Hepatic MFs synthesize ECM components primarily as a response to TGFβ1 which can be 
released in the scenario of a CLD by either activated inflammatory cells, mostly Kupffer cells 
or monocyte/macrophages recruited from circulation, as well as by HSC/MFs themselves 
in a paracrine and autocrine manner. TGFβ1 operates mainly through classic downstream 
signalling and then involving Smads-2 and -3. Connective tissue growth factor (CTGF) and 
cannabinoids have been also identified as potent profibrogenic signals for HSC/MFs 
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(Friedman, 2008b) and the list of putative pro-fibrogenic polypeptides also include vascular 
endothelial growth factor - A (VEGF-A) (Medina et al., 2004; Parola et al. 2008). To this list 
one should also add leptin, which is a key adipokine that has been implicated in 
fibrogenesis in relation to NAFLD development towards NASH (Marra & Bertolani, 2009; 
Lee & Friedman, 2011). In particular, leptin has been reported to promote HSC fibrogenesis 
and to enhance tissue inhibitor of metalloprotease type 1 (TIMP-1) expression (see later for 
the role of TIMP-1 over-expression). Leptin operates through its receptor (ObR) and leads to 
the stimulation of Janus kinase (Jak)-signal transduction and activates the Jak-signal 
transduction and activator of transcription (STAT) signalling pathway and, partially, 
through suppression of peroxisome proliferator-activated receptor-γ (PPARγ), the latter 
being an anti-fibrogenic nuclear receptor able to reverse HSC activation and to maintain 
HSC quiescence. The action of leptin is usually counteracted by the circulating levels of 
adiponectin and indeed adiponectin levels have been reported to decrease in liver fibrosis 
(Marra & Bertolani, 2009; Lee & Friedman, 2011).  
Where ECM remodelling is concerned, according to current literature HSC/MFs mainly 
express metallo-proteinases (MMPs) able to degrade basement membrane (MMP-2, MMP-9, 
MMP3 or stromelysin) that are less efficient to degrade fibrillar matrix, with a low 
expression of MMP-1 (interstitial collagenase). HSC/MFs also overexpress tissue inhibitor of 
metalloproteinase type 1 (TIMP-1) that, in turn, can inhibit interstitial collagenases and act 
as anti-apoptotic factor for HSC/MFs. Deposition of fibrillar matrix and formation of fibrotic 
septa is also favoured by the fact that HSC/MFs and, likely, all hepatic MFs, develop 
resistance to induction of apoptosis (El-Sharkawy et al., 2005; Novo et al., 2006; Friedman, 
2008b; Parola et al., 2008; Pinzani, 2009; Povero et al., 2010). Related to this concept are 
findings of the last decade suggesting that (Iredale, 2007; Parola et al., 2008; Pinzani, 2009; 
Povero et al., 2010) liver fibrosis and, possibly, initial stages of cirrhosis are potentially 
reversible in the presence of effective therapy and/or aetiology eradication. Experimental 
and clinical studies suggest that regression of histopathology develops as a result of 
increased apoptosis of HSC/MFs and MFs and is paralled by increased expression of 
interstitial collagenases by hepatic macrophages. However, it should be noted that based on 
the absence of any unequivocal clinical finding, most researchers still believe that advanced 
human cirrhosis (i.e., in the presence of a very significant derangement of vascular 
architecture) is unlikely to regress (Iredale, 2007; Henderson and Iredale, 2007; Parola et al., 
2008; Pinzani, 2009; Povero et al., 2010).  
4.3 HSCs as liver specific pericytes and the pro-angiogenic phenotype of HSC/MFs 
Angiogenesis can be defined as dynamic, hypoxia-dependent and growth factor – mediated 
process leading to the formation of new vessels from pre-existing ones. Hepatic 
angiogenesis is considered as a key component of the wound healing response to liver 
fibrosis and is essential for liver regeneration but it plays a relevant role also in promoting 
hepatic carcinogenesis and then the angiogenic process is strictly regulated by several 
factors (Medina et al., 2004; Fernandez et al., 2009; Valfrè di Bonzo, 2010). In this scenario 
one should first consider that quiescent HSC have been proposed to act as liver specific 
pericytes and that under conditions of chronic liver injury HSC/MFs acquire features of 
smooth muscle cells and the ability to contract in response to vasoactive (Friedman 2008a, 
2008b; Parola et al. 2008). HSC/MFs contractility is thought to contribute to both the genesis 
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(Friedman, 2008b) and the list of putative pro-fibrogenic polypeptides also include vascular 
endothelial growth factor - A (VEGF-A) (Medina et al., 2004; Parola et al. 2008). To this list 
one should also add leptin, which is a key adipokine that has been implicated in 
fibrogenesis in relation to NAFLD development towards NASH (Marra & Bertolani, 2009; 
Lee & Friedman, 2011). In particular, leptin has been reported to promote HSC fibrogenesis 
and to enhance tissue inhibitor of metalloprotease type 1 (TIMP-1) expression (see later for 
the role of TIMP-1 over-expression). Leptin operates through its receptor (ObR) and leads to 
the stimulation of Janus kinase (Jak)-signal transduction and activates the Jak-signal 
transduction and activator of transcription (STAT) signalling pathway and, partially, 
through suppression of peroxisome proliferator-activated receptor-γ (PPARγ), the latter 
being an anti-fibrogenic nuclear receptor able to reverse HSC activation and to maintain 
HSC quiescence. The action of leptin is usually counteracted by the circulating levels of 
adiponectin and indeed adiponectin levels have been reported to decrease in liver fibrosis 
(Marra & Bertolani, 2009; Lee & Friedman, 2011).  
Where ECM remodelling is concerned, according to current literature HSC/MFs mainly 
express metallo-proteinases (MMPs) able to degrade basement membrane (MMP-2, MMP-9, 
MMP3 or stromelysin) that are less efficient to degrade fibrillar matrix, with a low 
expression of MMP-1 (interstitial collagenase). HSC/MFs also overexpress tissue inhibitor of 
metalloproteinase type 1 (TIMP-1) that, in turn, can inhibit interstitial collagenases and act 
as anti-apoptotic factor for HSC/MFs. Deposition of fibrillar matrix and formation of fibrotic 
septa is also favoured by the fact that HSC/MFs and, likely, all hepatic MFs, develop 
resistance to induction of apoptosis (El-Sharkawy et al., 2005; Novo et al., 2006; Friedman, 
2008b; Parola et al., 2008; Pinzani, 2009; Povero et al., 2010). Related to this concept are 
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Povero et al., 2010) liver fibrosis and, possibly, initial stages of cirrhosis are potentially 
reversible in the presence of effective therapy and/or aetiology eradication. Experimental 
and clinical studies suggest that regression of histopathology develops as a result of 
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interstitial collagenases by hepatic macrophages. However, it should be noted that based on 
the absence of any unequivocal clinical finding, most researchers still believe that advanced 
human cirrhosis (i.e., in the presence of a very significant derangement of vascular 
architecture) is unlikely to regress (Iredale, 2007; Henderson and Iredale, 2007; Parola et al., 
2008; Pinzani, 2009; Povero et al., 2010).  
4.3 HSCs as liver specific pericytes and the pro-angiogenic phenotype of HSC/MFs 
Angiogenesis can be defined as dynamic, hypoxia-dependent and growth factor – mediated 
process leading to the formation of new vessels from pre-existing ones. Hepatic 
angiogenesis is considered as a key component of the wound healing response to liver 
fibrosis and is essential for liver regeneration but it plays a relevant role also in promoting 
hepatic carcinogenesis and then the angiogenic process is strictly regulated by several 
factors (Medina et al., 2004; Fernandez et al., 2009; Valfrè di Bonzo, 2010). In this scenario 
one should first consider that quiescent HSC have been proposed to act as liver specific 
pericytes and that under conditions of chronic liver injury HSC/MFs acquire features of 
smooth muscle cells and the ability to contract in response to vasoactive (Friedman 2008a, 
2008b; Parola et al. 2008). HSC/MFs contractility is thought to contribute to both the genesis 
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of increased portal resistance during early stages of fibrosis as well as, by contributing to 
angiogenesis, to the late and persistent increase in portal pressure found in the cirrhotic liver 
which is largely due to the distortion of hepatic angioarchitecture (i.e., a consequence of 
angiogenesis). HSC, in particular, are located in the perisinusoidal space of Disse and with 
their perisinusoidal processes can affect pericapillary resistance then contributing to 
modulate hepatic blood flow through contractility. HSC are sensitive to well known 
vasoactive mediators with contraction being elicited by Endothelin-1 (ET-1) whereas 
relaxation is induced by nitric oxide (NO) or carbon monoxide (CO).  
Under conditions of chronic liver disease, vascular derangement and excess ECM deposition 
contribute to create an hypoxic milieu which is a major and physiological stimulus for 
angiogenesis. Along these lines, in recent years it has become clear that HSC may respond to 
hypoxia and contribute to angiogenesis, particularly when activated to the myofibroblast - 
like pro-fibrogenic phenotype. The interested reader may refer to recent more 
comprehensive reviews for more details (Medina et al., 2004; Fernandez et al., 2009; Valfrè 
di Bonzo et al., 2009). A number of critical concepts and findings correlating MFs, 
fibrogenesis and angiogenesis should be outlined.    
First, angiogenesis and up-regulation of VEGF expression have been documented in 
experimental models of acute and chronic liver injury as well as in human fibrotic/cirrhotic 
liver, including chronic infection by HBV and HCV, and autoimmune diseases such as PBC 
and PSC. Moreover, in both experimental and clinical conditions angiogenesis and 
fibrogenesis develop in parallel and strict relationships between hypoxia, angiogenesis, 
VEGF expression and fibrogenesis have been outlined. Along these lines, VEGF expression 
is mostly limited to hepatocytes and to HSC/MFs and, possibly, other hepatic 
myofibroblasts. Other polypeptides have been involved in hepatic angiogenesis as a process 
associated with the fibrogenic progression process in CLDs, including, in particular, leptin 
and Hedgehog (Hh) ligands.  
Where hepatic MFs are concerned, these cells have also been reported to play a significant 
pro-angiogenic role. As for recent literature data, HSC/MFs can be considered as a hypoxia 
– sensitive, cyto- and chemokine-modulated cellular crossroad between necro-inflammation, 
pathological angiogenesis and fibrogenesis (reviewed in Fernandez et al., 2009; Valfrè di 
Bonzo et al., 2009). This statement is justified by the fact that HSC and HSC/MFs react to 
conditions of hypoxia and leptin by up-regulating transcription and synthesis of VEGF, 
Angiopoietin 1, as well as of their related receptor VEGFR-2 and Tie2. Moreover, HSC/MFs 
respond to the action of VEGF and Angiopoietin 1 in terms of proliferation, increased 
deposition of ECM components and increased migration and chemotaxis (Novo et al., 2007) 
in a redox-dependent way involving activation of Ras/ERK and JNK1/2 signaling 
pathways (Novo et al., 2011).  
According to this scenario, in both human and rat fibrotic/cirrhotic livers (Novo et al., 2007) 
-SMA-positive MFs able to express concomitantly VEGF, Ang-1 or the related receptors 
VEGFR-2 and Tie-2, are found at the leading edge of tiny and incomplete developing septa, 
but not in larger bridging septa. This distribution is likely to reflect the existence of an early 
phase of CLD, occurring in developing septa, in which fibrogenesis and angiogenesis may 
be driven/modulated by HSC/MFs, and of a later phase occurring in larger and more 
mature fibrotic septa where the chronic wound healing is less active and fibrogenic 
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transformation more established. In the late setting pro-angiogenic factors are expressed 
only by endothelial cells, a scenario that is likely to favour the stabilization of the newly 
formed vessels.  
As a final comment, the reader should note that angiogenesis is at present debated as a 
potential therapeutic target in the treatment of CLDs since the bulk of available 
experimental data indicate that anti-angiogenic therapy is effective in preventing 
progressive fibrogenesis (reviewed in Fernandez et al., 2009; Valfrè di Bonzo et al., 2009). 
Interestingly, to block angiogenesis also results in a significant inhibition of the 
development of portal hypertension, porto-systemic collateral vessels and hyperdynamic 
splanchnic circulation.  
4.4 HSC/MFs and their role in the modulation of inflammatory and immune response  
Persisting inflammatory response in a CLD is considered as one of the major “driving 
forces” sustaining fibrogenesis. HSC/MF and, likely, all MFs behave like target cells for 
inflammatory cytokines and other pro-inflammatory signals, including: a) ROS and other 
oxidative stress - related mediators like 4-hydroxy-2,3-nonenal or HNE, generated as a 
consequence of hepatocyte injury and necrosis; b) apoptotic bodies (engulfing and 
activating); c) bacterial endotoxin or other endogenous activators of Toll Like Receptor 4 
(TLR4) of innate immunity displayed by HSC/MFs. On the other hand, HSC/MFs have 
been unequivocally shown to represent the cell source (even in an autocrine manner) of a 
number of pro-inflammatory molecules, including TLR ligands, MCP-1 or CCL2 and other 
chemoattractants and chemokines (Pinzani & Marra, 2001; Bataller & Brenner, 2005; 
Friedman, 2008b).  
As a matter of fact, HSC are both a source of chemokines as well as a cellular target for their 
action: HSC express several chemokine receptors including CXCR3, CCR5 and CCR7 and 
have been reported to express at least CCL2, CCL3,CCL5, CXCL1, CXCL8, CXCL9 and 
CXCL10 ligands (Sahin et al., 2010). Within this panel of chemokines, CCR5 interaction with 
its ligand (RANTES or CCL5) is induced by NF-kB signalling and can stimulate HSC 
proliferation and migration. Moreover (reviewed in Lee & Friedman, 2011) CCR1, CCR5 and 
CXCL4 deficient mice have been reported to be associated with reduced inflammation and 
fibrosis. On the other hand, CXCL9, through its receptor CXCR3 operates as an anti-
fibrogenic mediators.  
HSC do not only secrete inflammatory chemokines but, by also interacting with immune 
cells through expression of adhesion molecules (mainly intercellular- and vascular-cell 
adhesion molecule - 1, ICAM-1 and VCAM-1, respectively) can modulate hepatic immune 
response in addition to natural-killer (NK) cells, T-cells, dendritic cells and of course 
professional phagocytes (Kupffer cells and macrophages recruited from peripheral blood) a 
scenario that is likely to be relevant for fibrogenesis progression (reviewed in Friedman, 
2008a; 2008b; Lee & Friedman, 2011). By expanding the concept previously introduced, 
HSC/MFs also express TLRs and then can respond to the presence of endotoxin (LPS). 
TLRs, which are pattern recognition receptors that sense pathogen-associated molecular 
patterns (PAMPs) to discriminate the products of microorganisms from the host, are 
expressed on Kupffer cells, endothelial cells, dendritic cells, biliary epithelial cells, HSC and 
hepatocytes in the liver. TLR signaling can induce potent innate immune responses in these 
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transformation more established. In the late setting pro-angiogenic factors are expressed 
only by endothelial cells, a scenario that is likely to favour the stabilization of the newly 
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CXCL4 deficient mice have been reported to be associated with reduced inflammation and 
fibrosis. On the other hand, CXCL9, through its receptor CXCR3 operates as an anti-
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HSC do not only secrete inflammatory chemokines but, by also interacting with immune 
cells through expression of adhesion molecules (mainly intercellular- and vascular-cell 
adhesion molecule - 1, ICAM-1 and VCAM-1, respectively) can modulate hepatic immune 
response in addition to natural-killer (NK) cells, T-cells, dendritic cells and of course 
professional phagocytes (Kupffer cells and macrophages recruited from peripheral blood) a 
scenario that is likely to be relevant for fibrogenesis progression (reviewed in Friedman, 
2008a; 2008b; Lee & Friedman, 2011). By expanding the concept previously introduced, 
HSC/MFs also express TLRs and then can respond to the presence of endotoxin (LPS). 
TLRs, which are pattern recognition receptors that sense pathogen-associated molecular 
patterns (PAMPs) to discriminate the products of microorganisms from the host, are 
expressed on Kupffer cells, endothelial cells, dendritic cells, biliary epithelial cells, HSC and 
hepatocytes in the liver. TLR signaling can induce potent innate immune responses in these 
 
Trends in Alcoholic Liver Disease Research – Clinical and Scientific Aspects 
 
144 
cell types and this is relevant since the liver is constantly exposed to PAMPs, such as LPS 
and bacterial DNA through bacterial translocation from intestine, particularly in the settings 
of alcoholic liver disease (ALD). Recent evidence demonstrates the role of TLRs in the 
activation of hepatic immune cells and HSC during liver fibrosis. Activated human 
HSC/MFs express not only TLR4 but also CD14 and MD2, forming the LPS receptor; LPS 
then lead to activation of nuclear factor kB (NF-kB) and c-Jun amino-terminal kinase (JNK) 
isoforms resulting in the synthesis and release of chemokines and adhesion molecules. 
Moreover, crosstalk between TLR4 signaling and TGF-beta signaling in hepatic stellate cells 
has been reported, suggesting an additional pro-fibrogenic mechanism (Aoyama et al., 
2010).  
Concerning the immune modulatory action, a number of relevant issues should be outlined 
for HSC and MFs (the interested reader may refer to excellent comprehensive reviews 
(Unanue, 2007; Friedman, 2008a; 2008b; Lee & Friedman, 2011): a) HSC can act as 
professional antigen presenting cells (reviewed in Unanue, 2007), able to stimulate either 
lymphocyte proliferation or apoptosis; b) HSC can regulate leukocyte behaviour and are 
affected by specific lymphocyte populations, with CD8 lymphocytes being more pro-
fibrogenic towards HSC/MFs than CD4 cells; c) HSC cells can induce locally 
immunotolerance throughout T cell suppression; d) natural killer (NK) cells seem able to 
selectively kill HSC/MFs, a scenario which is apparently stimulated by interferon and 
inhibited by ethanol. 
4.5 HSC/MFs and their putative role in liver regeneration and cancer 
At first the role of hepatic MFs in liver regeneration has been originally limited to the notion 
that these cells, particularly HSC/MFs, may contribute to sustain liver regeneration (for 
example following acute liver injury or partial hepatectomy) by producing growth factors 
for either mature hepatocytes or oval cells, bipotent progenitors of hepatocytes and 
cholangiocytes (Pinzani & Marra, 2001, Friedman 2008a, 2008b).  
Recently, HSC/MFs have been reported to contribute to the so called “liver stem cell niche” 
and were shown to express the stem cell marker CD133 (Kordes et al., 2007). This has led 
Authors to propose that HSC and possibly HSC/MFs may then directly differentiate into 
stem or precursor cells. This is indeed a fascinating hypothesis in the scenario of liver 
regeneration that may even (see Friedman 2008b) offer a further possible explanation for the 
fact that fibrosis is a “near-absolute” requirement for the development of hepatocellular 
carcinoma (HCC). One should consider the following facts and hypothesis: a) neoplastic 
cells may be envisaged to derive either from hepatic progenitor cells (HPCs) or adult and 
DNA-damaged hepatocytes being sustained by paracrine or survival factors released by 
MFs or directly from HSC/MFs through a process of mesenchymal to epithelial transition 
into HPCs; the latter hypothesis is highly speculative, but supported by the notion that in 
HSC/MFs operate hedgehog and Wnt signalling, two pathways that have been implicated 
in stem cell differentiation and cancer. Another study went further in proposing an even 
more speculative and fascinating scenario (Yang et al., 2008) in which HSC may represent a 
type of oval cell thus being potentially able to generate hepatocytes to repopulate injured 
livers. In this elegant study, since quiescent HSC express glial fibrillary acidic protein 
(GFAP), mice in which GFAP promoter elements regulated Cre-recombinase were crossed 
with ROSA-loxP-stop-loxP-green fluorescent protein (GFP) mice to generate GFAP-
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Cre/GFP double-transgenic mice. These mice were fed methionine choline-deficient, 
ethionine-supplemented diets to activate and expand HSC and oval cell populations. GFP-
positive progeny of GFAP-expressing precursor cells were then characterized by immune-
histochemistry. HSC, when activated by liver injury or culture, downregulated expression of 
GFAP but remained GFP(+); they became highly proliferative and began to co-express 
markers of mesenchymal and oval cells. These transitional cells apparently disappeared as 
GFP-expressing hepatocytes emerged, began to express albumin, and eventually 
repopulated large areas of the hepatic parenchyma. These findings led Authors to suggest 
that HSC are a peculiar type of precursor cell able to transit through a mesenchymal phase 
before to differentiate into hepatocytes during liver regeneration.  
5. Major mechanisms sustaining liver fibrogenesis: a major focus on ROS 
and ethanol 
According to current literature the mechanisms able to elicit and sustain liver fibrogenesis 
may be classified, from a general point of view, in three main groups including a) activation 
of chronic wound healing reaction, b) oxidative stress and c) altered modulation of 
epithelial-mesenchymal interactions. 
The chronic activation of the wound-healing reaction is the most common and relevant 
mechanism in hepatic fibrogenesis which is characterized by the following key general 
features: a) the persistence of hepatocellular/cholangiocellular damage with variable degree 
of necrosis and apoptosis; b) a complex inflammatory infiltrate including mononuclear cells 
and cells of the immune system; c) the activation of different types of ECM-producing cells 
(HSC, portal myofibroblasts, etc.) with marked proliferative, synthetic and contractile 
features; d) marked changes in the quality and quantity of the hepatic ECM associated with 
very limited or absent possibilities of remodeling in the presence of a persistent attempt of 
hepatic regeneration (Pinzani & Rombouts, 2004; Parola et al., 2008).  
In previous sections the attention has been already focussed on those main MF-related 
features that have outlined the role of several growth factors and cytokines involved in the 
chronic wound healing reaction and affecting the pro-fibrogenic potential of HSC/MF. For 
these reasons we will not further expand this issue and for more informations on pro-
fibrogenic mechanisms related to chronic activation of wound healing the interested reader 
may refer to a number of comprehensive reviews generated within the last decade (Pinzani 
and Marra, 2001; Parola and Robino, 2001; Pinzani and Rombouts, 2004; Bataller and 
Brenner, 2005; El-Sharkawy et al., 2005; Friedman, 2003, 2008a, 2008b; Iredale, 2007; Lee & 
Friedman, 2011; Kallis et al., 2007; Parola et al., 2008). Moreover, since the topic of EMT has 
been already extensively discussed in the section dedicated to the origin of hepatic MFs the 
putative and controversial role of this process will be not further analyzed.  
Whether the role of a derangement of epithelial – mesenchymal interactions is concerned, 
such a mechanism has been proposed as a major mechanism underlying fibrogenesis during 
the course of several cholangiopathies. Cholangiopathies are a group of progressive 
disorders representing a major cause of chronic cholestasis in adult and pediatric patients, 
and share a common scenario that involves coexistence of cholestasis, necrotic or apoptotic 
loss of cholangiocytes, cholangiocyte proliferation (i.e., ductular proliferation) as well as 
portal/periportal inflammation and fibrosis. All these conditions may be included in those 
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cell types and this is relevant since the liver is constantly exposed to PAMPs, such as LPS 
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leading to the pattern of biliary fibrosis and indeed it is well known that the ductular 
reaction can be considered as the most critical event: intense proliferation of these epithelial 
cells is associated with significant changes in the surrounding mesenchymal cells (first 
portal fibroblasts and then HSC with parenchyma invasion) and ECM. It has long been 
unclear whether the first event was represented by phenotypic changes in proliferating 
cholangiocytes or by changes in ECM leading to epithelial cell proliferation. However, an 
intense cross-talk between mesenchymal and epithelial (i.e.cholangiocytes) cells has been 
suggested to result in a release of cytokines and pro-inflammatory mediators possibly 
responsible for the overall mentioned scenario in cholangiopathies. As a matter of fact, 
cholangiocytes are now considered as active “actors” in pathological conditions by their ability 
to secrete chemokines like IL-6, tumour necrosis factor (TNF), IL-8 and MCP-1, as well as 
pro-fibrogenic factors (PDGF-BB, ET-1, CTGF, TGF2) : all these factors can be produced also 
by infiltrating immune, inflammatory or mesenchymal cells, and may affect in turn both 
epithelial cells and their intense cross-talk with mesenchymal cells sustaining the fibrogenic 
response (reviewed in Pinzani and Rombouts, 2004). The interested reader may refer for more 
details to a recent excellent review on the role of portal fibroblast and portal MFs and their 
interactions with activated/damaged cholangiocytes (Dranoff & Wells, 2010).  
In this section we will then mostly focus our attention on the general role of oxidative stress 
and reactive oxygen species, with a specific reference to the case of ALD.  
5.1 Oxidative stress and ROS in liver fibrogenesis: synopsis of general concepts and 
findings  
Involvement of oxidative stress has been documented in all human major clinical conditions 
of CLDs as well as in most experimental models of liver fibrogenesis (Parola & Robino, 2001; 
Novo & Parola, 2008), but it is likely to represent the predominant pro-fibrogenic 
mechanism mainly in NAFLD/NASH and ASH (and then ALD). Oxidative stress in CLDs, 
resulting from increased generation of ROS and other reactive intermediates as well as by 
decreased efficiency of antioxidant defenses, does not represent simply a potentially toxic 
consequence of chronic liver injury but actively contributes to excessive tissue remodelling 
and fibrogenesis. In this section just a few major concepts, strictly limited to fibrogenesis, 
will be recalled and for more details, particularly on aetiology – dependent mechanisms 
leading to oxidative stress, the reader may refer to more extensive reviews (Parola and 
Robino, 2001; Bataller and Brenner, 2005; Novo & Parola, 2008; Bataller et al., 2011).  
5.1.1 Oxidative stress and liver injury: redox-dependent injury is specific for 
hepatocytes  
CLDs are characterized, whatever the aetiology, by persisting liver injury and hepatocyte 
loss and severe oxidative stress can be considered as a major cause for both necrotic and 
apoptotic cell death of parenchymal cells whether resulting from inflammatory flares (i.e., 
HCV or HBV infection) through increased ROS generation by leukocytes, ethanol 
consumption, hepatic iron overload, antioxidant status or other conditions. Some relevant 
concepts should be recalled (reviewed in Novo & Parola, 2008):  
a. First, severe oxidative stress may lead to both hepatocyte necrosis and apoptosis, with 
necrosis mainly resulting from irreversible mitochondrial damage and/or inactivation 
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of executioner caspases; moreover, both necrosis and apoptosis can be found on the 
same section, in association with the other events of the chronic scenario (inflammation, 
fibrogenesis, angiogenesis, etc.);  
b. the level of ROS to which target cells are exposed may be critical in deciding whether 
these cells may survive or die, as described for the engagement of death receptors (DR) 
or TLR by respective ligands and the involvement of the critical kinase RIP (from 
Receptor Interacting Protein); along these lines, ROS-related sustained activation of JNK 
isoforms is a well characterized event leading to cell death in several conditions; 
moreover, in hepatocytes NF-kB inhibition sensitize cells to TNF-induced apoptosis by 
means of JNK sustained activation;  
c. ROS-related mitochondrial damage is a typical example of two way-injury since 
mitochondria can represent not only a source of ROS (particularly when their integrity 
is deranged) but also a target for their action in relation to cell death; ROS are critical in 
mediating cell death of fatty hepatocytes due to excess of free fatty acids (FFAs) in the 
liver of NAFLD and NASH patients; this may happen in FFAs-related up-regulation of 
TNF, increased Fas ligand binding to Fas (CD-95) or induction of endoplasmic 
reticulum (ER)-stress and the so called “unfolded protein response” (UPR) ;  
d. ER-stress, and then ROS, have been implicated also in hepatocyte apoptosis in chronic 
hepatitis C and ALD; 
e. not all reactive species are dangerous for a target cells: for example, nitric oxide (NO) 
and related reactive nitrogen species (RNS) can theoretically promote or prevent 
apoptotic cell death by interfering with either mitochondrial-dependent or -
independent signalling pathways.  
f. although ROS and more generally oxidative stress can lead to hepatocyte death, human 
hepatic MFs have been reported to easily survive to ROS, HNE and other pro-oxidants 
(Novo et al., 2006) and that this relies on the MFs activation-related specific “survival 
attitude” involving up-regulation of Bcl2, over-activation of pro-survival pathways, 
including NF-kB-related ones, and down-regulation of Bax (Elsharkawy et al., 2005; 
Novo et al., 2006). Hepatic MFs can then survive to conditions of oxidative stress 
usually operating in CLDs that, rather (see later), are more likely to sustain their pro-
inflammatory and pro-fibrogenic responses.  
5.1.2 ROS and oxidative stress-related mediators affect inflammatory and pro-
fibrogenic action of MFs 
ROS and other reactive mediators such as 4-hydroxynonenal (HNE, a major aldehydic end-
product of lipid peroxidation) can be generated outside MFs, here considered as potential 
“target” cells, being released either by activated inflammatory cells or injured hepatocytes. 
Indeed, oxidative stress, presumably by favouring mitochondrial permeability transition, is 
able to promote hepatocyte death (necrotic and/or apoptotic). In some of clinically relevant 
conditions generation of ROS within hepatocytes may represent a consequence of an altered 
metabolic state (like in NAFLD and NASH) or of ethanol metabolism (ALD, see next 
section), with ROS being then mainly generated by mitochondrial electron transport chain 
or through the involvement of selected cytochrome P450 isoforms like CYP2E1 (reviewed in 
Novo & Parola, 2008).  
Mediators of oxidative stress, whatever the source, aetiology or metabolic condition, are 
involved in the up-regulation or modulation of the expression of pro-inflammatory cytokines 
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leading to the pattern of biliary fibrosis and indeed it is well known that the ductular 
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of executioner caspases; moreover, both necrosis and apoptosis can be found on the 
same section, in association with the other events of the chronic scenario (inflammation, 
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b. the level of ROS to which target cells are exposed may be critical in deciding whether 
these cells may survive or die, as described for the engagement of death receptors (DR) 
or TLR by respective ligands and the involvement of the critical kinase RIP (from 
Receptor Interacting Protein); along these lines, ROS-related sustained activation of JNK 
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“target” cells, being released either by activated inflammatory cells or injured hepatocytes. 
Indeed, oxidative stress, presumably by favouring mitochondrial permeability transition, is 
able to promote hepatocyte death (necrotic and/or apoptotic). In some of clinically relevant 
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and chemokines by different cells, (including inflammatory cells as well as HSC/MFs or, 
presumably, MF-like cells, mostly through activation of NF-kB (Elsharkawy et al., 2005; Novo 
et al., 2008). In addition, the following major concepts may be recalled: a) ROS are involved in 
the process of phagocytosis, possibly by leading to amplification of the stimulating signal that 
follows engagement of Fc receptors on the surface of phagocytic cells; b) ROS may have a role 
in apoptosis – related removal of leukocytes during inflammatory responses; c) HNE as well as 
other 4-hydroxy-2,3-alkenals (HAKs), have been reported to be able to stimulate leukocyte 
chemotaxis at very low concentrations; d) ROS and HNE elicit in vivo and in vitro up-
regulation of the chemokine MCP-1, then sustaining recruitment/activation of 
monocytes/macrophages and Kupffer cells as well as chemotaxis of HSC/MFs. 
On the other hand, oxidative stress – related mediators released by damaged or activated 
neighbouring cells can directly affect the behaviour of human HSC/MFs: ROS or the 
reactive aldehyde HNE have been reported to up regulate expression of critical genes 
related to fibrogenesis including procollagen type I, MCP-1 and TIMP-1, possibly through 
activation of a number of critical signal transduction pathways and transcription factors, 
including activation of JNK, activator protein-1 (AP-1) and, only for ROS, NF-kB (Parola and 
Robino, 2001; Novo & Parola, 2008). It has also been reported that ROS may positively 
modulate proliferation of rat HSC/MFs but here a discrepancy exist with data with human 
cells in which ROS and HNE, unable to stimulate cell growth at low pro-fibrogenic doses, 
may rather inhibit basal and PDGF – stimulated DNA synthesis or even induce cell death. 
On the other hand, low levels of extracellular superoxide anion, but not H2O2 or HNE, are 
able to stimulate migration of human HSC/MFs through activation of Ras/Erk and JNK1/2 
signalling (reviewed in Novo & Parola, 2008; Novo et al., 2011).  
In addition to “profibrogenic” extracellular release by neighbouring cells, ROS generation 
within human and rat HSC/MFs has been reported to occur in response to several known 
pro-fibrogenic mediators, including angiotensin II, PDGF and the adipokine leptin. ROS 
generation here depends on activation by the cited mediators of a non-phagocytic NADPH 
oxidase (NOX) that has been detected in either human or rat HSC/MFs. ROS generated 
within HSC/MFs are likely to act also as positive modulators or pro-fibrogenic signalling 
pathways, as shown by the fact that selective inhibition of NOX usually reduce the 
phenotypic response. Moreover, the potential relevance of ROS generation by NOX in 
fibrogenesis has been disclosed by a study in which mice lacking p47phox (i.e., a crucial 
subunit of NOX) were protected from development of experimental fibrosis (Bataller et al., 
2003). Interestingly, intracellular and NADPH oxidase – related generation of ROS has been 
reported to follow “in vivo” and “in vitro” phagocytosis of apoptotic bodies from damaged 
hepatocytes by HSC/MFs, resulting in up-regulation of procollagen I expression (Zhan et 
al., 2006). More recently, as previously mentioned, our group has outlined that intracellular 
generation of ROS either linked to NADPH-oxidase activation following interactions of 
polypeptides with their receptors (PDGF, VEGF, MCP-1 and others) or in a ligand-
independent manner, is a critical event in mediating migration of both HSC/MFs and bone 
marrow-derived MSC in their MF-like phenotype (Novo et al., 2011).  
5.1.3 ROS, lipid peroxidation and immune response in human patients 
Another relevant concept to mention is the fact that oxidative stress may contribute to CLDs 
progression also by affecting immune response. Experimental studies (alcohol fed rodents) 
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and clinical data (patients affected by ALD, chronic HCV infection or NAFLD) indicate that 
oxidative stress is associated with the development of circulating IgG antibodies directed 
against epitopes derived from protein modified by lipid peroxidation products or against 
oxidized cardiolipin. Of relevance, titre of these antibodies correlate with disease severity 
and, as recently proposed for NAFLD patients, may serve as prognostic predictor of 
progression of NAFLD to advanced fibrosis (Albano et al., 2007 and reference therein). 
Along these lines, it should be also mentioned that a T cell mediated response towards lipid 
peroxidation derived antigens has been described in patients with advanced ALD (Stewart 
et al., 2004). Indeed, the body of evidence indicate that immune response triggered by 
oxidative stress may have a significant role in the progression of ALD, in the worstening of 
chronic hepatitis C by alcohol intake and, possibly, even in the progression of NAFLD.  
5.2 Oxidative stress and ROS in alcoholic liver disease  
As it is well known chronic ethanol consumption can lead to ALD, which encompasses a 
large spectrum of pathological liver changes, ranging from simple fatty liver with minimal 
injury to alcoholic steatohepatitis (ASH) and, in more advanced stages, fibrogenic 
progression to cirrhosis. Progression of ALD is now considered a multifactorial process 
involving nutritional, environmental and genetic factors, and ethanol consumption also 
represents one of the major host-related factors able to accelerate progression of fibrosis 
towards cirrhosis in chronic HCV patients and, possibly, in patients affected by CLDs with a 
different aetiology (Bataller & Brenner, 2005; Friedman, 2008b; Parola et al., 2008).  
In the last two decades the role of ROS and oxidative stress in the pathogenesis of ethanol-
induced liver injury has been extensively investigated (Arteel, 2003; Day & Cederbaum, 
2006; Albano, 2008; Novo & Parola, 2008; Cubero et al., 2009) and here a number of relevant 
concepts may be recalled.  
5.2.1 Major redox-related features in ALD  
A first relevant issue is represented by the fact that both experimental and clinical data 
indicate unequivocally that oxidative stress and lipid peroxidation are involved, with 
antioxidants and free radical scavengers being able, at least in animal models, to afford 
prevention (reviewed in Novo & Parola, 2008; Cubero et al., 2009). Moreover, ALD 
progression is accompanied by a progressive decrease in hepatic antioxidant defenses, 
suggesting then that both increased generation of ROS and decreased ability to inactivate or 
metabolize ROS have a pathogenic role.  
As a second point, one should note that ethanol-related ROS can be produced by the 
mitochondria respiratory chain, ethanol metabolizing (and ethanol-inducible) cytochrome 
P450 2E1 (CYP2E1) in hepatocytes, but not in HSCs, and NOXs of activated Kupffer cells or 
infiltrating neutrophils; moreover, NO produced by NO synthase of Kupffer cells and other 
reactive nitrogen species (RNS) has also been shown to contribute to ethanol-dependent 
hepatic injury (Arteel, 2003; Day & Cederbaum, 2006; Albano, 2008; Novo & Parola, 2008; 
Cubero et al., 2009). Indeed, in addition to the well known action of alcohol-dehydrogenase 
or ADH in metabolizing ethanol (when ethanol levels are low) CYP2E1 is an ethanol-
inducible isoform mainly observed in hepatocytes that plays a role in oxidation in the 
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and chemokines by different cells, (including inflammatory cells as well as HSC/MFs or, 
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and clinical data (patients affected by ALD, chronic HCV infection or NAFLD) indicate that 
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presence of high ethanol circulating levels and in chronic alcohol consumption. CYP2E1 
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when metabolizing ethanol leads to the generation of acetaldehyde as well as of the ethanol-
derived hydroxyethyl radical and major ROS including superoxide radical, hydrogen 
peroxide and hydroxyl-radical. Ethanol metabolism also leads to lipid peroxidation and 
related generation of reactive aldehydic end-products such as HNE and malonyldialdehyde 
(MDA).  
Third, ethanol-induced oxidative stress is likely to contribute to liver steatosis found in 
alcoholics by causing an impairment in either mitochondrial lipid oxidation or lipoprotein 
secretions, the latter being related to enhanced degradation of ApoB100 and/or oxidative 
alteration of lipoprotein glycosilation in Golgi apparatus (Albano, 2008; Novo & Parola, 
2008). Finally, CYP-2E1 generated ROS and formation of protein adducts by lipid 
peroxidation products may also affect proteasomal degradation, an event that has been 
proposed to lead to cytoplasmic aggregates of cytokeratins 8 and 18 and then the formation 
of Mallory's bodies (Bardag-Gorce et al., 2006).  
5.2.2 Ethanol-mediated and redox-dependent effects on MFs related to paracrine 
release of ROS from surrounding cells, including HSC  
When considering the role of redox-dependent events on the ALD-related fibrogenesis one 
may envisage a rather simplified scenario in which MFs represent the ideal target cells for 
ROS and other redox-related mediators released by the different hepatic cell populations 
operating in the complex microenvironment of ALD. Indeed, it is widely accepted that in 
early ALD (i.e., ASH) initiation of HSC activation is mainly due to paracrine stimulation by 
injured epithelial cells as well as inflammatory (macrophages plus neutrophils), endothelial 
as well as immune cells. Whether chronic ethanol consumption is concerned, a number of 
cell type - related issues (to be reconnected with previously mentioned concepts and 
findings) should be outlined (Albano, 2008; Novo & Parola, 2008; Cubero et al., 2009; 
Bataller et al., 2011): 
a. Hepatocytes. Under conditions of chronic ethanol consumption hepatocyte 
contribution depend on the CYP2E1-dependent generation of ROS and on consequent 
generation of aldehydic end-products of lipid peroxidation (mainly HNE) as well as 
on the levels of acetaldehyde (ACA). ROS, ACA and HNE have been all connected 
with paracrine HSC activation. In addition to the already mentioned ability of ROS 
and HNE to increase collagen production it should be recalled that also ACA can up-
regulate transcription of collagen type I (both COL1A1 and COL1A2) through a 
TGFβ-dependent mechanism. This is relevant since TGFβ is the most potent pro-
fibrogenic cytokine being able not only to sustain HSC activation and excess synthesis 
of ECM components but also to suppress hepatocyte proliferation and even to induce 
their apoptosis. It has been also suggested that the ethanol-related altered ratio of 
NAD+/NADH and NADP+/NADPH may also favor an increased synthesis of 
angiotensin II which has been reported to be a powerful fibrogenic cytokine (Bataller 
& Brenner, 2005).  
b. Kupffer cells (KC). Chronic ethanol consumption has been reported to impair gut 
permeability, an event potentially leading to overgrowth of Gram negative bacteria 
and subsequent translocation of endotoxin or lipopolysaccharide (LPS) from the 
intestinal lumen into portal circulation. LPS can trigger KC activation and indeed the 
influx of KC coincide with the appearance of HSC activation markers (α-SMA and 
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PDGF receptor-β or PDGFRβ). In addition to standard “macrophage-like” functions, 
one should consider that activation of KC leads to ROS generation through NOX, 
xanthine-oxidase, mitochondria or even CYP2E1 (detected in these cells), with ROS 
being then able to enhance HSC activation and collagen type I synthesis (Cubero et 
al., 2009). Along these lines, KC can also produce NO that has been described to 
counterbalance effect of ROS, then leading to decreased HSC proliferation, 
contractility and collagen type I synthesis; unfortunately, NO can also rapidly react 
with superoxide anion to generate peroxynitrite, a very powerful oxidizing 
intermediate whose effect on the synthesis of collagen type I and ECM components 
by HSC are at present unknown.  
c. Liver sinusoidal endothelial cells (LSEC). Under conditions of chronic ethanol 
consumption major reactive intermediates like ACA and ROS can induce LSEC 
injury. Indeed, injured LSEC have been reported to react by up-regulating the 
expression of fibronectin isoforms and of a number of critical mediators able to target 
HSC or HSC/MFs including VEGF and leptin (Friedman 2003, 2008b; Marra & 
Bertolani, 2009). Injured LSEC may also convert latent TGFβ into the active form 
(Ikejima et al., 2002).  
d. HSC/MFs. Once activated, HSC/MFs respond to stress conditions by secreting 
(paracrine/autocrine loops) inflammatory cytokines and chemokines such as mainly 
TNFα, TGFβ, IL-6, PDGF and CCL2 as well as other mediators like angiotensin II and 
the altered panel of MMPs and TIMPs described in section 4.2 . As mentioned before 
and pertinent to the condition of ALD, exposure to ROS, HNE and ACA HSC/MFs has 
been reported specifically to up-regulate synthesis of ECM components (reviewed in 
Novo & Parola, 2008; Cubero et al., 2009).  
6. Conclusions and perspectives 
The increasing knowledge on the pathogenesis of liver fibrogenesis (the process) leading 
to hepatic fibrosis (the result) has led to important changes in the clinical interpretation of 
the relevance of fibrogenic progression of any CLD. At present there is a need for an 
accurate and effective monitoring of the fibrotic progression of CLDs and for the 
effectiveness of the currently proposed treatments. Within the last five years more non-
invasive/dynamic methods for the evaluation of liver fibrosis have been described that 
are beginning to be very useful, particularly if associated to the detection of critical non-
invasive serum markers. This seems now mandatory in order to overcome the 
unavoidable limitations (lack of standardization, sampling error, inter-observer variability 
etc) of liver biopsy, although this invasive procedure is still regarded by most as the “gold 
standard” for assessing liver histology, disease activity and fibrosis progression. In 
addition, the identification of the genes involved in the progression of liver fibrosis would 
hopefully lead to the establishment of prognostic markers indicating a faster progression 
of fibrogenic CLDs and indeed several ongoing studies are addressing the relevance of 
gene expression and/or gene polymorphisms in defined subset of patients. However, in 
order to enable the rational development of therapeutic targets in CLDs we primarily 
need to continue to increase our knowledge on the complexity of the fibrogenic response, 
an issue that still remains a major objective of experimental and clinical studies designed 
to ascertain both the origin of fibrogenic cells (i.e., hepatic MFs) and, most important, of 
the mechanisms governing their “pathological behavior” in CLDs that results in the 
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PDGF receptor-β or PDGFRβ). In addition to standard “macrophage-like” functions, 
one should consider that activation of KC leads to ROS generation through NOX, 
xanthine-oxidase, mitochondria or even CYP2E1 (detected in these cells), with ROS 
being then able to enhance HSC activation and collagen type I synthesis (Cubero et 
al., 2009). Along these lines, KC can also produce NO that has been described to 
counterbalance effect of ROS, then leading to decreased HSC proliferation, 
contractility and collagen type I synthesis; unfortunately, NO can also rapidly react 
with superoxide anion to generate peroxynitrite, a very powerful oxidizing 
intermediate whose effect on the synthesis of collagen type I and ECM components 
by HSC are at present unknown.  
c. Liver sinusoidal endothelial cells (LSEC). Under conditions of chronic ethanol 
consumption major reactive intermediates like ACA and ROS can induce LSEC 
injury. Indeed, injured LSEC have been reported to react by up-regulating the 
expression of fibronectin isoforms and of a number of critical mediators able to target 
HSC or HSC/MFs including VEGF and leptin (Friedman 2003, 2008b; Marra & 
Bertolani, 2009). Injured LSEC may also convert latent TGFβ into the active form 
(Ikejima et al., 2002).  
d. HSC/MFs. Once activated, HSC/MFs respond to stress conditions by secreting 
(paracrine/autocrine loops) inflammatory cytokines and chemokines such as mainly 
TNFα, TGFβ, IL-6, PDGF and CCL2 as well as other mediators like angiotensin II and 
the altered panel of MMPs and TIMPs described in section 4.2 . As mentioned before 
and pertinent to the condition of ALD, exposure to ROS, HNE and ACA HSC/MFs has 
been reported specifically to up-regulate synthesis of ECM components (reviewed in 
Novo & Parola, 2008; Cubero et al., 2009).  
6. Conclusions and perspectives 
The increasing knowledge on the pathogenesis of liver fibrogenesis (the process) leading 
to hepatic fibrosis (the result) has led to important changes in the clinical interpretation of 
the relevance of fibrogenic progression of any CLD. At present there is a need for an 
accurate and effective monitoring of the fibrotic progression of CLDs and for the 
effectiveness of the currently proposed treatments. Within the last five years more non-
invasive/dynamic methods for the evaluation of liver fibrosis have been described that 
are beginning to be very useful, particularly if associated to the detection of critical non-
invasive serum markers. This seems now mandatory in order to overcome the 
unavoidable limitations (lack of standardization, sampling error, inter-observer variability 
etc) of liver biopsy, although this invasive procedure is still regarded by most as the “gold 
standard” for assessing liver histology, disease activity and fibrosis progression. In 
addition, the identification of the genes involved in the progression of liver fibrosis would 
hopefully lead to the establishment of prognostic markers indicating a faster progression 
of fibrogenic CLDs and indeed several ongoing studies are addressing the relevance of 
gene expression and/or gene polymorphisms in defined subset of patients. However, in 
order to enable the rational development of therapeutic targets in CLDs we primarily 
need to continue to increase our knowledge on the complexity of the fibrogenic response, 
an issue that still remains a major objective of experimental and clinical studies designed 
to ascertain both the origin of fibrogenic cells (i.e., hepatic MFs) and, most important, of 
the mechanisms governing their “pathological behavior” in CLDs that results in the 
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overall ability to sustain fibrotic progression of the disease towards the end-points of 
cirrhosis and related complications.  
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1. Introduction   
Hepatocellular death is a key mechanism in alcoholic liver diseases. Although ethanol has 
been described for many years as capable of increasing membrane fluidity, it is only recently 
that this fluidizing effect has been reported to be involved in ethanol-induced liver toxicity. 
In addition, in the last decade, a better understanding of plasma membrane has led to 
suggest that this membrane is not a random association of lipids, but is rather 
heterogeneous, with various microstructures enriched in specific components depending on 
their affinity. Special attention has been paid on lipid rafts that are cholesterol- and 
sphingolipid- rich microstructures, conferring them higher rigidity compared to other 
plasma membrane microdomains. As lipid rafts can also activate or suppress cell signaling 
pathways, lipid raft discovery provides new arguments for several researchers to revisit the 
fluidizing effect of ethanol by studying the possible ethanol-induced physical and 
biochemical alteration of lipid rafts. Thus, in this chapter, we have  considered to review the 
capacity of ethanol to induce a membrane remodeling, depicted as an increase in membrane 
fluidity and alterations of physical and biochemical properties of lipid rafts, and its 
relationship with ethanol liver toxicity. 
2. Membrane fluidity   
The Singer-Nicolson fluid mosaic model indicates that membranes consist of a phospholipid 
bilayer, where lipids, in a fluid phase, act as solvent for proteins (Singer & Nicolson, 1972). 
In this chapter, membrane fluidity means the relative freedom of motion for membrane 
components, especially phospholipids, and represents the combination of various types of 
mobility (Figure 1). Membrane fluidity is principally determined by the acyl chain swinging 
movement and phospholipid rotation. Thus, short chains and double bonds in acyl chains of 
phospholipids create spaces in the bilayer and promote membrane fluidization. At the 
opposite, the rigid steroid nucleus of cholesterol, lying next to the first 9 or 10 carbon atoms 
of the phospholipid acyl chains, prevents the swinging movement of the acyl chains thereby 
stiffening membranes. For the evaluation of this membrane parameter, most studies have 
used either electron paramagnetic resonance (EPR) with spin-labeled fatty acids, or 
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polarization of fluorescence with hydrophobic fluorescence polarization probes. An 
increased membrane fluidity for EPR is usually assessed by a decrease of order parameter 
(S), and for fluorescence, by a decrease of polarization (P), anisotropy (A) or microviscosity 
().   
 
Fig. 1. Different types of mobility of phospholipids. 
Any alteration of the optimal range for membrane fluidity has influence on many biological 
functions such as membrane enzyme and receptor activities, or transmembrane transport 
processes (Ho et al, 1994; Schachter, 1984; Stubbs et al, 1988). Furthermore, more recently, it 
was also shown its fundamental role in cell signalling responses to xenobiotic stress 
(polycyclic aromatic hydrocarbons, cisplatin or ethanol), leading to cell death such as 
apoptosis (Rebillard et al, 2007; Sergent et al, 2005; Tekpli et al, 2011). 
2.1 Plasma liver membranes 
Since the end of the seventies, many papers have provided strong evidence that ethanol 
very rapidly induces a fluidization of membranes as reported by several reviews (Goldstein, 
1987; Rottenberg, 1992; Wood & Schroeder, 1988).  
2.1.1 Tissue type-dependent effect of ethanol  
Using electron paramagnetic resonance, Chin and Goldstein (1977a) were the first to 
demonstrate the ability of ethanol used at low concentrations (from 20 mM - 40 mM) to 
increase in vitro membrane fluidity of erythrocyte and synaptosomal plasma membranes. In 
addition, they showed that continuous exposure of mice to ethanol provided in the diet for a 
short period (8 days) (Chin & Goldstein, 1977b) or by inhalation (3 days) (Lyon & Goldstein, 
1983) respectively restored a membrane fluidity near controls or even rigidified membranes 
in the inner hydrophobic regions, testifying an adaptation. Thus, in alcoholic patients, 
erythrocytes exhibited a decrease in membrane fluidity (Beaugé et al, 1985; Parmahamsa et 
al, 2004). However, the effect of ethanol on plasma membranes is different for the liver. 
Indeed, they become more fluid, mainly in the inner hydrophobic regions, for chronically 
ethanol-intoxicated rats (Schüller et al, 1984; Yamada & Lieber, 1984) and an increase in 
fluidity was also observed in plasma membranes isolated from Reuber H35 rat hepatoma 
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cells (Polokoff et al, 1985) or WRL-68 human hepatic cells (Gutierrez-Ruiz et al, 1995) 
following a long term treatment with ethanol (3 or 4 weeks). Such an effect could contribute 
to the special sensitivity of liver to ethanol toxicity. At the opposite, other organelles in the 
liver did not exhibit any membrane fluidification after ethanol intoxication of rats (Table 1). 
It should be noted that, when primary hepatocytes isolated from chronically ethanol-treated 
rats were cultured before the evaluation of plasma membrane fluidity by fluorescence 
polarization, an increased ordering was observed (Benedetti et al, 1991). 
 
Table 1. Effect of chronic ethanol intoxication on membrane fluidity of various organelles in 
the liver. (In all experiments, rats were fed a diet containing 36 % of total calories as ethanol 
for 30 to 40 days.) 
Whatever exposure modes (ingestion, inhalation or intraperitoneal injections) (Chin & 
Golstein, 1977b; Lyon & Golstein, 1983; Johnson et al, 1979), erythrocyte and synaptosomal 
plasma membranes isolated from ethanol-treated mice did not exhibit an increase in 
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membrane fluidity after a further in vitro ethanol addition in contrast to membranes isolated 
from untreated mice. Such an in vitro resistance was also observed in erythrocyte 
membranes from alcoholic patients (Beaugé et al, 1985). Even though liver plasma 
membranes remained more fluid after chronic rat intoxication (Schüller et al, 1984; Yamada 
& Lieber, 1984) or after long term ethanol treatment of cultured hepatocytes (Gutierrez-Ruiz 
et al, 1995; Polokoff et al, 1985), these isolated membranes also exhibited an in vitro 
resistance to the disordering effect of a further direct addition of ethanol. Finally, most of the 
papers quoted in table 1 indicated such a process for microsomes or mitochondria. This 
phenomenom could be related to several changes in membrane lipid composition (Johnson 
et al, 1979) ie an increase in cholesterol within brain and liver cell membranes in rats (Chin et 
al, 1978) and in monkeys (Cunningham et al, 1983), an increased ratio of saturated to 
polyunsaturated fatty acids (Johnson et al, 1979), or reduced concentrations of sialic acid and 
galactose in the membrane surface of human erythrocytes (Beaugé et al, 1985).  
2.1.2 Molecular mechanisms whereby ethanol could increase membrane fluidity 
These mechanisms, summarized in figure 2, can occur simultaneously. The first described 
mechanism was in brain membranes and concerns physical properties of ethanol which 
allow it to directly interact with the lipid bilayer, thus triggering a direct membrane disorder 
(Goldstein, 1984; Gurtovenko & Anwar, 2009; Marquês et al, 2011; Rottenberg, 1992). This 
theory was particularly developed in the field of drug tolerance and physical dependence, 
but, in the liver, other mechanisms were also described. First, it was proposed that the 
fluidizing effect of chronic ethanol treatment could be related to changes in membrane lipid 
composition as acyl chain saturation and cholesterol are well-described to affect membrane 
fluidity. Thus, Yamada et al (1984) related the increase in membrane fluidity of liver plasma 
membranes after chronic ethanol feeding to a decrease in cholesterol plasma membrane 
content by an unknown mechanism. In hepatoma cells chronically exposed to ethanol for 3 
weeks, the increase in membrane fluidity of plasma membranes was linked to the elevation 
of the ratio phosphatidylcholine/sphingomyelin (Polokoff et al, 1985). However, the main 
distinction of liver is that most of the ethanol metabolism occurs in this organ. Thus, ethanol 
metabolism appeared to play a key role since blocking ethanol metabolism by 
methylpyrazole inhibited changes in membrane fluidity both in acute intoxicated primary 
rat hepatocytes (Sergent et al, 2005), and in chronically treated hepatoma cells (Polokoff et 
al, 1985). Logically, as ethanol metabolism was involved, our team was interested in looking 
at the involvement of oxidative stress following an acute ethanol intoxication of primary rat 
hepatocytes. Using antioxidant such as thiourea (reactive oxygen species (ROS) scavenger) 
or vitamin E (lipid peroxidation inhibitor), we showed that oxidative stress played a role in 
the fluidizing effect of ethanol (Sergent et al, 2005). This new mechanism explained how 
ethanol could very rapidly (30 minutes) increase membrane fluidity since ROS production 
could be detected as soon as 15 minutes. Several molecular mechanisms can be proposed to 
explain the influence of oxidative stress on membrane fluidity. First, lipid peroxidation by-
products could increase membrane fluidity either by interacting with membrane proteins 
(Buko et al, 1996; Subramaniam et al, 1997), or more directly by their own rearrangement 
(Jain et al, 1994; Gabbita et al, 1998). ROS, by oxidizing tubulin could also disrupt 
microtubule cytoskeleton, thereby increasing membrane fluidity (Yoon et al, 1998; Remy-
Kristensen et al, 2000). In our model of primary rat hepatocytes, paclitaxel (a microtubule 
stabilizer) prevented from the fluidizing effect of ethanol (unpublished data).  
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2.2 Liver mitochondria membranes 
As shown above, a great body of evidence indicated that, in inner membranes of 
mitochondria, ethanol intoxication induced a decrease rather than an increase in fluidity. 
This was demonstrated for chronically intoxicated rats but also with HepG2 human 
hepatocytes treated with acetaldehyde, a product of ethanol metabolism (Lluis et al, 2003), 
providing a further proof of the involvement of ethanol metabolism in membrane fluidity 
changes. In addition, this decrease was related to an elevation of cholesterol content in 
mitochondria which concerns both outer and inner membranes. Finally, the acetaldehyde 
stimulation of cholesterol incorporation into mitochondria membranes was attributed to 
endothelium reticulum stress. 
2.3 Membrane pharmacology of ethanol liver toxicity by manipulation of membrane 
fluidity 
Since the eighties, many studies suggested the influence of ethanol fluidizing effect on 
membrane protein activities (McCall et al, 1989; Mills et al, 1985; Rubin & Rottenberg, 1982). 
Only recently, researchers became interested in determining the role of membrane fluidity 
changes in ethanol-induced hepatocellular death. Thus, manipulation of plasma membrane 
fluidity by exposing primary rat hepatocytes to membrane stabilizing agents 
(ursodeoxycholic acid (UDCA) or ganglioside GM1 (GM1)) led to the inhibition of ethanol-
induced cell death, while fluidizing compounds (tween 20 or A2C) enhanced it (Sergent et 
al, 2005). In order to explain how plasma membrane fluidity could affect cell death, 
oxidative stress was also studied. At the opposite of fluidizing compounds, membrane 
stabilizing agents were shown to protect from ethanol-induced lipid peroxidation, ROS 
production and the elevation of another prooxidant factor, namely low-molecular-weight 
iron. Low-molecular-weight iron consists of iron species that can trigger oxidative stress by 
catalyzing the formation of a highly reactive free radical, the hydroxyl radical. It should be 
noted that UDCA and GM1 displayed a protection towards ethanol-induced ROS 
production only when ROS were evaluated after 1 or 5 hours of incubation with ethanol. At 
15 minutes, no protection was afforded by membrane stabilizing agents, unlike the inhibitor  
 
 
Trends in Alcoholic Liver Disease Research – Clinical and Scientific Aspects 
 
162 
membrane fluidity after a further in vitro ethanol addition in contrast to membranes isolated 
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of ethanol metabolism, 4-methyl-pyrazole. This led us to postulate a sequence of events 
whereby the early ROS formation was mainly due to ethanol metabolism and the late phase 
to the increase in membrane fluidity (Figure 3). Interestingly, the increased mitochondrial 
membrane ordering was also associated with the development of oxidative stress. Indeed, 
stabilizing agents such as S-adenosyl-L methionine (SAME) or taurine conjugate of UDCA 
(tauroursodeoxycholic acid) protected from glutathione depletion in mitochondria obtained 
from the liver of rats chronically fed with ethanol (Colell et al, 1997; Colell et al, 2001). 
Reduced glutathione, the main non protein thiol in cells, plays an important role to detoxify 
hydrogen peroxide and other organic peroxides in mitochondria. Glutathione depletion in 
mitochondria made them more sensitive to ROS production and subsequent oxidative 
stress. Thus, it was demonstrated that the increased mitochondrial membrane 
microviscosity impaired the glutathione transporter which normally allows the glutathione 
transport from cytosol to mitochondrial matrix (Coll, 2003; Lluis et al, 2003) (Figure 3).  
 
(GSH : reduced glutathione; ROS : reactive oxygen species). 
Fig. 3. Relationship between membrane fluidity and ethanol-induced oxidative stress. 
Cholesterol involvement in this process should be pointed out. Indeed, as mitochondrial 
membrane enrichment in cholesterol was responsible for the decreased mitochondrial 
membrane fluidity, lovastatin, an inhibitor of hydroxymethylglutaryl coenzyme A involved 
in cholesterol synthesis, was able to protect hepatocytes from acetaldehyde sensitization to 
tumor necrosis factor (TNF) (Lluis et al, 2003). Similarly to membrane stabilizing agents, 
membrane fluidizer (A2C) restored the initial glutathione transport rate and mitochondrial 
content (Coll et al, 2003; Lluis et al, 2003). However, the use of membrane fluidizers should 
be done with caution since, from our results about the involvement of plasma membrane 
fluidization in ethanol-induced cell death, it appears that they can be injurious for 
hepatocytes. At the opposite, UDCA and its conjugates seem to be good candidates for a 
potential therapeutic use, because, due to their membrane stabilizing properties (Güldütuna 
et al, 1993), they restore the normality in membrane fluidity for every type of membranes. 
Thus, in case of ethanol intoxication, they were able to prevent both the increase of plasma 
membrane fluidity, as we observed in primary rat hepatocytes (Sergent, 2005), and the 
decrease in mitochondria membranes of hepatocytes from ethanol-fed rats (Colell et al, 
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2001). In addition, UDCA was also shown to protect rats from the increase in liver plasma 
membrane fluidity due to chronic ethanol intake and hence from liver lipid peroxidation 
and necrosis (Oliva et al, 1998). However, although UDCA is a therapeutically relevant bile 
acid, already used for preventing human primary biliary cirrhosis (Poupon et al, 2003; 
Corpechot et al, 2011), it did not exhibit any beneficial effect on a 6-month survival of 
patients with severe alcohol-induced cirrhosis, but possibly because of inappropriate dosage 
(Pelletier et al, 2003).  
3. Lipid rafts 
Because of the well-described effect of ethanol on plasma membrane fluidity, it is not 
surprising that some researchers about alcoholic liver diseases were interested in the 
possible involvement of lipid rafts in ethanol toxicity. Indeed, plasma membrane is not 
constituted by a random lipid distribution but rather by a selective lateral lipid segregation 
due to self-associative properties of sphingolipid and cholesterol, leading to the concept of 
"lipid rafts" (Simons & Toomre, 2000; Lingwood & Simons, 2010). Thus, lipid rafts are 
detergent-resistant, sphingolipid- and cholesterol-rich microdomains of the plasma 
membrane, which form highly ordered spatial nanoscale assemblies separated from other 
membrane regions composed of more unsaturated and loosely packed fatty acids (Figure 4).  
 
Fig. 4. Schematic representation of a lipid raft (without proteins). 
Lipid rafts as nanoscale assemblies are dynamics and after cell stimulation, can coalesced to 
larger levels to form raft platforms (Harder & Engelhardt, 2004).  Concerning proteins, lipid 
rafts are notably enriched in glycosylphosphatidylinositol (GPI) proteins, receptors such as 
cell death receptors and Toll-like receptors (TLR), and signaling proteins like mitogen-
activating protein kinases, protein kinases C etc.  Some proteins are raft residents, whereas 
others are recruited after cell stimulation with receptor-specific ligands. In addition, based 
on their mobility, lipid rafts, through their aggregation, can form platforms that assembly 
many proteins on a same place leading to the formation of a receptor cluster, which can then 
activate or suppress signaling pathways (Pike, 2003; Schmitz & Orso, 2002). One might 
suppose that ethanol, through its capacity to increase liver plasma membrane fluidity, can 
disturb these microdomains and hence, various cell signaling pathways. Consequently, in 
the last past decade, new investigations were undertaken to possibly link lipid rafts to 
ethanol toxicity. Researches were conducted in two directions: the main one concerned 
perturbation of innate immunity via TLR4 signaling and the other one, hepatocyte cell death 
via the activation of phospholipase C (PLC) signaling.  
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3.1 Lipid rafts in the TLR4 signaling dysfunction by ethanol 
Several components of innate immunity contribute to the pathogenesis of alcoholic liver 
disease (Gao et al, 2011). Here, we will mainly focus on lipopolysaccharide (LPS)/TLR4 
signaling pathways because of the necessary translocation of TLR4 receptor into lipid rafts 
for its activation. 
3.1.1 Involvement of LPS/TLR4 signaling pathway in alcoholic liver disease 
Strong evidence suggest that the immune cells of the liver (phagocytic cells such as 
neutrophils or resident Küpffer cells, and lymphocytes such as natural killer [NK] cells or T 
cells) play a crucial role in alcoholic liver disease including steatosis, hepatitis and fibrosis 
(Suh & Jeong, 2011). Thus, Küpffer cells are main actors in the immune response against 
endotoxin/lipopolysaccharide (LPS) via Toll-Like Receptor type 4 (TLR4) signaling pathway 
leading to the production of pro-inflammatory mediators such as cytokines (TNF-, 
interleukin [IL]-1, IL-6), chemokines (monocyte chemotactic protein-1 [MCP-1]), ROS and 
profibrogenic factors (transforming growth factor [TGF]-, platelet-derived growth factor 
[PDGF]), which subsequently activate hepatic stellate cells for the production of 
extracellular matrix (Jeong & Gao, 2008) (Gao et al, 2011) (Figure 5). Indeed, it is well 
established that ethanol intake, by increasing gut permeabilization, allows the uptake of LPS 
in portal circulation (Parlesak et al, 2000) promoting liver ethanol toxicity (Nanji et al, 1994). 
In addition, in the liver, TLR4 is also expressed on recruited macrophages, hepatocytes, 
sinusoidal endothelial cells and hepatic stellate cells (Seki & Brenner, 2008). Consequently, 
via TLR4 signalling, these last cells can also contribute to liver inflammation by releasing 
proinflammatory cytokines and chemokines. Finally, TLR4 signalling in hepatic stellate cells 
can also participate to the development of alcoholic fibrosis by enhancing TGF- signalling 
(Seki et al, 2007). Therefore, TLR4 receptor appeared crucial in the development of alcoholic 
liver disease (Gao et al, 2011).  
 
(HEP : hepatocytes; HSC: hepatic stellate cells; KC : Küpffer cells; IL : interleukin;  
LPS : lipopolysaccharide; MCP-1 : monocyte chemotactic protein-1 ; PDGF : platelet-derived growth 
factor; TGF: tumor growth factor; TLR4 : Toll-like receptor 4; TNF : tumor necrosis factor) 
Fig. 5. Contribution of TLR4 receptor to the pathogenesis of alcoholic liver disease. 
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3.1.2 Effects of ethanol on the recruitment of TLR4 into lipid rafts 
LPS does not bind TLR4 receptor directly, but is rather first bound to cell surface co-
receptors, the cluster of differentiation 14 (CD14) and the myeloid differentiation protein 2 
(MD-2), without cytoplasmic domains (Fitzgerald, 2004). However, TLR4 is the integrator of 
cell signalling since it has intracellular signaling domains. Close interactions between these 
membrane receptors are made possible by their recruitment and assembly within lipid rafts 
(Schmitz & Orso, 2002; Triantafilou et al, 2002). Thus, CD14 is a glycosyl 
phosphatidylinositol-linked protein which therefore constitutively resides in lipid rafts, 
while TLR4 needs translocation into rafts for the complex formation (Dolganiuc et al, 2006). 
Two features of the ethanol effect on TLR4 and other receptor signaling could be 
distinguished depending on ethanol concentration. 1) At high concentration (≥ 50 mM), 
ethanol prevented from LPS-induced redistribution pattern of the co-receptor CD14 within 
lipid rafts, and from the translocation of TLR4 receptor into rafts (Table 2). This alteration 
could partly explain why ethanol consumption is recognized as a risk factor for concomitant 
bacterial or viral infections (Nelson and Kolls, 2002; Szabo, 1999). Dai et al (2005) and 
Dolganiuc et al (2006) suggested that ethanol, at the concentration of 50 or 86 mM, may 
disrupt lipid rafts because similar effects were obtained with lipid raft disrupters. However, 
a protein raft marker, flotillin did not exhibit any alteration and no clear evidence of lipid 
raft disruption was given, since the cholesterol decrease was detected in culture media 
instead of lipid rafts. They also attributed changes in partitioning cellular membrane in raft 
and nonraft structures to the increase in bulk membrane fluidity (Dolganiuc et al, 2006) 
without checking this influence by the use of membrane stabilizing agents or measuring the 
increase in membrane fluidity directly in lipid rafts. Their hypothesis would be that ethanol 
by this way could disrupt lipid protein interactions (Szabo et al, 2007). Only at very high 
concentrations (200 mM), a lipid raft disruption was really observed in RAW 264.7 
macrophages (Fernandez-Lizarbe et al, 2008). However, at 50 mM, in primary rat cortical 
astrocytes, a partial disruption of lipid raft could be detected suggesting that ethanol at this 
concentration induced both effects : i) disruption leading to the inhibition of lipid raft –
induced cell signalling, and ii) promotion of TLR4 recruitment in lipid rafts (see below)) 
(Blanco et al, 2008). More recently, it was also demonstrated an ethanol inhibition of lipid 
raft-mediated T-Cell Receptor (TCR) signalling in human CD4+ T cells and in Jurkat T cells, 
but no alteration of lipid raft markers  was observed suggesting that ethanol had no direct 
effect on lipid rafts (Ghare et al, 2011). Interestingly, the authors proposed a post-
translational modification of proteins to explain the inhibition of protein translocation into 
lipid rafts. These mechanisms could also be explored for the other models. 2) At lower 
concentration (≤ 50 mM), mimicking LPS effects both in macrophages and astrocytes, 
ethanol induced the recruitment of TLR4 into lipid rafts, thus allowing the activation of 
TLR4 dependent cell signalling (Table 2). A similar process was also observed for IL-1R1 
(IL1 receptor 1) (Blanco et al, 2008). Thus, ethanol triggered cytokine and other 
inflammatory mediator secretion via lipid raft-dependent signalling pathway. According to 
Blanco et al (2008), low ethanol concentrations (10 – 50 mM) may facilitate protein-protein 
and protein-lipid interactions within the membrane microdomains to promote receptor 
recruitment into the lipid rafts. Even if this effect has not yet been directly described in the 
liver, lipid rafts might participate to the mechanisms involved in the enhancement by 
chronic ethanol treatment of liver inflammation associated with the activation of IL-1R1 
receptor in rat liver and hepatocytes (Valles et al, 2003), or TLR4 in immune cells ( Szabo & 
Bala, 2010). 
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(ERK : extracellular regulated kinase; IL : interleukin; IRAK : interleukin-1 receptor associated kinase; 
LAT : linker for activation of T cells; lck : lymphocyte-specific protein tyrosine kinase;  
LPS : lipopolysaccharide; NF-kB : nuclear factor kappa B; PHA : phytohaemagglutinin;  
PLC: phospholipase C; TCR : T cell receptor; TNF : tumor necrosis factor). 
Table 2. Effects of acute ethanol exposure on lipid raft-mediated receptor activation. 
(In these studies, rafts were isolated by their in vitro property to resist to solubilization in 
non-ionic detergents at low temperature and to float and concentrate in low-density sucrose 
(Brown & Rose, 1992), leading to raft and non-raft fractions.) 
3.2 Lipid rafts in ethanol-induced hepatocyte damage 
Another approach was to consider the role of lipid rafts in ethanol-induced oxidative stress. 
The occurrence of oxidative stress in alcoholic liver disease and its relationship with ethanol 
liver damage have been extensively documented (Albano, 2008; Cederbaum et al, 2009; De 
Minicis & Brenner, 2008; Wu & Cederbaum, 2009), but less is known about the possible role 
of lipid rafts. Thus, it was shown by our team that lipid raft disrupters were able to protect 
from ethanol-induced ROS production and lipid peroxidation in primary rat hepatocytes 
(Nourissat et al, 2008). In addition, we have showed for the first time that oxidative changes 
within lipid rafts are a prerequisite for the oxidative stress to develop in rat hepatocytes. 
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Thus, ethanol metabolism, by producing a rapid and mild oxidative stress, was able to 
induce oxidative damage within lipid rafts leading to their clustering following protein 
crosslinkages (Figure 6).  
 
 
(CHO : carbonyl group; ROS : reactive oxygen species; SH : thiol group) 
 
Fig. 6. Ethanol-induced lipid raft clustering via oxidative stress and protein crosslinkage. 
Protein crosslinkages were obtained by the formation of disulfide bridges from two 
intermolecular thiol (SH) groups from several rafts, and by the formation of adducts with 
malondialdehyde, a well-known product of lipid peroxidation in ethanol treated-rat 
hepatocytes (Nourissat et al, 2008). This aldehyde like 4-hydroxynonenal can react with 
nucleophile residues in proteins to form carbonyl groups which then may form Schiff base 
with a lysine of another protein. Such a protein can be included in another raft leading to 
raft clustering (Figure 6). Interestingly, according to experiments performed on the 
translocation of TLR4 (see above) which proposed a role for membrane fluidity without 
fully demonstrating it, we expressly proved the involvement of the fluidizing effect in the 
ethanol-induced lipid raft clustering by the use of membrane stabilizer or fluidizers. In 
addition, ethanol was shown to be able to fluidize lipid rafts, but at a lesser extent compared 
to bulk membranes. These results also confirmed our previous results which showed the 
pivotal role of the increased membrane fluidity in ethanol-induced cell death of rat 
hepatocytes (Sergent et al, 2005), thereby emphasizing on the contribution of membrane 
remodeling in ethanol liver toxicity. Finally, lipid raft clustering also participated to the 
activation of phospholipase C--dependent signaling pathway. Indeed, this clustering 
induced translocation of phospholipase C- into rafts, which induced elevation of low-
molecular-weight-iron, a potent prooxidant factor, and hence, lipid peroxidation. To 
summarize, ethanol metabolism, by producing a mild oxidative stress can rapidly affect 
both membrane fluidity and lipid rafts, thus promoting lipid raft aggregation (Figure 7). 
Then, this lipid raft clustering, by activating phospholipase C- dependent signaling 
pathway, may in turn trigger amplification of oxidative stress and cell death (Figure 7).  
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(LMW iron: low molecular weight iron; PLC: phospholipase C) 
Fig. 7. Amplification of oxidative stress via lipid raft clustering during acute ethanol 
intoxication of rat hepatocytes. 
In this context, new therapeutic approach, called membrane lipid therapy (Escriba et al, 
2006), could be a very effective strategy to protect hepatocytes from membrane-dependent 
oxidative damage in alcoholic liver damage, especially as an increasing body of evidence 
indicated that some dietary compounds such as plant flavonoids (Tarahosky et al, 2008) or 
fatty fish long-chain polyunsaturated n-3 fatty acids (n-3 PUFAs) (Wassal & Stillwell, 2009) 
might modify physical and chemical properties of lipid rafts. Thus, n-3 PUFAs have been 
extensively described as efficient modifiers of lipid and protein composition of lipid rafts in 
many cell types such as T lymphocytes (Fan et al, 2004; Stulnig, 2001), Caco-2 cells 
(Duraisamy et al, 2007), retinal vascular endothelial cells (Chen et al, 2007) and macrophages 
(Wong et al, 2009). In this context, the nutrional significance of lipid rafts has been recently 
pointed out (Yaqoob and Shaikh, 2010). 
4. Conclusion 
Taken altogether, these studies show that physical alterations of membranes (changes in 
membrane fluidity and microstructures) can be considered as an additional mechanism 
involved in ethanol liver toxicity. It is only in the last past decade that membrane 
remodeling appeared to be linked to ethanol liver toxicity (Figure 8). Therefore, further 
studies are needed in order to determine the role of lipid rafts in chronic ethanol 
intoxication, to further explore the downstream cell signaling after lipid raft clustering such 
as pathways involved in the elevation of low-molecular weight iron cell content, or to 
understand whether receptor recruitment in lipid raft might participate to alcoholic liver 
disease. In addition, other investigation should shed light on the possible beneficial effect of 
the modulation of membrane fluidity and lipid raft. Thus, statins that are already currently 
used in patients suffering from hypercholesterolemia, have demonstrated their efficiency to 
protect hepatocytes from acetaldehyde sentization to TNF (Lluis et al, 2003), and might  also 
be proposed to disrupt lipid rafts. Finally, nutritional compounds such as plant flavonoids 
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or fatty fish long-chain polyunsaturated n-3 fatty acids might represent a new therapeutic 
approach for patients with alcoholic liver disease based upon modulation of the membrane 
structures. 
 
Fig. 8. Evolution of the "membrane remodelling" concept for alcoholic liver diseases. 
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1. Introduction 
Excessive alcohol consumption causes a variety of liver diseases including alcoholic 
steatosis, alcoholic hepatitis (AH), liver fibrosis, cirrhosis and hepatocellular carcinoma 
(Mandayam et al. 2004). Alcoholic steatosis is, generally, a benign lesion if the patient 
abstains from alcohol intake, whereas AH observed in the approximately 20% of heavy 
drinkers is much more serious and requires treatment with the development of 
hepatocellular necrosis and inflammation (Menon et al., 2001). The severe form of AH, 
severe alcoholic hepatitis (SAH), is characterized by multiorgan failure with manifestations 
of acute hepatic failure and is associated with high morbidity and mortality (Haber et al., 
2003; Ishii et al., 1993; Maddrey et al., 1978; Mookerjee et al., 2003; Sougioultzis, 2005). 
Alcohol-induced liver injury (ALD) occurs through the multiple steps involving a range 
from innate immune cells to the liver parenchymal cells, and out of many factors 
contributing to the pathogenesis of ALD gut-derived endotoxin plays a central role in the 
induction of steatosis, inflammation, and fibrosis in the liver (Bode & Bode, 2005; Fukui et 
al., 1991; Mandrekar & Szabo, 2009; McClain et al, 2005; Nolan, 2010; Vidali et al., 2008). AH 
is a multifactorial process involving gut-derived endotoxin-induced Kupffer cell activation 
via hepatic reticuloendothelial dysfunction and increased intestinal permeability, and 
subsequent cytokine stimulation. Additional factors include ethanol metabolism to toxic 
products, oxidative stress, acetaldehyde adducts, nutritional impairment and impaired 
hepatic regeneration (Haber et al., 2003; Ishii et al., 1993, Mookerjee et al., 2003; Nath & 
Szabo, 2009; Nolan, 2010; Sakaguchi et al., 2011; Sougioultzis et al., 2005; Tsukamoto et al., 
2009; Wu & Cederbaum, 2009). In SAH pathogenesis, endotoxemia may trigger enhanced 
pro-inflammatory cytokine production, potentially causing a systemic inflammatory 
response syndrome together with microcirculatory disturbances, systemic haemodynamic 
derangements, and subsequent multiorgan failure (Fukui, 2005; Haber et al., 2003; Ishii et 
al., 1993; Mookerjee et al., 2003; Sougioultzis et al., 2005).  
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ADAMTS13 (a disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 
13) is a metalloproteinase that specifically cleaves multimeric von Willebrand factor (VWF) 
between Tyr1605 and Met1606 residues in the A2 domain (Moake 2002; Fujimura et al., 
2002). In the absence of ADAMTS13 activity (ADAMTS13:AC), unusually large VWF 
multimers (UL-VWFMs) are released from vascular endothelial cells (ECs) and improperly 
cleaved, causing them to accumulate and to induce the formation of platelet thrombi in the 
microvasculature under conditions of high shear stress. Currently, a severe deficiency in 
ADAMTS13:AC, which results either from genetic mutations in the ADAMTS13 gene 
(Upshaw-Schulman syndrome, USS) (Fujimura et al., 2002; Kokame et al., 2002; Levy et al., 
2001, Moake, 2002) or acquired autoantibodies against ADAMTS13 (Furlan et al., 1998; Tsai 
& Lian, 1998), is thought to be a specific feature of thrombotic thrombocytopenic purpura 
(TTP) (Amorosi & Ultmann, 1966; Moschcowitz, 1924). 
In 2000, we demonstrated that a decreased plasma ADAMTS13:AC in patients with cirrhotic 
biliary atresia can be fully restored after liver transplantation, indicating that the liver is the 
main organ producing ADAMTS13 (Matsumoto et al., 2000). One year later, northern blot 
analysis showed that the 4.6-kilobase ADAMTS13 mRNA was highly expressed in the liver 
(Levy et al., 2001; Soejima, et al., 2001; Zheng et al., 2001), and subsequently both in situ 
hybridization and immunohistochemistry clearly indicated that ADAMTS13 is produced 
exclusively in hepatic stellate cells (HSCs) (Uemura et al., 2005a). Platelets (Suzuki et al., 
2004), vascular ECs (Turner et al., 2006), and kidney podocytes (Manea et al., 2007) also have 
been implicated as ADAMTS13-producing cells, but the amount produced by these cell 
types in the liver appears to be far less than that produced by HSCs.  
Mannucci et al. (Mannucci et al., 2001) originally reported a reduction of the ADAMTS13:AC 
in advanced liver cirrhosis (LC). Since HSCs were shown to be the major producing cells of 
ADAMTS13 in the liver (Uemura et al., 2005a), much attention has been paid to the potential 
role of ADAMTS13 in the pathophysiology of liver diseases associated with sinusoidal 
and/or systemic microcirculatory disturbances (Feys et al., 2007; Ishikawa et al., 2010; Ko et 
al., 2006; Kobayashi et al., 2009; Lisman et al., 2006; Matsuyama et al., 2007; Matsumoto et 
al., 2007; Okano et al., 2010; Park et al., 2002; Pereboom et al., 2009; Uemura et al., 2005b; 
Uemura et al., 2008a; Uemura et al., 2008b; Uemura et al., 2010; Yagita et al., 2005). 
ADAMTS13:AC is significantly decreased in patients with hepatic veno-occlusive disease 
(VOD) (Matsumoto et al., 2007; Park et al., 2002), AH (Ishikawa et al.,2010; Matsuyama et al., 
2007; Uemura et al., 2005b, Uemura et al., 2008b), LC (Feys et al., 2007; Uemura et al., 2008a), 
and patients undergoing living-donor related liver transplantation (Ko et al., 2006; 
Kobayashi et al.,2009; Pereboom et al., 2009) and partial hepatectomy (Okano et al.,2010).  
Furthermore, hepatitis C virus (HCV)-related LC patient with ADAMTS13 inhibitor 
(ADAMTS13:INH) typically develops TTP (Yagita et al., 2005). 
In this review, we will address interesting findings from our previous studies showing that 
plasma ADAMTS13:AC and its related parameters are potentially involved in the severity of 
liver disturbances and the development of multiorgan failure in patients with AH (Ishikawa 
et al., 2010; Matsuyama et al., 2007; Uemura et al., 2005b; Uemura et al., 2008b). We will 
focus on the importance of ADAMTS13 determination for a better understanding of 
pathophysiology and/or for possible therapeutic approaches of ADAMTS13 
supplementation in this disease. 
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2. Alcohol-related thrombocytopenia and effects of alcohol on hemostasis 
Alcohol-related thrombocytopenia is independent of nutritional state or the presence of liver 
functional abnormalities, anemia, or leucopenia (Lindenbaum & Hargrove, 1968; Paintal et 
al., 1975; Post & Desforges, 1968a, 1968b; Rubin & Rand, 1994). Both quantitative and 
qualitative platelet abnormalities appear during alcohol consumption (Cowan, 1980). A 
decrease in circulating platelets was first reported in 3 alcoholics who responded to folic 
acid administration (Sullivan & Herbert, 1964). Subsequently, alcohol has been shown to 
exert a direct toxic effect on blood platelets in 5 chronic alcoholics with ten episodes of 
thrombocytopenia (Lindenbaum & Hargrove, 1968) and in 8 patients with acute alcoholism 
(Post & Desforges, 1968a), who showed no evidence of liver cirrhosis, splenomegaly, folate 
deficiency, or massive hemorrhage, indicating the presence of alcohol-related 
thrombocytopenia. Additionally, thrombocytopenia was observed in alcoholics on 
intravenous injection of ethanol (Post & Desforges, 1968b). The platelet counts in patients 
with alcohol-related thrombocytopenia return to normal quickly (2-3 days) after ingestion of 
ethanol is discontinued. Thereafter, the number of platelets increases, and maximum counts 
occur 5-21 days after cessation of alcohol (Cowan & Hines, 1971), when rebound 
thrombocytosis after alcohol abuse in some patients may contribute to thromboembolic 
disease (Haselager & Vreeken, 1977). Potential mechanisms for alcohol-related 
thrombocytopenia may involve a suppressive effect of alcohol on megakaryocyte 
maturation and platelet release (Sullivan & Herbert, 1964), reduced platelet survival time 
(Cowan, 1980), alterations of platelet structure (Cowan, 1980), and abnormalities of platelet 
metabolism involving adenosine nucleotides and eicosanoids (Cowan, 1980). The spectrum 
of platelet function defects in alcoholics is complex. In actively drinking alcoholic patients 
admitted to the hospital for detoxification, platelet aggregation in platelet-rich plasma is 
considerably reduced in response to agonists (Haut & Cowan, 1974; Neiman et al., 1989; 
Rubin & Rand, 1994), whereas platelet aggregation is greater in chronic alcoholics compared 
to normal healthy controls both on admission and 1 week after hospitalization (Arai et al., 
1986). It is necessary to clarify the role of platelet function not only in platelet aggregation in 
vitro, but also in platelet-endothelial interactions under shear stress during alcohol-related 
thrombocytopenia (Siegel-Axel & Gawaz, 2007). 
Alternatively, recent epidemiologic studies have consistently shown that regular light-to-
moderate alcohol intake protects against ischemic stroke including coronary heart disease 
and peripheral arterial disease (Camargo et al., 1997; Lippi et al., 2010; Mukamal et al., 2001; 
Rimm et al., 1996). Such beneficial effects may be attributable to a number of factors 
including the inhibition of platelet aggregation and adhesion, the decrease in plasma levels 
of VWF, fibrinogen, and coagulation factor VII, or the increase in nitric oxide bioavailability 
and high-density lipoprotein cholesterol (Lippi et al., 2010; Rubin R, 1999). In contrast, soft 
blood clots are often observed in cadaveric blood in cases of sudden death after excess 
alcohol consumption, which enhances the procoagulant status via VWF release, and IL-6-
related interaction with lipopolysaccharide (LPS) (Kasuda et al., 2009). Additionally, both 
chronic alcoholism and acute alcohol intoxication have increasingly been recognized as risk 
factors for circulatory disorders, including thrombotic complications and hemorrhage 
(Hillbom & Kaste, 1982; Hillbom & Kaste, 1983, Numminen et al., 2000). Patients with 
chronic alcoholism show a higher incidence of pulmonary infarction, cerebral infarction, and 
venous thrombosis in their extremities after abstinence (Haselager & Vreeken, 1977; Hillbom 
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2. Alcohol-related thrombocytopenia and effects of alcohol on hemostasis 
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1986). It is necessary to clarify the role of platelet function not only in platelet aggregation in 
vitro, but also in platelet-endothelial interactions under shear stress during alcohol-related 
thrombocytopenia (Siegel-Axel & Gawaz, 2007). 
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Rimm et al., 1996). Such beneficial effects may be attributable to a number of factors 
including the inhibition of platelet aggregation and adhesion, the decrease in plasma levels 
of VWF, fibrinogen, and coagulation factor VII, or the increase in nitric oxide bioavailability 
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blood clots are often observed in cadaveric blood in cases of sudden death after excess 
alcohol consumption, which enhances the procoagulant status via VWF release, and IL-6-
related interaction with lipopolysaccharide (LPS) (Kasuda et al., 2009). Additionally, both 
chronic alcoholism and acute alcohol intoxication have increasingly been recognized as risk 
factors for circulatory disorders, including thrombotic complications and hemorrhage 
(Hillbom & Kaste, 1982; Hillbom & Kaste, 1983, Numminen et al., 2000). Patients with 
chronic alcoholism show a higher incidence of pulmonary infarction, cerebral infarction, and 
venous thrombosis in their extremities after abstinence (Haselager & Vreeken, 1977; Hillbom 
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et al., 1985; Walbran et al., 1981), probably due to alterations of haemostatic and fibrinolytic 
parameters that may be largely influenced by drinking pattern, nutritional balance, and 
genetic background (Arai et al., 1986; Enomoto et al., 1991; Lippi et al., 2010; Mukamal et al., 
2001). 
3. Hepatic microcirculation and microcirculatory disturbances in ALD 
Hepatic microcirculation comprises a unique system of capillaries, called sinusoids, which 
are lined by three different cell types: sinusoidal endothelial cells (SECs), HSCs, and Kupffer 
cells (Kmieć, 2001). The SECs modulate microcirculation between hepatocytes and the 
sinusoidal space through the sinusoidal endothelial fenestration. The SECs have tremendous 
endocytic capacity, including for VWF and the extracellular matrix, and secrete many 
vasoactive substances (Kmieć, 2001). The HSCs are located in the space of Disse adjacent to 
the SECs, and regulates sinusoidal blood flow by contraction or relaxation induced by 
vasoactive substances (Rockey, 2001). Kupffer cells are intrasinusoidally-located tissue 
macrophages, and secrete potent inflammatory mediators during the early phase of liver 
inflammation (Kmieć, 2001). Intimate cell-to-cell interaction has been found between these 
sinusoidal cells and hepatocytes (Kmieć, 2001, Rockey, 2001). 
Vascular ESs play a pivotal role in hemostasis and thrombosis (Fujimura et al., 2002; Moake, 
2002). VWF is a marker of endothelial cell activation (damage), and plays an essential role in 
hemostasis (Fujimura et al., 2002; Moake, 2002). In the normal state, VWF immunostaining is 
usually positive in large vessels, but negative in the SECs (Hattori et al., 1991). On the 
occurrence of liver injury accompanied by a necroinflammatory process, the SECs become 
positive for VWF, presumably in association with the capillarization of hepatic sinusoids 
(Schaffner & Popper, 1963). Subsequently, platelets adhere to subendothelial tissue 
mediated by UL-VWFM. ADAMTS13 then cleaves UL-VWFM into smaller VWF multimers. 
This interaction of ADAMTS13 and UL-VWFM is the initial step in hemostasis (Fujimura, et 
al., 2002; Moake, 2002). 
Hepatic microcirculatory disturbances are considered to play an important pathogenic role 
in ALD. These disturbances include narrowing of the sinusoidal space due to ballooned 
hepatocytes and perisinusoidal fibrosis (French et al., 1984), imbalances between endothelin 
and nitric oxide (Oshita et al., 1993), and contraction of HSCs (Itatsu et al., 1988). After liver 
injury, fibrogenesis within the Disse’s space and a decrease in the number of sinusoidal 
endothelial fenestrations together with narrowing of their diameter may lead to 
neocapillarization of the endothelium (Horn et al., 1987; Mak & Lieber, 1984). Sinusoidal 
lining cells and the scar-parenchyma interface are stained by anti-VWF antibodies, even at 
the early stages of ALD (Urashima et al., 1993), indicating capillarization of the SECs. 
Interestingly, in SAH patients, mild to severe hepatic veno-occlusive disease (VOD) was 
frequently observed (Goodman & Ishak, 1982; Kishi et al., 2000), and the degree of ascites 
became more severe as VOD progressed (Kishi et al., 2000), suggesting that the hepatic 
circulatory disturbance involves not only the sinusoidal microcirculation but also the 
hepatic terminal veins. 
In patients with LC and fulminant hepatitis, VWF plasma levels are remarkably high 
(Albornoz et al., 1999; Ferro et al., 1996; Langley et al., 1985). In LC, immunostaining for 
VWF antigen (VWF:Ag) shows positive cells predominantly at the scar-parenchyma 
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interface, within the septum, and in the sinusoidal lining cells (Knittel, et al., 1995), and 
many fibrin thrombi are demonstrated in the hepatic sinusoid in patients with fulminant 
hepatitis (Rake et al., 1971), and in rats with dimethylnitrosamine (DMN) induced acute 
hepatic failure (Fujiwara et al., 1988). Portal or hepatic vein thrombosis is often observed in 
advanced LC (Amitrano et al., 2004; Wanless et al., 1995), and microthrombi formation is 
seen in one or multiple organs in one-half of autopsied cirrhotic patients (Oka & Tanaka, 
1979). Such a hypercoagulable state in liver diseases may be involved in hepatic 
parenchymal destruction, the acceleration of liver fibrosis and disease progression (Northup 
et al., 2008; Pluta et al., 2010). 
A deficiency of anticoagulant proteins (antithrombin, protein C and protein S) and the high 
levels of several procoagulant factors (Factor VIII and VWF) may contribute to 
hypercoagulability in advanced liver diseases (Northup et al., 2008). Locally, the SEC 
dysfunction could lead to the development of a hypercoagulable state at the hepatic 
sinusoids corresponding to the site of liver injury, even in the presence of a systemic 
hypocoagulable state (Northup et al., 2008). Considering that ADAMTS13 is synthesized in 
HSCs and its substrate, UL-VWFM, is produced in transformed SECs during liver injury, 
decreased plasma ADAMTS13:AC may involve not only sinusoidal microcirculatory 
disturbances, but also subsequent progression of liver diseases, finally leading to multiorgan 
failure. Based on these findings, it is of particular interest to evaluate the activity of plasma 
ADAMTS13:AC in patients with liver diseases including AH and SAH.  
4. Cleavage of UL-VWFM byADAMTS13 
Although the mechanism by which TTP develops in the absence of ADAMTS13:AC has not 
been fully elucidated, accumulating evidence has provided a hypothesis as illustrated in Fig. 
1. (Fujimura et al., 2008). UL-VWFMs are produced exclusively in vascular ECs and stored 
in an intracellular organelle termed Weidel-pallade bodies (WPBs) and then released into 
the circulation upon stimulation. Under physiological conditions, epinephrine acts as an 
endogenous stimulus, but under non-physiological conditions, DDAVP (1-deamino-8-D-
arginine vasopressin), hypoxia, and several cytokines such as interleukin IL-2, IL-6, IL-8 and 
tumor necrosis factor (TNFα) act as stimuli that up-regulate VWF release. Once ECs are 
stimulated, UL-VWFMs and P-selectin, both stored in WPBs, move to the membrane surface 
of ECs, where P-selectin anchors UL-VWFMs on the ECs surface (Padilla et al., 2004). Under 
these circumstances, high shear stress generated in the microvasculature induces a change in 
the UL-VWFM from a globular to an extended form (Siedlecki et al., 1996). The ADAMTS13 
protease efficiently cleaves the active extended form of UL-VWFM between the Tyr1605 and 
Met1606 residues in the A2 domain (Dent et al., 1990). In this context, it has been postulated 
that multiple exocites within the disintegrin-like/TSP1/cysteine-rich/spacer (DTCS) 
domains of ADAMTS13 play an important role in the interaction with the unfolded VWF-
A2 domain (Akiyama et al., 2009). ADAMTS13 may more efficiently cleave newly released 
UL-VWFMs that exist as solid-phase enzymes anchored to the vascular EC surface by 
binding to CD36, because CD36 is a receptor for TSP1, which is a repeated domain within 
the ADAMTS13 molecule (Davis et al., 2009). When ADAMTS13 activity is reduced, UL-
VWFM interacts more intensively with platelet GPIb and generates signals that further 
accelerate platelet activation (Fujimura et al., 2002; Moake, 2002) . A series of these reactions 
leads to platelet microaggregates and thrombocytopenia. However, little information has 
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been available on the cleavage of the UL-VWFMs by ADAMTS13 in the sinusoidal 





























Fig. 1. Proposed mechanism of platelet thrombi formation under high shear stress in the 
absence of ADAMTS13:AC. 
Unusually large von Willebrand factor multimers (UL-VWFMs) are produced in vascular 
endothelial cells (ECs) and stored in Weidel-pallade bodies (WPBs). UL-VWFMs are 
released from WPBs into the circulation upon stimulation by cytokines, hypoxia, DDAVP 
and epinephrine. P-selectin that co-migrates from WPBs anchors UL-VWFMs on the 
vascular EC surface. Under these circumstances, high shear stress changes the molecular 
conformation of UL-VWFMs from a globular to an extended form, allowing ADAMTS13 to 
access this molecule. In the absence of ADAMTS13:AC, UL-VWFMs remain uncleaved, 
allowing them to excessively interact with platelet glycoprotein (GP)Ibα and activate 
platelets via intra-platelet signaling, which result in the formation of platelet thrombi. 
Cytokines, endotoxin, and/or the inhibitor against ADAMTS13 may be candidates to 
decrease ADAMTS13 activity. (The dotted circle indicates a VWF subunit, which contains a 
set of binding domains with factor VIII, subendothelial collagen, platelet GPIbα, and 
integrin αIIbβ3.) (Partially modified from Fujimura et al, 2008).  
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5. Assays for plasma ADAMTS13:AC and ADAMTS13:INH 
ADAMTS13:AC was determined with a classic VWFM assay in the presence of 1.5 mol/L 
urea using purified plasma derived VWF as a substrate, according to the method described 
by Furlan et al. (Furlan et al., 1996); the detection limit of this assay was 3% of the normal 
control in our laboratory (Kinoshita et al., 2001). In 2005, we developed a novel chromogenic 
ADAMTS13-act-ELISA using both an N- and C-terminal tagged recombinant VWF substrate 
(termed GST-VWF73-His). This assay was highly sensitive, and the detection limit was 0.5% 
of the normal control (Kato et al., 2006). Plasma ADAMTS13:AC levels highly correlated 
between VWFM assay and ADAMTS13-act-ELISA (Mean±SD, 102±23% vs. 99.1±21.5%, 
r2=0.72, p<0.01) (Kato et al., 2006) . No interference of the ADAMTS13-act-ELISA occurred 
even in the presence of hemoglobin, bilirubin or chylomicrons in the samples, thus enabling 
distinction from the FRETS-VWF73 assay (Kokame et., 2005; Meyer et al., 2007). Because of 
its high sensitivity, easy handling, and lack of interference from plasma components, the 
ADAMTS13-act-ELISA is recommended for routine laboratory use. 
The ADAMTS13:INH has also been evaluated with the chromogenic act-ELISA by means of 
the Bethesda method (Kasper et al., 1975). Prior to the assay, the test samples were heat-
treated at 56C for 60 min to eliminate endogenous enzyme activity, mixed with an equal 
volume of intact normal pooled plasma, and incubated for 2 hours at 37C. The residual 
enzyme activity is measured after incubation. One Bethesda unit is defined as the amount of 
inhibitor that reduces activity by 50% of the control value, and values greater than 0.5 U/ml 
are significant. 
6. ADAMTS13 activity and its related parameters in AH 
Plasma ADAMTS13:AC was assayed according to the method of Furlan et al. (Furlan et al., 
1996) with slight modifications (Mori et al., 2002). ADAMTS13:AC was markedly decreased 
in fatal SAH cases with multiorgan failure, in contrast to a mild-to-moderate decrease in 
SAH and AH survivors (Fig. 2a) (Uemura et al., 2005b; Matsuyama et al., 2007). 
Interestingly, ADAMTS13:AC in fatal SAH cases with multiorgan failure was extremely 
low, which is consistent with typical TTP. The VWF:AG level was remarkably increased in 
AH, especially in fatal SAH cases (Fig. 2b). Accordingly, VWF:AG relative to 
ADAMTS13:AC was extremely high in fatal SAH cases compared to AH and SAH survivors 
(Fig. 2c).  
During recovery, ADAMTS13:AC returned to a normal range, and both VWF:AG levels and 
levels of VWF:AG relative to ADAMTS13:AC decreased in AH and SAH survivors; 
however, in fatal SAH cases, the activity remained extremely low while the VWF:AG levels 
were still high, resulting in an extremely high ratio of VWF:AG to ADAMTS13:AC  
(Matsuyama et al., 2007; Uemura et al., 2005b). These results suggest that plasma 
ADAMTS13:AC and its substrate, VWF:AG, are closely correlated with the severity of liver 
disturbance and may be useful markers for predicting the clinical outcome of AH, especially 
in SAH with multiorgan failure. Indeed, the prognosis was very poor in three SAH patients 
with extremely low ADAMTS13:AC and markedly high VWF:Ag. Furthermore, cirrhotic 
patients with superimposed AH showed higher levels of VWF:Ag (576% vs. 303%, p<0.005) 
and VWF:Ag relative to ADAMTS13:AC (14.0 vs. 5.3, p<0.01) than those with AH without 
LC, indicating that cirrhotic patients with superimposed AH may be a high risk for hepatic  
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Fig. 2. Plasma values of ADAMTS13:AC, VWF:Ag, and the ratio of VWF:Ag to 
ADAMTS13:AC in the patients with AH, SAH, and alcoholic LC.  
ADAMTS13:AC was significantly lower in AH, SAH and LC patients than in healthy 
subjects (a). The activity further decreased in the patients with SAH compared to those with 
AH and LC. In three fatal SAH cases, ADAMTS13:AC was extremely low. VWF:Ag was 
significantly higher in AH, SAH and LC patients than in healthy subjects (b). The antigen 
further increased in SAH patients compared to AH patients. In the three fatal SAH patients, 
VWF:Ag was extremely high. VWF:Ag relative to ADAMTS13 activity was markedly higher 
in AH, SAH and LC patients than in healthy subjects (c). It further increased in patients with 
SAH compared to those with AH and LC. In the three fatal SAH cases, it was extremely 
high. The dotted lines show the upper limit of the normal range, and dot-dashed lines the 
lower limit of the normal range. The normal range was 102±23% (mean±2SD, n=60) in 
ADAMTS13:AC, 100±53% in VWF:Ag, and 1.0 ± 0.4 for the ratio of VWF:Ag to 
ADAMTS13:AC, respectively. Open and shaded circles indicate survivors and the closed 
circles indicate non-survivors. The shaded circles show alcoholic LC with superimposed 
AH. AH=alcoholic hepatitis, SAH=severe alcoholic hepatitis, LC=alcoholic liver cirrhosis, 
ADAMTS13:AC=ADAMTS13 activity, VWF:Ag=von Willebrand factor antigen, 
VWF:Ag/ADAMTS13:AC=the ratio of VWF antigen to ADAMTS13 activity. *p<0.05, 
**p<0.01, and ***p<0.005 significantly different between the two groups. (Partially modified 
from Uemura et al., 2005b and Matsuyama et al., 2007).  
failure (Matsuyama et al., 2007; Uemura et al., 2005b). In addition, in LC patients, 
ADAMTS13:AC tended to be lower as the cirrhotic stage progressed, suggesting that 
decreased ADAMTS13:AC is related to the functional liver capacity. Similar findings that 
ADAMTS13:AC decreases with increasing cirrhosis severity was recently reported (Feys et 
al., 2007; Uemura et al., 2008a). 
In an univariate analysis ADAMTS13:AC was significantly correlated with 10 clinical 
variables, including functional liver capacity, inflammation signs, renal function, and 
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platelet counts (Uemura et al., 2005b, 2008b) . VWF:Ag was significantly correlated with 
nine clinical variables, including functional liver capacity, anemia, inflammation signs, and 
platelet counts (Matsuyama et al., 2007; Uemura et al., 2008b). The factors associated with 
decreased ADAMTS13:AC and increased VWF:Ag, reduced functional liver capacity, 
augmented inflammation, and thrombocytopenia are consistent with the clinical 
characteristics that frequently appear in AH and SAH (Fujimoto et al., 1999; Haber et al., 
2003; Ishii et al., 1993; Maddrey et al., 1978; McClain et al., 1999; Mookerjee et al., 2003). 
Remarkably, the imbalance between the ADAMTS13:AC and VWF:Ag levels might provide 
another mechanism for thrombocytopenia that usually occurs in AH even in the absence of 
signs of apparent disseminated intravascular coagulation (DIC). 
On admission, UL-VWFM was detected in 4 (80.0%) of 5 SAH patients and in 5 (55.6% ) of 9 
AH patients, whose ADAMTS13:AC was less than 50% of normal control plasma levels (Fig. 
3a) (Matsuyama et al., 2007). UL-VWFM-positive patients showed lower ADAMTS13:AC, 
higher plasma VWF:Ag, and a higher ratio of VWF:Ag to ADAMTS13:AC than UL-VWFM-
negative patients (mean ADAMTS13:AC = 22% vs. 43%, p<0.02; VWF:Ag = 724% vs. 372 %, 
p<0.05; the ratio of VWF:Ag to ADAMTS13:AC = 66.0 vs. 8.2, p<0.01, respectively). In 
particular, UL-VWFM was detected in three fatal SAH patients with multiorgan failure 
(cases 1, 2, and 3, Fig. 3a) (Matsuyama et al., 2007). These findings of enhanced UL-VWFM 
production with deficient ADAMTS13 activity may, in part, contribute not only to the 
development of multiorgan failure but also to the progression of liver injury through 
microcirculatory disturbances in AH. Our results suggest an additional mechanism to 
explain multiorgan failure with liver disturbance, particularly in SAH patients. In order to 
confirm a TTP-like phenomenon as described above, it will be necessary to confirm the 
presence or absence of the platelet thrombi using samples obtained from liver and other 











Fig. 3. The VWF multimer analysis and the difference in endotoxin level between UL-
VWFM positive and negative patients in AH and SAH patients on admission.  
UL-VWFM was detected in 4 of 5 SAH patients (80.0%, cases 1, 2, 3, and 5), and 3 of these 
patients died of hepatic failure with multiorgan failure (cases 1, 2 and 3) (a). In addition, UL-
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VWFM was detected in 5 of 9 AH patients (55.6%, cases 6, 7, 8, 10, and 11), who had a 
moderate ADAMTS13 deficiency together with markedly high VWF:AG values (a). Plasma 
endotoxin concentrations were higher in UL-VWFM positive patients than UL-VWFM 
negative ones (b). AH=alcoholic hepatitis, SAH=severe alcoholic hepatitis, ADAMTS13: 
AC=ADAMTS13 activity, VWF:Ag=von Willebrand factor antigen, UL-VWFM= unusually 
large VWF multimer, NP shows the normal control plasma. (Partially modified from 
Matsuyama et al., 2007 and Ishikawa et al., 2010). 
Hepatic microcirculatory disturbances are considered to play an important pathogenic role 
in ALD. VWF immunostaining was positive in sinusoidal lining cells and the scar-
parenchyma interface even at the early stages of ALD (Urashima et al., 1993). Deficiencies in 
plasma ADAMTS13:AC and augmented VWF production in transformed vascular ESc 
might play an important role in sinusoidal microcirculatory disturbances and subsequent 
liver injury in AH patients. Furthermore, in SAH patients mild to severe hepatic veno-
occlusive disease (VOD) was frequently observed  (Goodman & Ishak, 1982; Kishi et al., 
2000). After stem cell transplantation (SCT), plasma ADAMTS13:AC was significantly lower 
in patients with hepatic VOD than those without (Park et al., 2002). Prophylactic infusion of 
fresh frozen plasma (FFP) as a source of ADAMTS13 may be useful in preventing the 
development of hepatic VOD after SCT (Matsumoto et al., 2007), indicating a causative role 
of increased VWF production relative to decreased ADAMTS13:AC. Our present findings of 
markedly decreased ADAMTS13:AC and markedly increased VWF:AG may be involved in 
the pathogenesis of VOD in SAH patients. 
7. Potential role of decreased ADAMTS13:AC in AH 
The reason why ADAMTS13:AC decreases in AH and SAH patients remains to be clarified, 
but potential mechanisms may include: enhanced consumption due to the degradation of 
large quantities of UL-VWFM (Mannucci et al., 2001); cytokinemia- and/or endotoxemia-
induced deficiency of ADAMTS13 (Ishikawa et al., 2010); the presence of inhibitors as 
detected in the majority of patients with “idiopathic” pregnancy- or drug-associated TTP 
(Fujimura & Matsumoto, 2010; Ishikawa et al., 2010); the decreased production of 
ADAMTS13 in HSCs (Kume et al., 2007); and the direct inhibition of the protease by ethanol 
and/or its metabolites. It is controversial whether ADAMTS13 deficiency is caused by 
decreased production in the liver. Kume et al. reported that HSC apoptosis plays an 
essential role in decreased ADAMTS13:AC using dimethylnitrosamine-treated rats, but not 
carbon tetrachloride (CCl4)-treated animals (Kume et al., 2007), whereas Niiya et al. found 
upregulation of ADAMTS13 antigen and proteolytic activity in liver tissue using rats with 
CCl4-induced liver fibrosis (Niiya et al., 2006). In our study, the ADAMTS13:AC gradually 
decreased (Fig. 4, upper panels), and the VWF:Ag progressively elevated with concomitant 
increase in concentrations of IL-6, IL-8, and TNFα from normal range to over 100 g/mL on 
admission (Fig. 4, lower panels) (Ishikawa et al., 2010).  
The incidence of UL-VWFM detected in plasma became higher as concentrations of IL-6, IL-
8, and TNFα increased (Ishikawa et al., 2010). At the recovery stage in survivors with AH 
and SAH, the ADAMTS13:AC increased to normal range, the VWF:Ag decreased, and the 
UL-VWFM disappeared with the decrease in the concentration of IL-6 and IL-8, whereas in a 
non-survivor with SAH, the ADAMTS13:AC remained at extremely low levels, the VWF:Ag 
was still high, and the UL-VWFM was persistently present with the increase in  
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Fig. 4. Relation of plasma cytokine levels to ADAMTS13:AC and VWF:Ag in AH and SAH 
patients on admissionin.  
ADAMTS13:AC concomitantly decreased with increasing concentrations of plasma IL-6 and 
IL-8, and the activity decreased in patients with TNFα concentrations higher than the 
normal range compared to those without (upper panels). On the other hand, VWF:Ag 
concomitantly increased with increasing concentrations of plasma IL-6 and IL-8, and the 
values increased in patients with TNFα concentration higher than the normal range 
compared to those without (lower panels). Shaded area shows normal ranges. IL-6= 
interleukin 6, IL-8=interleukin 8, TNFα=tumor necrosis factor α, N=normal range. *p<0.05,  
**p<0.005, and ***p<0.001 significantly different between the two groups. 
ADAMTS13:AC=ADAMTS13 activity, VWF:Ag=von Willebrand factor antigen. (Partially 
modified from Ishikawa et al., 2010).  
concentrations of these cytokines (Ishikawa et al., 2010). These results indicate that the 
decrease in the ADAMTS13:AC and the increase in VWF:Ag in addition to UL-VWFM may 
be closely associated with increased proinflammatory cytokines including IL-6, IL-8, and 
TNFα. Recently, it was demonstrated that IL-6 inhibited the action of ADAMTS13 under 
flow condition, and both IL-8 and TNFα stimulated the release of UL-VWFM using human 
umbilical vein ECs (Bernardo et al., 2004). IFN-γ, IL-4, and TNFα also inhibit ADAMTS13 
synthesis and activity in rat primary HSCs (Cao et al., 2008). Additionally, inflammation-
associated ADAMTS13 deficiency promotes formation of UL-VWFM (Bockmeyer et al., 
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2008; Claus et al., 2010). However, it is unknown whether IL-6 directly hampers the cleavage 
of UL-VWFM or if IL-6 down-regulates gene expression of ADAMTS13 whereby modifying 
the promoter activity. 
Our study shows that plasma endotoxin concentration determined by a chromogenic 
substrate assay (Obayashi et al., 1984; Obayashi et al., 1985) was higher in patients with SAH 
and AH than in healthy subjects, and was markedly higher in patients with SAH than in AH 
(Fig. 5a) (Ishikawa et al., 2010). Our results are consistent with data previously reported 
(Fujimoto et al., 2000; Fukui et al., 1991; Fukui, 2005) most likely due to hepatic 
reticuloendothelial dysfunction and increased intestinal permeability caused by the opening 
of intestinal tight junctions by alcohol and its metabolite (Purohit et al., 2008). Upon 
admission, the endotoxin concentration correlated inversely with ADAMTS13 activity (Fig. 
5b, upper panel), and positively with VWF:Ag (Fig. 5b, lower panel), and was higher in 
patients with UL-VWFM than those without (Fig. 3b). At the recovery stage, the endotoxin 
concentration decreased with the increase in ADAMTS13:AC and the decrease in VWF:Ag, 
and the disappearance of UL-VWFM together with the reduction of IL-6 and IL-8 














Fig. 5. Plasma endotoxin concentration and relation of endotoxin to ADAMTS13:AC and 
VWF:Ag in patients with alcoholic hepatitis. 
Upon admission, plasma endotoxin concentrations were higher in patients with AH and 
SAH than in normal subjects, and the values were higher in SAH patients compared to AH 
(a). In addition, the endotoxin concentration correlated inversely with ADAMTS13:AC  
(r= - 0.474, p<0.01) (b, upper panel), and positively with VWF:Ag (r= - 0.406, p<0.05) (b, 
lower panel). N=normal healthy control, AH=alcoholic hepatitis, SAH=severe alcoholic 
hepatitis, ADAMTS13:AC=ADAMTS13 activity, VWF:Ag=von Willebrand factor antigen. 
Open circles indicate survivors, and closed circles nonsurvivors. Shaded area shows normal 
range. (Partially modified from Ishikawa et al., 2010). 
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may be closely related to the decrease in the ADAMTS13:AC and the appearance of UL-
VWFM through the enhanced cytokinemia, leading to systemic microcirculatory 
disturbances and multiorgan failure, particularly in SAH patients. Intravenous infusion of 
endotoxin to healthy volunteers caused a decrease in plasma ADAMTS13:AC together with 
the appearance of UL-VWFM (Reiter et al., 2005). Severe secondary ADAMTS13 deficiency 
can be associated with sepsis-induced DIC and may contribute to the development of renal 
failure (Ono et al., 2006). These  observations may support our data and hypothesis. 
In response to alcohol intake, innate immune cells initiate and maintain hepatic 
inflammation via pattern recognition receptors, toll-like receptor 4 (TLR4) (Akira et al., 2006; 
Szabo, 1999). The TLR4 involves the co-receptors CD14 and myeloid differentiation (MD) 
protein 2 (MD2), and the LPS binding protein (LBP) (Chow et al., 1999; Visintin et al., 2001), 
which directly binds LPS and facilitates the association between LPS and CD14 (Wright et 
al., 1989). The activation of TLR4 in Kupffer cells by LPS is a key pathogenic mediator of 
ALD through production of inflammatory cytokines (TNFα and IL-6) and reactive oxygen 
species (Byun & Jeong, 2010; Soares et al., 2010). More recently, the disruption of interferon 
regulatory factor 3 in liver parenchymal cells has been shown to increase liver injury due to 
the deregulated expression of pro- and anti-inflammatory cytokines via Myd88-independent 
pathways (Hritz et al., 2008; Petrasek et al., 2011). It will be of particular interest to clarify 
the relation of ADAMTS13 to endotoxin-induced cytokinemia via the TLR4 signaling 
cascade in ALD.  
Alternatively, another mechanism to reduce the activity of ADAMTS13 is the action of the 
plasma inhibitor against ADAMTS13. In our study, the inhibitor was detected in 80% of 
SAH patients and 21.4% of AH patients upon admission, and its inhibitory activity averaged 
1.5 BU/ml in SAH and 1.0 BU/ml in AH (Ishikawa et al., 2010). Patients with the inhibitor 
showed lower ADAMTS13:AC and higher VWF:Ag than those without. At the recovery 
stage, the inhibitor was detected in 5 patients but disappeared with increased 
ADAMTS13:AC and decreased VWF:Ag, together with the decrease in concentrations of 
cytokines and endotoxin. Interestingly, patients with AH and SAH who had the inhibitor 
showed higher levels of serum total bilirubin, polymorphonuclear neutrophil count, plasma 
C-reactive protein, and plasma endotoxin concentration, and lower serum albumin levels 
than those with AH who had no inhibitor (Ishikawa et al., 2010). These results indicate that 
the decrease in the ADAMTS13:AC may be caused by the presence of its inhibitor, which is 
closely related to lower functional liver capacity, marked inflammation, and enhanced 
endotoxemia in patients with AH and SAH. Intravenous infusion of endotoxin to healthy 
volunteers induced the decrease in plasma ADAMTS13:AC together with the increase in 
VWF:Ag and the appearance of UL-VWFM during acute systemic inflammation (Reiter et 
al., 2005). From our results and previously reported findings (Reiter et al., 2005), 
endotoxemia itself might be a candidate to reduce plasma ADAMTS13:AC together with 
inflammatory cytokines in AH patients. It will be necessary to clarify what kinds of inhibitor 
is involved in association with inflammatory cytokines and endotoxin. Recently, we 
encountered two patient who developed TTP; one occurred in the course of hepatitis C virus 
(HCV)-related advanced LC (Yagita et al., 2005) and another occurred a month after 
pegylated-interferon alpha-2a therapy in a HCV-related case of chronic hepatitis (Kitano et 
al, 2006). In both cases, plasma ADAMTS13:AC was extremely low, and the inhibitor against 
ADAMTS13 was detected in the patient’s heated plasma (2.0 BU/ml, 1.6 BU/ml, 
respectively) and purified IgG (0.19 BU/mg IgG, 0.4 BU/mg IgG, respectively). 
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VWFM through the enhanced cytokinemia, leading to systemic microcirculatory 
disturbances and multiorgan failure, particularly in SAH patients. Intravenous infusion of 
endotoxin to healthy volunteers caused a decrease in plasma ADAMTS13:AC together with 
the appearance of UL-VWFM (Reiter et al., 2005). Severe secondary ADAMTS13 deficiency 
can be associated with sepsis-induced DIC and may contribute to the development of renal 
failure (Ono et al., 2006). These  observations may support our data and hypothesis. 
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Szabo, 1999). The TLR4 involves the co-receptors CD14 and myeloid differentiation (MD) 
protein 2 (MD2), and the LPS binding protein (LBP) (Chow et al., 1999; Visintin et al., 2001), 
which directly binds LPS and facilitates the association between LPS and CD14 (Wright et 
al., 1989). The activation of TLR4 in Kupffer cells by LPS is a key pathogenic mediator of 
ALD through production of inflammatory cytokines (TNFα and IL-6) and reactive oxygen 
species (Byun & Jeong, 2010; Soares et al., 2010). More recently, the disruption of interferon 
regulatory factor 3 in liver parenchymal cells has been shown to increase liver injury due to 
the deregulated expression of pro- and anti-inflammatory cytokines via Myd88-independent 
pathways (Hritz et al., 2008; Petrasek et al., 2011). It will be of particular interest to clarify 
the relation of ADAMTS13 to endotoxin-induced cytokinemia via the TLR4 signaling 
cascade in ALD.  
Alternatively, another mechanism to reduce the activity of ADAMTS13 is the action of the 
plasma inhibitor against ADAMTS13. In our study, the inhibitor was detected in 80% of 
SAH patients and 21.4% of AH patients upon admission, and its inhibitory activity averaged 
1.5 BU/ml in SAH and 1.0 BU/ml in AH (Ishikawa et al., 2010). Patients with the inhibitor 
showed lower ADAMTS13:AC and higher VWF:Ag than those without. At the recovery 
stage, the inhibitor was detected in 5 patients but disappeared with increased 
ADAMTS13:AC and decreased VWF:Ag, together with the decrease in concentrations of 
cytokines and endotoxin. Interestingly, patients with AH and SAH who had the inhibitor 
showed higher levels of serum total bilirubin, polymorphonuclear neutrophil count, plasma 
C-reactive protein, and plasma endotoxin concentration, and lower serum albumin levels 
than those with AH who had no inhibitor (Ishikawa et al., 2010). These results indicate that 
the decrease in the ADAMTS13:AC may be caused by the presence of its inhibitor, which is 
closely related to lower functional liver capacity, marked inflammation, and enhanced 
endotoxemia in patients with AH and SAH. Intravenous infusion of endotoxin to healthy 
volunteers induced the decrease in plasma ADAMTS13:AC together with the increase in 
VWF:Ag and the appearance of UL-VWFM during acute systemic inflammation (Reiter et 
al., 2005). From our results and previously reported findings (Reiter et al., 2005), 
endotoxemia itself might be a candidate to reduce plasma ADAMTS13:AC together with 
inflammatory cytokines in AH patients. It will be necessary to clarify what kinds of inhibitor 
is involved in association with inflammatory cytokines and endotoxin. Recently, we 
encountered two patient who developed TTP; one occurred in the course of hepatitis C virus 
(HCV)-related advanced LC (Yagita et al., 2005) and another occurred a month after 
pegylated-interferon alpha-2a therapy in a HCV-related case of chronic hepatitis (Kitano et 
al, 2006). In both cases, plasma ADAMTS13:AC was extremely low, and the inhibitor against 
ADAMTS13 was detected in the patient’s heated plasma (2.0 BU/ml, 1.6 BU/ml, 
respectively) and purified IgG (0.19 BU/mg IgG, 0.4 BU/mg IgG, respectively). 
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Furthermore, we could detect IgG-inhibitor by western blot in 4 patients with advanced LC, 
who showed extremely lower ADAMTS13 activity (<3% of controls), but had no apparent 
clinical features of TTP, indicating the existence of “subclinical TTP” (Uemura et al., 2008a). 
Of 108 patients with idiopathic TTP whose plasma samples were sent to our department of 
Blood Transfusion Medicine, the inhibitor was detected in 54 (79.4%) of 68 patients 
analyzed, and its inhibitor activity was 0.5 to 2.0 BU/ml in 33 cases (61.1%), and more than 
2.0 BU/ml in the remaining 21 cases (38.9%) (Matsumoto et al., 2004). Taken together, these 
observations suggest that the inhibitor activity detected in our patients with SAH and AH 
would be enough to reduce the activity of plasma ADAMTS13. 
8. Clinical significance of plasma ADAMTS13:AC determination and future 
perspective in severe liver diseases 
The introduction of ADAMTS13 to the field of hepatology not only enabled us to confirm 
the diagnosis of TTP early, but also provided novel insight into the pathophysiology of liver 
diseases. Some diseases were shown to be TTP itself, but others did not show any apparent 
clinical features of TTP, even in the presence of markedly decreased ADAMTS13:AC and 
increased UL-VWFM that correlate with TTP. Such TTP-like states, but not DIC, may 
indicate “subclinical TTP” as seen in advanced LC (Uemura et al., 2008a, Uemura et al., 
2010) and SAH patients (Matsuyama et al., 2007; Uemura et al., 2005b; Uemura et al., 2008b), 
or “local TTP” as shown in patients with hepatic VOD after SCT (Matsumoto et al., 2007; 
Park et al., 2002) and patients with adverse events after living-donor liver transplantation 
(Ko et al., 2006). One would be unable to detect such TTP-like phenomena without the 
determination of ADAMTS13:AC, because the interaction of ADAMTS13 and UL-VWFM is 
the initial step in hemostasis, and their abnormalities do occur even in the absence of 
apparent imbalance in other conventional hemostatic factors. One could, then, notice that 
the origin of VWF, the substrate of ADAMS13, is indeed transformed hepatic sinusoidal 
and/or extrahepatic ECs, but not hepatocytes.  The procoagulant and anticoagulant proteins 
synthesized in hepatocytes decrease as liver disease progresses, whereas VWF markedly 
increases. Under such circumstances, ADAMTS13 deficiency may lead to microcirculatory 
disturbances not only in the liver, but also in the systemic circulation. The determination of 
ADAMTS13 and its related parameters will thus be quite useful for better understanding the 
pathophysiology and for providing appropriate treatments especially in severe liver disease 
patients.  
Regarding FFP infusion as a unique source of ADAMTS13, we clearly showed that pre-
existing UL-VWFMs in the plasma of USS patients began to disappear within 1 hour and 
completely disappeared 24 hours after ADAMTS13 was replenished with infusions of FFP 
(Yagi et al., 2001), indicating that exogenous ADAMTS13 could efficiently cleave both UL-
VWFMs pre-existing in the circulation and the newly produced molecules at the ECs’ surface. 
Furthermore, prophylactic FFP infusion may be instrumental in preventing the development 
of hepatic VOD after SCT (Matsumoto et al., 2007). Our five patients with SAH were treated 
with FFP infusion together with supportive care, and two of them survived, but the remaining 
three did not (Ishikawa et al., 2010). One of the non-survivors showed a transient increase in 
ADAMTS13:AC during FFP infusion, which ultimately decreased. The other two patients died 
of hepatic failure (Ishikawa et al., 2010). The administration of FFP may be useful, in part, as a 
supplementation of ADAMTS13, but the effects might depend on the severity of the liver 
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disturbance, or the degree of liver regeneration and multiorgan failure in SAH patients. 
Additionally, it is extremely important to monitor plasma ADAMTS13:AC in the treatment of 
thrombocytopenia associated with allograft dysfunction after liver transplantation. This is 
because the infusions of a platelet concentrate, but not FFP, under an imbalance of decreased 
ADAMTS13:AC to enhanced UL-VWFM production, may further exacerbate the formation of 
platelet aggregates mediated by uncleaved UL-VWFM, leading to graft failure via the “local 
TTP” mechanism (Ko et al., 2006). FFP infusion as ADAMTS13 replacement therapy may 
improve both liver dysfunction and thrombocytopenia in liver transplant patients.  
From our point of view, it will be indispensable to measure ADAMTS13:AC when patients 
are encountered with unexplained thrombocytopenia in the course of liver disease.  We are 
particularly interested in the conduct of clinical trials with recombinant ADAMTS13 
preparations in severe liver diseases, including SAH, advanced LC, hepatic VOD and liver 
transplant patients. Further investigations will be necessary to define candidates for 
ADAMTS13 supplementation therapy, and to evaluate its potential therapeutic efficacy in 
















Fig. 6. A working hypothesis of ADAMTS13 and its related parameters in the progression of 
alcoholic hepatitis. 
9. Conclusion 
Enhanced gut-derived endotoxemia via hepatic reticuloendothelial dysfunction and 
increased intestinal permeability and subsequent cytokinemia may result in SECs injury and 
systemic inflammatory response syndrome, leading to microcirculatory disturbance in 
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9. Conclusion 
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systemic inflammatory response syndrome, leading to microcirculatory disturbance in 
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hepatic sinusoid and multiple organs, and finally, to the necrosis of hapatocytes and 
multiorgan failure in patients with AH, and particularly in patients with SAH (Fig. 6.). The 
imbalance between the enhanced production of UL-VWFM and the deficient activity of 
ADAMTS13 may, in part, contribute to not only sinusoidal microcirculatory disturbances 
and subsequent liver injury in AH, but also to the development of multiorgan failure 
through impaired organ microcirculation in SAH. Decreased ADAMTS13:AC and increased 
VWF:Ag could be induced by pro-inflammatory cytokinemia and the plasma inhibitor 
against ADAMTS13, both of which may be closely related to enhanced endotoxemia (Fig. 
6.). The determination of ADAMTS13:AC and its substrate will give us new insights into the 
pathophysiology of acute ALD and help to elucidate additional therapeutic strategies 
including ADAMTS13 supplementation for this disease. 
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1. Introduction 
In 1988 Starzl challenged the consensus view from 1983 that only a small percentage of 
patients with alcoholic liver disease (ALD) would be expected to meet the criteria for 
transplantation (National Institute of Health [NIH], 1984). Starzl and his team reported the 
successful liver transplantation (LT) of patients with ALD, and suggested that few patients 
returned to alcohol after liver transplantation (Starzl et al., 1988). Since then ALD has become 
one of the most common indications for LT in adults. However, despite this success, there 
remains significant debate and controversy regarding the indication, as several studies over 
time have shown that the public may not be supportive of the idea of allocating a limited 
resource, such as the liver graft, to patients with ALD. This chapter will discuss the pre-
transplant evaluation of patients with ALD, the debate over the treatment of acute alcoholic 
hepatitis, and the outcome of LT for ALD, including the issue of relapse. Finally, certain ethical 
concerns such as the use of living donors and future challenges will be analyzed. 
2. Pre-transplant evaluation of patients with ALD 
Patients with ALD, as part of their pre-transplant evaluation, are assessed by a multi-
disciplinary team consisting of hepatologists, surgeons, social workers and psychiatrists. 
The decision to list the patient depends on the status of the liver disease, which is expressed 
in most centers by the Model for End-stage Liver Disease (MELD) score. This is a relatively 
objective measurement of the patients’ degree of liver disease by using the patient’s 
bilirubin, creatinine and INR serum values to calculate the MELD score. The latter is 
empirically capped at 40 and represents a continuous variable ranging from 6 to 40 and it 
has proven to be highly accurate in assessing 3 month mortality once a cirrhotic patient is on 
the waiting list (Kamath et al., 2001). There is however the assertion that ALD patients may 
be under-referred for LT in the United States (Kotlyar et al. 2008). This may be because ALD 
may represent a negative determinant for many physicians to refer patients for LT, or there 
may be a lack of recognition of the contribution of excessive alcohol consumption to liver 
failure in the community. One study identified patients with liver failure in whom alcohol 
consumption was not recognized or acknowledged by the referring physicians (Day et al., 
2008). It is not clear whether this was a purposeful omission or a genuine lack of recognition, 
but it does underscore the need for careful attention to the presence of alcoholic disorders in 
patients with liver failure.  
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2.1 Abstinence prior to LT for ALD 
Patients with ALD undergo the standard pre-transplant evaluation, whose goal is to 
determine the suitability of the potential candidate to undergo the LT, as well as the urgency 
with which this has to be performed, based on the severity of the liver disease. Specifically 
for patients with ALD the issue of abstinence is critical in making these determinations. The 
apprehension that candidates for LT with ALD are likely to relapse and cause damage to the 
graft, makes it important to select those patients with the lower risk of relapse. To ensure 
this formal pretransplant substance misuse evaluations are required, including a broad 
psychosocial and substance abuse assessment. Factors analyzed include the pattern of 
previous alcohol use, diagnosis of alcohol use disorder, length of abstinence and features 
that would indicate a higher risk of future return to alcohol consumption (Dobbels et al., 
2009; Gedaly et al., 2008). People judged suitable for LT are patients with severe end-stage 
liver disease, a clear understanding of the risks and benefits involved in the procedure, and 
a favorable psychiatric profile including acceptance of their alcoholism and factors in their 
family and social network that would ensure post-transplant sobriety. 
Pretransplant abstinence offers the advantages of allowing the liver disease an opportunity to 
stabilize, as well as testing the patient’s commitment and resolve to proceed with this 
treatment. The transplant team with the support of the psychiatrists and the abuse specialists 
has the ability during that period to evaluate the patient and the presence of a support 
network, as well as monitor their resolve through frequent visits, as well as unannounced 
testing. There remains significant debate regarding the extent of the required abstinence 
period. Specifically, the vast majority of transplant centers (85%) in the United States require 6 
months of abstinence prior to transplantation, with a significant number expecting the patients 
to sign a formal contract (Everhart & Beresford, 1997). This view was changed in 2005, 
following the UNOS and French Consensus Conference on LT, as there was not an agreement 
in the literature regarding the 6 month sobriety period (Mathurin, 2005).  
People in favor of the 6 month abstinence period cite 3 main advantages. First, the period of 
pretransplantation abstinence may allow liver recovery, even to the extent of a LT becoming 
unnecessary, with one study showing significant improvement within 3 months (Veldt et al., 
2002). Second, it can help identify those patients unable to abstain, and thus more likely to 
relapse after the LT. This cannot happen reliably when a patient presents with decompensated 
liver disease, as “death-bed repentance”, no matter how genuine, may not accurately reflect 
future intentions. Finally, the time of abstinence can and should be used for intensive 
rehabilitation and treatment for the alcohol dependence, as relapse is more frequent within the 
first year after quitting alcohol. Others have questioned the need for an arbitrary period of 
abstinence pre-LT. All agree that the 6 month period is not based on prospectively gathered 
data, but rather on custom and practice (Neuberger et al., 2002). The main argument against 
the enforced time period of abstinence has been that it may be more of a selection method 
favored by insurance companies, rather than an effective predictor for post-transplant 
abstinence. Some of the key studies in the field have advocated that full psychosocial 
assessment as part of the pretransplant evaluation of the ALD patient may be more important 
than a universal application of a 6 month abstinence rule (Pfitzmann et al., 2007). Additionally, 
these studies have shown that the frequency of both minor and harmful drinking is frequent in 
the first 5 years after LT, despite careful pre-transplant assessment, although it is equally 
useful to distinguish between harmful drinking and “slips” (DiMartini et al., 2006; Pfitzmann 
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et al., 2007). Setting a fixed time period for pre-LT abstinence as a rigid rule, fails to take into 
account the multiple clinical and psychosocial variables of ALD patients. Patients with ALD 
are not immune from hepatocellular carcinoma (HCC), and as such cannot have an arbitrary 
waiting time period placed on them, as in that case there is the real danger of the HCC getting 
outside Milan criteria, and thereby precluding any chance of a LT. This is not to say that there 
should not be a proper evaluation of the severity of the alcohol dependence in these patients, 
or measures taken to achieve sustained abstinence and prevent relapse; however, in order to 
reach a consensus on a period of abstinence prior to the LT, large, multicentric, randomized 
longitudinal prospective studies are needed to analyze the decision making methods carefully 
and completely (Beresford & Everson, 2000). 
The question of the 6 month abstinence period prior to a LT is only part of the effort to 
identify predictors of post-LT relapse. In addition to the studies supporting that the length 
of sobriety is a strong predictor of recidivism, there are others reporting that patients with a 
DSM-IV diagnosis of abuse had a lower relapse probability than those with alcohol 
dependence (DiMartini et al., 2006; Karim et al., 2010). DiMartini et al. showed that variables 
such as alcohol dependence, short length of sobriety, family history of alcohol consumption 
and the use of other substances identified patients with a major risk of relapse (DiMartini et 
al., 2010). Despite that there are studies showing that pre-LT behavior is a poor predictor of 
relapse, or that other variables such as demographic, family and social ones come into play 
(De Gottardi et al., 2007; Foster et al., 1997; Kelly et al., 2006; Pfitzmann et al., 2007). Overall, 
this multitude of often competing possible predictors of recidivism, further stresses the need 
for an accurate stratification of potential candidates to identify those most likely to remain 
abstinent, and thus benefit the most from a LT. 
2.2 Comorbidities associated with ALD 
There is a significant number of comorbidities among patients with ALD which ultimately 
may limit their suitability for LT, unless properly addressed. Some of these comorbidities may 
be a direct effect of alcoholism, or they may be medical conditions commonly occurring in 
alcoholics. Patients with alcoholic cirrhosis may have alcohol related heart disease, such as 
alcoholic cardiomyopathy, in addition to the cirrhotic cardiomyopathy that is attributed to 
cirrhosis itself, and this may be related to the total lifetime use of alcohol (Urbano-Marquez et 
al., 1989). Alcoholic cardiomyopathy has specific diagnostic criteria and is associated with 
active alcohol intake. For that reason interventions that would lead to alcohol cessation would 
also prevent progression to cardiac failure. Additional medical comorbidities include 
neurologic disease ranging from myopathy to fixed deficits, with the latter being at times hard 
to differentiate from the hepatic encephalopathy that is associated with cirrhosis and can be 
reversible following LT (Keefe, 1997). Chronic pancreatitis and malnutrition are other 
problems commonly seen in these patients, whereas one cannot ignore the coexistence of other 
liver disease, such as chronic hepatitis C virus (HCV) infection or hepatocellular carcinoma 
(HCC), which can affect the urgency of LT, and especially the overall prognosis. 
2.3 Acute alcoholic hepatitis 
Acute alcoholic hepatitis (AH) represents a treatment dilemma for the medical team, as it 
may occur in patients with previously normal liver or with established cirrhosis. Patients 
with a previously normal liver present an opportunity, from a technical standpoint, as the 
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liver transplantation is significantly easier with the absence of the trademarks of end-stage 
liver disease, such as portal hypertension (Figure 1 a, b).  
 
 
Fig. 1. a, b: Different types of livers encountered in patients with alcoholic liver disease. (a) 
This patient has acute alcoholic hepatitis on top of previously established cirrhosis. The 
hepatectomy stage of the LT is much more challenging in this patient. (b) This patient has 
acute alcoholic hepatitis without any previous evidence of cirrhosis, with the liver revealing 
some edema, but no cirrhosis. 
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Unfortunately, in the severe form, even with maximal medical treatment, there is a 40-50% 
mortality within 1 month after diagnosis (Dureja & Lucey, 2010). This very high mortality, 
despite the organ shortage, has led to many advocating LT for that subset of patients who 
have failed medical treatment. To date, only corticosteroids and pentoxifylline are 
considered to potentially improve short-term survival, although the results of meta-analysis 
remain controversial (Imperiale et al., 1990; Mathurin et al., 2011). Currently, the majority of 
transplant centers are reluctant to offer LT for patients with acute AH, although there is an 
effort to identify that subset of patients that will fail medical treatment with corticosteroids 
and likely benefit the most from LT. Experience has been mixed regarding transplantation 
for these patients, although there are some encouraging new studies, where strict selection 
can lead to favorable results, both in terms of survival, as well as in terms of relapse (Castel 
et al., 2009; Tome & Lucey, 2003). One of these studies was a European multicenter study 
about a carefully selected group of patients suffering from their first episode of severe AH 
and for whom medical treatment had failed. They had received a favorable psychosocial 
assessment and had excellent intermediate survival and low frequency of significant 
drinking after LT (Castel et al., 2009). Based on these results, transplant groups on both sides 
of the Atlantic have argued in favor of placement on the LT waiting list of patients with life-
threatening AH who meet criteria. 
3. Outcome of LT for ALD and ethical issues 
3.1 Outcome of LT for ALD 
The overall survival of patients who underwent LT for ALD is statistically comparable to 
that of patients who underwent LT for other indications. Data from the European Liver 
Transplant Registry 2008 revealed 1-, 5-, and 10-year patient survival rates for ALD of 96%, 
88% and 76% respectively, as compared to 97%, 80% and 72% for patients with other 
indications (European Liver Transplantation Registry [ELTR], 2008). Similar survival rates 
have been reported for ALD patients in the US after LT: 92% at 1 year, 86% at 3 and 5 years 
and 76% at 9 years (Bhagat et al., 2009). It has been shown that patients with ALD had 
similar patient and graft survival rates, if not better in some cases, compared to those of 
patients undergoing LT for other indications (Dumortier et al., 2007; Mutimer et al., 2006; 
Romano et al., 1999). In a “perfect” world patients would have a single aetiology for their 
end-stage liver disease, unfortunately in the real world patients may undergo LT for ALD in 
the presence of other comorbidities, which can significantly affect the result. The most 
common is HCV, where there have been data of a more rapid progression of the liver 
disease in immunocompetent patients with the combination of ALD and HCV (Cromie et 
al., 1996; Pessione et al., 1998). However, other, more recent studies have shown that 
patients transplanted for ALD  plus HCV had a better survival than patients with HCV 
alone and similar survival to those with ALD alone (Aguilera et al., 2009). This could be 
partly explained by the greater use of antiviral treatment in patients with HCV and ALD, as 
they were younger than the HCV alone patients. Furthermore, data from the European Liver 
Transplantation Registry have shown similar post-LT survival rates between patients with 
ALD and ALD plus a viral etiology (HCV and HBV), although patients with ALD plus HCV 
had a significantly shorter survival compared to those with ALD plus HBV infection (Burra 
et al., 2010). These data support the notion that ALD represents a good indication for LT, 
even in the presence of hepatitis virus infection. 
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Regarding long-term morbidity and survival in patients with ALD, there appears to be an 
effect from a high prevalence of medical comorbidities, including de novo cancers. In one 
study of a group of patients undergoing LT for ALD, 5 year graft and patient survival were 
significantly lower than non-alcoholics undergoing LT, mainly due to cardiorespiratory, 
cerebrovascular and neoplastic problems (Jain et al., 2000). When compared to patients 
receiving LT for other indications, those transplanted for ALD are at a greater risk of de 
novo malignancy, and especially aerodigestive cancers possibly due to the chronic alcohol 
use (Oo et al., 2005; Watt et al., 2009). These comorbidities are associated with worse 
survival (Bellamy et al., 2001; Duvoux et al., 1999). These studies do not show an association 
between new-onset cancers and alcoholic relapse. An important factor may be the high 
prevalence of chronic heavy tobacco use in this population, in combination with the 
immunosuppression. This presents the question of whether patients with ALD require 
specific surveillance programs for de novo tumours after LT. Also, if the link between 
tobacco use and death from either cancer or cardiovascular disease holds true, then an 
obvious way to improve post-transplant health is through the promotion of smoking 
cessation, especially in LT recipients with alcoholism. 
3.2 Impact of recidivism on survival after LT for ALD 
Not unexpectedly, better survival rates were observed for patients that remained abstinent 
after LT than those who returned to alcohol use. Still in trying to identify the impact of 
recidivism on survival after LT, first we have to overcome the problem of a lack of a 
commonly accepted definition and the fact that the reported rates of recidivism vary widely 
at different follow-up periods post-LT. In one of the better prospective studies, DiMartini et 
al., showed that 22% of patients had used some alcohol by the first year after LT and 42% 
had a drink by 5 years (DiMartini et al., 2006). By 5 years, 26% drank at a heavier use pattern 
and 20% in a frequent pattern. In another prospective study by DiMartini et al., there were 
five different patterns of alcohol consumption identified, based on the time of relapse and 
the subsequent pattern (DiMartini et al., 2010). Approximately 80% of the patients either did 
not drink or consumed only small amounts rarely. Among the remaining 20%, there were 3 
patterns of harmful drinking, varied according to the time of relapse and the consumption 
of alcohol (sustained, heavy use or subsequently modified drinking). These data were 
similar to the retrospective data from Tang et al., who found harmful drinking in 16% of the 
patients (Tang et al., 1998). The problem of identifying a commonly-accepted definition for 
recidivism and the prevailing rates is made more difficult by the fact that most of these 
studies are based on data obtained through self-report questionnaires, interviews with 
patients and/or family members, or even retrospective analysis of routine screening tests. In 
all of this there is an apparent risk of underestimation. 
However, there is disagreement on the impact of recidivism on post-transplant survival. 
Specifically, there have been studies showing no significant impact on survival rates 
(Burra et al., 2003; Gerhardt et al., 1996). These have been contradicted by other studies 
reporting 5- and 10-year survivals of 69% and 20% respectively in patients with alcohol 
relapse following LT, and the argument that attention needs to be paid to the different 
patterns of relapse, rather than the overall rate (DiMartini et al., 2006). It does appear that 
the long-term survival of patients who resume heavy drinking is lower compared to those 
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who remain abstinent or have minor slips (Cuadrado et al., 2005; Pfitzmann et al., 2007). 
Interestingly enough, a significant factor for the decreased survival appears to be an 
association with developing malignancies, rather than recurrent end-stage liver disease. 
The influence of slips on LT outcome remains unclear, but there is the general perception 
that, although a slip should be considered an adverse event, it is unlikely to cause harm if 
it does not lead to a full-blown relapse (Cuadrado et al., 2005; Pfitzmann et al., 2007). One 
area where clinicians should pay particular attention to alcohol recidivism is when it is 
combined with concomitant HCV infection, since it may exacerbate the liver damage with 
rapid progression to cirrhosis and graft loss (Bellamy et al., 2001; Neuberger et al., 2002; 
Tome & Lucey, 2003). This can often lead to a late onset of acute or chronic rejection, 
whose management can be a nightmare in the patient with HCV recurrence (which is the 
vast majority of patients).  
A question closely related to the effect of recidivism on survival after LT for ALD, is that of 
the quality of life after the LT. In a study in the UK of patients undergoing LT for ALD over 
a 10-year period, it was seen that overall in the long term at least 50% of the patients will 
drink again at some time post-LT, although at lower levels of alcohol intake than before the 
transplant (Perreira et al., 2000). The group at greatest risk for harmful drinking appears to 
be the patients with the most predictive factors for relapse, and thus the group that would 
benefit the most from professional counselling. Even so, the overall quality of life after LT 
for ALD, based on three different questionnaires, is high and in general similar to the level 
expected in the general population. When everything is put together regarding the issue of 
recidivism after LT for ALD, the challenge is the need for improved methodology and tools 
in monitoring post-transplantation abstinence, in order to better evaluate the effect of 
relapse. Ultimately, the question is critical, as it raises the issue of proper stewardship of a 
limited resource for society. 
3.3 Cost-effectiveness of LT for ALD 
As liver transplantation has not really been the subject of a randomized controlled trial, 
there is some uncertainty regarding the magnitude of the benefit and cost-effectiveness 
for specific patient groups. In an attempt to answer this question a study from England 
and Wales attempted an economic evaluation of liver transplantation in that area 
(Longworth et al., 2003). Cost-effectiveness was measured using incremental cost per 
quality-adjusted life years (QALY; commonly referred to as cost-utility analysis). The 
results of a comparison group, representing experience in the absence of LT, are estimated 
using a combination of observed data from patients waiting for transplant and published 
prognostic models. The analysis was limited to three disease groups for which prognostic 
models were available at the beginning of the study, one of which was the group of 
patients with ALD. Overall, a higher proportion of patients with ALD were assessed for a 
transplant but not placed on the waiting list. The estimated gain in quality-adjusted life-
years from transplantation was positive for each of the disease groups. The mean 
incremental cost per quality-adjusted life-year from time of listing to 27 months was 
€54,000 (€13,500 to €93,500). The study showed that LT increases survival and health-
related quality of life of ALD patients, although the cost-effectiveness estimates within 
that 27 month period were poorer for patients with ALD than for patients with PBC or 
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in monitoring post-transplantation abstinence, in order to better evaluate the effect of 
relapse. Ultimately, the question is critical, as it raises the issue of proper stewardship of a 
limited resource for society. 
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As liver transplantation has not really been the subject of a randomized controlled trial, 
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for specific patient groups. In an attempt to answer this question a study from England 
and Wales attempted an economic evaluation of liver transplantation in that area 
(Longworth et al., 2003). Cost-effectiveness was measured using incremental cost per 
quality-adjusted life years (QALY; commonly referred to as cost-utility analysis). The 
results of a comparison group, representing experience in the absence of LT, are estimated 
using a combination of observed data from patients waiting for transplant and published 
prognostic models. The analysis was limited to three disease groups for which prognostic 
models were available at the beginning of the study, one of which was the group of 
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PSC. The authors suggested that this may reflect the cost of the higher number of ALD 
patients assessed for each transplant. 
3.4 Ethical issues 
The indication of ALD for LT is unlike many of the others as it involves the proper use of a 
scarce resource for patients with a potentially “self-inflicted” disease. Some have argued 
that since alcohol dependence as an “addiction” carries a neurobiological and a genetic 
component, then it may be more appropriate to treat it more as a medical condition. This 
does not answer the problem fully, as what matters is the outcome and if we accept that self-
control has no role in the management of alcoholism then relapse would be all but a 
certainty. Others have challenged the ethics of the “6-month abstinence” rule, based on lack 
of evidence making it an arbitrary decision (Everhart & Beresford, 1997). Studies have found 
that although neither the presence of histological alcoholic hepatitis in the explant, nor any 
history of drinking within 6 months correlated with subsequent relapses (Tome et al., 2002; 
Wells et al., 2007). Against this background of conflicting data, there is a lack of consensus 
from country to country regarding the timing and suitability of patients with ALD for LT. 
One has to consider whether rules such as the “6-month” one represent an attempt towards 
an ethical approach to patient selection for LT, or whether they are a matter of practicality. 
For example, in the United States, the evaluation process usually results in the presentation 
of a comprehensive clinical and psychosocial assessment to the transplant program’s 
selection committee. When the selection committee decides to recommend transplantation, 
the approval of the third party payer is necessary before the patient is placed on the waiting 
list. The 6-month rule has been widely adopted by the US insurance industry, without 
adequate data, leading to anecdotal reports of the difficult decisions involved (Boren, 1994). 
There are certain lessons that can be drawn regarding sobriety and prognosis after LT for 
ALD, which may have more validity than simply following the 6-month rule. Specifically, 
no single measure is a reliable prognosticator for future relapses into harmful drinking after 
transplantation, and although the duration of abstinence has been associated with 
subsequent drinking, it is an imprecise prognostic tool. Furthermore, there is more value in 
a careful evaluation by a trained addiction specialist with a special interest in transplant 
medicine, with such a psychosocial assessment helping determine the risk of relapse into 
significant alcohol abuse, but not with an absolute certainty. Finally, when all is said and 
done, the severely ill patient who has been drinking recently, but has other favorable 
prognostic indicators with respect to post-transplant behavior, represents a very difficult 
question for any transplant program.  
Another issue is that since the need to restrict access to LT for patients with ALD is based on 
the donor shortage, then it could be argued that these recipients should be held to different 
standards when there is the possibility of a living donor. The answer to this question should 
still relate to the outcome and long-term results of LT for this group of patients, as no matter 
how willing the living donor may be, it must be made certain that the benefit to the recipient 
is worth the risk to the donor. Consideration of ALD patients as recipients for Living Donor 
Liver Transplantation (LDLT) has raised similar issues as those seen with cadaveric 
donation for these patients. Since most living donors are closely related to the recipient, they 
have watched the progression of ALD in the recipients over time and many may not regard 
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the pathogenesis of ALD as totally unavoidable. This would result to donors seeing 
recipient relapses with alcohol, no matter how frequent or clinically significant, as 
ingratitude. Thus, for every patient with ALD being considered for LDLT there are 
individual conditions and relationships, which dictate significant less tolerance with alcohol 
relapse in LDLT compared to cadaveric donation. 
The answer to many of these concerns has been the utilization of the 6 month abstinence 
rule by most programs. Notwithstanding the shortcomings of this rule regarding its 
predictive capacity that have been described elsewhere in this chapter, there are also 
certain issues unique to LDLT that may limit its use. Specifically, with a cadaveric LT there 
is the “luxury” of waiting given the organ shortage, and so that period can be used to test 
the abstinence and intervene; in LDLT the biggest advantage is the short preparative 
period and waiting time needed, something which would be negated by the strict use of 
the 6 month rule. Additionally, there are several Asian countries where, because of 
religious considerations, LDLT is the main type of LT, as cadaveric donation is limited or 
nonexistent. Thus, in these countries patients with ALD may have limited options. These 
two points are not meant to suggest that patients with ALD should be able to proceed with 
LDLT without addressing the issue of alcohol abuse and the possibility of recidivism, as 
that would be a disservice to the gift of the donor. A study by Hwang et al. from the Asan 
Medical Center in Korea of patients with ALD undergoing LDLT concluded that the 
pretransplant abstinence seemed to be beneficial and that for ethical reasons the 6 month 
abstinence rule should be strictly observed in LDLT (Hwang et al., 2006). When 
considering the ethical aspects of living organ donation, it is certainly reasonable to 
exclude recipients with significant factors for relapse. Also, we need to consider the unique 
aspects of the donor-recipient relationship, similar to those seen in the case of LDLT for 
patients with HCC. Along these lines a factor that may help is that a very close relationship 
between the donor and the recipient may be critical in preventing alcohol relapse or at least 
an escalation to significant alcohol abuse. The same study from South Korea found 3- and 
5-year relapse rates of 20% in these patients undergoing LDLT for ALD, lower than many 
of the studies with cadaveric LT (Hwang et al., 2006). This issue cannot be simply ignored 
as in Korea, for example, at the Asan Medical Center 134 LDLTs had been performed by 
2003, of which only four were for ALD (Moon & Lee, 2004). Although the actual prevalence 
of ALD in S. Korea may not be known, it is thought that 6% of patients with cirrhosis have 
ALD. This means that the trends are changing, as the 20-year vaccination program for 
Hepatitis B virus has reduced the incidence of the disease in the population, there is a 
gradual increase in alcohol consumption which will eventually lead to a higher need for 
LDLT for patients with ALD. 
4. Future challenges 
4.1 Psychosocial assessment 
Evaluating the role of LT in the treatment of patients with ALD is a work in progress as 
significant challenges remain. Chief among them is the need for improved psychometric 
tools and assessments that would be able to predict with greater accuracy the pattern of 
alcohol use after transplant and the effect of that on the liver graft. This could lead to  
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the pathogenesis of ALD as totally unavoidable. This would result to donors seeing 
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individual conditions and relationships, which dictate significant less tolerance with alcohol 
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The answer to many of these concerns has been the utilization of the 6 month abstinence 
rule by most programs. Notwithstanding the shortcomings of this rule regarding its 
predictive capacity that have been described elsewhere in this chapter, there are also 
certain issues unique to LDLT that may limit its use. Specifically, with a cadaveric LT there 
is the “luxury” of waiting given the organ shortage, and so that period can be used to test 
the abstinence and intervene; in LDLT the biggest advantage is the short preparative 
period and waiting time needed, something which would be negated by the strict use of 
the 6 month rule. Additionally, there are several Asian countries where, because of 
religious considerations, LDLT is the main type of LT, as cadaveric donation is limited or 
nonexistent. Thus, in these countries patients with ALD may have limited options. These 
two points are not meant to suggest that patients with ALD should be able to proceed with 
LDLT without addressing the issue of alcohol abuse and the possibility of recidivism, as 
that would be a disservice to the gift of the donor. A study by Hwang et al. from the Asan 
Medical Center in Korea of patients with ALD undergoing LDLT concluded that the 
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4.1 Psychosocial assessment 
Evaluating the role of LT in the treatment of patients with ALD is a work in progress as 
significant challenges remain. Chief among them is the need for improved psychometric 
tools and assessments that would be able to predict with greater accuracy the pattern of 
alcohol use after transplant and the effect of that on the liver graft. This could lead to  
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more targeted interventions with higher likelihood of success. A number of predictive 
tools have been considered as part of the assessment. The University of Michigan 
Alcoholism Prognosis Scale examines a number of psychosocial domains with a higher 
score suggesting increased stability leading to improved prognosis and Lucey et al. have 
suggested this broad-based tool as a useful alternative to the fixed pre-LT abstinence 
period (Lucey et al., 1997). Other tools include the alcohol abstinence self-Efficacy Scale 
which rates an individual’s ability to self-determine in the context of relapse precipitants 
(DiClemente et al., 1994). Although it has shown good reliability and validity in alcohol 
treatment settings, it has yet to be proven in the liver transplant setting. Beresford, an 
addiction psychiatrist from the University of Michigan, who introduced the concept of 
psychosocial assessment of ALD transplant candidates, alerted the transplant community 
to the clinical insights into the factors involved in maintaining sobriety reported in the 
addiction literature (Beresford, 1994). Based on the studies of Vaillant and of Strauss and 
Bacon, he constructed a panel of negative prognostic factors that he used to assess 
prospective ALD patients as candidates for LT (Strauss & Bacon, 1951; Vaillant, 1995). 
These included psychiatric comorbid conditions, such as uncontrolled polysubstance 
abuse or unstable character disorder, a history of many failed rehabilitation attempts, 
social isolation as shown by lack of a fixed employment and living alone without a spouse 
or companion.  
All of this has led to psychosocial assessment becoming part of the norm in liver transplant 
centers, where the use of agreed clinical guidelines and candidate selection criteria offer the 
assessment team a framework upon which to base complex decisions and an opportunity to 
explain the assessment and decision to the patient. It also allows transplant centers the 
opportunity to audit their selections and outcomes against accepted listing criteria. These 
observations, together with those by DiMartini documenting the five patterns of alcohol use, 
need validation in a large prospective cohort, and if successful can help clinicians identify 
tailored monitoring and interventions. Behavioral and pharmacological therapies may be 
necessary and helpful, but it is essential that they are individualized and that the support 
required is discussed and agreed upon with the candidate and their support system 
(DiMartini et al., 2010). 
4.2 Genetic element of ALD 
Also, further data are needed to clarify the element of genetic predisposition in alcohol 
abuse, as this too could help identify people at greater risk. Recent high-throughput 
technologies, such as micro arrays, genomics and proteomics have led to novel concepts in 
our understanding of several liver pathologies (Decaciuc et al., 2004; Seth et al., 2006). 
Application of these technologies has identified novel pathways that could not have been 
discovered using traditional methods and opened up several lines of investigation for 
understanding the mechanism involved in alcohol-mediated liver injury. Hepatic gene 
profiling using DNA micro arrays are reported from animal models of ALD and human 
ALD (Decaciuc et al., 2004; Seth et al., 2006). The ALD transcriptome profile is dominated by 
alcohol metabolism and inflammation related molecules, thus differing from other liver 
diseases (Seth et al., 2003). Additionally, several functional groups of genes showed similar 
qualitative and quantitative changes also in rodents as a result of chronic alcohol exposure 
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regardless of the type of array platform (Decaciuc et al., 2004). This finding shows the 
existence of common mechanisms of alcohol effect on the liver across species.  
In the past, genetic studies in ALD have focused on genes involved in alcohol metabolism 
(ADH, ALDH, CYP2E1), oxidative stress (GST, superoxide dismutase), endotoxin (TNF-a, 
CD14, TLR4), cytokines (IL-10), immune (cytotoxic T-lymphocyte antigen-4) and fibrosis 
(collagen, MMPs, osteopontin, TGF-b) and have been extensively reviewed (Stickel & 
Osterreicher, 2006). All appear to have an effect, but to date the search for single nucleotide 
polymorphisms (SNPs) in a hypothesis-driven candidate gene approach has been rather 
disappointing in identifying risk factors for ALD. Some of the reasons have been that most 
of the studies involved have either lacked statistical power due to small sample size, or 
investigated polymorphisms in a single or a few candidate genes or were subject to 
population stratification, Type 1 and 2 errors, or have failed to account for factors such as 
obesity and the confounding effect of Non-alcoholic steatohepatitis (NASH). Susceptibility 
to ALD, like most other multifactorial complex diseases, is controlled by a number of genes, 
each of which makes its own contribution. Therefore, what is needed is a genome-wide 
approach, in carefully designed large studies in order to identify various degree of risk 
genetic variants associated with ALD. The lack of an a priori hypothesis has helped Genome 
Wide Association (GWA) technologies yield successful outcomes in a variety of several 
common liver diseases (Karlsen et al., 2010; Kolleritis et al., 2009; Romeo et al., 2008). 
Advantage should also be taken of the understanding gained from research in other liver 
diseases, such as NASH, that show increasing parallels with ALD development. Recent 
advances in newer technologies enabling genome wide search for millions of SNPs, whole 
genome sequencing, global epigenetic profiles, and non-coding regulatory elements 
(miRNA) are the future research areas to construct the architecture of ALD and identify 
ways to predict and intervene in its progression. In these times of financial turmoil, a global 
well-coordinated effort is required to invest in future research to provide answers for a 
problem common in all different countries. 
5. Conclusion 
Liver transplantation has become over the last few decades one of the main treatments for 
advanced ALD. However, in order to optimize the results of this treatment, as well as fully 
establish its societal acceptance, it is imperative that careful patient selection takes place and 
that attention is paid not only to the peri-operative but also to the pre- and post-transplant 
periods. We need to stratify ALD potential transplant candidates according to the risk of 
relapse. Unfortunately, as we have seen in this chapter, to date the results reported from 
different studies are mostly inconclusive regarding the evaluation of predictive factors for 
alcoholic relapse after LT. Also, a defined pre-LT abstinence period for ALD candidates for 
transplantation appears to be justified, both as a way to ensure compliance, as well as an 
opportunity to effect some interventions to possibly recover liver function to the extent that 
a LT might not be needed. Even so, there are no strong data supporting the 6 month 
abstinence rule, and that means that we need to reach a consensus on this specific issue by 
conducting longitudinal, prospective studies. Just as important is the need to avoid the ease 
that strict “yes or no” rules and regulations offer (such as the 6 month rule) and concentrate 
more on creating and using improved psychomotor tools and assessments that will allow us 
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to better evaluate and help these patients. The question of the definition of alcohol relapse is 
another area where further studies are needed. The reason is that although a number of 
patients return to some degree of alcohol use after LT, recidivism leading to liver disease 
threatening the graft is uncommon. Additionally, post-LT surveillance programs for the 
early detection of cardiovascular problems and de novo malignancies are also needed, given 
the apparent higher prevalence in this population. To fully achieve this, patients with ALD 
need to be evaluated and followed by a team of professionals, including internists, surgeons, 
hepatologists, psychiatrists and social workers who will be able to fully address their 
complicated needs. 
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to better evaluate and help these patients. The question of the definition of alcohol relapse is 
another area where further studies are needed. The reason is that although a number of 
patients return to some degree of alcohol use after LT, recidivism leading to liver disease 
threatening the graft is uncommon. Additionally, post-LT surveillance programs for the 
early detection of cardiovascular problems and de novo malignancies are also needed, given 
the apparent higher prevalence in this population. To fully achieve this, patients with ALD 
need to be evaluated and followed by a team of professionals, including internists, surgeons, 
hepatologists, psychiatrists and social workers who will be able to fully address their 
complicated needs. 
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Alcoholic liver disease occurs after prolonged heavy drinking. Not everyone who 
drinks alcohol in excess develops serious forms of alcoholic liver disease. It is likely 
that genetic factors determine this individual susceptibility, and a family history of 
chronic liver disease may indicate a higher risk. Other factors include being overweight 
and iron overload. This book presents state-of-the-art information summarizing the 
current understanding of a range of alcoholic liver diseases. It is hoped that the target 
readers - hepatologists, clinicians, researchers and academicians  - will be afforded new 
ideas and exposed to subjects well beyond their own scientific disciplines. Additionally, 
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